No., subject, TM-score, RMSD, Sequence Identity, Subject length, Aligned length, Description
1, 3flqA, 1.0000, 0.00, 1.000, 345, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((S)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN
2, 1r3cA, 0.9943, 0.55, 0.997, 349, 345, THE STRUCTURE OF P38ALPHA C162S MUTANT
3, 2zazA, 0.9936, 0.65, 1.000, 345, 345, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH 4-ANILINO QUINOLINE INHIBITOR
4, 5xyyA, 0.9916, 0.75, 1.000, 350, 345, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
5, 1ouyA, 0.9915, 0.76, 1.000, 350, 345, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROPYRIDO- PYRIMIDINE INHIBITOR
6, 3fmjA, 0.9902, 0.46, 0.997, 344, 343, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 4-(5-METHYL-3-PHENYL- ISOXAZOL-4-YL)-PYRIMIDIN-2-YLAMINE
7, 2zb0A, 0.9902, 0.80, 1.000, 349, 345, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
8, 3flzA, 0.9901, 0.48, 1.000, 347, 343, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 8-METHYL-6-PHENOXY-2- (TETRAHYDRO-PYRAN-4-YLAMINO)-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
9, 1wbwA, 0.9900, 0.82, 1.000, 351, 345, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
10, 3flyA, 0.9899, 0.49, 1.000, 347, 343, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-ISOPROPYLAMINO-8-METHYL-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
11, 3fmlA, 0.9892, 0.32, 1.000, 342, 342, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6224
12, 3fmhA, 0.9890, 0.53, 1.000, 347, 343, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((R)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
13, 1bl6A, 0.9890, 0.81, 1.000, 351, 345, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB216995
14, 1w84A, 0.9886, 0.85, 1.000, 351, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
15, 1bmkA, 0.9882, 0.83, 0.994, 351, 345, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB218655
16, 1m7qA, 0.9881, 0.80, 1.000, 348, 344, CRYSTAL STRUCTURE OF P38 MAP KINASE IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
17, 1w7hA, 0.9880, 0.79, 1.000, 351, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
18, 1bl7A, 0.9878, 0.84, 1.000, 351, 345, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB220025
19, 1oukA, 0.9875, 0.83, 1.000, 348, 344, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR
20, 3s3iA, 0.9872, 0.83, 1.000, 349, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
21, 1wboA, 0.9862, 0.91, 1.000, 351, 345, FRAGMENT BASED P38 INHIBITORS
22, 1wbvA, 0.9860, 1.05, 1.000, 351, 345, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
23, 5etcA, 0.9859, 0.94, 1.000, 355, 345, STRUCTURE OF INACTIVE MAPK14 WITH ORDERED ACTIVATION LOOP
24, 3flsA, 0.9857, 0.71, 0.997, 343, 343, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24- DIFLUORO-PHENOXY)-2-((R)-2-METHANESULFONYL-1-METHYL- ETHYLAMINO)-8-METHYL-8H-PYRIDO[23-D]PYRIMIDIN-7-ONE
25, 1p38A, 0.9856, 0.90, 0.994, 351, 345, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTOMS RESOLUTION
26, 3flwA, 0.9852, 0.42, 1.000, 345, 341, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH PAMAPIMOD
27, 3fknA, 0.9848, 0.59, 1.000, 346, 342, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO7125
28, 1di9A, 0.9844, 0.93, 1.000, 348, 344, THE STRUCTURE OF P38 MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH 4-[3-METHYLSULFANYLANILINO]-67- DIMETHOXYQUINAZOLINE
29, 3fmkA, 0.9842, 0.61, 1.000, 346, 342, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 6-(24-DIFLUORO-PHENOXY)- 8-METHYL-2-((S)-1-METHYL-2-TETRAZOL-2-YL-ETHYLAMINO)-8H-PYRIDO[23- D]PYRIMIDIN-7-ONE
30, 5mz3A, 0.9840, 1.10, 0.997, 350, 345, P38 ALPHA MUTANT C162S IN COMPLEX WITH CMPD2 [N-(4-METHYL-3-(4455- TETRAMETHYL-132-DIOXABOROLAN-2-YL)PHENYL)-3-(TRIFLUOROMETHYL) BENZAMIDE]
31, 3rinA, 0.9840, 0.91, 1.000, 349, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
32, 1zzlA, 0.9836, 0.96, 1.000, 351, 345, CRYSTAL STRUCTURE OF P38 WITH TRIAZOLOPYRIDINE
33, 1oveA, 0.9836, 0.95, 0.994, 349, 345, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A DIHYDROQUINOLINONE
34, 1wbtA, 0.9835, 1.12, 1.000, 351, 345, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
35, 1w83A, 0.9835, 1.13, 1.000, 351, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
36, 3mptA, 0.9832, 0.84, 1.000, 347, 343, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A PYRROLE-2- CARBOXAMIDE INHIBITOR
37, 3hrbA, 0.9832, 0.85, 1.000, 344, 344, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
38, 3fmnA, 0.9832, 0.51, 1.000, 341, 341, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO2530
39, 1wbnA, 0.9832, 1.13, 1.000, 351, 345, FRAGMENT BASED P38 INHIBITORS
40, 1oz1A, 0.9832, 0.33, 1.000, 344, 340, P38 MITOGEN-ACTIVATED KINASE IN COMPLEX WITH 4-AZAINDOLE INHIBITOR
41, 3gfeA, 0.9829, 1.03, 1.000, 352, 345, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR
42, 2yixA, 0.9829, 1.00, 1.000, 351, 345, TRIAZOLOPYRIDINE INHIBITORS OF P38
43, 3d7zA, 0.9827, 0.93, 1.000, 348, 344, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
44, 3fmmA, 0.9825, 0.69, 1.000, 346, 342, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6226
45, 3kq7A, 0.9820, 1.11, 1.000, 348, 344, STRUCTURE OF HUMAN P38ALPHA WITH N-[4-METHYL-3-(6-{[2-(1- METHYLPYRROLIDIN-2-YL)ETHYL]AMINO}PYRIDINE-3-AMIDO)PHENYL]- 2-(MORPHOLIN-4-YL)PYRIDINE-4-CARBOXAMIDE
46, 3nnwA, 0.9815, 1.14, 1.000, 349, 345, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP802
47, 1wbsA, 0.9812, 1.17, 1.000, 351, 345, IDENTIFICATION OF NOVEL P38 ALPHA MAP KINASE INHIBITORS USING FRAGMENT-BASED LEAD GENERATION.
48, 1a9uA, 0.9812, 1.07, 1.000, 351, 345, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/SB203580
49, 2zb1A, 0.9809, 0.91, 1.000, 345, 343, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH BIPHENYL AMIDE INHIBITOR
50, 3nnuA, 0.9808, 1.09, 1.000, 348, 344, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP1376
51, 3dt1A, 0.9797, 1.10, 1.000, 356, 345, P38 COMPLEXED WITH A QUINAZOLINE INHIBITOR
52, 2gfsA, 0.9795, 0.55, 1.000, 344, 340, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3201195
53, 3nnvA, 0.9794, 1.08, 1.000, 348, 344, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH DP437
54, 3d83A, 0.9794, 1.05, 1.000, 347, 343, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIPHENYL AMIDE INHIBITOR
55, 1w82A, 0.9791, 1.16, 1.000, 351, 345, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
56, 3mw1A, 0.9789, 0.80, 1.000, 342, 342, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH SMALL MOLECULE INHIBITOR
57, 3e92A, 0.9785, 0.99, 0.997, 348, 343, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
58, 3gc7A, 0.9784, 1.05, 0.997, 349, 345, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH A DIHYDROQUINAZOLINONE
59, 3u8wA, 0.9782, 1.18, 1.000, 349, 345, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A TRIAZOLOPYRIDAZINONE INHIBITOR
60, 1yqjA, 0.9779, 1.18, 1.000, 356, 345, CRYSTAL STRUCTURE OF P38 ALPHA IN COMPLEX WITH A SELECTIVE PYRIDAZINE INHIBITOR
61, 3fsfA, 0.9775, 0.64, 0.997, 340, 340, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH 3-(26- DICHLORO-PHENYL)-7-[4-(2-DIETHYLAMINO-ETHOXY)-PHENYLAMINO]- 1-METHYL-34-DIHYDRO-1H-PYRIMIDO[45-D]PYRIMIDIN-2-ONE
62, 3iphA, 0.9768, 0.82, 1.000, 345, 341, CRYSTAL STRUCTURE OF P38 IN COMPLEX WITH A BIPHENYLAMIDE INHIBITOR
63, 3e93A, 0.9763, 0.94, 0.994, 346, 341, CRYSTAL STRUCTURE OF P38 KINASE IN COMPLEX WITH A BIARYL AMIDE INHIBITOR
64, 3fklA, 0.9759, 0.71, 0.997, 344, 340, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO9552
65, 3itzA, 0.9758, 1.20, 1.000, 357, 345, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDAZINE INHIBITOR
66, 5etiA, 0.9737, 1.28, 0.997, 355, 345, STRUCTURE OF DEAD KINASE MAPK14
67, 3fkoA, 0.9735, 0.70, 0.994, 343, 339, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO3668
68, 3fskA, 0.9734, 0.55, 1.000, 342, 338, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO6257
69, 2i0hA, 0.9731, 1.18, 0.997, 349, 345, THE STRUCTURE OF P38ALPHA IN COMPLEX WITH AN ARYLPYRIDAZINONE
70, 3flnC, 0.9728, 0.61, 0.994, 343, 338, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH R1487
71, 5xyxA, 0.9709, 0.37, 1.000, 337, 336, THE STRUCTURE OF P38 ALPHA IN COMPLEX WITH A TRIAZOL INHIBITOR
72, 5uojA, 0.9679, 0.82, 0.991, 343, 338, THE STRUCTURE OF THE MAP KINASE P38 AT 2.1 ANGSTROMS RESOLUTION
73, 1r39A, 0.9671, 1.16, 1.000, 345, 341, THE STRUCTURE OF P38ALPHA
74, 3fi4A, 0.9646, 0.58, 0.997, 339, 335, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO4499
75, 3fl4A, 0.9643, 0.60, 1.000, 339, 335, P38 KINASE CRYSTAL STRUCTURE IN COMPLEX WITH RO5634
76, 1wfcA, 0.9633, 0.85, 1.000, 340, 336, STRUCTURE OF APO UNPHOSPHORYLATED P38 MITOGEN ACTIVATED PROTEIN KINASE P38 (P38 MAP KINASE) THE MAMMALIAN HOMOLOGUE OF THE YEAST HOG1 PROTEIN
77, 1lezA, 0.9613, 1.20, 0.991, 343, 338, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS ACTIVATOR MKK3B
78, 3ha8A, 0.9605, 1.03, 1.000, 342, 338, THE COMPLEX STRUCTURE OF THE MAP KINASE P38/COMPOUND 14B
79, 3ds6D, 0.9543, 1.70, 1.000, 349, 345, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
80, 2lgcA, 0.9539, 1.80, 1.000, 359, 345, JOINT NMR AND X-RAY REFINEMENT REVEALS THE STRUCTURE OF A NOVEL DIBENZO[AD]CYCLOHEPTENONE INHIBITOR/P38 MAP KINASE COMPLEX IN SOLUTION
81, 1lewA, 0.9539, 1.11, 0.994, 341, 335, CRYSTAL STRUCTURE OF MAP KINASE P38 COMPLEXED TO THE DOCKING SITE ON ITS NUCLEAR SUBSTRATE MEF2A
82, 5larA, 0.9532, 1.60, 0.971, 350, 341, CRYSTAL STRUCTURE OF P38 ALPHA MAPK14 IN COMPLEX WITH VPC00628
83, 3lhjA, 0.9522, 1.19, 1.000, 341, 337, CRYSTAL STRUCTURE OF P38A MITOGEN-ACTIVATED PROTEIN KINASE IN COMPLEX WITH A PYRAZOLOPYRIDINONE INHIBITOR.
84, 5etfA, 0.9502, 1.03, 0.991, 338, 333, STRUCTURE OF DEAD KINASE MAPK14 WITH BOUND THE KIM DOMAIN OF MKK6
85, 4ka3A, 0.9499, 1.11, 0.991, 340, 334, STRUCTURE OF MAP KINASE IN COMPLEX WITH A DOCKING PEPTIDE
86, 2y8oA, 0.9497, 1.17, 0.997, 339, 334, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A MAPK DOCKING PEPTIDE
87, 2onlB, 0.9496, 1.19, 0.997, 339, 335, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
88, 3p4kA, 0.9495, 1.06, 0.988, 338, 333, THE THIRD CONFORMATION OF P38A MAP KINASE OBSERVED IN PHOSPHORYLATED P38A AND IN SOLUTION
89, 2okrA, 0.9488, 1.21, 1.000, 339, 335, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
90, 3ds6C, 0.9479, 1.74, 0.997, 349, 345, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
91, 4eh2A, 0.9467, 1.02, 1.000, 337, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F1 AND RL87
92, 2onlA, 0.9465, 1.20, 1.000, 338, 334, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
93, 4looA, 0.9460, 1.72, 0.974, 349, 342, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (MONOCLINIC CRYSTAL FORM)
94, 4eh3A, 0.9452, 1.28, 0.994, 339, 334, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F2 AND RL87
95, 4ewqA, 0.9449, 1.67, 0.965, 346, 340, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A PYRIDAZINE BASED INHIBITOR
96, 3ds6A, 0.9449, 1.49, 0.994, 343, 339, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
97, 4f9yA, 0.9442, 1.15, 0.997, 339, 334, HUMAN P38 ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
98, 3fc1X, 0.9440, 0.95, 1.000, 330, 330, CRYSTAL STRUCTURE OF P38 KINASE BOUND TO PYRIMIDO-PYRIDAZINONE INHIBITOR
99, 4kinB, 0.9436, 1.34, 0.988, 341, 337, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
100, 3py3A, 0.9434, 1.60, 0.982, 355, 337, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38ALPHA MAP KINASE
101, 3ds6B, 0.9426, 1.59, 0.991, 343, 339, P38 COMPLEX WITH A PHTHALAZINE INHIBITOR
102, 4eh8A, 0.9425, 1.06, 0.997, 336, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F7 AND RL87
103, 4eh7A, 0.9417, 1.17, 0.997, 337, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F6 AND RL87
104, 3hv3A, 0.9417, 1.16, 0.988, 335, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH RL49
105, 4eh6A, 0.9413, 1.03, 1.000, 335, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F5 AND RL87
106, 3hegA, 0.9410, 1.35, 0.991, 333, 333, P38 IN COMPLEX WITH SORAFENIB
107, 3bx5A, 0.9408, 1.35, 1.000, 338, 334, P38 ALPHA MAP KINASE COMPLEXED WITH BMS-640994
108, 2okrD, 0.9408, 1.20, 1.000, 339, 332, CRYSTAL STRUCTURE OF THE P38A-MAPKAP KINASE 2 HETERODIMER
109, 3nwwA, 0.9406, 1.34, 0.991, 339, 334, P38 ALPHA KINASE COMPLEXED WITH A 2-AMINOTHIAZOL-5-YL-PYRIMIDINE BASED INHIBITOR
110, 4f9wA, 0.9405, 1.08, 1.000, 336, 332, HUMAN P38ALPHA MAPK IN COMPLEX WITH A NOVEL AND SELECTIVE SMALL MOLECULE INHIBITOR
111, 3gcqA, 0.9404, 1.20, 0.988, 337, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH RL45
112, 4zthA, 0.9401, 1.30, 0.994, 339, 334, STRUCTURE OF HUMAN P38AMAPK-ARYLPYRIDAZINYLPYRIDINE FRAGMENT COMPLEX USED IN INHIBITOR DISCOVERY
113, 4dljA, 0.9398, 0.95, 1.000, 336, 330, HUMAN P38 MAP KINASE IN COMPLEX WITH RL163
114, 2ghmA, 0.9398, 1.15, 0.982, 336, 332, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-895449
115, 3rocA, 0.9393, 1.19, 1.000, 337, 333, CRYSTAL STRUCTURE OF HUMAN P38 ALPHA COMPLEXED WITH A PYRIMIDINONE COMPOUND
116, 3qudA, 0.9390, 1.57, 1.000, 345, 335, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO-BENZOPHENONE
117, 1yw2A, 0.9389, 1.48, 0.985, 341, 335, MUTATED MUS MUSCULUS P38 KINASE (MP38)
118, 4fa2A, 0.9386, 1.31, 0.994, 339, 334, HUMAN P38 ALPHA MITOGEN-ACTIVATED KINASE IN COMPLEX WITH SB239063
119, 3hllA, 0.9385, 1.23, 1.000, 337, 333, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH PH-797804
120, 3c5uA, 0.9385, 1.34, 0.994, 338, 334, P38 ALPHA MAP KINASE COMPLEXED WITH A BENZOTHIAZOLE BASED INHIBITOR
121, 2balA, 0.9385, 1.24, 0.997, 337, 332, P38ALPHA MAP KINASE BOUND TO PYRAZOLOAMINE
122, 3hv4A, 0.9383, 1.51, 0.991, 339, 335, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
123, 3newA, 0.9382, 1.01, 0.991, 334, 330, P38-ALPHA COMPLEXED WITH COMPOUND 10
124, 3gcuA, 0.9382, 1.53, 0.991, 339, 335, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
125, 4r3cA, 0.9379, 1.09, 1.000, 335, 331, CRYSTAL STRUCTURE OF P38 ALPHA MAP KINASE IN COMPLEX WITH A NOVEL ISOFORM SELECTIVE DRUG CANDIDATE
126, 4eh4A, 0.9379, 1.31, 0.994, 337, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F3 AND RL87
127, 3kf7A, 0.9379, 1.22, 1.000, 337, 333, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A TRIAZOLOPYRIMIDINE COMPOUND
128, 3hv5A, 0.9377, 1.55, 0.991, 339, 335, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
129, 3hl7A, 0.9376, 1.16, 0.994, 336, 332, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH SD-0006
130, 4kiqB, 0.9372, 1.28, 0.991, 338, 334, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
131, 1ywrA, 0.9372, 1.39, 0.991, 338, 334, CRYSTAL STRUCTURE ANALYSIS OF INACTIVE P38 KINASE DOMAIN IN COMPLEX WITH A MONOCYCLIC PYRAZOLONE INHIBITOR
132, 3hv6A, 0.9371, 1.15, 0.991, 331, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH RL39
133, 4aa4A, 0.9369, 1.68, 0.985, 347, 335, P38ALPHA MAP KINASE BOUND TO CMPD 22
134, 5o8uA, 0.9368, 1.21, 0.997, 331, 331, COVALENT INHIBITOR 4B BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S252C
135, 4kinA, 0.9366, 1.36, 0.985, 338, 334, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
136, 3mh0A, 0.9366, 1.24, 0.994, 332, 332, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
137, 3o8tA, 0.9365, 1.17, 0.994, 332, 331, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG-MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
138, 3objA, 0.9363, 1.26, 0.991, 332, 332, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
139, 3hp2A, 0.9363, 1.29, 0.997, 341, 333, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIDINONE COMPOUND
140, 3l8sA, 0.9361, 1.22, 0.988, 334, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH CP-547632
141, 4dliA, 0.9357, 1.15, 0.991, 334, 330, HUMAN P38 MAP KINASE IN COMPLEX WITH RL87
142, 4a9yA, 0.9357, 1.03, 0.997, 334, 329, P38ALPHA MAP KINASE BOUND TO CMPD 8
143, 2bakA, 0.9357, 1.03, 0.997, 334, 329, P38ALPHA MAP KINASE BOUND TO MPAQ
144, 3oc1A, 0.9356, 1.14, 0.997, 330, 330, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
145, 3hucA, 0.9356, 1.36, 0.997, 337, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH RL40
146, 3lfeA, 0.9355, 1.22, 0.985, 334, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH RL116
147, 3hv5B, 0.9354, 1.53, 0.991, 339, 335, HUMAN P38 MAP KINASE IN COMPLEX WITH RL24
148, 3bv2A, 0.9349, 1.17, 0.997, 337, 330, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 30
149, 3lfcA, 0.9345, 1.26, 0.985, 334, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH RL99
150, 3lfaA, 0.9345, 1.10, 0.997, 333, 330, HUMAN P38 MAP KINASE IN COMPLEX WITH DASATINIB
151, 5n66A, 0.9343, 1.15, 0.997, 332, 330, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9J
152, 3p79A, 0.9343, 1.23, 0.991, 332, 331, P38 INHIBITOR-BOUND
153, 3zyaA, 0.9341, 1.35, 0.991, 346, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH 2-AMINO-PHENYLAMINO- DIBENZOSUBERONE
154, 3queA, 0.9341, 1.55, 0.991, 343, 334, HUMAN P38 MAP KINASE IN COMPLEX WITH SKEPINONE-L
155, 4kiqC, 0.9340, 1.34, 0.991, 338, 334, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
156, 4ehvA, 0.9340, 1.33, 0.997, 337, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F10 AND RL87
157, 3pg3A, 0.9338, 1.27, 0.982, 337, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH RL182
158, 3p78A, 0.9337, 1.24, 0.991, 332, 331, P38 INHIBITOR-BOUND
159, 5etaA, 0.9336, 1.21, 0.997, 336, 330, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
160, 4kipB, 0.9335, 1.36, 0.991, 338, 334, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
161, 3bv3A, 0.9333, 1.44, 0.997, 338, 333, MORPHOLINO PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 2
162, 5n65A, 0.9331, 1.06, 1.000, 333, 329, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9H
163, 3hv4B, 0.9330, 1.51, 0.991, 338, 334, HUMAN P38 MAP KINASE IN COMPLEX WITH RL51
164, 3iw7A, 0.9329, 1.47, 0.985, 335, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH AN IMIDAZO-PYRIDINE
165, 3iw6A, 0.9328, 1.52, 0.985, 337, 334, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZYLPIPERAZIN- PYRROL
166, 2rg5A, 0.9327, 1.45, 0.997, 333, 333, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11B
167, 3p7bA, 0.9323, 1.27, 0.991, 332, 331, P38 INHIBITOR-BOUND
168, 3uvpA, 0.9321, 1.43, 1.000, 334, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH A BENZAMIDE SUBSTITUTED BENZOSUBERONE
169, 3iw8A, 0.9320, 1.30, 0.982, 334, 332, STRUCTURE OF INACTIVE HUMAN P38 MAP KINASE IN COMPLEX WITH A THIAZOLE-UREA
170, 2ghlA, 0.9319, 1.26, 0.991, 334, 330, MUTANT MUS MUSCULUS P38 KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-874743
171, 6anlA, 0.9318, 1.36, 0.991, 338, 332, STRUCTURE-BASED DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZO[12-B]PYRIDAZINE-BASED P38 MAP KINASE INHIBITORS
172, 3mh2A, 0.9318, 1.18, 0.997, 330, 330, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
173, 3k3jA, 0.9318, 0.96, 0.997, 329, 327, P38ALPHA BOUND TO NOVEL DFG-OUT COMPOUND PF-00416121
174, 3hp5A, 0.9316, 1.16, 1.000, 330, 330, CRYSTAL STRUCTURE OF HUMAN P38ALPHA COMPLEXED WITH A PYRIMIDOPYRIDAZINONE COMPOUND
175, 3lfbA, 0.9313, 1.32, 0.985, 333, 332, HUMAN P38 MAP KINASE IN COMPLEX WITH RL98
176, 3mvlB, 0.9312, 1.46, 1.000, 339, 334, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
177, 4aa5A, 0.9311, 1.72, 0.982, 340, 334, P38ALPHA MAP KINASE BOUND TO CMPD 33
178, 3mh3A, 0.9311, 1.33, 0.994, 334, 331, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
179, 2puuA, 0.9309, 1.29, 0.985, 330, 330, CRYSTAL STRUCTURE OF P38 COMPLEX WITH 1-(5-TERT-BUTYL-2-P- TOLYL-2H-PYRAZOL-3-YL)-3-[4-(6-MORPHOLIN-4-YLMETHYL- PYRIDIN-3-YL)NAPHTHALEN-1-YL]UREA
180, 4kinC, 0.9308, 1.65, 0.997, 338, 336, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
181, 4kipA, 0.9307, 1.36, 0.994, 337, 333, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 2-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-13-THIAZOLE-5-CARBOXAMIDE
182, 3zs5A, 0.9307, 1.40, 0.997, 340, 332, STRUCTURAL BASIS FOR KINASE SELECTIVITY OF THREE CLINICAL P38ALPHA INHIBITORS
183, 3ocgA, 0.9307, 1.36, 1.000, 336, 332, P38 ALPHA KINASE COMPLEXED WITH A 5-AMINO-PYRAZOLE BASED INHIBITOR
184, 2gtnA, 0.9307, 1.61, 0.985, 337, 333, MUTATED MAP KINASE P38 (MUS MUSCULUS) IN COMPLEX WITH INHBITOR PG-951717
185, 3mh1A, 0.9306, 1.40, 0.994, 337, 332, MUTAGENESIS OF P38 MAP KINASE ESTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
186, 3gcuB, 0.9305, 1.49, 0.994, 337, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH RL48
187, 1zyjA, 0.9304, 1.29, 1.000, 331, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1A
188, 3gcsA, 0.9303, 1.21, 0.988, 331, 330, HUMAN P38 MAP KINASE IN COMPLEX WITH SORAFENIB
189, 3k3iA, 0.9302, 1.08, 0.997, 332, 328, P38ALPHA BOUND TO NOVEL DGF-OUT COMPOUND PF-00215955
190, 3tg1A, 0.9301, 1.21, 0.994, 334, 330, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH A MAPK DOCKING PARTNER
191, 3mvlA, 0.9301, 1.51, 0.997, 339, 334, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7K
192, 3p5kA, 0.9299, 1.32, 0.991, 332, 331, P38 INHIBITOR-BOUND
193, 3iw5A, 0.9296, 1.54, 0.979, 336, 333, HUMAN P38 MAP KINASE IN COMPLEX WITH AN INDOLE DERIVATIVE
194, 4aacA, 0.9293, 1.75, 0.985, 350, 334, P38ALPHA MAP KINASE BOUND TO CMPD 29
195, 3obgA, 0.9293, 1.40, 0.994, 332, 332, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MUTANTS IN RESPONSE TO INHIBITOR BINDING
196, 2rg6A, 0.9293, 1.56, 1.000, 335, 335, PHENYLALANINE PYRROLOTRIAZINE P38 ALPHA MAP KINASE INHIBITOR COMPOUND 11J
197, 4eh5A, 0.9292, 0.82, 1.000, 329, 325, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F4 AND RL87
198, 4e5aX, 0.9291, 0.97, 0.991, 332, 326, THE W197A MUTANT OF P38A MAP KINASE
199, 3zsgA, 0.9290, 1.43, 0.997, 337, 332, X-RAY STRUCTURE OF P38ALPHA BOUND TO TAK-715
200, 2ozaB, 0.9290, 1.58, 0.979, 340, 335, STRUCTURE OF P38ALPHA COMPLEX
201, 4kiqA, 0.9289, 1.47, 0.994, 338, 334, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
202, 4lopB, 0.9286, 2.41, 0.994, 350, 345, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
203, 2qd9A, 0.9286, 1.12, 0.997, 330, 328, P38 ALPHA MAP KINASE INHIBITOR BASED ON HETEROBICYCLIC SCAFFOLDS
204, 3hubA, 0.9285, 1.30, 0.988, 335, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH SCIOS-469
205, 3mpaA, 0.9284, 1.26, 0.994, 331, 330, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
206, 4kinD, 0.9283, 1.71, 0.994, 339, 336, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH 5-(2-CHLOROPHENYL)-N-(5-(CYCLOPROPYLCARBAMOYL)-2- METHYLPHENYL)-2-THIOPHENECARBOXAMIDE
207, 3hv7A, 0.9283, 1.22, 0.994, 330, 329, HUMAN P38 MAP KINASE IN COMPLEX WITH RL38
208, 5n64A, 0.9282, 0.96, 0.997, 329, 326, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9G
209, 1kv1A, 0.9282, 1.05, 0.997, 331, 327, P38 MAP KINASE IN COMPLEX WITH INHIBITOR 1
210, 4eh9A, 0.9281, 1.41, 0.994, 334, 330, HUMAN P38 MAP KINASE IN COMPLEX WITH NP-F11 AND RL87
211, 3o8pA, 0.9278, 1.40, 0.994, 336, 331, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
212, 3ctqA, 0.9274, 1.57, 0.985, 336, 332, STRUCTURE OF MAP KINASE P38 IN COMPLEX WITH A 1-O-TOLYL-12 3-TRIAZOLE-4-CARBOXAMIDE
213, 3mgyA, 0.9272, 1.24, 1.000, 329, 329, MUTAGENESIS OF P38 MAP KINASE ESHTABLISHES KEY ROLES OF PHE169 IN FUNCTION AND STRUCTURAL DYNAMICS AND REVEALS A NOVEL DFG-OUT STATE
214, 3gcvA, 0.9271, 1.66, 0.985, 338, 334, HUMAN P38 MAP KINASE IN COMPLEX WITH RL62
215, 5n67A, 0.9269, 0.90, 1.000, 327, 325, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9L
216, 4e6cA, 0.9268, 1.08, 1.000, 330, 327, P38A-PERIFOSINE COMPLEX
217, 3p7cA, 0.9268, 1.39, 0.991, 332, 331, P38 INHIBITOR-BOUND
218, 3nnxA, 0.9268, 1.49, 0.985, 336, 332, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38 ALPHA IN COMPLEX WITH DP802
219, 4kiqD, 0.9261, 1.49, 0.991, 338, 334, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 14 (P38-H5) COMPLEX WITH ETHYL 6-((5-(CYCLOPROPYLCARBAMOYL)-2-METHYLPHENYL) CARBAMOYL)-1H-INDOLE-1-CARBOXYLATE
220, 3uvqA, 0.9260, 1.20, 1.000, 333, 328, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOSUBERONE DERIVATIVE
221, 2gtmA, 0.9258, 1.66, 0.985, 341, 332, MUTATED MOUSE P38 MAP KINASE DOMAIN IN COMPLEX WITH INHIBITOR PG-892579
222, 1zz2A, 0.9253, 1.65, 0.997, 337, 333, TWO CLASSES OF P38ALPHA MAP KINASE INHIBITORS HAVING A COMMON DIPHENYLETHER CORE BUT EXHIBITING DIVERGENT BINDING MODES
223, 5n68A, 0.9252, 1.04, 0.997, 328, 326, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9M
224, 4l8mA, 0.9251, 1.48, 0.994, 339, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH A DIBENZOXEPINONE
225, 4lopD, 0.9250, 2.17, 0.939, 351, 342, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
226, 5n63A, 0.9249, 0.99, 0.997, 325, 324, CRYSTAL STRUCTURE OF P38ALPHA IN COMPLEX WITH LIPID POCKET LIGAND 9C
227, 5etaB, 0.9248, 1.35, 0.997, 335, 330, STRUCTURE OF MAPK14 WITH BOUND THE KIM DOMAIN OF THE TOXOPLASMA PROTEIN GRA24
228, 3p7aA, 0.9245, 1.60, 0.991, 332, 331, P38 INHIBITOR-BOUND
229, 3o8uA, 0.9243, 1.42, 0.994, 332, 331, CONFORMATIONAL PLASTICITY OF P38 MAP KINASE DFG MOTIF MUTANTS IN RESPONSE TO INHIBITOR BINDING
230, 5o8vA, 0.9242, 0.99, 0.997, 328, 325, COVALENT INHIBITOR 4A BOUND TO THE LIPID POCKET OF P38ALPHA MUTANT S251C
231, 3hvcA, 0.9240, 1.04, 1.000, 327, 326, CRYSTAL STRUCTURE OF HUMAN P38ALPHA MAP KINASE
232, 2fslX, 0.9239, 1.16, 0.991, 332, 327, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-A
233, 3lfdA, 0.9238, 1.34, 0.985, 331, 330, HUMAN P38 MAP KINASE IN COMPLEX WITH RL113
234, 2ewaA, 0.9238, 0.92, 0.997, 330, 324, DUAL BINDING MODE OF PYRIDINYLIMIDAZOLE TO MAP KINASE P38
235, 4loqB, 0.9237, 2.35, 0.965, 351, 342, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
236, 4geoA, 0.9236, 1.40, 0.985, 326, 326, P38A MAP KINASE DEF-POCKET PENTA MUTANT (M194A L195A H228A I229A Y258A)
237, 4lopA, 0.9232, 2.16, 0.944, 351, 342, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
238, 4tyhB, 0.9231, 1.43, 0.976, 335, 330, TERNARY COMPLEX OF P38 AND MK2 WITH A P38 INHIBITOR
239, 3zshA, 0.9231, 1.16, 0.997, 331, 327, X-RAY STRUCTURE OF P38ALPHA BOUND TO SCIO-469
240, 3gcpA, 0.9230, 1.47, 0.985, 337, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH SB203580
241, 3gi3A, 0.9229, 1.54, 0.994, 330, 330, CRYSTAL STRUCTURE OF A N-PHENYL-N -NAPHTHYLUREA ANALOG IN COMPLEX WITH P38 MAP KINASE
242, 5mtxA, 0.9224, 1.36, 0.997, 331, 329, DIBENZOOXEPINONE INHIBITOR 12B IN COMPLEX WITH P38 MAPK
243, 4loqD, 0.9220, 2.49, 0.965, 351, 344, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
244, 3hecA, 0.9219, 1.49, 0.997, 329, 329, P38 IN COMPLEX WITH IMATINIB
245, 3mvmA, 0.9209, 1.70, 1.000, 335, 335, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
246, 4loqA, 0.9202, 2.52, 0.994, 352, 345, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
247, 4aa0A, 0.9202, 1.08, 0.997, 328, 324, P38ALPHA MAP KINASE BOUND TO CMPD 2
248, 4lopC, 0.9200, 2.07, 0.985, 341, 335, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM)
249, 2fsmX, 0.9199, 1.19, 0.991, 326, 326, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327S) ACTIVATING MUTANT FORM-B
250, 2npqA, 0.9195, 1.12, 0.994, 326, 325, A NOVEL LIPID BINDING SITE IN THE P38 ALPHA MAP KINASE
251, 5wjjA, 0.9190, 1.36, 0.991, 338, 327, STRUCTURE-BASED DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZO[12-B]PYRIDAZINE-BASED P38 MAP KINASE INHIBITORS
252, 1ianA, 0.9188, 1.04, 0.997, 328, 324, HUMAN P38 MAP KINASE INHIBITOR COMPLEX
253, 4e8aA, 0.9186, 1.09, 0.997, 327, 324, THE CRYSTAL STRUCTURE OF P38A MAP KINASE IN COMPLEX WITH PIA24
254, 5mtyA, 0.9184, 1.38, 1.000, 328, 328, DIBENZOSUBERONE INHIBITOR 8E IN COMPLEX WITH P38 MAPK
255, 4e6aA, 0.9181, 1.09, 1.000, 324, 324, P38A-PIA23 COMPLEX
256, 3lffA, 0.9168, 1.62, 0.988, 335, 331, HUMAN P38 MAP KINASE IN COMPLEX WITH RL166
257, 4e5bA, 0.9167, 1.05, 0.997, 324, 323, STRUCTURE OF P38A MAP KINASE WITHOUT BOG
258, 2fsoX, 0.9163, 1.05, 0.997, 325, 323, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A) ACTIVATING MUTANT
259, 5o90A, 0.9161, 1.23, 0.985, 330, 325, CRYSTAL STRUCTURE OF A P38ALPHA T185G MUTANT IN COMPLEX WITH TAB1 PEPTIDE.
260, 2yisA, 0.9157, 1.21, 0.994, 325, 324, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE.
261, 3oefX, 0.9156, 1.73, 0.985, 334, 329, CRYSTAL STRUCTURE OF Y323F INACTIVE MUTANT OF P38ALPHA MAP KINASE
262, 3mvmB, 0.9153, 1.76, 0.997, 332, 332, P38 ALPHA MAP KINASE COMPLEXED WITH PYRROLOTRIAZINE INHIBITOR 7V
263, 2fstX, 0.9151, 1.17, 0.994, 324, 324, MITOGEN ACTIVATED PROTEIN KINASE P38ALPHA (D176A+F327L) ACTIVATING MUTANT
264, 3l8xA, 0.9133, 1.30, 0.997, 326, 326, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-PYRIMIDINE BASED INHIBITOR
265, 2yiwA, 0.9131, 1.27, 0.994, 325, 324, TRIAZOLOPYRIDINE INHIBITORS OF P38 KINASE
266, 2baqA, 0.9128, 1.58, 0.988, 329, 325, P38ALPHA BOUND TO RO3201195
267, 5ml5A, 0.9120, 1.40, 0.994, 326, 324, HUMAN P38ALPHA MAPK IN COMPLEX WITH IMIDAZOLYL PYRIDINE INHIBITOR 11B
268, 5tcoA, 0.9117, 1.50, 0.994, 327, 327, HUMAN P38 MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 1
269, 3gc8B, 0.9117, 2.35, 0.728, 346, 338, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
270, 1kv2A, 0.9097, 1.07, 0.997, 325, 321, HUMAN P38 MAP KINASE IN COMPLEX WITH BIRB 796
271, 3uvrA, 0.9095, 1.53, 0.988, 331, 327, HUMAN P38 MAP KINASE IN COMPLEX WITH KM064
272, 3s4qA, 0.9093, 1.39, 0.982, 326, 326, P38 ALPHA KINASE COMPLEXED WITH A PYRAZOLO-TRIAZINE BASED INHIBITOR
273, 4loqC, 0.9079, 2.15, 0.982, 337, 332, STRUCTURAL BASIS OF AUTOACTIVATION OF P38 ALPHA INDUCED BY TAB1 (TETRAGONAL CRYSTAL FORM WITH BOUND SULPHATE)
274, 3gc9B, 0.9069, 1.84, 0.716, 339, 331, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
275, 3gc8A, 0.9061, 2.30, 0.704, 347, 338, THE STRUCTURE OF P38BETA C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE
276, 4ynoA, 0.9054, 1.85, 0.595, 342, 333, CRYSTAL STRUCTURE OF MAPK13 AT INACTIVE FORM
277, 3od6X, 0.9025, 2.25, 0.923, 344, 336, CRYSTAL STRUCTURE OF P38ALPHA Y323T ACTIVE MUTANT
278, 2bajA, 0.9022, 1.75, 0.960, 337, 327, P38ALPHA BOUND TO PYRAZOLOUREA
279, 3zsiA, 0.9021, 1.47, 0.988, 326, 322, X-RAY STRUCTURE OF P38ALPHA BOUND TO VX-745
280, 3npcA, 0.9014, 1.98, 0.503, 357, 330, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
281, 4h3bA, 0.8996, 1.94, 0.491, 351, 330, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
282, 5ekoA, 0.8994, 1.91, 0.596, 341, 332, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
283, 4h3bC, 0.8994, 1.94, 0.491, 351, 330, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH SAB PEPTIDE
284, 4h36A, 0.8982, 1.98, 0.491, 353, 330, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH ATF2 PEPTIDE
285, 4eyjA, 0.8981, 1.79, 0.596, 338, 329, MAPK13 COMPLEX WITH INHIBITOR
286, 3npcB, 0.8974, 2.13, 0.515, 356, 330, CRYSTAL STRUCTURE OF JNK2 COMPLEXED WITH BIRB796
287, 3odzX, 0.8970, 2.04, 0.946, 335, 333, CRYSTAL STRUCTURE OF P38ALPHA Y323R ACTIVE MUTANT
288, 4eymA, 0.8961, 1.91, 0.598, 340, 331, MAPK13 COMPLEX WITH INHIBITOR
289, 3gp0A, 0.8958, 2.02, 0.729, 333, 329, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 11 (P38 BETA) IN COMPLEX WITH NILOTINIB
290, 3zu7A, 0.8940, 1.87, 0.480, 344, 327, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE MAP KINASE ERK2
291, 4ic8B, 0.8935, 1.96, 0.442, 336, 330, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
292, 5eknA, 0.8934, 1.77, 0.596, 336, 327, CRYSTAL STRUCTURE OF MAPK13 COMPLEX WITH INHIBITOR
293, 3gc9A, 0.8924, 1.94, 0.726, 335, 328, THE STRUCTURE OF P38BETA C119S C162S IN COMPLEX WITH A DIHYDROQUINAZOLINONE INHIBITOR
294, 4h39A, 0.8911, 1.83, 0.483, 340, 325, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH JIP1 PEPTIDE
295, 5nzzE, 0.8910, 2.32, 0.961, 343, 334, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
296, 5nzzG, 0.8897, 2.31, 0.988, 342, 334, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
297, 3coiA, 0.8873, 2.14, 0.589, 344, 331, CRYSTAL STRUCTURE OF P38DELTA KINASE
298, 5nzzF, 0.8850, 2.32, 0.967, 341, 332, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
299, 5tbeA, 0.8847, 1.99, 0.970, 332, 328, HUMAN P38ALPHA MAP KINASE IN COMPLEX WITH DIBENZOSUBERONE COMPOUND 2
300, 3ptgA, 0.8810, 1.87, 0.492, 340, 325, DESIGN AND SYNTHESIS OF A NOVEL ORALLY EFFICACIOUS TRI-SUBSTITUTED THIOPHENE BASED JNK INHIBITOR
301, 3zuvC, 0.8783, 2.46, 0.483, 357, 329, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
302, 4ic8A, 0.8772, 1.97, 0.451, 325, 324, CRYSTAL STRUCTURE OF THE APO ERK5 KINASE DOMAIN
303, 4o2zA, 0.8765, 2.63, 0.375, 363, 333, CRYSTAL STRUCTURE OF MPK3 FROM LEISHMANIA DONOVANI LDBPK_100540 IN THE PRESENCE OF NVP-BBT594
304, 4mygA, 0.8737, 2.12, 0.613, 335, 323, MAPK13 ACTIVE FORM
305, 3erkA, 0.8734, 2.52, 0.471, 350, 329, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/SB220025
306, 3vugA, 0.8730, 2.62, 0.489, 356, 333, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
307, 3vuiA, 0.8722, 2.53, 0.480, 355, 331, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M2 IN MAP KINASE JNK1
308, 4i5hA, 0.8721, 2.28, 0.483, 335, 325, CRYSTAL STRUCTURE OF A DOUBLE MUTANT RAT ERK2 COMPLEXED WITH A TYPE II QUINAZOLINE INHIBITOR
309, 5lenB, 0.8717, 2.19, 0.472, 346, 326, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX WITH JNK1A1 AND JIP1 PEPTIDE
310, 6f5eB, 0.8716, 2.19, 0.472, 346, 326, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_D12_10_47 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
311, 3vuhA, 0.8715, 2.55, 0.480, 355, 331, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M3 IN MAP KINASE JNK1
312, 3vukA, 0.8713, 2.51, 0.489, 355, 331, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M5 IN MAP KINASE JNK1
313, 4iz5B, 0.8711, 2.27, 0.463, 347, 328, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
314, 4iz5C, 0.8710, 2.28, 0.463, 347, 328, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
315, 4iz5A, 0.8709, 2.28, 0.466, 347, 328, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
316, 3zuvA, 0.8709, 2.60, 0.480, 357, 329, CRYSTAL STRUCTURE OF A DESIGNED SELECTED ANKYRIN REPEAT PROTEIN IN COMPLEX WITH THE PHOSPHORYLATED MAP KINASE ERK2
317, 2erkA, 0.8709, 2.49, 0.482, 351, 328, PHOSPHORYLATED MAP KINASE ERK2
318, 4iz5D, 0.8706, 2.28, 0.463, 347, 328, STRUCTURE OF THE COMPLEX BETWEEN ERK2 PHOSPHOMIMETIC MUTANT AND PEA-15
319, 4mygB, 0.8704, 2.18, 0.598, 335, 323, MAPK13 ACTIVE FORM
320, 4izaA, 0.8700, 2.38, 0.476, 346, 328, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
321, 5nzzH, 0.8699, 2.46, 0.979, 335, 329, CRYSTAL STRUCTURE OF PHOSPHORYLATED P38AMAPK IN COMPLEX WITH TAB1 
322, 1wzyA, 0.8699, 2.46, 0.459, 350, 329, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A PYRAZOLOPYRIDAZINE DERIVATIVE
323, 4ic7A, 0.8691, 2.65, 0.451, 355, 328, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
324, 4b99A, 0.8691, 2.44, 0.452, 335, 325, CRYSTAL STRUCTURE OF MAPK7 (ERK5) WITH INHIBITOR
325, 3vudA, 0.8671, 2.48, 0.491, 355, 330, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
326, 5lw1H, 0.8665, 2.55, 0.473, 355, 332, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
327, 2fysA, 0.8657, 2.54, 0.476, 348, 330, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
328, 4ic7D, 0.8653, 2.64, 0.456, 353, 327, CRYSTAL STRUCTURE OF THE ERK5 KINASE DOMAIN IN COMPLEX WITH AN MKK5 BINDING FRAGMENT
329, 4qp4A, 0.8652, 2.42, 0.486, 337, 327, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
330, 4qp8B, 0.8640, 2.43, 0.480, 337, 327, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
331, 5lw1B, 0.8639, 2.59, 0.473, 355, 332, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
332, 2gmxA, 0.8638, 2.77, 0.470, 357, 332, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
333, 4iz7A, 0.8637, 2.47, 0.477, 344, 327, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
334, 4hysA, 0.8637, 1.62, 0.508, 321, 313, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-(4- INDAZOL-1-YL-PYRIMIDIN-2-YLAMINO)-CYCLOHEXAN
335, 1erkA, 0.8637, 2.63, 0.471, 357, 329, STRUCTURE OF SIGNAL-REGULATED KINASE
336, 5lw1E, 0.8636, 2.68, 0.471, 355, 333, CRYSTAL STRUCTURE OF DARPIN-DARPIN RIGID FUSION VARIANT DD_232_11_D12 IN COMPLEX JNK1A1 AND JIP1 PEPTIDE
337, 4awiA, 0.8636, 2.63, 0.473, 352, 332, HUMAN JNK1ALPHA KINASE WITH 4-PHENYL-7-AZAINDOLE IKK2 INHIBITOR.
338, 2no3A, 0.8636, 2.56, 0.470, 357, 330, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
339, 2gphA, 0.8631, 2.58, 0.477, 345, 329, DOCKING MOTIF INTERACTIONS IN THE MAP KINASE ERK2
340, 4iz7C, 0.8626, 2.32, 0.475, 340, 326, STRUCTURE OF NON-PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
341, 4qp7A, 0.8624, 2.47, 0.483, 337, 327, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
342, 4qp4B, 0.8624, 2.41, 0.482, 335, 326, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
343, 5v61A, 0.8623, 2.48, 0.485, 348, 326, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP2
344, 1golA, 0.8617, 2.68, 0.465, 357, 329, COORDINATES OF RAT MAP KINASE ERK2 WITH AN ARGININE MUTATION AT POSITION 52
345, 2h96A, 0.8610, 2.74, 0.464, 358, 332, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
346, 1ukiA, 0.8602, 1.98, 0.511, 328, 317, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
347, 5byyA, 0.8598, 2.51, 0.461, 338, 323, ERK5 IN COMPLEX WITH SMALL MOLECULE
348, 4qp8A, 0.8596, 2.45, 0.482, 335, 326, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-7- (PYRIDIN-3-YL)-5H-PYRROLO[23-B]PYRAZINE
349, 3v3vA, 0.8593, 2.58, 0.486, 351, 329, STRUCTURAL AND FUNCTIONAL ANALYSIS OF QUERCETAGETIN A NATURAL JNK1 INHIBITOR
350, 3c9wB, 0.8587, 2.45, 0.480, 336, 325, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
351, 4qp7B, 0.8586, 2.45, 0.482, 335, 326, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 2-(1H-PYRAZOL-4-YL)-5H- PYRROLO[23-B]PYRAZINE
352, 3c9wA, 0.8586, 2.35, 0.485, 336, 324, CRYSTAL STRUCTURE OF ERK-2 WITH HYPOTHEMYCIN COVALENTLY BOUND
353, 4qp9A, 0.8584, 2.36, 0.477, 335, 325, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-PROPYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
354, 5nhvA, 0.8582, 2.53, 0.469, 345, 326, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
355, 4g1wA, 0.8581, 1.73, 0.508, 322, 313, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 7-FLUORO-3- [4-(2-HYDROXY-ETHANESULFONYL)-BENZYL]-4-OXO-1-PHENYL-14-DIHYDRO- QUINOLINE-2-CARBOXYLIC ACID METHYL ESTER
356, 5v62A, 0.8579, 2.51, 0.485, 349, 326, PHOSPHO-ERK2 BOUND TO BIVALENT INHIBITOR SBP3
357, 4hyuA, 0.8579, 1.73, 0.508, 322, 313, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-{4-[4-(3- METHANESULFONYL-PROPOXY)-INDAZOL-1-YL]-PYRIMIDIN-2-YLAMINO}- CYCLOHEXAN
358, 4erkA, 0.8579, 2.74, 0.465, 350, 329, THE COMPLEX STRUCTURE OF THE MAP KINASE ERK2/OLOMOUCINE
359, 3o17A, 0.8576, 2.72, 0.471, 357, 331, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
360, 3o2mA, 0.8575, 2.56, 0.479, 358, 330, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
361, 4xrjA, 0.8572, 2.59, 0.471, 344, 325, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
362, 6g97A, 0.8570, 2.62, 0.469, 344, 326, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
363, 4fmqA, 0.8570, 2.71, 0.474, 350, 331, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
364, 3v6sB, 0.8569, 2.33, 0.485, 340, 324, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
365, 6g93A, 0.8564, 2.43, 0.464, 343, 323, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
366, 6eq9A, 0.8561, 2.49, 0.474, 350, 327, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AMP-PCP 
367, 2fysB, 0.8561, 2.48, 0.480, 338, 325, CRYSTAL STRUCTURE OF ERK2 COMPLEX WITH KIM PEPTIDE DERIVED FROM MKP3
368, 5nhhA, 0.8560, 2.64, 0.471, 348, 327, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
369, 4zsjA, 0.8560, 2.70, 0.457, 344, 324, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
370, 3vumA, 0.8560, 2.52, 0.480, 347, 327, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M7 IN MAP KINASE JNK1
371, 4izyA, 0.8558, 1.77, 0.508, 322, 313, CRYSTAL STRUCTURE OF JNK1 IN COMPLEX WITH JIP1 PEPTIDE AND 4-{4-[4-(4- METHANESULFONYL-PIPERIDIN-1-YL)-INDOL-1-YL]-PYRIMIDIN-2-YLAMINO}- CYCLOHEXAN
372, 4s2zA, 0.8553, 2.67, 0.465, 346, 327, ERK2 INTRINSICALLY ACTIVE MUTANT R65S
373, 5hd7A, 0.8550, 2.66, 0.468, 347, 327, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT MUTANT SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
374, 3vulA, 0.8550, 2.39, 0.489, 344, 325, CRYSTAL STRUCTURE OF A CYSTEINE-DEFICIENT MUTANT M1 IN MAP KINASE JNK1
375, 5umoA, 0.8548, 2.68, 0.471, 347, 327, STRUCTURE OF EXTRACELLULAR SIGNAL-REGULATED KINASE
376, 4qtbA, 0.8547, 2.71, 0.463, 351, 328, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
377, 6emhB, 0.8546, 2.44, 0.471, 344, 325, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
378, 4zsgA, 0.8545, 2.87, 0.457, 347, 326, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
379, 4nifB, 0.8545, 2.75, 0.474, 349, 331, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
380, 3v6rB, 0.8544, 2.69, 0.477, 346, 327, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
381, 4xneA, 0.8539, 2.63, 0.471, 344, 325, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
382, 4nifE, 0.8539, 2.73, 0.471, 348, 331, HETERODIMERIC STRUCTURE OF ERK2 AND RSK1
383, 2xs0A, 0.8537, 2.56, 0.482, 346, 328, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
384, 2gmxB, 0.8529, 2.75, 0.468, 357, 331, SELECTIVE AMINOPYRIDINE-BASED C-JUN N-TERMINAL KINASE INHIBITORS WITH CELLULAR ACTIVITY
385, 4gvaA, 0.8525, 2.59, 0.469, 345, 324, ADP-BOUND FORM OF THE ERK2 KINASE
386, 4zzmA, 0.8524, 2.56, 0.469, 344, 324, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
387, 4qtdA, 0.8522, 2.89, 0.461, 355, 334, STRUCTURE OF HUMAN JNK1 IN COMPLEX WITH SCH772984 AND THE AMPPNP- HYDROLYSED TRIPHOSPHATE REVEALING THE SECOND TYPE-I BINDING MODE
388, 3v6sA, 0.8521, 2.53, 0.472, 349, 326, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
389, 1ukhA, 0.8519, 1.68, 0.503, 321, 310, STRUCTURAL BASIS FOR THE SELECTIVE INHIBITION OF JNK1 BY THE SCAFFOLDING PROTEIN JIP1 AND SP600125
390, 4fv7A, 0.8517, 2.57, 0.471, 342, 323, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E94
391, 2h96B, 0.8516, 2.66, 0.467, 357, 330, DISCOVERY OF POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PYRIDINE CARBOXAMIDE C-JUN NH2-TERMINAL KINASE INHIBITORS
392, 5v60A, 0.8515, 2.60, 0.485, 347, 326, PHOSPHO-ERK2 BOUND TO AMP-PCP
393, 5nhlA, 0.8514, 2.62, 0.469, 345, 326, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
394, 3o2mB, 0.8514, 2.67, 0.473, 358, 330, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM COMPLEX WITH A BIARYL TETRAZOL (A-82118)
395, 2g01A, 0.8513, 2.66, 0.468, 355, 329, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
396, 4h3qA, 0.8511, 2.82, 0.470, 352, 332, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
397, 4qtbB, 0.8508, 2.75, 0.460, 348, 328, STRUCTURE OF HUMAN ERK1 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
398, 2no3B, 0.8508, 2.78, 0.467, 357, 330, NOVEL 4-ANILINOPYRIMIDINES AS POTENT JNK1 INHIBITORS
399, 6g9aA, 0.8506, 2.62, 0.469, 341, 322, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
400, 4gt3A, 0.8505, 2.69, 0.469, 347, 326, ATP-BOUND FORM OF THE ERK2 KINASE
401, 4fuxA, 0.8505, 2.57, 0.467, 342, 323, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E75
402, 2y9qA, 0.8503, 2.79, 0.479, 349, 330, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
403, 5nhjA, 0.8502, 2.72, 0.471, 345, 327, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
404, 6g9jA, 0.8501, 2.81, 0.471, 347, 327, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
405, 5ax3A, 0.8501, 2.47, 0.480, 329, 321, CRYSTAL STRUCTURE OF ERK2 COMPLEXED WITH ALLOSTERIC AND ATP- COMPETITIVE INHIBITORS.
406, 6g9dA, 0.8497, 2.75, 0.466, 345, 326, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
407, 6emhA, 0.8497, 2.65, 0.469, 344, 326, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
408, 2zoqA, 0.8497, 2.67, 0.472, 351, 326, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
409, 3v6rA, 0.8495, 2.58, 0.483, 349, 327, DISCOVERY OF POTENT AND SELECTIVE COVALENT INHIBITORS OF JNK
410, 4x21B, 0.8493, 2.21, 0.494, 336, 320, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
411, 4y5hA, 0.8491, 2.74, 0.483, 349, 329, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
412, 4xozA, 0.8491, 2.62, 0.471, 341, 323, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
413, 4e73A, 0.8491, 1.78, 0.513, 318, 310, CRYSTAL STRUCTURE OF JNK1BETA-JIP IN COMPLEX WITH AN AZAQUINOLONE INHBITOR
414, 4s31A, 0.8490, 2.75, 0.465, 347, 327, CRYSTAL STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE 1 WTERK2 AT 1.45A
415, 5o7iA, 0.8486, 2.60, 0.464, 340, 319, ERK5 IN COMPLEX WITH A PYRROLE INHIBITOR 
416, 4qteA, 0.8482, 2.75, 0.471, 348, 327, STRUCTURE OF ERK2 IN COMPLEX WITH VTX-11E 4-{2-[(2-CHLORO-4- FLUOROPHENYL)AMINO]-5-METHYLPYRIMIDIN-4-YL}-N-[(1S)-1-(3- CHLOROPHENYL)-2-HYDROXYETHYL]-1H-PYRROLE-2-CARBOXAMIDE
417, 5hd4A, 0.8481, 2.75, 0.468, 347, 327, DISSECTING THERAPEUTIC RESISTANCE TO ERK INHIBITION RAT WILD TYPE SCH772984 IN COMPLEX WITH (3R)-1-(2-OXO-2-{4-[4-(PYRIMIDIN-2-YL) PHENYL]PIPERAZIN-1-YL}ETHYL)-N-[3-(PYRIDIN-4-YL)-2H-INDAZOL-5- YL]PYRROLIDINE-3-CARBOXAMIDE
418, 4l7fA, 0.8480, 2.64, 0.465, 354, 329, CO-CRYSTAL STRUCTURE OF JNK1 AND AX13587
419, 4izaC, 0.8479, 2.37, 0.478, 335, 322, STRUCTURE OF DUALLY PHOSPHORYLATED ERK2 BOUND TO THE PEA-15 DEATH EFFECTOR DOMAIN
420, 4fv3A, 0.8478, 2.74, 0.466, 346, 326, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK6
421, 4zslA, 0.8477, 2.71, 0.458, 341, 321, MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR
422, 5lcjA, 0.8476, 2.74, 0.463, 345, 326, IN-GEL ACTIVITY-BASED PROTEIN PROFILING OF A CLICKABLE COVALENT ERK 1/2 INHIBITOR
423, 4fv6A, 0.8476, 2.35, 0.477, 332, 321, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E57
424, 3pg1A, 0.8475, 2.33, 0.348, 341, 319, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR (1.95 ANGS RESOLUTION)
425, 6g9hA, 0.8474, 2.67, 0.463, 343, 324, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
426, 6ge0A, 0.8473, 2.67, 0.466, 343, 324, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
427, 3i60A, 0.8471, 2.54, 0.474, 335, 323, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-4-(2-(2-CHLOROPHENYLAMINO)-5- METHYLPYRIMIDIN-4-YL)-N-(2-HYDROXY-1-PHENYLETHYL)-1H-PYRROLE-2- CARBOXAMIDE
428, 6g91A, 0.8468, 2.79, 0.465, 344, 325, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
429, 6g9kA, 0.8467, 2.68, 0.466, 343, 324, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
430, 3pzeA, 0.8466, 2.69, 0.474, 347, 329, JNK1 IN COMPLEX WITH INHIBITOR
431, 5nhoA, 0.8465, 2.73, 0.466, 343, 326, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
432, 3o17B, 0.8461, 2.87, 0.468, 357, 331, CRYSTAL STRUCTURE OF JNK1-ALPHA1 ISOFORM
433, 4o6eA, 0.8459, 2.30, 0.478, 328, 318, DISCOVERY OF 5678-TETRAHYDROPYRIDO[34-D]PYRIMIDINE INHIBITORS OF ERK2
434, 4s30A, 0.8458, 2.67, 0.466, 342, 324, ERK2 INTRINSICALLY ACTIVE MUTANT (I84A)
435, 5bveA, 0.8456, 2.42, 0.481, 330, 320, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
436, 4h3pA, 0.8456, 2.53, 0.471, 342, 325, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
437, 4gsbA, 0.8456, 2.73, 0.471, 343, 325, MONOCLINIC CRYSTAL FORM OF THE APO-ERK2
438, 1tvoA, 0.8456, 2.91, 0.468, 350, 329, THE STRUCTURE OF ERK2 IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
439, 5lckA, 0.8453, 2.73, 0.468, 345, 325, A CLICKABLE COVALENT ERK 1/2 INHIBITOR
440, 3odyX, 0.8453, 2.36, 0.972, 321, 320, CRYSTAL STRUCTURE OF P38ALPHA Y323Q ACTIVE MUTANT
441, 5byzA, 0.8449, 2.95, 0.455, 348, 325, ERK5 IN COMPLEX WITH SMALL MOLECULE
442, 4qtaA, 0.8449, 2.55, 0.481, 335, 324, STRUCTURE OF HUMAN ERK2 IN COMPLEX WITH SCH772984 REVEALING A NOVEL INHIBITOR-INDUCED BINDING POCKET
443, 4fv8A, 0.8449, 2.57, 0.471, 333, 323, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E63
444, 4ux9A, 0.8447, 2.40, 0.470, 343, 321, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
445, 4kkhA, 0.8443, 2.95, 0.482, 351, 332, THE CRYSTAL STRUCTURE OF INHIBITOR-BOUND JNK3
446, 3sa0A, 0.8443, 2.78, 0.466, 354, 326, COMPLEX OF ERK2 WITH NORATHYRIOL
447, 4x21A, 0.8442, 2.27, 0.487, 336, 320, THE MAP KINASE JNK3 AS TARGET FOR HALOGEN BONDING
448, 2g01B, 0.8442, 2.78, 0.468, 356, 329, PYRAZOLOQUINOLONES AS NOVEL SELECTIVE JNK1 INHIBITORS
449, 2zoqB, 0.8441, 2.69, 0.474, 351, 325, STRUCTURAL DISSECTION OF HUMAN MITOGEN-ACTIVATED KINASE ERK1
450, 5awmA, 0.8440, 2.81, 0.473, 345, 328, THE CRYSTAL STRUCTURE OF JNK FROM DROSOPHILA MELANOGASTER REVEALS AN EVOLUTIONARILY CONSERVED TOPOLOGY WITH THAT OF MAMMALIAN JNK PROTEINS.
451, 4kkgA, 0.8435, 2.91, 0.473, 353, 332, CRYSTAL STRUCTURE OF APO AND AMP-BOUND JNK3
452, 4g6oA, 0.8435, 2.64, 0.469, 339, 322, CRYSTAL STRUCTURE OF THE ERK2
453, 4s34A, 0.8433, 2.75, 0.465, 343, 325, ERK2 (I84A) IN COMPLEX WITH AMP-PNP
454, 5ci6B, 0.8432, 2.70, 0.463, 350, 326, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
455, 4qp1B, 0.8432, 2.64, 0.472, 343, 322, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
456, 4ux9C, 0.8431, 2.38, 0.484, 333, 320, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
457, 4zzoA, 0.8430, 2.55, 0.472, 339, 320, HUMAN ERK2 IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR
458, 6g9nA, 0.8429, 2.66, 0.464, 344, 323, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
459, 4n4sA, 0.8427, 2.75, 0.460, 342, 328, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
460, 4s33A, 0.8426, 2.83, 0.462, 347, 327, ERK2 R65S MUTANT COMPLEXED WITH AMP-PNP
461, 5u6iA, 0.8423, 2.65, 0.483, 339, 321, DISCOVERY OF MLI-2 AN ORALLY AVAILABLE AND SELECTIVE LRRK2 INHIBITOR THAT REDUCES BRAIN KINASE ACTIVITY
462, 4xrlA, 0.8421, 2.56, 0.470, 337, 319, CRYSTAL STRUCTURE AT ROOM TEMPERATURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
463, 4qpaB, 0.8421, 2.62, 0.463, 345, 322, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
464, 4kkeA, 0.8420, 2.95, 0.467, 354, 332, THE CRYSTAL STRUCTURE OF AMP-BOUND JNK3
465, 5bvdA, 0.8417, 2.37, 0.480, 330, 319, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
466, 2b9iA, 0.8415, 2.47, 0.445, 338, 321, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM MSG5
467, 6g9mA, 0.8414, 2.71, 0.467, 341, 323, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
468, 1pmuA, 0.8414, 2.50, 0.486, 342, 323, THE CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PHENANTROLINE INHIBITOR
469, 4qp3A, 0.8411, 2.55, 0.474, 339, 321, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
470, 4fv2A, 0.8411, 2.78, 0.465, 344, 325, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK5
471, 4fv0A, 0.8411, 2.64, 0.474, 341, 321, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK3
472, 3qywA, 0.8411, 2.58, 0.475, 340, 320, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
473, 3w55A, 0.8410, 2.63, 0.469, 335, 324, THE STRUCTURE OF ERK2 IN COMPLEX WITH FR148083
474, 4zznA, 0.8409, 2.56, 0.469, 338, 320, HUMAN ERK2 IN COMPLEX WITH AN INHIBITOR
475, 4xj0A, 0.8409, 2.51, 0.469, 345, 320, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
476, 2ojiA, 0.8409, 2.71, 0.477, 344, 323, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
477, 2b9hA, 0.8409, 2.48, 0.445, 337, 321, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM STE7
478, 3r63A, 0.8408, 2.80, 0.465, 347, 325, STRUCTURE OF ERK2 (SPE) MUTANT (S246E)
479, 2wajA, 0.8406, 3.06, 0.480, 348, 333, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH A 1-ARYL-34- DIHYDROISOQUINOLINE INHIBITOR
480, 4fv9A, 0.8403, 2.54, 0.474, 331, 321, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH E71
481, 4n4sB, 0.8401, 2.60, 0.466, 337, 324, A DOUBLE MUTANT RAT ERK2 IN COMPLEX WITH A PYRAZOLO[34-D]PYRIMIDINE INHIBITOR
482, 4s32A, 0.8399, 2.85, 0.459, 346, 327, CRYSTAL STRUCTURE OF ERK2 AMP-PNP COMPLEX
483, 5ke0A, 0.8398, 2.69, 0.483, 340, 321, DISCOVERY OF 1-1H-PYRAZOLO 43-C PYRIDINE-6-YL UREA INHIBITORS OF EXTRACELLULAR SIGNAL REGULATED KINASE ERK FOR THE TREATMENT OF CANCERS
484, 4qp6A, 0.8397, 2.46, 0.469, 339, 320, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
485, 3e7oA, 0.8397, 2.69, 0.506, 342, 322, CRYSTAL STRUCTURE OF JNK2
486, 3cgfA, 0.8397, 2.80, 0.473, 346, 328, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
487, 3teiA, 0.8396, 2.57, 0.475, 339, 324, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
488, 2b9jA, 0.8396, 2.71, 0.449, 337, 323, CRYSTAL STRUCTURE OF FUS3 WITH A DOCKING MOTIF FROM FAR1
489, 3g9nA, 0.8392, 2.95, 0.480, 346, 331, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-PHENYLINDOLIN-2-ONE
490, 5k4iA, 0.8389, 2.57, 0.486, 336, 323, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH COMPOUND 22
491, 4xp3A, 0.8388, 2.66, 0.472, 339, 320, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
492, 3g90X, 0.8388, 2.81, 0.477, 345, 329, JNK-3 BOUND TO (Z)-5-FLUORO-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL) METHYL)-3-(HYDROXYIMINO)INDOLIN-2-ONE
493, 4qnyB, 0.8386, 2.67, 0.388, 339, 322, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
494, 4fv4A, 0.8386, 2.51, 0.475, 329, 320, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK7
495, 6gdmA, 0.8385, 2.81, 0.467, 341, 323, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
496, 5bvfA, 0.8384, 2.36, 0.476, 327, 317, TETRAHYDROPYRROLO-DIAZEPENONES AS INHIBITORS OF ERK2 KINASE
497, 6emhC, 0.8383, 2.38, 0.489, 334, 319, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
498, 5nguA, 0.8383, 2.62, 0.464, 339, 321, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
499, 4g6nA, 0.8379, 2.68, 0.470, 341, 321, CRYSTAL STRUCTURE OF THE ERK2
500, 2f49B, 0.8379, 2.73, 0.448, 337, 324, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
501, 4n0sA, 0.8377, 2.77, 0.467, 348, 323, COMPLEX OF ERK2 WITH CAFFEIC ACID
502, 2ojjA, 0.8374, 2.79, 0.467, 344, 323, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-N-(1-(3- CHLORO-4-FLUOROPHENYL)-2-HYDROXYETHYL)-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
503, 5buiA, 0.8371, 2.50, 0.474, 338, 321, ERK2 COMPLEXED WITH 2-PYRIDIYL TETRAHYDROAZAINDAZOLE
504, 1pmnA, 0.8371, 2.83, 0.480, 344, 327, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE- PYRIMIDINE INHIBITOR
505, 5nhfA, 0.8369, 2.64, 0.464, 339, 321, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
506, 4xp2A, 0.8368, 2.58, 0.461, 337, 319, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
507, 4zxtA, 0.8367, 2.81, 0.460, 348, 324, COMPLEX OF ERK2 WITH CATECHOL
508, 3oxiA, 0.8365, 1.88, 0.495, 322, 309, DESIGN AND SYNTHESIS OF DISUBSTITUTED THIOPHENE AND THIAZOLE BASED INHIBITORS OF JNK FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
509, 1jnkA, 0.8365, 2.99, 0.479, 346, 330, THE C-JUN N-TERMINAL KINASE (JNK3S) COMPLEXED WITH MGAMP-PNP
510, 5nhpA, 0.8359, 2.61, 0.469, 338, 320, HUMAN ERK2 WITH AN ERK1/2 INHIBITOR
511, 4qyyA, 0.8359, 2.58, 0.470, 337, 319, DISCOVERY OF NOVEL DUAL MECHANISM ERK INHIBITORS BY AFFINITY SELECTION SCREENING OF AN INACTIVE KINASE STATE
512, 6gdqA, 0.8356, 2.59, 0.464, 339, 319, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
513, 2f49A, 0.8354, 2.70, 0.444, 335, 322, CRYSTAL STRUCTURE OF FUS3 IN COMPLEX WITH A STE5 PEPTIDE
514, 4u79A, 0.8353, 2.52, 0.489, 337, 321, CRYSTAL STRUCTURE OF HUMAN JNK3 IN COMPLEX WITH A BENZENESULFONAMIDE INHIBITOR.
515, 6g8xA, 0.8352, 2.64, 0.475, 338, 318, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
516, 4w4wA, 0.8352, 2.86, 0.473, 349, 328, JNK2/3 IN COMPLEX WITH N-(2-METHYLPYRIDIN-4-YL)-3-{4- [(PHENYLCARBAMOYL)AMINO]-1H-PYRAZOL-1-YL}BENZAMIDE
517, 6g92A, 0.8350, 2.91, 0.466, 343, 324, FRAGMENT-BASED DISCOVERY OF A HIGHLY POTENT; ORALLY BIOAVAILABLE INHIBITOR WHICH MODULATES THE PHOSPHORYLATION AND CATALYTIC ACTIVITY OF ERK1/2 
518, 5bujA, 0.8350, 2.48, 0.480, 331, 319, ERK2 COMPLEXED WITH A N-H TETRAHYDROAZAINDAZOLE
519, 3i5zA, 0.8345, 2.61, 0.477, 331, 321, CRYSTAL STRUCTURE OF ERK2 BOUND TO (S)-N-(2-HYDROXY-1-PHENYLETHYL)-4- (5-METHYL-2-(PHENYLAMINO)PYRIMIDIN-4-YL)-1H-PYRROLE-2-CARBOXAMIDE
520, 4fv1A, 0.8341, 2.84, 0.463, 342, 324, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK4
521, 3eljA, 0.8340, 2.89, 0.466, 347, 328, JNK1 COMPLEXED WITH A BIS-ANILINO-PYRROLOPYRIMIDINE INHIBITOR.
522, 4xp0A, 0.8331, 2.66, 0.475, 336, 318, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
523, 2fa2A, 0.8331, 2.62, 0.447, 333, 320, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
524, 3e7oB, 0.8329, 2.12, 0.518, 326, 313, CRYSTAL STRUCTURE OF JNK2
525, 4qp1A, 0.8327, 2.52, 0.473, 342, 317, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH N-CYCLOHEXYL-9H-PURIN-6- AMINE
526, 6eq9B, 0.8324, 2.25, 0.491, 332, 316, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH AMP-PCP 
527, 2b9fA, 0.8324, 2.83, 0.453, 337, 322, CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED FUS3
528, 3rtpA, 0.8313, 2.37, 0.494, 331, 318, DESIGN AND SYNTHESIS OF BRAIN PENETRANT SELECTIVE JNK INHIBITORS WITH IMPROVED PHARMACOKINETIC PROPERTIES FOR THE PREVENTION OF NEURODEGENERATION
529, 2zdtA, 0.8313, 2.84, 0.483, 342, 325, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
530, 4fv5A, 0.8312, 2.51, 0.476, 330, 319, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK9
531, 4qp2A, 0.8310, 2.50, 0.465, 336, 318, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
532, 4h3pD, 0.8310, 2.57, 0.474, 338, 321, CRYSTAL STRUCTURE OF HUMAN ERK2 COMPLEXED WITH A MAPK DOCKING PEPTIDE
533, 4ux9D, 0.8304, 2.78, 0.449, 344, 325, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
534, 5wp1A, 0.8298, 2.76, 0.475, 340, 320, COMPLEX OF ERK2 WITH 5;7-DIHYDROXYCHROMONE 
535, 3qyzA, 0.8294, 2.60, 0.472, 339, 318, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
536, 5bueA, 0.8289, 2.51, 0.478, 329, 318, ERK2 COMPLEXED WITH N-BENZYLPYRIDONE TETRAHYDROAZAINDAZOLE
537, 4ux9B, 0.8287, 2.40, 0.484, 327, 314, CRYSTAL STRUCTURE OF JNK1 BOUND TO A MKK7 DOCKING MOTIF
538, 2f9gA, 0.8286, 2.47, 0.454, 332, 317, CRYSTAL STRUCTURE OF FUS3 PHOSPHORYLATED ON TYR182
539, 1pmeA, 0.8283, 2.54, 0.490, 333, 314, STRUCTURE OF PENTA MUTANT HUMAN ERK2 MAP KINASE COMPLEXED WITH A SPECIFIC INHIBITOR OF HUMAN P38 MAP KINASE
540, 4qp6B, 0.8282, 2.86, 0.473, 334, 319, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 5H-PYRROLO[23-B]PYRAZINE
541, 3ohtB, 0.8281, 2.81, 0.805, 331, 318, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
542, 2fa2B, 0.8277, 2.67, 0.442, 332, 319, CRYSTAL STRUCTURE OF FUS3 WITHOUT A PEPTIDE FROM STE5
543, 3ohtA, 0.8276, 2.83, 0.805, 331, 318, CRYSTAL STRUCTURE OF SALMO SALAR P38ALPHA
544, 3g9lX, 0.8271, 2.76, 0.488, 336, 324, JNK3 BOUND TO (Z)-1-((6-FLUORO-4H-BENZO[D][13]DIOXIN-8-YL)METHYL)-3- (HYDROXYIMINO)-4-STYRYLINDOLIN-2-ONE
545, 4xj0B, 0.8269, 2.61, 0.465, 338, 316, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR 14K
546, 5ci6A, 0.8267, 2.63, 0.459, 335, 318, CRYSTAL STRUCTURE OF ARABIDOPSIS THALIANA MPK6
547, 2excX, 0.8260, 2.59, 0.483, 335, 321, INHIBITOR COMPLEX OF JNK3
548, 4yr8A, 0.8258, 2.15, 0.510, 320, 308, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
549, 4y46A, 0.8255, 2.76, 0.491, 340, 320, PYRIDOPYRIMIDINONE DERIVATIVES AS POTENT AND SELECTIVE C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
550, 2xrwA, 0.8254, 2.79, 0.485, 348, 324, LINEAR BINDING MOTIFS FOR JNK AND FOR CALCINEURIN ANTAGONISTICALLY CONTROL THE NUCLEAR SHUTTLING OF NFAT4
551, 3ttiA, 0.8250, 2.92, 0.483, 341, 325, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-930 AN ORALLY ACTIVE ANTI-FIBROTIC JNK INHIBITOR
552, 3oy1A, 0.8250, 2.38, 0.491, 329, 316, HIGHLY SELECTIVE C-JUN N-TERMINAL KINASE (JNK) 2 AND 3 INHIBITORS WITH IN VITRO CNS-LIKE PHARMACOKINETIC PROPERTIES
553, 3o71A, 0.8250, 3.00, 0.466, 340, 328, CRYSTAL STRUCTURE OF ERK2/DCC PEPTIDE COMPLEX
554, 4qnyA, 0.8248, 2.66, 0.391, 333, 317, CRYSTAL STRUCTURE OF MAPK FROM LEISHMANIA DONOVANI LDBPK_331470
555, 4whzA, 0.8247, 2.93, 0.486, 342, 325, DESIGN AND SYNTHESIS OF HIGHLY POTENT AND ISOFORM SELECTIVE JNK3 INHIBITORS: SAR STUDIES ON AMINOPYRAZOLE DERIVATIVES
556, 2z7lA, 0.8243, 2.58, 0.482, 329, 313, UNPHOSPHORYLATED MITOGEN ACTIVATED PROTEIN KINASE ERK2 IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN 2-YL]AMINO}PHENYL)ACETIC ACID
557, 4w4yA, 0.8234, 2.98, 0.486, 350, 325, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-METHYLPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
558, 1cm8B, 0.8226, 2.81, 0.599, 327, 319, PHOSPHORYLATED MAP KINASE P38-GAMMA
559, 1cm8A, 0.8225, 2.81, 0.599, 327, 319, PHOSPHORYLATED MAP KINASE P38-GAMMA
560, 4yr8C, 0.8224, 2.01, 0.482, 318, 305, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
561, 3nieA, 0.8221, 3.08, 0.367, 369, 327, CRYSTAL STRUCTURE OF PF11_0147
562, 3fv8A, 0.8213, 2.36, 0.489, 331, 313, JNK3 BOUND TO PIPERAZINE AMIDE INHIBITOR SR2774.
563, 4qp3B, 0.8210, 2.69, 0.478, 331, 314, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH (S)-2-((9H-PURIN-6-YL) AMINO)-3-PHENYLPROPAN-1-OL
564, 2ojgA, 0.8207, 2.74, 0.473, 337, 317, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH NN-DIMETHYL-4-(4- PHENYL-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
565, 6emhD, 0.8204, 2.45, 0.486, 331, 315, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
566, 4qp2B, 0.8194, 2.83, 0.479, 329, 315, CRYSTAL STRUCTURE OF ERKS IN COMPLEX WITH 5-CHLOROBENZO[D]OXAZOL-2- AMINE
567, 3oz6A, 0.8190, 2.84, 0.375, 343, 315, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
568, 4z9lA, 0.8181, 2.71, 0.489, 333, 319, THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR
569, 4qpaA, 0.8179, 2.90, 0.468, 331, 316, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH 7-(1-BENZYL-1H-PYRAZOL-4- YL)-2-(PYRIDIN-4-YL)-5H-PYRROLO[23-B]PYRAZINE
570, 1pmvA, 0.8170, 3.08, 0.470, 347, 328, THE STRUCTURE OF JNK3 IN COMPLEX WITH A DIHYDROANTHRAPYRAZOLE INHIBITOR
571, 6ekdA, 0.8168, 2.18, 0.494, 325, 308, CRYSTAL STRUCTURE OF JNK3 IN COMPLEX WITH A PYRIDINYLIMIDAZOLE INHIBITOR 
572, 4xoyA, 0.8168, 2.29, 0.485, 326, 307, CRYSTAL STRUCTURE OF ERK2 IN COMPLEX WITH AN INHIBITOR
573, 4w4xA, 0.8148, 3.03, 0.483, 342, 321, JNK2/3 IN COMPLEX WITH 3-(4-{[(4-FLUOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
574, 3fi2A, 0.8145, 2.58, 0.486, 326, 313, CRYSTAL STRUCTURE OF JNK3 WITH AMINO-PYRAZOLE INHIBITOR SR- 3451
575, 3nieB, 0.8136, 3.07, 0.358, 367, 324, CRYSTAL STRUCTURE OF PF11_0147
576, 4w4vA, 0.8134, 2.83, 0.483, 342, 319, JNK2/3 IN COMPLEX WITH 3-(4-{[(2-CHLOROPHENYL)CARBAMOYL]AMINO}-1H- PYRAZOL-1-YL)-N-(2-METHYLPYRIDIN-4-YL)BENZAMIDE
577, 4fuyA, 0.8133, 2.59, 0.476, 329, 309, CRYSTAL STRUCTURE OF THE ERK2 COMPLEXED WITH EK2
578, 2b1pA, 0.8131, 2.61, 0.492, 331, 317, INHIBITOR COMPLEX OF JNK3
579, 3fi3A, 0.8123, 2.56, 0.484, 328, 314, CRYSTAL STRUCTURE OF JNK3 WITH INDAZOLE INHIBITOR SR-3737
580, 3cgoA, 0.8120, 2.77, 0.489, 332, 315, IRAK-4 INHIBITORS (PART II)- A STRUCTURE BASED ASSESSMENT OF IMIDAZO[12 A]PYRIDINE BINDING
581, 3kvxA, 0.8114, 2.45, 0.497, 327, 310, JNK3 BOUND TO AMINOPYRIMIDINE INHIBITOR SR-3562
582, 3ttjA, 0.8110, 2.74, 0.483, 333, 317, CRYSTAL STRUCTURE OF JNK3 COMPLEXED WITH CC-359 A JNK INHIBITOR FOR THE PREVENTION OF ISCHEMIA-REPERFUSION INJURY
583, 2p33A, 0.8110, 2.79, 0.489, 332, 315, SYNTHESIS AND SAR OF AMINOPYRIMIDINES AS NOVEL C-JUN N- TERMINAL KINASE (JNK) INHIBITORS
584, 2ok1A, 0.8104, 2.81, 0.495, 333, 319, CRYSTAL STRUCTURE OF JNK3 BOUND TO N-BENZYL-4-(4-(3- CHLOROPHENYL)-1H-PYRAZOL-3-YL)-1H-PYRROLE-2-CARBOXAMIDE
585, 6dcgA, 0.8100, 2.61, 0.469, 326, 309, DISCOVERY OF MK-8353: AN ORALLY BIOAVAILABLE DUAL MECHANISM ERK INHIBITOR FOR ONCOLOGY 
586, 2zduA, 0.8078, 2.58, 0.486, 330, 313, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH AN ISOQUINOLONE INHIBITOR
587, 3uibA, 0.8077, 2.27, 0.360, 309, 303, MAP KINASE LMAMPK10 FROM LEISHMANIA MAJOR IN COMPLEX WITH SB203580
588, 3rp9A, 0.8070, 2.82, 0.358, 350, 316, CRYSTAL STRUCTURE OF THE APO MAPK FROM TOXOPLASMA GONDII 25.M01780 OR TGME49_007820
589, 2r9sB, 0.8070, 2.36, 0.497, 325, 308, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
590, 3da6A, 0.8062, 2.59, 0.500, 328, 312, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-METHYL- 4-(3-(2-(METHYLAMINO)PYRIMIDIN-4-YL)PYRIDIN-2-YLOXY) NAPHTHALEN-1-YL)-1H-BENZO[D]IMIDAZOL-2-AMINE
591, 4yr8E, 0.8054, 2.29, 0.510, 317, 304, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
592, 6cpwA, 0.8053, 2.73, 0.471, 328, 310, DISCOVERY OF 3(S)-THIOMETHYL PYRROLIDINE ERK INHIBITORS FOR ONCOLOGY 
593, 2o0uA, 0.8042, 2.80, 0.494, 331, 314, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-{3-CYANO-6-[3-(1- PIPERIDINYL)PROPANOYL]-4567-TETRAHYDROTHIENO[23-C]PYRIDIN-2-YL}- 1-NAPHTHALENECARBOXAMIDE
594, 3n9xB, 0.8030, 3.15, 0.375, 374, 323, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
595, 2r9sA, 0.8016, 2.44, 0.497, 325, 308, C-JUN N-TERMINAL KINASE 3 WITH 35-DISUBSTITUTED QUINOLINE INHIBITOR
596, 3n9xA, 0.8005, 3.16, 0.368, 374, 323, CRYSTAL STRUCTURE OF MAP KINASE FROM PLASMODIUM BERGHEI PB000659.00.0
597, 3oz6B, 0.7985, 3.14, 0.373, 341, 316, CRYSTAL STRUCTURE OF MAPK FROM CRYPTOSPORIDIUM PARVUM CGD2_1960
598, 2o2uA, 0.7913, 2.51, 0.502, 319, 305, CRYSTAL STRUCTURE OF HUMAN JNK3 COMPLEXED WITH N-(3-CYANO-4567- TETRAHYDRO-1-BENZOTHIEN-2-YL)-2-FLUOROBENZAMIDE
599, 4yr8F, 0.7794, 1.86, 0.470, 300, 287, CRYSTAL STRUCTURE OF JNK IN COMPLEX WITH A REGULATOR PROTEIN
600, 1j1cB, 0.7490, 3.07, 0.306, 364, 288, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
601, 1j1bB, 0.7483, 3.10, 0.306, 364, 288, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
602, 5airB, 0.7481, 3.00, 0.301, 361, 286, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
603, 3i4bA, 0.7474, 2.95, 0.308, 359, 286, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
604, 5airA, 0.7473, 2.90, 0.306, 353, 284, STRUCTURAL ANALYSIS OF MOUSE GSK3BETA FUSED WITH LRP6 PEPTIDE.
605, 1r0eB, 0.7468, 2.88, 0.311, 344, 283, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
606, 1r0eA, 0.7460, 2.87, 0.307, 344, 283, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH 3-INDOLYL-4- ARYLMALEIMIDE INHIBITOR
607, 1h8fB, 0.7455, 2.90, 0.311, 350, 283, GLYCOGEN SYNTHASE KINASE 3 BETA.
608, 2jd5B, 0.7454, 3.45, 0.266, 360, 293, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
609, 1h8fA, 0.7454, 2.89, 0.311, 352, 283, GLYCOGEN SYNTHASE KINASE 3 BETA.
610, 4nm0A, 0.7450, 2.94, 0.305, 356, 285, CRYSTAL STRUCTURE OF PEPTIDE INHIBITOR-FREE GSK-3/AXIN COMPLEX
611, 4achA, 0.7442, 2.99, 0.310, 350, 284, GSK3B IN COMPLEX WITH INHIBITOR
612, 4nm5A, 0.7441, 3.01, 0.301, 361, 286, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 C-MOTIF
613, 1q97B, 0.7440, 3.48, 0.266, 361, 293, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
614, 4achB, 0.7438, 2.91, 0.307, 350, 283, GSK3B IN COMPLEX WITH INHIBITOR
615, 3sd0A, 0.7435, 2.95, 0.307, 350, 283, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
616, 4acdB, 0.7433, 3.01, 0.313, 350, 284, GSK3B IN COMPLEX WITH INHIBITOR
617, 4accA, 0.7433, 3.02, 0.310, 350, 284, GSK3B IN COMPLEX WITH INHIBITOR
618, 4acdA, 0.7432, 3.03, 0.306, 350, 284, GSK3B IN COMPLEX WITH INHIBITOR
619, 1q99B, 0.7429, 3.47, 0.270, 364, 293, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
620, 4nm7A, 0.7427, 3.04, 0.304, 355, 286, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED WNT RECEPTOR LRP6 E-MOTIF
621, 1j1cA, 0.7427, 2.97, 0.307, 354, 283, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH ADP
622, 1q8zB, 0.7425, 3.42, 0.267, 364, 292, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
623, 4accB, 0.7423, 3.01, 0.310, 350, 284, GSK3B IN COMPLEX WITH INHIBITOR
624, 4nm3A, 0.7420, 3.00, 0.302, 357, 285, CRYSTAL STRUCTURE OF GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N- TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
625, 4acgA, 0.7418, 3.04, 0.310, 350, 284, GSK3B IN COMPLEX WITH INHIBITOR
626, 3sd0B, 0.7417, 2.97, 0.307, 349, 283, IDENTIFICATION OF A GLYCOGEN SYNTHASE KINASE-3B INHIBITOR THAT ATTENUATES HYPERACTIVITY IN CLOCK MUTANT MICE
627, 5kpkA, 0.7416, 2.81, 0.310, 346, 281, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
628, 1j1bA, 0.7416, 2.98, 0.307, 354, 283, BINARY COMPLEX STRUCTURE OF HUMAN TAU PROTEIN KINASE I WITH AMPPNP
629, 4nu1A, 0.7414, 3.06, 0.304, 356, 286, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE GSK-3/AXIN COMPLEX BOUND TO PHOSPHORYLATED N-TERMINAL AUTO-INHIBITORY PS9 PEPTIDE
630, 3pupB, 0.7414, 3.02, 0.307, 347, 283, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
631, 3pupA, 0.7414, 3.02, 0.307, 346, 283, STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OS1)
632, 4acgB, 0.7413, 2.99, 0.307, 350, 283, GSK3B IN COMPLEX WITH INHIBITOR
633, 1q8yB, 0.7413, 3.45, 0.271, 357, 292, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
634, 4b7tA, 0.7412, 3.06, 0.306, 350, 284, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND LEUCETTINE L4
635, 5f94A, 0.7410, 2.96, 0.307, 346, 283, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
636, 5f94B, 0.7406, 2.95, 0.311, 349, 283, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 15: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-METHOXYPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
637, 2jldB, 0.7405, 3.03, 0.311, 349, 283, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
638, 3i4bB, 0.7403, 3.01, 0.311, 347, 283, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH A PYRIMIDYLPYRROLE INHIBITOR
639, 5kpkB, 0.7398, 2.76, 0.311, 344, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0209
640, 3m1sB, 0.7398, 3.05, 0.311, 349, 283, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
641, 2jldA, 0.7397, 3.02, 0.311, 349, 283, EXTREMELY TIGHT BINDING OF RUTHENIUM COMPLEX TO GLYCOGEN SYNTHASE KINASE 3
642, 5kpmB, 0.7387, 2.85, 0.313, 345, 281, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
643, 4e7wA, 0.7386, 2.89, 0.335, 359, 281, STRUCTURE OF GSK3 FROM USTILAGO MAYDIS
644, 4pteB, 0.7377, 2.91, 0.312, 347, 282, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
645, 1q41B, 0.7377, 2.84, 0.311, 343, 280, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
646, 5kpmA, 0.7376, 2.77, 0.311, 344, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD3731
647, 4ptcB, 0.7374, 3.02, 0.311, 347, 283, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
648, 1o9uA, 0.7372, 2.83, 0.318, 349, 280, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE
649, 4cxaC, 0.7370, 3.31, 0.304, 330, 289, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
650, 3zdiA, 0.7370, 2.89, 0.313, 348, 281, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH AXIN PEPTIDE AND INHIBITOR 7D
651, 2ow3B, 0.7370, 2.84, 0.311, 351, 280, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
652, 4ptcA, 0.7369, 3.04, 0.311, 342, 283, STRUCTURE OF A CARBOXAMIDE COMPOUND (3) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-OXO-4H-1LAMBDA~4~3-THIAZOLE-5-CARBOXAMIDE) TO GSK3B
653, 4pteA, 0.7358, 2.98, 0.313, 341, 281, STRUCTURE OF A CARVOXAMIDE COMPOUND (15) (N-[4-(ISOQUINOLIN-7-YL) PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) TO GSK3B
654, 3m1sA, 0.7358, 2.95, 0.313, 348, 281, STRUCTURE OF RUTHENIUM HALF-SANDWICH COMPLEX BOUND TO GLYCOGEN SYNTHASE KINASE 3
655, 3sayB, 0.7357, 2.83, 0.311, 347, 280, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
656, 5hlnA, 0.7355, 2.86, 0.307, 346, 280, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
657, 4j71B, 0.7352, 2.78, 0.315, 347, 279, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
658, 3zrlA, 0.7351, 2.88, 0.314, 345, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
659, 3zrmA, 0.7350, 2.86, 0.314, 344, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
660, 1q8zA, 0.7345, 3.59, 0.271, 354, 292, THE APOENZYME STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P
661, 5oy4A, 0.7343, 2.96, 0.309, 349, 282, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
662, 4j71A, 0.7340, 2.84, 0.314, 347, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 1R
663, 5f95A, 0.7339, 2.98, 0.314, 345, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
664, 2ow3A, 0.7337, 2.68, 0.313, 346, 278, GLYCOGEN SYNTHASE KINASE-3 BETA IN COMPLEX WITH BIS- (INDOLE)MALEIMIDE PYRIDINOPHANE INHIBITOR
665, 3zrkB, 0.7335, 2.96, 0.310, 348, 281, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
666, 5hvyA, 0.7334, 2.76, 0.323, 335, 282, CDK8/CYCC IN COMPLEX WITH COMPOUND 20
667, 3zrkA, 0.7334, 2.90, 0.314, 345, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
668, 4j1rA, 0.7331, 2.85, 0.314, 343, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
669, 4j1rD, 0.7330, 2.86, 0.314, 345, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
670, 3zrlB, 0.7330, 2.87, 0.314, 347, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK-3BETA INHIBITORS
671, 1gngA, 0.7329, 2.97, 0.309, 348, 282, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
672, 2bpmA, 0.7328, 2.60, 0.379, 302, 277, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
673, 1q99A, 0.7327, 3.55, 0.271, 354, 291, CRYSTAL STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINSAE SKY1P COMPLEXED WITH THE NON-HYDROLYZABLE ATP ANALOGUE AMP-PNP
674, 3zrmB, 0.7326, 2.87, 0.314, 347, 280, IDENTIFICATION OF 2-(4-PYRIDYL)THIENOPYRIDINONES AS GSK- 3BETA INHIBITORS
675, 4j1rC, 0.7325, 2.88, 0.314, 344, 280, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
676, 5oy4B, 0.7321, 3.15, 0.306, 353, 284, GSK3BETA COMPLEX WITH N-(6-(34-DIHYDROXYPHENYL)-1H-PYRAZOLO[34- B]PYRIDIN-3-YL)ACETAMIDE
677, 3q3bB, 0.7320, 2.93, 0.313, 341, 278, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
678, 1q3dB, 0.7319, 2.98, 0.317, 339, 278, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
679, 3q3bA, 0.7317, 2.87, 0.317, 344, 278, 6-AMINO-4-(PYRIMIDIN-4-YL)PYRIDONES: NOVEL GLYCOGEN SYNTHASE KINASE-3 INHIBITORS
680, 1q3wA, 0.7315, 2.86, 0.317, 344, 278, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
681, 5hlnB, 0.7312, 2.83, 0.315, 346, 279, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021
682, 1q3wB, 0.7308, 2.94, 0.317, 341, 278, GSK-3 BETA COMPLEXED WITH ALSTERPAULLONE
683, 1uv5A, 0.7306, 3.21, 0.310, 348, 284, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH 6-BROMOINDIRUBIN-3 -OXIME
684, 1f5qA, 0.7304, 2.39, 0.372, 296, 274, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
685, 4j1rB, 0.7303, 2.87, 0.315, 346, 279, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH INHIBITOR 15R
686, 5lxdB, 0.7300, 3.03, 0.311, 385, 286, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
687, 1q5kA, 0.7300, 3.05, 0.314, 345, 280, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
688, 2wxvA, 0.7299, 2.65, 0.372, 302, 277, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
689, 1q3dA, 0.7299, 2.86, 0.315, 339, 276, GSK-3 BETA COMPLEXED WITH STAUROSPORINE
690, 2o5kA, 0.7298, 3.04, 0.306, 350, 281, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A BENZOIMIDAZOL INHIBITOR
691, 6fyrA, 0.7297, 3.45, 0.260, 355, 289, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CPD-2 AT 1.42A 
692, 2wihA, 0.7297, 2.64, 0.375, 302, 277, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
693, 5acbD, 0.7295, 3.19, 0.310, 319, 284, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
694, 5lxdA, 0.7294, 3.05, 0.311, 385, 286, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 1610 (COMPOUND 2)
695, 3sayA, 0.7293, 2.88, 0.309, 347, 278, CRYSTAL STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE 3 BETA (GSK3B) IN COMPLEX WITH INHIBITOR 142
696, 1i09B, 0.7291, 2.97, 0.317, 341, 278, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
697, 4yc3A, 0.7290, 2.36, 0.357, 295, 272, CDK1/CYCLINB1/CKS2 APO
698, 1w98A, 0.7286, 2.61, 0.380, 297, 276, THE STRUCTURAL BASIS OF CDK2 ACTIVATION BY CYCLIN E
699, 1howA, 0.7285, 3.46, 0.272, 346, 287, THE X-RAY CRYSTAL STRUCTURE OF SKY1P AN SR PROTEIN KINASE IN YEAST
700, 1vywA, 0.7284, 2.68, 0.375, 302, 277, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
701, 1gngB, 0.7276, 3.14, 0.310, 355, 284, GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3) COMPLEX WITH FRATTIDE PEPTIDE
702, 2c4gA, 0.7273, 2.79, 0.381, 301, 278, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
703, 6gn1A, 0.7272, 2.77, 0.315, 339, 276, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
704, 3f88B, 0.7267, 2.74, 0.315, 340, 276, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
705, 2wpaA, 0.7267, 2.72, 0.375, 302, 277, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
706, 2bpmC, 0.7267, 2.65, 0.382, 299, 275, STRUCTURE OF CDK2-CYCLIN A WITH PHA-630529
707, 5acbC, 0.7266, 3.35, 0.312, 324, 285, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
708, 3f88A, 0.7265, 2.74, 0.315, 340, 276, GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR COMPLEX
709, 4cfwA, 0.7264, 2.59, 0.380, 299, 274, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
710, 4afjA, 0.7264, 2.91, 0.314, 342, 277, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
711, 5kplB, 0.7261, 2.85, 0.319, 339, 276, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
712, 2i6lA, 0.7261, 2.86, 0.371, 292, 280, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
713, 1pyxA, 0.7260, 2.96, 0.317, 343, 278, GSK-3 BETA COMPLEXED WITH AMP-PNP
714, 2jd5A, 0.7258, 3.53, 0.263, 353, 289, SKY1P BOUND TO NPL3P-DERIVED SUBSTRATE PEPTIDE
715, 1q4lA, 0.7258, 2.95, 0.315, 342, 276, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
716, 1finA, 0.7258, 2.60, 0.380, 298, 274, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
717, 5kplA, 0.7257, 2.76, 0.314, 339, 274, GLYCOGEN SYNTHASE KINASE 3 BETA COMPLEXED WITH BRD0705
718, 2wipA, 0.7256, 2.67, 0.380, 297, 276, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
719, 6gn1B, 0.7255, 2.80, 0.312, 339, 276, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 BETA (GSK3B) IN COMPLEX WITH PIK-75 
720, 3du8B, 0.7254, 2.90, 0.315, 339, 276, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
721, 3du8A, 0.7254, 2.82, 0.316, 336, 275, CRYSTAL STRUCTURE OF GSK-3 BETA IN COMPLEX WITH NMS-869553A
722, 5hlpA, 0.7253, 2.73, 0.316, 337, 275, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
723, 2bkzA, 0.7253, 2.77, 0.379, 302, 277, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
724, 1pkdA, 0.7250, 2.51, 0.381, 296, 273, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
725, 2i40C, 0.7246, 2.62, 0.383, 296, 274, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
726, 4cfwC, 0.7244, 2.57, 0.380, 297, 274, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
727, 3gb2A, 0.7244, 2.90, 0.314, 340, 277, GSK3BETA INHIBITOR COMPLEX
728, 1h24A, 0.7244, 2.47, 0.379, 293, 272, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
729, 5fgkA, 0.7243, 2.67, 0.332, 331, 277, CDK8-CYCC IN COMPLEX WITH 8-[3-(3-AMINO-1H-INDAZOL-6-YL)-5-CHLORO- PYRIDINE-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
730, 3f5xC, 0.7243, 2.61, 0.380, 298, 274, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
731, 2wxvC, 0.7242, 2.69, 0.378, 299, 275, STRUCTURE OF CDK2-CYCLIN A WITH A PYRAZOLO(43-H) QUINAZOLINE-3-CARBOXAMIDE INHIBITOR
732, 5if1A, 0.7241, 2.54, 0.381, 298, 273, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
733, 4cfxA, 0.7240, 2.56, 0.381, 298, 273, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
734, 4cfvA, 0.7240, 2.66, 0.378, 300, 275, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
735, 2wihC, 0.7239, 2.68, 0.378, 299, 275, STRUCTURE OF CDK2-CYCLIN A WITH PHA-848125
736, 2iw6C, 0.7237, 2.50, 0.381, 295, 273, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
737, 1pyxB, 0.7237, 2.95, 0.315, 338, 276, GSK-3 BETA COMPLEXED WITH AMP-PNP
738, 5cyiA, 0.7236, 2.56, 0.381, 298, 273, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
739, 4cxaA, 0.7236, 3.29, 0.308, 329, 286, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLIN K COMPLEX BOUND TO AMPPNP
740, 4cfnA, 0.7235, 2.50, 0.382, 296, 272, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
741, 4bcmC, 0.7235, 2.52, 0.381, 294, 273, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
742, 2c4gC, 0.7235, 2.76, 0.377, 300, 276, STRUCTURE OF CDK2-CYCLIN A WITH PHA-533514
743, 4cfuA, 0.7234, 2.63, 0.372, 299, 274, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
744, 6b8jA, 0.7233, 2.96, 0.315, 344, 279, CO-STRUCTURE OF HUMAN GLYCOGEN SYNTHASE KINASE BETA WITH A SELECTIVE (5-IMIDAZOL-2-YL-4-PHENYLPYRIMIDIN-2-YL)[2-(2-PYRIDYLAMINO) ETHYL]AMINE INHIBITOR
745, 1okvA, 0.7233, 2.63, 0.376, 295, 274, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
746, 1h27A, 0.7233, 2.49, 0.379, 296, 272, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
747, 1finC, 0.7233, 2.66, 0.380, 298, 274, CYCLIN A-CYCLIN-DEPENDENT KINASE 2 COMPLEX
748, 5lqeA, 0.7232, 2.54, 0.381, 295, 273, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
749, 4bcnC, 0.7231, 2.58, 0.380, 295, 274, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
750, 4afjB, 0.7231, 2.95, 0.307, 346, 277, 5-ARYL-4-CARBOXAMIDE-13-OXAZOLES: POTENT AND SELECTIVE GSK-3 INHIBITORS
751, 1h28C, 0.7231, 2.65, 0.376, 296, 274, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
752, 5nevA, 0.7229, 2.56, 0.381, 295, 273, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
753, 5aikC, 0.7229, 2.88, 0.281, 342, 278, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
754, 5aikB, 0.7229, 2.88, 0.281, 342, 278, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
755, 1h26A, 0.7228, 2.55, 0.377, 296, 273, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
756, 1h1rA, 0.7228, 2.54, 0.381, 296, 273, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
757, 1fvvC, 0.7228, 2.63, 0.380, 298, 274, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
758, 4bcmA, 0.7227, 2.51, 0.382, 295, 272, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
759, 1vywC, 0.7227, 2.71, 0.378, 299, 275, STRUCTURE OF CDK2/CYCLIN A WITH PNU-292137
760, 1h25A, 0.7227, 2.50, 0.379, 293, 272, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
761, 5lqeC, 0.7226, 2.56, 0.381, 296, 273, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
762, 2wmbA, 0.7226, 2.56, 0.377, 296, 273, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
763, 4eooC, 0.7225, 2.61, 0.376, 297, 274, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
764, 1ol2A, 0.7225, 2.63, 0.376, 296, 274, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
765, 5nevC, 0.7224, 2.56, 0.381, 296, 273, CDK2/CYCLIN A IN COMPLEX WITH COMPOUND 73
766, 5l2wA, 0.7224, 2.71, 0.377, 297, 276, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK2/CYCLINE AND DINACICLIB.
767, 4cfmA, 0.7224, 2.50, 0.382, 296, 272, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
768, 1q97A, 0.7224, 3.45, 0.269, 351, 286, THE STRUCTURE OF THE SACCHAROMYCES CEREVISIAE SR PROTEIN KINASE SKY1P WITH BOUND ATP
769, 1oi9C, 0.7223, 2.51, 0.377, 296, 273, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
770, 1h1sA, 0.7222, 2.57, 0.381, 296, 273, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
771, 5hbjA, 0.7221, 2.94, 0.325, 342, 280, CDK8-CYCC IN COMPLEX WITH 8-[2-AMINO-3-CHLORO-5-(1-METHYL-1H-INDAZOL- 5-YL)-PYRIDIN-4-YL]-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
772, 5cyiC, 0.7221, 2.55, 0.381, 296, 273, CDK2/CYCLIN A COVALENT COMPLEX WITH 6-(CYCLOHEXYLMETHOXY)-N-(4- (VINYLSULFONYL)PHENYL)-9H-PURIN-2-AMINE (NU6300)
773, 4bcpA, 0.7221, 2.51, 0.382, 298, 272, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
774, 1pkdC, 0.7221, 2.57, 0.381, 296, 273, THE CRYSTAL STRUCTURE OF UCN-01 IN COMPLEX WITH PHOSPHO- CDK2/CYCLIN A
775, 1h28A, 0.7221, 2.56, 0.377, 296, 273, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P107
776, 4cfnC, 0.7220, 2.66, 0.378, 296, 275, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
777, 1okwA, 0.7220, 2.58, 0.377, 296, 273, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
778, 1e9hC, 0.7220, 2.57, 0.377, 296, 273, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
779, 5aikA, 0.7219, 2.90, 0.281, 344, 278, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
780, 2v22A, 0.7219, 2.65, 0.383, 296, 274, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
781, 1h1qA, 0.7219, 2.56, 0.381, 296, 273, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
782, 5if1C, 0.7218, 2.66, 0.383, 296, 274, CRYSTAL STRUCTURE APO CDK2/CYCLIN A
783, 3f7zB, 0.7218, 2.79, 0.316, 339, 275, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
784, 1h1rC, 0.7218, 2.56, 0.381, 296, 273, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6086
785, 5a4tA, 0.7217, 2.89, 0.282, 341, 277, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
786, 2uueA, 0.7217, 2.66, 0.383, 296, 274, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
787, 1oi9A, 0.7217, 2.53, 0.382, 295, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
788, 4iq6B, 0.7216, 2.81, 0.322, 332, 273, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
789, 4f6wA, 0.7215, 2.58, 0.331, 330, 275, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 1 (N-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-4-[2-({[3-TERT-BUTYL- 1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]CARBAMOYL}AMINO)ETHYL]PIPERAZINE- 1-CARBOXAMIDE)
790, 3f5xA, 0.7215, 2.61, 0.377, 297, 273, CDK-2-CYCLIN COMPLEX WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
791, 1blxA, 0.7215, 3.10, 0.331, 305, 281, P19INK4D/CDK6 COMPLEX
792, 5hq0A, 0.7214, 2.51, 0.347, 292, 274, TERNARY COMPLEX OF HUMAN PROTEINS CDK1 CYCLIN B AND CKS2 BOUND TO AN INHIBITOR
793, 4y72A, 0.7214, 2.51, 0.347, 292, 274, HUMAN CDK1/CYCLINB1/CKS2 WITH INHIBITOR
794, 4bcoA, 0.7212, 2.61, 0.381, 298, 273, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
795, 2wmaA, 0.7212, 2.58, 0.377, 296, 273, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
796, 2g9xA, 0.7212, 2.59, 0.381, 298, 273, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
797, 1oguA, 0.7212, 2.52, 0.382, 296, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
798, 1jstA, 0.7212, 2.33, 0.383, 297, 269, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
799, 2wfyA, 0.7211, 2.59, 0.377, 295, 273, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
800, 2jgzA, 0.7211, 2.48, 0.384, 288, 271, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 IN COMPLEX WITH CYCLIN B
801, 3rgfA, 0.7210, 2.75, 0.335, 321, 278, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC
802, 2iw8A, 0.7210, 2.58, 0.381, 297, 273, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
803, 5a3xA, 0.7209, 2.92, 0.281, 342, 278, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
804, 1p5eC, 0.7209, 2.59, 0.381, 296, 273, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
805, 1h1sC, 0.7209, 2.58, 0.381, 296, 273, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6102
806, 3anrA, 0.7208, 2.93, 0.281, 342, 278, HUMAN DYRK1A/HARMINE COMPLEX
807, 4nctA, 0.7207, 2.88, 0.282, 341, 277, HUMAN DYRK1A IN COMPLEX WITH PKC412
808, 2c5nC, 0.7206, 2.65, 0.383, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
809, 3tnwA, 0.7205, 2.43, 0.385, 295, 270, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
810, 3bhvA, 0.7205, 2.53, 0.382, 297, 272, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
811, 2bkzC, 0.7205, 2.76, 0.375, 298, 275, STRUCTURE OF CDK2-CYCLIN A WITH PHA-404611
812, 1ol1A, 0.7205, 2.68, 0.376, 296, 274, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
813, 1oiuA, 0.7205, 2.53, 0.382, 296, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
814, 5aikD, 0.7204, 2.88, 0.282, 342, 277, HUMAN DYRK1A IN COMPLEX WITH LDN-211898
815, 2eu9A, 0.7204, 3.39, 0.268, 345, 284, CRYSTAL STRUCTURE OF CLK3
816, 4yc6G, 0.7203, 2.57, 0.347, 285, 274, CDK1/CKS1
817, 4nctD, 0.7203, 2.89, 0.278, 331, 277, HUMAN DYRK1A IN COMPLEX WITH PKC412
818, 4bcnA, 0.7203, 2.49, 0.384, 296, 271, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
819, 3k2lA, 0.7203, 3.24, 0.308, 402, 286, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2)
820, 3eocC, 0.7203, 2.50, 0.384, 293, 271, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
821, 2wpaC, 0.7203, 2.77, 0.378, 299, 275, OPTIMISATION OF 66-DIMETHYL PYRROLO 34-C PYRAZOLES: IDENTIFICATION OF PHA-793887 A POTENT CDK INHIBITOR SUITABLE FOR INTRAVENOUS DOSING
822, 1h24C, 0.7202, 2.61, 0.381, 293, 273, CDK2/CYCLIN A IN COMPLEX WITH A 9 RESIDUE RECRUITMENT PEPTIDE FROM E2F
823, 1fvvA, 0.7202, 2.67, 0.376, 298, 274, THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
824, 3kvwA, 0.7201, 3.14, 0.323, 403, 285, CRYSTAL STRUCTURE OF DUAL-SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 2 (DYRK2) IN COMPLEX WITH AN INDIRUBIN LIGAND
825, 3ddpA, 0.7201, 2.60, 0.381, 297, 273, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
826, 5hlpB, 0.7200, 2.69, 0.320, 335, 272, X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937
827, 3dogA, 0.7200, 2.56, 0.382, 297, 272, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
828, 2wipC, 0.7200, 2.72, 0.380, 292, 274, STRUCTURE OF CDK2-CYCLIN A COMPLEXED WITH 8-ANILINO-1- METHYL-45-DIHYDRO-1H-PYRAZOLO[43-H] QUINAZOLINE-3- CARBOXYLIC ACID
829, 1oiyC, 0.7200, 2.60, 0.381, 296, 273, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
830, 3bhtA, 0.7199, 2.54, 0.379, 297, 272, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
831, 3bhuA, 0.7198, 2.55, 0.379, 297, 272, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
832, 1e9hA, 0.7198, 2.51, 0.376, 295, 271, THR 160 PHOSPHORYLATED CDK2 - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR INDIRUBIN-5-SULPHONATE BOUND
833, 5a3xB, 0.7197, 2.95, 0.281, 340, 278, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
834, 3anqA, 0.7197, 2.95, 0.281, 342, 278, HUMAN DYRK1A/INHIBITOR COMPLEX
835, 2wevC, 0.7197, 2.58, 0.385, 296, 273, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
836, 3my5A, 0.7196, 2.50, 0.376, 296, 271, CDK2/CYCLINA IN COMPLEX WITH DRB
837, 4eomA, 0.7194, 2.56, 0.375, 296, 272, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
838, 4eokC, 0.7194, 2.72, 0.378, 299, 275, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
839, 2whbA, 0.7194, 2.63, 0.385, 296, 273, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
840, 1h1qC, 0.7194, 2.59, 0.381, 296, 273, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU6094
841, 5lxcB, 0.7193, 3.21, 0.305, 385, 285, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
842, 1urcA, 0.7193, 2.68, 0.383, 296, 274, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
843, 4un0C, 0.7192, 2.97, 0.318, 308, 277, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
844, 4eoqA, 0.7192, 2.50, 0.380, 295, 271, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
845, 4cfxC, 0.7191, 2.61, 0.381, 298, 273, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6-CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
846, 3eocA, 0.7190, 2.52, 0.384, 295, 271, CDK2/CYCLINA COMPLEXED WITH A IMIDAZO TRIAZIN-2-AMINE
847, 2c5oA, 0.7190, 2.69, 0.383, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
848, 6ft7B, 0.7189, 3.23, 0.246, 356, 284, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
849, 2c5xA, 0.7189, 2.69, 0.383, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
850, 5hbeA, 0.7188, 2.89, 0.333, 344, 279, CDK8-CYCC IN COMPLEX WITH 8-[3-CHLORO-5-(1-METHYL-22-DIOXO-2 3- DIHYDRO-1H-2L6-BENZO[C]ISOTHIAZOL-5-YL)-PYRIDIN- 4-YL]-1-OXA-38- DIAZA-SPIRO[4.5]DECAN-2-ONE
851, 4f7nA, 0.7188, 2.67, 0.330, 334, 276, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 11 (1- [3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(5- HYDROXYPENTYL)UREA)
852, 3f7zA, 0.7188, 2.83, 0.319, 339, 273, X-RAY CO-CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3BETA IN COMPLEX WITH AN INHIBITOR
853, 5lmkA, 0.7187, 2.53, 0.384, 296, 271, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
854, 5bnjA, 0.7187, 2.88, 0.338, 343, 278, CDK8/CYCC IN COMPLEX WITH 8-{3-CHLORO-5-[4-(1-METHYL-1H-PYRAZOL-4-YL)- PHENYL]-PYRIDIN- 4-YL}-28-DIAZA-SPIRO[4.5]DECAN-1-ONE
855, 3ddpC, 0.7187, 2.64, 0.381, 298, 273, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR CR8
856, 1oiyA, 0.7187, 2.45, 0.385, 293, 270, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
857, 6ft7A, 0.7186, 3.25, 0.246, 356, 284, CRYSTAL STRUCTURE OF CLK3 IN COMPLEX WITH COMPOUND 8A 
858, 5a4lA, 0.7186, 2.93, 0.282, 341, 277, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
859, 2v22C, 0.7186, 2.63, 0.385, 296, 273, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
860, 4bcqA, 0.7185, 2.67, 0.377, 292, 273, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
861, 4bckA, 0.7185, 2.75, 0.380, 298, 274, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
862, 2iw6A, 0.7185, 2.46, 0.385, 292, 270, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
863, 2x1nA, 0.7184, 2.70, 0.383, 296, 274, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
864, 2cciA, 0.7184, 2.58, 0.375, 296, 272, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
865, 2c5oC, 0.7184, 2.69, 0.383, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
866, 1q8yA, 0.7184, 3.39, 0.270, 351, 285, THE STRUCTURE OF THE YEAST SR PROTEIN KINASE SKY1P WITH BOUND ADP
867, 1q4lB, 0.7184, 2.98, 0.314, 337, 274, GSK-3 BETA COMPLEXED WITH INHIBITOR I-5
868, 3ddqA, 0.7183, 2.54, 0.384, 296, 271, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
869, 2uueC, 0.7183, 2.65, 0.385, 296, 273, REPLACE: A STRATEGY FOR ITERATIVE DESIGN OF CYCLIN BINDING GROOVE INHIBITORS
870, 2c5nA, 0.7183, 2.70, 0.380, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND  INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
871, 5a3xD, 0.7182, 2.92, 0.282, 331, 277, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
872, 2wfyC, 0.7182, 2.64, 0.377, 296, 273, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
873, 1q5kB, 0.7182, 3.08, 0.314, 344, 277, CRYSTAL STRUCTURE OF GLYCOGEN SYNTHASE KINASE 3 IN COMPLEXED WITH INHIBITOR
874, 1okwC, 0.7182, 2.63, 0.377, 296, 273, CYCLIN A BINDING GROOVE INHIBITOR AC-ARG-ARG-LEU-ASN-(M-CL-PHE)-NH2
875, 5a54A, 0.7181, 2.94, 0.282, 341, 277, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
876, 5a4qA, 0.7181, 2.95, 0.282, 341, 277, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
877, 2whbC, 0.7181, 2.65, 0.385, 296, 273, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
878, 2cchA, 0.7181, 2.65, 0.377, 296, 273, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
879, 1ol1C, 0.7181, 2.61, 0.385, 296, 273, CYCLIN A BINDING GROOVE INHIBITOR H-CIT-CIT-LEU-ILE-(P-F-PHE)-NH2
880, 1gy3C, 0.7181, 2.59, 0.375, 295, 272, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
881, 6b3eA, 0.7180, 3.06, 0.317, 309, 278, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
882, 2c5vC, 0.7180, 2.69, 0.383, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
883, 2c5vA, 0.7180, 2.69, 0.380, 296, 274, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
884, 1p5eA, 0.7180, 2.50, 0.376, 296, 271, THE STRUCTURE OF PHOSPHO-CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMOBENZOTRIAZOLE (TBS)
885, 4crlA, 0.7179, 2.80, 0.335, 339, 278, CRYSTAL STRUCTURE OF HUMAN CDK8-CYCLIN C IN COMPLEX WITH CORTISTATIN A
886, 3anrB, 0.7179, 3.00, 0.281, 342, 278, HUMAN DYRK1A/HARMINE COMPLEX
887, 2i40A, 0.7179, 2.25, 0.386, 291, 267, CDK2/CYCLIN A COMPLEXED WITH A THIOPHENE CARBOXAMIDE INHIBITOR
888, 4yc6C, 0.7178, 2.60, 0.347, 285, 274, CDK1/CKS1
889, 4nctB, 0.7178, 2.95, 0.282, 333, 277, HUMAN DYRK1A IN COMPLEX WITH PKC412
890, 4f7jA, 0.7178, 2.74, 0.326, 326, 276, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 3 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-(2-HYDROXYETHYL) UREA)
891, 4f6uA, 0.7178, 2.78, 0.325, 334, 277, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 5 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[3-(MORPHOLIN-4-YL) PROPYL]UREA)
892, 2cjmC, 0.7178, 2.54, 0.384, 294, 271, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
893, 5a4eA, 0.7177, 2.94, 0.282, 341, 277, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
894, 4fx3A, 0.7177, 2.66, 0.381, 298, 273, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
895, 5icpA, 0.7176, 2.98, 0.335, 343, 281, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (5-METHYL-IMIDAZO[51-B][134]THIADIAZOL-2-YL)-METHANONE
896, 4bckC, 0.7176, 2.65, 0.377, 293, 273, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
897, 2x1nC, 0.7176, 2.72, 0.383, 296, 274, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
898, 1q41A, 0.7176, 2.88, 0.318, 339, 274, GSK-3 BETA COMPLEXED WITH INDIRUBIN-3 -MONOXIME
899, 5ztnB, 0.7175, 3.20, 0.312, 395, 285, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
900, 3tnwC, 0.7175, 2.59, 0.382, 291, 272, STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH CAN508
901, 1ol2C, 0.7174, 2.62, 0.385, 296, 273, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ASN-(P-F-PHE)-NH2
902, 2wevA, 0.7173, 2.72, 0.383, 296, 274, TRUNCATION AND OPTIMISATION OF PEPTIDE INHIBITORS OF CDK2 CYCLIN A THROUGH STRUCTURE GUIDED DESIGN
903, 5idpA, 0.7172, 2.89, 0.335, 342, 278, CDK8-CYCC IN COMPLEX WITH (3-AMINO-1H-INDAZOL-5-YL)-[(S)-2-(4-FLUORO- PHENYL)-PIPERIDIN-1-YL]-METHANONE
904, 5a4tB, 0.7172, 2.96, 0.282, 339, 277, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
905, 5a4qB, 0.7172, 2.97, 0.282, 335, 277, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
906, 4ptgA, 0.7172, 2.88, 0.322, 333, 273, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
907, 4eooA, 0.7172, 2.47, 0.378, 294, 270, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
908, 2c5xC, 0.7172, 2.64, 0.385, 296, 273, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
909, 1gy3A, 0.7172, 2.61, 0.379, 295, 272, PCDK2/CYCLIN A IN COMPLEX WITH MGADP NITRATE AND PEPTIDE SUBSTRATE
910, 4nstA, 0.7171, 3.24, 0.317, 322, 281, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
911, 3anqB, 0.7171, 3.01, 0.281, 343, 278, HUMAN DYRK1A/INHIBITOR COMPLEX
912, 6b3eC, 0.7170, 2.90, 0.319, 307, 276, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLINK IN COMPLEX WITH AN INHIBITOR
913, 5lxcA, 0.7170, 3.16, 0.307, 383, 283, CRYSTAL STRUCTURE OF DYRK2 IN COMPLEX WITH EHT 5372 (COMPOUND 1)
914, 5a4eD, 0.7170, 2.94, 0.285, 331, 277, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
915, 1urcC, 0.7169, 2.74, 0.383, 296, 274, CYCLIN A BINDING GROOVE INHIBITOR ACE-ARG-LYS-LEU-PHE-GLY
916, 4yc6A, 0.7168, 2.62, 0.354, 285, 274, CDK1/CKS1
917, 5ztnA, 0.7167, 3.21, 0.312, 395, 285, THE CRYSTAL STRUCTURE OF HUMAN DYRK2 IN COMPLEX WITH CURCUMIN 
918, 4fx3C, 0.7167, 2.76, 0.380, 298, 274, CRYSTAL STRUCTURE OF THE CDK2/CYCLIN A COMPLEX WITH OXINDOLE INHIBITOR
919, 3ej1C, 0.7166, 2.56, 0.384, 294, 271, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
920, 5a4tD, 0.7163, 2.93, 0.283, 332, 276, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
921, 2pk9A, 0.7163, 2.19, 0.368, 287, 266, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
922, 1okvC, 0.7163, 2.66, 0.377, 296, 273, CYCLIN A BINDING GROOVE INHIBITOR H-ARG-ARG-LEU-ILE-PHE-NH2
923, 5a3xC, 0.7162, 2.89, 0.286, 333, 276, DYRK1A IN COMPLEX WITH HYDROXY BENZOTHIAZOLE FRAGMENT
924, 3eidA, 0.7162, 2.36, 0.384, 292, 268, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
925, 3anrC, 0.7161, 3.01, 0.281, 337, 278, HUMAN DYRK1A/HARMINE COMPLEX
926, 2iw9A, 0.7160, 2.45, 0.387, 293, 269, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
927, 5myvB, 0.7159, 3.10, 0.272, 349, 279, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
928, 3anqC, 0.7159, 3.02, 0.281, 340, 278, HUMAN DYRK1A/INHIBITOR COMPLEX
929, 5i5zA, 0.7158, 2.92, 0.342, 345, 278, CDK8-CYCC IN COMPLEX WITH 8-(1-METHYL-22-DIOXO-23-DIHYDRO-1H-2L6- BENZO[C]ISOTHIAZOL-5-YL)-[16]NAPHTHYRIDINE-2-CARBOXYLIC ACID METHYLAMIDE
930, 4or5F, 0.7158, 3.37, 0.330, 324, 285, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
931, 3ej1A, 0.7157, 2.58, 0.380, 295, 271, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
932, 3eidC, 0.7157, 2.38, 0.384, 290, 268, CDK2/CYCLINA COMPLEXED WITH A PYRAZOLOPYRIDAZINE INHIBITOR
933, 2uzlC, 0.7157, 2.65, 0.379, 295, 272, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
934, 3anrD, 0.7156, 2.93, 0.283, 340, 276, HUMAN DYRK1A/HARMINE COMPLEX
935, 2cchC, 0.7156, 2.70, 0.377, 296, 273, THE CRYSTAL STRUCTURE OF CDK2 CYCLIN A IN COMPLEX WITH A SUBSTRATE PEPTIDE DERIVED FROM CDC MODIFIED WITH A GAMMA- LINKED ATP ANALOGUE
936, 5a54B, 0.7154, 2.99, 0.282, 339, 277, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
937, 4azfA, 0.7154, 3.05, 0.312, 404, 282, HUMAN DYRK2 IN COMPLEX WITH LEUCETTINE L41
938, 3qhrC, 0.7154, 2.75, 0.376, 297, 274, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
939, 1f5qC, 0.7154, 2.24, 0.368, 288, 266, CRYSTAL STRUCTURE OF MURINE GAMMA HERPESVIRUS CYCLIN COMPLEXED TO HUMAN CYCLIN DEPENDENT KINASE 2
940, 5a4lB, 0.7153, 3.00, 0.282, 339, 277, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
941, 4eorA, 0.7153, 2.46, 0.387, 293, 269, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
942, 4bchA, 0.7153, 3.26, 0.326, 308, 282, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
943, 2wo6B, 0.7153, 2.99, 0.282, 339, 277, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
944, 4yc6E, 0.7152, 2.50, 0.346, 285, 272, CDK1/CKS1
945, 4nstC, 0.7152, 3.03, 0.317, 317, 278, CRYSTAL STRUCTURE OF HUMAN CDK12/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
946, 2cciC, 0.7152, 2.69, 0.374, 296, 273, CRYSTAL STRUCTURE OF PHOSPHO-CDK2 CYCLIN A IN COMPLEX WITH A PEPTIDE CONTAINING BOTH THE SUBSTRATE AND RECRUITMENT SITES OF CDC6
947, 5hbhA, 0.7151, 2.93, 0.336, 336, 280, CDK8-CYCC IN COMPLEX WITH 5-{5-CHLORO-4-[1-(2-METHOXY-ETHYL)-18- DIAZA-SPIRO[4.5]DEC-8-YL]-PYRIDIN-3-YL}-1-METHYL-13-DIHYDRO- BENZO[C]ISOTHIAZOLE 22-DIOXIDE
948, 5a4lD, 0.7151, 2.94, 0.279, 334, 276, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
949, 2uzeA, 0.7151, 2.65, 0.379, 295, 272, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
950, 4nctC, 0.7150, 2.92, 0.283, 339, 276, HUMAN DYRK1A IN COMPLEX WITH PKC412
951, 4eosA, 0.7150, 2.65, 0.382, 296, 272, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
952, 2uzeC, 0.7150, 2.67, 0.379, 295, 272, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
953, 5a4qD, 0.7149, 2.96, 0.283, 334, 276, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
954, 4eolC, 0.7149, 2.79, 0.375, 299, 275, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
955, 3qhrA, 0.7149, 2.76, 0.376, 297, 274, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
956, 3eb0A, 0.7149, 2.80, 0.337, 311, 273, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
957, 5a54D, 0.7148, 2.94, 0.279, 334, 276, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
958, 4bcqC, 0.7148, 2.72, 0.381, 292, 273, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
959, 3anqD, 0.7148, 2.94, 0.283, 334, 276, HUMAN DYRK1A/INHIBITOR COMPLEX
960, 4g6lA, 0.7147, 2.89, 0.336, 336, 277, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
961, 4eojA, 0.7147, 2.52, 0.378, 295, 270, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
962, 5ceiA, 0.7146, 3.00, 0.326, 345, 279, CRYSTAL STRUCTURE OF CDK8:CYCLIN C COMPLEX WITH COMPOUND 22
963, 3my1A, 0.7144, 3.24, 0.335, 314, 281, STRUCTURE OF CDK9/CYCLINT1 IN COMPLEX WITH DRB
964, 2cjmA, 0.7144, 2.37, 0.386, 285, 267, MECHANISM OF CDK INHIBITION BY ACTIVE SITE PHOSPHORYLATION: CDK2 Y15P T160P IN COMPLEX WITH CYCLIN A STRUCTURE
965, 6cnhA, 0.7143, 2.56, 0.298, 321, 272, HUMAN PRPF4B IN COMPLEX WITH REBASTINIB
966, 4f7lA, 0.7143, 2.59, 0.333, 328, 273, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 2 (TERT- BUTYL [3-({[3-TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5- YL]CARBAMOYL}AMINO)PROPYL]CARBAMATE)
967, 2vx3B, 0.7142, 3.02, 0.282, 340, 277, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
968, 4eoiC, 0.7141, 2.69, 0.381, 296, 273, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
969, 2vx3D, 0.7141, 3.02, 0.282, 342, 277, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
970, 2c6tC, 0.7141, 2.69, 0.382, 295, 272, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
971, 5myvC, 0.7140, 3.22, 0.271, 348, 280, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
972, 2uzlA, 0.7140, 2.67, 0.382, 295, 272, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
973, 4ifcA, 0.7139, 2.94, 0.296, 327, 277, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
974, 3tniA, 0.7139, 3.12, 0.331, 297, 278, STRUCTURE OF CDK9/CYCLIN T F241L
975, 3qhwC, 0.7139, 2.77, 0.376, 297, 274, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
976, 3lq5A, 0.7139, 3.14, 0.332, 307, 280, STRUCTURE OF CDK9/CYCLINT IN COMPLEX WITH S-CR8
977, 3qhwA, 0.7138, 2.77, 0.376, 297, 274, STRUCTURE OF A PCDK2/CYCLINA TRANSITION-STATE MIMIC
978, 5g6vA, 0.7137, 2.93, 0.310, 308, 277, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
979, 4f7sA, 0.7137, 3.04, 0.326, 339, 279, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN THE DMG-IN CONFORMATION
980, 5g6vB, 0.7136, 2.84, 0.322, 302, 273, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INHIBITOR
981, 2uzdC, 0.7136, 2.64, 0.384, 295, 271, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
982, 4imyA, 0.7133, 3.24, 0.331, 314, 281, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
983, 4ez7A, 0.7133, 2.99, 0.362, 302, 279, CDK2 IN COMPLEX WITH STAUROSPORINE AND 2 MOLECULES OF 8-ANILINO-1- NAPHTHALENE SULFONIC ACID
984, 1qmzA, 0.7132, 2.71, 0.374, 296, 273, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
985, 5hnbA, 0.7131, 2.97, 0.338, 342, 278, CDK8-CYCC IN COMPLEX WITH [6-HYDROXY-3-(3-METHYL-BENZYL)-1H-INDAZOL-5- YL]-((S)-3-HYDROXY-PYRROLIDIN-1-YL)-METHANONE
986, 4imyC, 0.7131, 3.24, 0.331, 310, 281, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
987, 4eosC, 0.7131, 2.71, 0.381, 296, 273, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
988, 4eopC, 0.7131, 2.71, 0.381, 296, 273, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
989, 1qmzC, 0.7131, 2.71, 0.377, 296, 273, PHOSPHORYLATED CDK2-CYCLYIN A-SUBSTRATE PEPTIDE COMPLEX
990, 5y86A, 0.7129, 3.26, 0.310, 391, 284, CRYSTAL STRUCTURE OF KINASE 
991, 2wo6A, 0.7129, 2.97, 0.278, 344, 277, HUMAN DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A IN COMPLEX WITH A CONSENSUS SUBSTRATE PEPTIDE
992, 5idnA, 0.7128, 2.90, 0.342, 336, 278, CDK8-CYCC IN COMPLEX WITH [(S)-2-(4-CHLORO-PHENYL)-PYRROLIDIN-1-YL]- (3-METHYL-1H-PYRAZOLO[34-B]PYRIDIN-5-YL)-METHANONE
993, 4yljB, 0.7127, 3.08, 0.281, 347, 278, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
994, 4i3zA, 0.7126, 2.70, 0.379, 295, 272, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
995, 3pxzA, 0.7126, 2.97, 0.371, 302, 278, CDK2 TERNARY COMPLEX WITH JWS648 AND ANS
996, 2vx3A, 0.7126, 3.08, 0.281, 346, 278, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
997, 2b54A, 0.7126, 2.81, 0.351, 298, 276, HUMAN CYCLIN DEPENDENT KINASE 2 (CKD2)COMPLEXED WITH DIN- 232305
998, 1jstC, 0.7126, 2.54, 0.378, 297, 270, PHOSPHORYLATED CYCLIN-DEPENDENT KINASE-2 BOUND TO CYCLIN A
999, 4ifcB, 0.7125, 2.91, 0.297, 329, 276, CRYSTAL STRUCTURE OF ADP-BOUND HUMAN PRPF4B KINASE DOMAIN
1000, 4bcgA, 0.7125, 3.23, 0.338, 312, 281, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1001, 3nizA, 0.7125, 2.63, 0.363, 288, 273, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH ADP BOUND.
1002, 4imyE, 0.7124, 3.23, 0.325, 313, 280, THE AFF4 SCAFFOLD BINDS HUMAN P-TEFB ADJACENT TO HIV TAT
1003, 4f6sA, 0.7124, 2.93, 0.329, 328, 277, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 7 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]UREA)
1004, 2uzbA, 0.7124, 2.71, 0.382, 295, 272, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1005, 4krdA, 0.7123, 2.76, 0.359, 294, 273, CRYSTAL STRUCTURE OF PHO85-PCL10 COMPLEX
1006, 4ec8A, 0.7123, 3.27, 0.327, 325, 281, STRUCTURE OF FULL LENGTH CDK9 IN COMPLEX WITH CYCLINT AND DRB
1007, 3pxfA, 0.7123, 2.95, 0.371, 302, 278, CDK2 IN COMPLEX WITH TWO MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
1008, 3eb0C, 0.7123, 2.80, 0.338, 310, 272, CRYSTAL STRUCTURE OF CGD4_240 FROM CRYPTOSPORIDIUM PARVUM IN COMPLEX WITH INDIRUBIN E804
1009, 1v0bA, 0.7123, 2.75, 0.360, 286, 275, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1010, 4i3zC, 0.7122, 2.71, 0.379, 295, 272, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 2 MAGNESIUM IONS
1011, 4f70A, 0.7122, 2.78, 0.336, 327, 274, CRYSTAL STRUCTURE OF HUMAN CDK8/CYCC IN COMPLEX WITH COMPOUND 4 (1-[3- TERT-BUTYL-1-(4-METHYLPHENYL)-1H-PYRAZOL-5-YL]-3-[2-(MORPHOLIN-4-YL) ETHYL]UREA)
1012, 1unlA, 0.7122, 2.75, 0.364, 292, 272, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
1013, 1g3nE, 0.7122, 2.70, 0.351, 293, 271, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1014, 5xs2A, 0.7120, 2.99, 0.320, 366, 281, CDK8-CYCC IN COMPLEX WITH COMPOUND 17:3-CHLORO-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
1015, 5t31B, 0.7120, 2.73, 0.321, 333, 271, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
1016, 4ylkA, 0.7120, 3.06, 0.277, 341, 278, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-CHLORO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5S
1017, 4ii5A, 0.7120, 2.71, 0.379, 295, 272, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
1018, 3miaA, 0.7120, 3.17, 0.332, 324, 280, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH ATP-BOUND HUMAN P-TEFB
1019, 4ii5C, 0.7119, 2.72, 0.379, 295, 272, STRUCTURE OF PCDK2/CYCLINA BOUND TO ADP AND 1 MAGNESIUM ION
1020, 4bcfA, 0.7119, 3.23, 0.331, 307, 281, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1021, 4bbmA, 0.7119, 3.45, 0.288, 314, 285, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1022, 2c6tA, 0.7119, 2.69, 0.376, 295, 271, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1023, 4yllA, 0.7118, 3.06, 0.277, 340, 278, CRYSTAL STRUCTURE OF DYRK1AA IN COMPLEX WITH 10-BROMO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLONE-6-CARBOXYLIC ACID INHIBITOR 5T
1024, 4or5A, 0.7118, 3.33, 0.330, 319, 282, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB AND AFF4
1025, 1g3nA, 0.7118, 2.71, 0.351, 293, 271, STRUCTURE OF A P18(INK4C)-CDK6-K-CYCLIN TERNARY COMPLEX
1026, 4iirB, 0.7115, 2.84, 0.302, 327, 275, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
1027, 4bcjA, 0.7115, 3.32, 0.337, 309, 282, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1028, 4eonA, 0.7114, 2.75, 0.377, 299, 273, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1029, 4bciA, 0.7114, 3.20, 0.339, 308, 280, STRUCTURE OF CDK9 IN COMPLEX WITH CYCLIN T AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1030, 5a4tC, 0.7112, 2.90, 0.292, 332, 274, DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT
1031, 4eopA, 0.7112, 2.62, 0.384, 297, 271, THR 160 PHOSPHORYLATED CDK2 Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1032, 4yljD, 0.7111, 3.12, 0.281, 347, 278, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
1033, 3mi9A, 0.7111, 3.27, 0.331, 328, 281, CRYSTAL STRUCTURE OF HIV-1 TAT COMPLEXED WITH HUMAN P-TEFB
1034, 3pxqA, 0.7110, 2.91, 0.375, 298, 277, CDK2 IN COMPLEX WITH 3 MOLECULES OF 8-ANILINO-1-NAPHTHALENE SULFONATE
1035, 2pmiC, 0.7110, 2.12, 0.365, 285, 263, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
1036, 4eonC, 0.7108, 2.82, 0.376, 298, 274, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1037, 5efqA, 0.7107, 3.23, 0.306, 321, 278, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
1038, 4ianA, 0.7106, 2.89, 0.305, 321, 275, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
1039, 4mq1B, 0.7105, 2.98, 0.283, 340, 276, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1040, 3tn8A, 0.7105, 3.21, 0.323, 304, 279, CDK9/CYCLIN T IN COMPLEX WITH CAN508
1041, 5efqC, 0.7104, 3.14, 0.313, 325, 278, CRYSTAL STRUCTURE OF HUMAN CDK13/CYCLIN K IN COMPLEX WITH ADP-ALUMINUM FLUORIDE
1042, 4mq1D, 0.7102, 2.94, 0.284, 336, 275, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1043, 4eoiA, 0.7101, 2.55, 0.387, 294, 269, THR 160 PHOSPHORYLATED CDK2 K89D Q131E - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1044, 5mxxA, 0.7100, 3.18, 0.294, 361, 279, CRYSTAL STRUCTURE OF HUMAN SR PROTEIN KINASE 1 (SRPK1) IN COMPLEX WITH COMPOUND 1
1045, 5a4qC, 0.7100, 2.93, 0.292, 332, 274, DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT
1046, 4yu2D, 0.7100, 3.18, 0.280, 346, 279, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
1047, 2vx3C, 0.7100, 3.09, 0.278, 338, 277, CRYSTAL STRUCTURE OF THE HUMAN DUAL SPECIFICITY TYROSINE- PHOSPHORYLATION-REGULATED KINASE 1A
1048, 1jwhA, 0.7100, 3.24, 0.295, 336, 278, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1049, 2uzbC, 0.7099, 2.57, 0.387, 292, 269, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1050, 4ijpB, 0.7098, 2.94, 0.297, 333, 276, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
1051, 4ec9A, 0.7097, 3.21, 0.337, 306, 279, CRYSTAL STRUCTURE OF FULL-LENGTH CDK9 IN COMPLEX WITH CYCLIN T
1052, 2b53A, 0.7097, 2.59, 0.360, 294, 272, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DIN- 234325
1053, 5a54C, 0.7096, 2.92, 0.288, 332, 274, DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT
1054, 2uzdA, 0.7096, 2.70, 0.376, 295, 271, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1055, 1ungA, 0.7096, 3.04, 0.358, 288, 274, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1056, 4yu2B, 0.7095, 3.19, 0.280, 347, 279, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
1057, 1wbpA, 0.7095, 3.18, 0.283, 350, 279, SRPK1 BOUND TO 9MER DOCKING MOTIF PEPTIDE
1058, 1buhA, 0.7095, 2.45, 0.361, 287, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK2 KINASE COMPLEX WITH CELL CYCLE-REGULATORY PROTEIN CKSHS1
1059, 5lqfA, 0.7094, 2.74, 0.351, 287, 271, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
1060, 1ykrA, 0.7094, 2.75, 0.360, 298, 275, CRYSTAL STRUCTURE OF CDK2 WITH AN AMINOIMIDAZO PYRIDINE INHIBITOR
1061, 5t31A, 0.7092, 2.86, 0.321, 334, 271, EXPLOITING AN ASP-GLU SWITCH IN GLYCOGEN SYNTHASE KINASE 3 TO DESIGN PARALOG SELECTIVE INHIBITORS FOR USE IN ACUTE MYELOID LEUKEMIA
1062, 5f95B, 0.7089, 2.99, 0.321, 338, 271, CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH COMPOUND 18: 2- [(CYCLOPROPYLCARBONYL)AMINO]-N-(4-PHENYLPYRIDIN-3-YL)PYRIDINE-4- CARBOXAMIDE
1063, 4yljC, 0.7089, 3.15, 0.281, 346, 278, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
1064, 4mq1A, 0.7089, 3.00, 0.283, 345, 276, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1065, 5uq2A, 0.7088, 2.91, 0.388, 296, 273, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
1066, 5a4eB, 0.7088, 3.02, 0.282, 322, 273, DYRK1A IN COMPLEX WITH METHOXY BENZOTHIAZOLE FRAGMENT
1067, 1i09A, 0.7088, 2.81, 0.320, 338, 269, STRUCTURE OF GLYCOGEN SYNTHASE KINASE-3 (GSK3B)
1068, 5a4lC, 0.7087, 2.94, 0.292, 332, 274, DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT
1069, 4iirA, 0.7085, 2.90, 0.298, 325, 275, CRYSTAL STRUCTURE OF AMPPNP-BOUND HUMAN PRPF4B KINASE DOMAIN
1070, 1unlB, 0.7085, 3.01, 0.353, 292, 275, STRUCTURAL MECHANISM FOR THE INHIBITION OF CD5-P25 FROM THE ROSCOVITINE ALOISINE AND INDIRUBIN.
1071, 4eokA, 0.7084, 2.56, 0.384, 293, 268, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1072, 1wakA, 0.7082, 3.20, 0.283, 353, 279, X-RAY STRUCTURE OF SRPK1
1073, 4yljA, 0.7081, 3.22, 0.280, 346, 279, CRYSTAL STRUCTURE OF DYRK1A IN COMPLEX WITH 10-IODO-SUBSTITUTED 11H- INDOLO[32-C]QUINOLINE-6-CARBOXYLIC ACID INHIBITOR 5J
1074, 5m4cA, 0.7079, 3.08, 0.293, 329, 276, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER LOW-SALT CONDITIONS
1075, 3begA, 0.7079, 3.15, 0.288, 348, 278, CRYSTAL STRUCTURE OF SR PROTEIN KINASE 1 COMPLEXED TO ITS SUBSTRATE ASF/SF2
1076, 4krcA, 0.7078, 2.89, 0.358, 297, 274, CRYSTAL STRUCTURE OF PHO85-PCL10-ATP-GAMMA-S COMPLEX
1077, 4mq2D, 0.7077, 3.12, 0.282, 329, 277, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1078, 4un0D, 0.7076, 2.52, 0.331, 276, 266, CRYSTAL STRUCTURE OF THE HUMAN CDK12-CYCLINK COMPLEX
1079, 4yu2A, 0.7075, 3.13, 0.281, 348, 278, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
1080, 4yu2C, 0.7074, 3.23, 0.280, 346, 279, CRYSTAL STRUCTURE OF DYRK1A WITH HARMINE-DERIVATIZED ANNH-75 INHIBITOR
1081, 4mq2B, 0.7074, 3.02, 0.279, 338, 276, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1082, 4mq2A, 0.7073, 3.16, 0.277, 343, 278, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1083, 4kd1A, 0.7073, 2.75, 0.354, 298, 274, CDK2 IN COMPLEX WITH DINACICLIB
1084, 3e3pB, 0.7072, 3.14, 0.299, 337, 278, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1085, 5xv7A, 0.7071, 3.20, 0.283, 350, 279, SRPK1 IN COMPLEX WITH ALECTINIB
1086, 4eolA, 0.7071, 2.69, 0.378, 294, 270, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR RO3306
1087, 3e3pA, 0.7071, 3.27, 0.294, 337, 279, GLYCOGEN SYNTHASE KINASE FROM LEISHMANIA MAJOR
1088, 1h1pA, 0.7071, 2.77, 0.379, 296, 272, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1089, 2x7gA, 0.7069, 3.15, 0.266, 344, 278, STRUCTURE OF HUMAN SERINE-ARGININE-RICH PROTEIN-SPECIFIC KINASE 2 (SRPK2) BOUND TO PURVALANOL B
1090, 5uq1C, 0.7068, 2.89, 0.386, 289, 272, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
1091, 5my8A, 0.7068, 3.22, 0.301, 355, 279, CRYSTAL STRUCTURE OF SRPK1 IN COMPLEX WITH SPHINX31
1092, 3qqlA, 0.7068, 2.65, 0.360, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR L3
1093, 4ijpA, 0.7067, 3.02, 0.297, 330, 276, CRYSTAL STRUCTURE OF HUMAN PRPF4B KINASE DOMAIN IN COMPLEX WITH 4-{5- [(2-CHLORO-PYRIDIN-4-YLMETHYL)-CARBAMOYL]-THIOPHEN-2-YL}- BENZO[B]THIOPHENE-2-CARBOXYLIC ACID AMINE
1094, 5a14A, 0.7066, 2.61, 0.388, 284, 268, HUMAN CDK2 WITH TYPE II INHIBITOR
1095, 4mq1C, 0.7066, 3.01, 0.284, 328, 275, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1096, 5nqcA, 0.7065, 3.17, 0.298, 331, 275, CK2ALPHA IN COMPLEX WITH NMR154
1097, 2oxyA, 0.7064, 3.30, 0.272, 327, 279, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1098, 5xqxA, 0.7063, 3.06, 0.335, 340, 278, HUMAN CDK8-CYCC IN COMPLEX WITH COMPOUND 4: N-METHYL-4-(4-PYRIDYL)-1H- PYRROLE-2-CARBOXAMIDE
1099, 3wikA, 0.7061, 3.32, 0.290, 334, 279, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND10 COMPLEX
1100, 4wuaA, 0.7060, 3.15, 0.288, 344, 278, CRYSTAL STRUCTURE OF HUMAN SRPK1 COMPLEXED TO AN INHIBITOR SRPIN340
1101, 4dglC, 0.7060, 3.23, 0.293, 334, 276, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1102, 3o0gA, 0.7060, 2.61, 0.366, 289, 268, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1103, 3l1sA, 0.7059, 2.78, 0.320, 336, 269, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1104, 1j91A, 0.7059, 3.40, 0.271, 327, 280, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
1105, 4mq2C, 0.7057, 3.15, 0.282, 339, 277, THE CRYSTAL STRUCTURE OF DYRK1A WITH A BOUND PYRIDO[23-D]PYRIMIDINE INHIBITOR
1106, 5myvA, 0.7056, 3.23, 0.265, 352, 279, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1107, 1fq1B, 0.7056, 2.74, 0.371, 295, 272, CRYSTAL STRUCTURE OF KINASE ASSOCIATED PHOSPHATASE (KAP) IN COMPLEX WITH PHOSPHO-CDK2
1108, 5m4fA, 0.7055, 3.12, 0.297, 330, 276, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER LOW-SALT CONDITIONS
1109, 2exmA, 0.7055, 2.80, 0.354, 298, 274, HUMAN CDK2 IN COMPLEX WITH ISOPENTENYLADENINE
1110, 1h27C, 0.7054, 2.57, 0.378, 291, 267, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P27
1111, 3r83A, 0.7053, 2.68, 0.360, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-92
1112, 3r8pA, 0.7052, 2.64, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-6
1113, 1pw2A, 0.7051, 2.62, 0.354, 294, 271, APO STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2
1114, 1h1pC, 0.7050, 2.90, 0.377, 296, 273, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH THE INHIBITOR NU2058
1115, 5k5nA, 0.7049, 2.91, 0.314, 331, 271, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
1116, 5lqfD, 0.7048, 2.60, 0.362, 285, 268, CDK1/CYCLINB1/CKS2 IN COMPLEX WITH NU6102
1117, 5b0xA, 0.7046, 3.31, 0.291, 329, 278, CRYSTAL STRUCTURE OF THE CK2A/BENZOIC ACID DERIVATIVE COMPLEX
1118, 4ptgB, 0.7046, 3.02, 0.322, 332, 270, STRUCTURE OF A CARBOXAMINE COMPOUND (26) (2-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}-4-METHOXYPYRIMIDINE-5-CARBOXAMIDE) TO GSK3B
1119, 2pmiA, 0.7046, 2.25, 0.366, 284, 262, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE- RESPONSIVE SIGNAL TRANSDUCTION PATHWAY WITH BOUND ATP-GAMMA-S
1120, 5n1vB, 0.7043, 3.39, 0.295, 331, 278, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
1121, 1hclA, 0.7043, 2.72, 0.359, 294, 273, HUMAN CYCLIN-DEPENDENT KINASE 2
1122, 5k5nB, 0.7042, 3.02, 0.315, 334, 270, CRYSTAL STRUCTURE OF GSK-3BETA COMPLEXED WITH PF-04802367 A HIGHLY SELECTIVE BRAIN-PENETRANT KINASE INHIBITOR
1123, 4f9aC, 0.7041, 2.88, 0.266, 317, 274, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1124, 5aneA, 0.7040, 2.64, 0.354, 294, 271, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-METHOXY-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1125, 6fykB, 0.7039, 3.26, 0.255, 349, 278, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1126, 5n1vA, 0.7039, 3.44, 0.290, 331, 279, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH PYRAZOLO-PYRIMIDINE MACROCYCLIC LIGAND
1127, 4ianB, 0.7039, 2.92, 0.303, 319, 274, CRYSTAL STRUCTURE OF APO HUMAN PRPF4B KINASE DOMAIN
1128, 3wowA, 0.7039, 3.44, 0.289, 334, 280, CRYSTAL STRUCTURE OF HUMAN CK2A WITH AMPPNP
1129, 3r71A, 0.7039, 2.64, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-162
1130, 5unpB, 0.7038, 3.18, 0.254, 347, 276, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
1131, 3blqA, 0.7038, 3.06, 0.337, 295, 273, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH ATP
1132, 6fykC, 0.7037, 3.37, 0.251, 349, 279, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1133, 5unpA, 0.7037, 3.18, 0.254, 347, 276, STRUCTURE OF CDC2-LIKE KINASE 2 (CLK2) IN COMPLEX WITH COMPOUND T-025 [N2-METHYL-N4-(PYRIMIDIN-2-YLMETHYL)-5-(QUINOLIN-6-YL)-7H-PYRROLO[2; 3-D]PYRIMIDINE-2;4-DIAMINE] 
1134, 5osjA, 0.7037, 2.72, 0.368, 292, 272, CDK2(WT) WITH COVALENT ADDUCT AT C177
1135, 4f9aA, 0.7036, 2.91, 0.270, 315, 274, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1136, 4azeA, 0.7035, 3.22, 0.281, 348, 278, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
1137, 4azeC, 0.7033, 3.23, 0.281, 348, 278, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
1138, 1hckA, 0.7033, 2.65, 0.354, 294, 271, HUMAN CYCLIN-DEPENDENT KINASE 2
1139, 3rm6A, 0.7032, 2.69, 0.360, 293, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-80
1140, 5csvA, 0.7031, 3.18, 0.299, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 6 BOUND
1141, 5l1zA, 0.7030, 3.26, 0.323, 310, 279, TAR COMPLEX WITH HIV-1 TAT-AFF4-P-TEFB
1142, 4ogrE, 0.7030, 3.27, 0.323, 310, 279, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1143, 4azeB, 0.7030, 3.14, 0.282, 345, 277, HUMAN DYRK1A IN COMPLEX WITH LEUCETTINE L41
1144, 2xnbA, 0.7029, 2.74, 0.357, 296, 272, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
1145, 6fykA, 0.7028, 3.19, 0.256, 349, 277, X-RAY STRUCTURE OF CLK2-KD(136-496)/INDAZOLE1 AT 2.39A 
1146, 5cspA, 0.7027, 3.18, 0.299, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
1147, 3rpoA, 0.7027, 2.65, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-156
1148, 3r7yA, 0.7027, 2.67, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-2-88
1149, 2zjwA, 0.7027, 3.40, 0.287, 332, 279, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH ELLAGIC ACID
1150, 2clxA, 0.7027, 2.63, 0.356, 293, 270, 4-ARYLAZO-35-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY CRYSTAL STRUCTURE IN COMPLEX WITH CDK2 SELECTIVITY AND CELLULAR EFFECTS
1151, 1pjkA, 0.7027, 3.38, 0.291, 331, 278, CRYSTAL STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
1152, 6fylA, 0.7026, 3.30, 0.252, 340, 278, X-RAY STRUCTURE OF CLK2-KD(136-496)/CX-4945 AT 1.95A 
1153, 4f9bA, 0.7025, 3.03, 0.269, 318, 275, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1154, 6fypA, 0.7023, 3.33, 0.264, 348, 280, X-RAY STRUCTURE OF CLK3-KD(GP-[275-632]; NON-PHOS.)/CX-4945 AT 2.29A 
1155, 4gcjA, 0.7023, 3.43, 0.365, 304, 282, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
1156, 3h30A, 0.7023, 3.23, 0.298, 333, 275, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
1157, 1pxiA, 0.7021, 2.68, 0.354, 294, 271, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(25-DICHLORO-THIOPHEN-3-YL)-PYRIMIDIN-2- YLAMINE
1158, 2a0cX, 0.7020, 2.68, 0.358, 294, 271, HUMAN CDK2 IN COMPLEX WITH OLOMOUCINE II A NOVEL 269- TRISUBSTITUTED PURINE CYCLIN-DEPENDENT KINASE INHIBITOR
1159, 1pxjA, 0.7020, 2.67, 0.358, 294, 271, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YLAMINE
1160, 5anjA, 0.7019, 2.65, 0.351, 291, 271, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH N-(9H-PURIN-6-YL) THIOPHENE-2-CARBOXAMIDE  PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1161, 4md7E, 0.7018, 3.41, 0.295, 332, 278, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1162, 4f99A, 0.7017, 2.95, 0.270, 312, 274, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND NUCLEOTIDE
1163, 3juhA, 0.7017, 3.15, 0.299, 334, 274, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
1164, 5osmA, 0.7016, 2.80, 0.357, 292, 272, CDK2(F80C C177A) WITH COVALENT ADDUCT AT C80
1165, 3raiA, 0.7016, 2.68, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-160
1166, 3c13A, 0.7016, 3.25, 0.302, 328, 275, LOW PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1167, 3bqcA, 0.7015, 3.25, 0.302, 328, 275, HIGH PH-VALUE CRYSTAL STRUCTURE OF EMODIN IN COMPLEX WITH THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1168, 3r7vA, 0.7013, 2.80, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-9
1169, 3r7eA, 0.7013, 2.82, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-67
1170, 4md7H, 0.7012, 3.43, 0.295, 330, 278, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1171, 3rpsA, 0.7012, 3.30, 0.293, 334, 276, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1172, 3qx2A, 0.7011, 2.72, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-190
1173, 4md7G, 0.7010, 3.44, 0.295, 332, 278, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1174, 3qxoA, 0.7010, 2.70, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-84
1175, 4f9bC, 0.7008, 2.99, 0.270, 316, 274, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND PHA767491
1176, 3py1A, 0.7008, 3.41, 0.362, 302, 282, CDK2 TERNARY COMPLEX WITH SU9516 AND ANS
1177, 3r6xA, 0.7007, 2.85, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-158
1178, 3r28A, 0.7007, 2.81, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-140
1179, 3pxrA, 0.7007, 2.77, 0.360, 294, 272, APO CDK2 CRYSTALLIZED FROM JEFFAMINE
1180, 2ds1A, 0.7007, 2.55, 0.362, 290, 268, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1181, 5motA, 0.7006, 3.31, 0.298, 328, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0627 BOUND
1182, 1j91B, 0.7006, 3.27, 0.271, 327, 277, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 4567- TETRABROMOBENZOTRIAZOLE
1183, 4md7F, 0.7005, 3.44, 0.295, 332, 278, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME
1184, 3ofmA, 0.7004, 3.30, 0.308, 325, 276, STRUCTURE OF A HUMAN CK2ALPHA PRIME THE PARALOG ISOFORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM HOMO SAPIENS
1185, 3r73A, 0.7003, 2.87, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-164
1186, 3qzhA, 0.7003, 2.85, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-124
1187, 4iq6A, 0.7002, 2.77, 0.328, 324, 265, GSK-3BETA WITH INHIBITOR 6-CHLORO-N-CYCLOHEXYL-4-(1H-PYRROLO[23- B]PYRIDIN-3-YL)PYRIDIN-2-AMINE
1188, 3rm7A, 0.7002, 2.84, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-91
1189, 3qrtA, 0.7002, 2.84, 0.366, 294, 273, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC2-55
1190, 3q9wA, 0.7002, 3.23, 0.303, 328, 274, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 8.5
1191, 3mb6A, 0.7002, 3.35, 0.304, 329, 276, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (CPA)
1192, 3w8lA, 0.7001, 3.15, 0.292, 326, 274, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1193, 3gc0A, 0.7001, 2.71, 0.349, 278, 269, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA IN COMPLEX WITH AMP
1194, 3fe3B, 0.7001, 2.77, 0.230, 317, 269, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
1195, 5m4uA, 0.7000, 3.51, 0.308, 332, 279, ORTHORHOMBIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1196, 5h8bA, 0.7000, 3.44, 0.295, 331, 278, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1197, 4nh1A, 0.7000, 3.45, 0.290, 330, 279, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1198, 4aguC, 0.7000, 2.80, 0.306, 278, 268, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1199, 4nh1B, 0.6999, 3.45, 0.290, 332, 279, CRYSTAL STRUCTURE OF A HETEROTETRAMERIC CK2 HOLOENZYME COMPLEX CARRYING THE ANDANTE-MUTATION IN CK2BETA AND CONSISTENT WITH PROPOSED MODELS OF AUTOINHIBITION AND TRANS-AUTOPHOSPHORYLATION
1200, 5oniA, 0.6998, 3.51, 0.294, 334, 279, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1201, 5myvD, 0.6998, 3.26, 0.266, 351, 278, CRYSTAL STRUCTURE OF SRPK2 IN COMPLEX WITH COMPOUND 1
1202, 3kxhA, 0.6998, 3.40, 0.273, 326, 278, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR (2-DYMETHYLAMMINO-4567-TETRABROMOBENZOIMIDAZOL-1YL- ACETIC ACID (K66)
1203, 3r1qA, 0.6997, 2.86, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-102
1204, 3qzfA, 0.6997, 2.86, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-52
1205, 3qwkA, 0.6997, 2.88, 0.366, 294, 273, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-150
1206, 3qqfA, 0.6997, 2.85, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR L1
1207, 3owlA, 0.6997, 3.37, 0.296, 330, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
1208, 4l42A, 0.6994, 2.87, 0.259, 299, 270, CRYSTAL STRUCTURES OF HUMAN P70S6K1-PIF
1209, 3royA, 0.6994, 2.89, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-154
1210, 3r1yA, 0.6993, 2.75, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-134
1211, 2xmyA, 0.6993, 2.79, 0.357, 295, 272, DISCOVERY AND CHARACTERISATION OF 2-ANILINO-4-(THIAZOL-5-YL) PYRIMIDINE TRANSCRIPTIONAL CDK INHIBITORS AS ANTICANCER AGENTS
1212, 2c5yA, 0.6993, 2.68, 0.368, 290, 269, DIFFERENTIAL BINDING OF INHIBITORS TO ACTIVE AND INACTIVE CDK2 PROVIDES INSIGHTS FOR DRUG DESIGN
1213, 1pxpA, 0.6993, 2.78, 0.347, 294, 271, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- N N -DIMETHYL-BENZENE-14-DIAMINE
1214, 3r1sA, 0.6992, 2.74, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-127
1215, 3qziA, 0.6992, 2.94, 0.359, 294, 273, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-126
1216, 4fbxA, 0.6991, 3.31, 0.297, 333, 276, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT CRYSTALLIZED IN THE PRESENCE OF A BISUBSTRATE INHIBITOR
1217, 3l1sB, 0.6990, 3.07, 0.321, 330, 268, 3-ARYL-4-(ARYLHYDRAZONO)-1H-PYRAZOL-5-ONES: HIGHLY LIGAND EFFICIENT AND POTENT INHIBITORS OF GSK3
1218, 3axwA, 0.6990, 3.34, 0.297, 329, 276, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA COMPLEXED WITH A POTENT INHIBITOR
1219, 4rj3A, 0.6989, 2.62, 0.358, 287, 268, CDK2 WITH EGFR INHIBITOR COMPOUND 8
1220, 4md8E, 0.6989, 3.48, 0.290, 332, 279, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1221, 1pxoA, 0.6989, 2.77, 0.358, 294, 271, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(2-AMINO-4-METHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YL]-(3-NITRO-PHENYL)-AMINE
1222, 5omyA, 0.6988, 3.38, 0.289, 332, 277, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1223, 4rllA, 0.6988, 3.27, 0.302, 329, 275, CRYSTAL STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1224, 3owjA, 0.6988, 3.33, 0.301, 328, 276, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A PYRIDOCARBAZOLE DERIVATIVE INHIBITOR
1225, 3lfsA, 0.6988, 2.66, 0.364, 290, 269, CRYSTAL STRUCTURE OF CDK2 WITH SAR37 AN AMINOINDAZOLE TYPE INHIBITOR
1226, 2c6iA, 0.6988, 2.70, 0.352, 292, 270, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1227, 2c69A, 0.6988, 2.65, 0.361, 292, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1228, 3wilA, 0.6987, 3.53, 0.290, 331, 279, CRYSTAL STRUCTURE OF THE CK2ALPHA/COMPOUND3 COMPLEX
1229, 3pj8A, 0.6987, 2.61, 0.368, 288, 269, STRUCTURE OF CDK2 IN COMPLEX WITH A PYRAZOLO[43-D]PYRIMIDINE BIOISOSTERE OF ROSCOVITINE.
1230, 3ngaB, 0.6987, 3.48, 0.295, 331, 278, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1231, 6fyiA, 0.6986, 3.19, 0.255, 336, 275, X-RAY STRUCTURE OF CLK2-KD(130-496)/TG003 AT 2.6A 
1232, 5t1hA, 0.6986, 3.33, 0.292, 331, 277, CRYSTAL STRUCTURE OF CK2
1233, 4md8G, 0.6986, 3.48, 0.290, 332, 279, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1234, 2pvrA, 0.6986, 3.36, 0.293, 328, 276, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 (C- TERMINAL DELETION MUTANT 1-335) IN COMPLEX WITH TWO SULFATE IONS
1235, 2c6kA, 0.6985, 2.71, 0.356, 292, 270, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1236, 4ub7A, 0.6984, 3.48, 0.291, 334, 278, HIGH-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26) SHOWING AN EXTREME DISTORTION OF THE ATP-BINDING LOOP COMBINED WITH A PI-HALOGEN BOND
1237, 3qx4A, 0.6984, 2.77, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-78
1238, 2oxyB, 0.6984, 3.31, 0.274, 327, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1239, 5xvuC, 0.6983, 3.19, 0.303, 321, 274, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1240, 5xvuB, 0.6983, 3.19, 0.303, 321, 274, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1241, 5owhA, 0.6983, 3.23, 0.295, 334, 275, HIGH SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3-AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1242, 5h8gA, 0.6983, 3.21, 0.296, 324, 274, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7B
1243, 3u9cA, 0.6983, 3.36, 0.290, 331, 276, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1244, 3q9xB, 0.6982, 3.43, 0.292, 330, 277, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1245, 3nr9C, 0.6981, 3.25, 0.257, 347, 276, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1246, 1y8yA, 0.6981, 2.66, 0.357, 292, 269, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
1247, 5ooiA, 0.6979, 3.41, 0.307, 329, 277, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1248, 2c6mA, 0.6979, 2.71, 0.356, 290, 270, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1249, 2c6lA, 0.6979, 2.61, 0.362, 291, 268, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1250, 5xvuA, 0.6978, 3.18, 0.303, 321, 274, CRYSTAL STRUCTURE OF THE PROTEIN KINASE CK2 CATALYTIC DOMAIN FROM PLASMODIUM FALCIPARUM BOUND TO ATP
1251, 4md9L, 0.6978, 3.48, 0.295, 328, 278, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1252, 3h30B, 0.6977, 2.98, 0.299, 333, 271, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2 WITH 56-DICHLORO-1-BETA-D- RIBOFURANOSYLBENZIMIDAZOLE
1253, 5oslA, 0.6976, 3.32, 0.295, 328, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 7
1254, 4gubA, 0.6976, 3.45, 0.291, 329, 278, CASEIN KINASE II BOUND TO INHIBITOR
1255, 3qwjA, 0.6976, 2.82, 0.360, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-142
1256, 3nr9A, 0.6976, 3.24, 0.257, 341, 276, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1257, 5cvgA, 0.6975, 3.10, 0.295, 326, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH A NOVEL CLOSED CONFORMATION OF THE AD LOOP
1258, 4md8H, 0.6975, 3.51, 0.290, 331, 279, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1259, 4fklA, 0.6975, 2.57, 0.360, 290, 267, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1260, 3owkA, 0.6975, 3.41, 0.300, 330, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A BENZOPYRIDOINDOLE DERIVATIVE INHIBITOR
1261, 3blrA, 0.6975, 3.19, 0.336, 300, 274, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1 IN COMPLEX WITH FLAVOPIRIDOL
1262, 1ds5B, 0.6975, 3.39, 0.270, 328, 278, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1263, 5mohA, 0.6974, 3.23, 0.300, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0583 BOUND.
1264, 4md9G, 0.6974, 3.45, 0.295, 329, 278, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1265, 4ib5C, 0.6974, 3.53, 0.294, 332, 279, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1266, 3u87A, 0.6974, 3.50, 0.291, 329, 278, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1267, 2vtlA, 0.6974, 2.58, 0.363, 290, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1268, 2v0dA, 0.6974, 2.73, 0.359, 292, 270, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1269, 1h4lB, 0.6974, 2.64, 0.371, 278, 264, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
1270, 5m56B, 0.6973, 3.48, 0.306, 328, 278, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1271, 3ngaA, 0.6973, 3.40, 0.292, 331, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH CX-4945
1272, 2qnjA, 0.6973, 3.05, 0.246, 318, 272, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
1273, 1na7A, 0.6973, 3.30, 0.291, 326, 275, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2
1274, 4anmA, 0.6972, 3.50, 0.269, 328, 279, COMPLEX OF CK2 WITH A CDC7 INHIBITOR
1275, 2uzoA, 0.6972, 2.71, 0.359, 290, 270, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1276, 4grbA, 0.6971, 3.27, 0.296, 327, 274, CASEIN KINASE 2 (CK2) BOUND TO INHIBITOR
1277, 3qa0B, 0.6971, 3.39, 0.297, 330, 276, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1278, 3e3bX, 0.6971, 3.39, 0.310, 334, 277, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF HUMAN PROTEIN KINASE CK2ALPHA PRIME WITH A POTENT INDAZOLE-DERIVATIVE INHIBITOR
1279, 2vtmA, 0.6971, 2.57, 0.363, 290, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1280, 1v0pA, 0.6971, 2.58, 0.367, 277, 267, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1281, 5ts8A, 0.6969, 3.50, 0.265, 332, 279, Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 56-DIBROMOBENZOTRIAZOLE
1282, 5oniB, 0.6969, 3.55, 0.290, 334, 279, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1283, 5m4iA, 0.6969, 3.37, 0.289, 331, 277, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO-FLAVONOL (FLC21) CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1284, 3fwqB, 0.6969, 3.19, 0.297, 334, 273, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
1285, 1jwhB, 0.6969, 3.60, 0.287, 335, 282, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 HOLOENZYME
1286, 5h8eA, 0.6968, 3.40, 0.296, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1287, 1b38A, 0.6968, 2.60, 0.360, 290, 267, HUMAN CYCLIN-DEPENDENT KINASE 2
1288, 4ogrA, 0.6967, 3.24, 0.329, 314, 277, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1289, 3q9yA, 0.6967, 3.31, 0.295, 327, 275, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 8.5
1290, 2c68A, 0.6967, 2.70, 0.361, 290, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1291, 5ooiB, 0.6966, 3.21, 0.310, 325, 274, STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) IN COMPLEX WITH THE INDENOINDOLE-TYPE INHIBITOR 4P
1292, 5m56A, 0.6966, 3.46, 0.310, 331, 277, MONOCLINIC COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT (ISOFORM CK2ALPHA ) WITH THE INHIBITOR 4 -CARBOXY-68-CHLORO- FLAVONOL (FLC21)
1293, 3u9cB, 0.6966, 3.39, 0.293, 331, 276, STRUCTURE OF A C-TERMINAL DELETION MUTANT OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH THE ATP-COMPETITIVE INHIBITOR RESORUFIN
1294, 3qruA, 0.6966, 2.90, 0.363, 295, 273, CDK2 IN COMPLEX WITH INHIBITOR NSK-MC1-12
1295, 3lfqA, 0.6966, 2.61, 0.367, 289, 267, CRYSTAL STRUCTURE OF CDK2 WITH SAR60 AN AMINOINDAZOLE TYPE INHIBITOR
1296, 6fyvA, 0.6965, 3.18, 0.259, 329, 274, X-RAY STRUCTURE OF CLK4-KD(146-480)/CX-4945 AT 2.46A 
1297, 5cu4A, 0.6965, 3.30, 0.291, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1298, 4md8F, 0.6965, 3.53, 0.290, 332, 279, CRYSTAL STRUCTURE OF FULL-LENGTH SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E)
1299, 3juhB, 0.6965, 3.16, 0.300, 334, 273, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PROTEIN KINASE CK2ALPHA WITH ALTERED COSUBSTRATE SPECIFICITY
1300, 2r3fA, 0.6965, 2.60, 0.360, 290, 267, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1301, 1oirA, 0.6965, 2.57, 0.365, 286, 266, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1302, 4md9E, 0.6964, 3.40, 0.289, 329, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1303, 3r0tA, 0.6964, 3.29, 0.299, 327, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-5279
1304, 3nszA, 0.6964, 3.13, 0.294, 327, 272, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH AMPPN
1305, 3be9A, 0.6964, 3.58, 0.275, 327, 280, STRUCTURE-BASED DESIGN AND SYNTHESIS OF NOVEL MACROCYCLIC PYRAZOLO[15-A] [135]TRIAZINE COMPOUNDS AS POTENT INHIBITORS OF PROTEIN KINASE CK2 AND THEIR ANTICANCER ACTIVITIES
1306, 3amyA, 0.6964, 2.86, 0.299, 318, 268, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA COMPLEXED WITH APIGENIN
1307, 1lr4A, 0.6964, 3.50, 0.269, 327, 279, ROOM TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1308, 5n9kA, 0.6963, 3.41, 0.301, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF107 (5)
1309, 4l44A, 0.6963, 3.20, 0.256, 321, 277, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM II)
1310, 3rkbA, 0.6963, 2.84, 0.373, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-73
1311, 3q04A, 0.6963, 3.38, 0.297, 328, 276, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 8.5
1312, 1h4lA, 0.6963, 2.66, 0.371, 278, 264, STRUCTURE AND REGULATION OF THE CDK5-P25(NCK5A) COMPLEX
1313, 5os8A, 0.6962, 3.34, 0.295, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 11
1314, 4fkuA, 0.6962, 2.90, 0.369, 293, 271, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1315, 3tiyA, 0.6962, 2.84, 0.351, 293, 271, CDK2 IN COMPLEX WITH NSC 35676
1316, 3pvgA, 0.6962, 3.47, 0.273, 326, 278, CRYSTAL STRUCTURE OF Z. MAYS CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 4567-TETRABROMO-1-CARBOXYMETHYLBENZIMIDAZOLE (K68)
1317, 1w8cA, 0.6962, 2.59, 0.360, 290, 267, CO-CRYSTAL STRUCTURE OF 6-CYCLOHEXYLMETHOXY-8-ISOPROPYL-9H- PURIN-2-YLAMINE AND MONOMERIC CDK2
1318, 1b39A, 0.6962, 2.71, 0.362, 290, 268, HUMAN CYCLIN-DEPENDENT KINASE 2 PHOSPHORYLATED ON THR 160
1319, 5y9mA, 0.6961, 3.43, 0.304, 320, 276, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
1320, 3r9dA, 0.6961, 2.87, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-135
1321, 2c6oA, 0.6961, 2.70, 0.357, 290, 269, CRYSTAL STRUCTURE OF THE HUMAN CDK2 COMPLEXED WITH THE TRIAZOLOPYRIMIDINE INHIBITOR
1322, 1h07A, 0.6961, 2.61, 0.378, 285, 267, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1323, 5oo0A, 0.6960, 2.70, 0.372, 288, 269, CDK2(WT) COVALENT ADDUCT WITH D28 AT C177
1324, 4ek3A, 0.6960, 2.60, 0.367, 287, 267, CRYSTAL STRUCTURE OF APO CDK2
1325, 1zoeA, 0.6960, 3.46, 0.273, 325, 278, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
1326, 1gz8A, 0.6960, 2.64, 0.362, 290, 268, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 2-AMINO-6-(3 -METHYL-2 -OXO)BUTOXYPURINE
1327, 3r8uA, 0.6959, 2.85, 0.357, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR RC-1-132
1328, 3blhA, 0.6959, 2.92, 0.340, 291, 268, CRYSTAL STRUCTURE OF HUMAN CDK9/CYCLINT1
1329, 2qnjB, 0.6959, 3.19, 0.231, 322, 273, KINASE AND UBIQUITIN-ASSOCIATED DOMAINS OF MARK3/PAR-1
1330, 1lp4A, 0.6959, 3.49, 0.272, 327, 279, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 WITH MG-AMPPNP
1331, 3rk7A, 0.6957, 2.83, 0.362, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-71
1332, 3rk5A, 0.6957, 2.94, 0.360, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR RC-2-72
1333, 3qxpA, 0.6957, 2.84, 0.365, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-3-89
1334, 3mb7A, 0.6957, 3.51, 0.303, 330, 277, HUMAN CK2 CATALYTIC DOMAIN IN COMPLEX WITH A DIFURANE DERIVATIVE INHIBITOR (AMR)
1335, 2wu6A, 0.6957, 3.50, 0.260, 350, 281, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH DKI
1336, 1zohA, 0.6957, 3.43, 0.274, 326, 277, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES INHIBITORS
1337, 4md9P, 0.6956, 3.27, 0.295, 328, 275, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1338, 3pe1A, 0.6956, 3.30, 0.299, 327, 274, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR CX-4945
1339, 5cqwA, 0.6955, 3.40, 0.297, 331, 276, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1340, 3rk9A, 0.6955, 2.84, 0.362, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-74
1341, 3g33A, 0.6955, 2.94, 0.335, 291, 269, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1342, 2vtrA, 0.6955, 2.60, 0.360, 290, 267, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1343, 1ds5C, 0.6955, 3.39, 0.274, 328, 277, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1344, 3qqkA, 0.6954, 2.84, 0.369, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR L4
1345, 3iggA, 0.6954, 2.62, 0.363, 290, 267, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFQ WITH CDK-2
1346, 1dawA, 0.6954, 3.46, 0.277, 327, 278, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-AMPPNP
1347, 5yf9B, 0.6953, 3.33, 0.310, 319, 274, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
1348, 5otzA, 0.6953, 3.29, 0.296, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 1
1349, 4kwpA, 0.6953, 3.36, 0.298, 329, 275, CRYSTAL STRUCTURE OF HUMAN CK2-ALPHA IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR (K164) AT 1.25 A RESOLUTION
1350, 1lpuA, 0.6953, 3.51, 0.272, 327, 279, LOW TEMPERATURE CRYSTAL STRUCTURE OF THE APO-FORM OF THE CATALYTIC SUBUNIT OF PROTEIN KINASE CK2 FROM ZEA MAYS
1351, 4f9cA, 0.6952, 2.87, 0.268, 306, 272, HUMAN CDC7 KINASE IN COMPLEX WITH DBF4 AND XL413
1352, 3pzhA, 0.6952, 3.49, 0.273, 327, 278, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH EMODIN AT 1.92 A RESOLUTION
1353, 3pe2A, 0.6952, 3.25, 0.300, 327, 273, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR CX-5011
1354, 5t1hB, 0.6951, 3.42, 0.297, 331, 276, CRYSTAL STRUCTURE OF CK2
1355, 5movA, 0.6951, 3.25, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0633 BOUND
1356, 4ek4A, 0.6951, 2.57, 0.365, 287, 266, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1357, 3qtwA, 0.6951, 2.85, 0.354, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-13
1358, 3q9zB, 0.6951, 3.49, 0.296, 332, 277, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1359, 1pf8A, 0.6951, 2.93, 0.360, 298, 272, CRYSTAL STRUCTURE OF HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH A NUCLEOSIDE INHIBITOR
1360, 3ql8A, 0.6950, 2.87, 0.362, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-260
1361, 4erwA, 0.6949, 2.66, 0.381, 292, 268, CDK2 IN COMPLEX WITH STAUROSPORINE
1362, 3rpsB, 0.6949, 3.25, 0.299, 334, 274, STRUCTURE OF HUMAN CK2ALPHA IN COMPLEX WITH THE ATP-COMPETITIVE INHIBITOR 3-(4567-TETRABROMO-1H-BENZOTRIAZOL-1-YL)PROPAN-1-OL
1363, 3pwdA, 0.6949, 3.55, 0.272, 327, 279, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH NBC (Z1)
1364, 2r3rA, 0.6949, 2.64, 0.363, 290, 267, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1365, 1h0vA, 0.6949, 2.65, 0.362, 288, 268, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[(R)-PYRROLIDINO-5 -YL]METHOXYPURINE
1366, 1h01A, 0.6949, 2.59, 0.361, 286, 266, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1367, 2qc6A, 0.6948, 3.52, 0.272, 326, 279, PROTEIN KINASE CK2 IN COMPLEX WITH DBC
1368, 1dayA, 0.6948, 3.47, 0.277, 327, 278, CRYSTAL STRUCTURE OF A BINARY COMPLEX OF PROTEIN KINASE CK2 (ALPHA-SUBUNIT) AND MG-GMPPNP
1369, 3le6A, 0.6947, 2.51, 0.366, 283, 265, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A PYRAZOLOBENZODIAZEPINE INHIBITOR
1370, 5h8bB, 0.6946, 3.46, 0.292, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 2
1371, 3s00A, 0.6946, 2.87, 0.353, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR L4-14
1372, 3r9hA, 0.6946, 2.85, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-142
1373, 3qqjA, 0.6946, 2.90, 0.347, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR L2
1374, 5cquA, 0.6945, 3.31, 0.296, 328, 274, MONOCLINIC COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1375, 4lynA, 0.6945, 2.74, 0.384, 287, 268, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH (2S)-N-(5-(((5-TERT-BUTYL-13-OXAZOL-2-YL)METHYL)SULFANYL)-13- THIAZOL-2-YL)-2-PHENYLPROPANAMIDE
1376, 3rpvA, 0.6945, 2.95, 0.375, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR RC-2-88
1377, 3qtqA, 0.6945, 2.85, 0.369, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-1-137
1378, 5owlB, 0.6944, 3.42, 0.293, 332, 276, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1379, 5mhqA, 0.6944, 2.76, 0.349, 291, 269, CCT068127 IN COMPLEX WITH CDK2
1380, 5kwhA, 0.6944, 3.38, 0.293, 331, 276, CRYSTAL STRUCTURE OF CK2
1381, 4aaaA, 0.6944, 3.30, 0.289, 295, 277, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN
1382, 3uliA, 0.6944, 2.77, 0.369, 286, 268, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) BOUND TO AZABENZIMIDAZOLE DERIVATIVE
1383, 5oulA, 0.6943, 3.38, 0.295, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 9
1384, 3qa0A, 0.6943, 3.40, 0.293, 330, 276, CRYSTAL STRUCTURE OF THE APO-FORM OF HUMAN CK2 ALPHA AT PH 6.5
1385, 2r3pA, 0.6943, 2.60, 0.361, 289, 266, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1386, 1ds5A, 0.6943, 3.45, 0.270, 328, 278, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1387, 3rniA, 0.6942, 2.93, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-3-86
1388, 1om1A, 0.6942, 3.57, 0.269, 325, 279, CRYSTAL STRUCTURE OF MAIZE CK2 ALPHA IN COMPLEX WITH IQA
1389, 5yf9X, 0.6941, 3.38, 0.310, 319, 274, CRYSTAL STRUCTURE OF CK2A2 FORM-2 
1390, 5n9nA, 0.6941, 3.35, 0.302, 329, 275, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE TIGHT-BINDING DIBENZOFURAN INHIBITOR TF85 (4A)
1391, 5n9lA, 0.6941, 3.39, 0.297, 329, 276, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH THE ATP-COMPETITIVE DIBENZOFURAN INHIBITOR TF (4B)
1392, 3mtlA, 0.6941, 2.68, 0.326, 294, 267, CRYSTAL STRUCTURE OF THE PCTAIRE1 KINASE IN COMPLEX WITH INDIRUBIN E804
1393, 4l46A, 0.6940, 2.87, 0.259, 317, 270, CRYSTAL STRUCTURES OF HUMAN P70S6K1-WT
1394, 4ez3A, 0.6940, 2.97, 0.353, 294, 272, CDK2 IN COMPLEX WITH NSC 134199
1395, 4ek5A, 0.6940, 2.60, 0.365, 289, 266, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1396, 3s0oA, 0.6940, 2.88, 0.351, 293, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-1-138
1397, 5cu2A, 0.6939, 3.51, 0.296, 328, 277, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1398, 4rlkA, 0.6939, 3.60, 0.272, 327, 279, CRYSTAL STRUCTURE OF Z. MAYS CK2ALPHA IN COMPLEX WITH THE ATP- COMPETITIVE INHIBITOR 4-[(E)-(FLUOREN-9-YLIDENEHYDRAZINYLIDENE)- METHYL] BENZOATE
1399, 2pvnA, 0.6939, 3.49, 0.277, 327, 278, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1400, 3u4uA, 0.6938, 3.30, 0.296, 327, 274, CASEIN KINASE 2 IN COMPLEX WITH AZ-INHIBITOR
1401, 3kxgA, 0.6938, 3.52, 0.270, 326, 278, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR 34567-PENTABROMO-1H-INDAZOLE (K64)
1402, 3g33C, 0.6938, 2.76, 0.335, 291, 266, CRYSTAL STRUCTURE OF CDK4/CYCLIN D3
1403, 3fwqA, 0.6938, 3.14, 0.298, 334, 272, INACTIVE CONFORMATION OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT
1404, 5h8eB, 0.6937, 3.47, 0.292, 331, 277, CRYSTAL STRUCTURE OF CK2 WITH COMPOUND 7H
1405, 4dgnA, 0.6937, 3.51, 0.270, 325, 278, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR LUTEOLIN
1406, 3u87B, 0.6937, 3.48, 0.289, 329, 277, STRUCTURE OF A CHIMERIC CONSTRUCT OF HUMAN CK2ALPHA AND HUMAN CK2ALPHA  IN COMPLEX WITH A NON-HYDROLYSABLE ATP-ANALOGUE
1407, 1m2pA, 0.6937, 3.50, 0.270, 325, 278, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO- ANTHRAQUINONE/CK2 KINASE COMPLEX
1408, 5cqwB, 0.6936, 3.42, 0.293, 331, 276, TETRAGONAL COMPLEX STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A BENZOTRIAZOLE-BASED INHIBITOR GENERATED BY CLICK-CHEMISTRY
1409, 4ib5A, 0.6936, 3.54, 0.291, 331, 278, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1410, 4dgoA, 0.6936, 3.43, 0.274, 325, 277, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH TYRPHOSTIN AG99
1411, 3kxnA, 0.6936, 3.35, 0.272, 327, 276, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR TETRAIODOBENZIMIDAZOLE (K88)
1412, 5x8iA, 0.6935, 3.26, 0.275, 328, 273, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
1413, 4ubaA, 0.6935, 3.58, 0.291, 333, 278, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1414, 5oueA, 0.6934, 3.38, 0.295, 328, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
1415, 4dgmA, 0.6934, 3.51, 0.270, 326, 278, CRYSTAL STRUCTURE OF MAIZE CK2 IN COMPLEX WITH THE INHIBITOR APIGENIN
1416, 2r3oA, 0.6934, 2.62, 0.357, 289, 266, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1417, 1ds5D, 0.6934, 3.47, 0.270, 328, 278, DIMERIC CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT IN COMPLEX WITH TWO BETA PEPTIDES MIMICKING THE ARCHITECTURE OF THE TETRAMERIC PROTEIN KINASE CK2 HOLOENZYME.
1418, 5kwhB, 0.6933, 3.47, 0.292, 331, 277, CRYSTAL STRUCTURE OF CK2
1419, 4ogrI, 0.6933, 3.34, 0.327, 318, 278, CRYSTAL STRUCTURE OF P-TEFB COMPLEX WITH AFF4 AND TAT
1420, 4jqeA, 0.6933, 3.39, 0.272, 369, 276, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH AMPPN
1421, 3rawA, 0.6933, 3.51, 0.261, 351, 280, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
1422, 3fl5A, 0.6933, 3.51, 0.273, 324, 278, PROTEIN KINASE CK2 IN COMPLEX WITH THE INHIBITOR QUINALIZARIN
1423, 1pxlA, 0.6933, 2.65, 0.363, 290, 267, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR [4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]- (4-TRIFLUOROMETHYL-PHENYL)-AMINE
1424, 3r8lA, 0.6932, 2.86, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR L3-4
1425, 1jamA, 0.6932, 3.54, 0.277, 327, 278, CRYSTAL STRUCTURE OF APO-FORM OF Z. MAYS CK2 PROTEIN KINASE ALPHA SUBUNIT
1426, 4ubaB, 0.6931, 3.32, 0.296, 333, 274, LOW-SALT STRUCTURE OF PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH 4 - CARBOXY-68-BROMO-FLAVONOL (FLC26)
1427, 3r8vA, 0.6931, 2.92, 0.353, 294, 272, CDK2 IN COMPLEX WITH INHIBITOR RC-1-135
1428, 3qzgA, 0.6931, 2.97, 0.347, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR JWS-6-76
1429, 3qtuA, 0.6931, 2.87, 0.352, 294, 270, CDK2 IN COMPLEX WITH INHIBITOR RC-2-132
1430, 3fe3A, 0.6931, 2.84, 0.239, 317, 268, CRYSTAL STRUCTURE OF THE KINASE MARK3/PAR-1: T211A-S215A DOUBLE MUTANT
1431, 4md9K, 0.6930, 3.35, 0.293, 328, 276, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1432, 4ib5B, 0.6930, 3.52, 0.291, 329, 278, STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT IN COMPLEX WITH A CK2BETA-COMPETITIVE CYCLIC PEPTIDE
1433, 3ns9A, 0.6929, 2.64, 0.357, 289, 266, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR BS-194
1434, 2i6lB, 0.6929, 2.75, 0.362, 269, 265, CRYSTAL STRUCTURE OF HUMAN MITOGEN ACTIVATED PROTEIN KINASE 6 (MAPK6)
1435, 3q9xA, 0.6928, 3.43, 0.293, 330, 276, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH EMODIN AT PH 6.5
1436, 3qu0A, 0.6927, 2.91, 0.354, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-38
1437, 3lfnA, 0.6927, 2.67, 0.386, 285, 267, CRYSTAL STRUCTURE OF CDK2 WITH SAR57 AN AMINOINDAZOLE TYPE INHIBITOR
1438, 3at2A, 0.6927, 3.35, 0.295, 334, 275, CRYSTAL STRUCTURE OF CK2ALPHA
1439, 2pvkA, 0.6927, 3.59, 0.272, 327, 279, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1440, 5y9mX, 0.6926, 3.41, 0.309, 319, 275, CRYSTAL STRUCTURE OF CK2A2 FORM 3 
1441, 5cvfA, 0.6926, 3.31, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 5 BOUND
1442, 1e1vA, 0.6926, 2.71, 0.358, 290, 268, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU2058
1443, 4l45A, 0.6925, 2.82, 0.257, 317, 269, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389E
1444, 3kxmA, 0.6925, 3.54, 0.273, 326, 278, CRYSTAL STRUCTURE OF Z. MAYS CK2 KINASE ALPHA SUBUNIT IN COMPLEX WITH THE INHIBITOR K74
1445, 1ob3A, 0.6925, 2.66, 0.375, 277, 267, STRUCTURE OF P. FALCIPARUM PFPK5
1446, 2r3iA, 0.6924, 2.63, 0.361, 289, 266, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1447, 4md9M, 0.6923, 3.61, 0.290, 331, 279, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1448, 4aguA, 0.6923, 2.91, 0.307, 277, 267, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1449, 5uq1A, 0.6922, 2.86, 0.389, 288, 265, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1 COMPLEX
1450, 5mp8A, 0.6922, 3.29, 0.293, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1451, 3qtxA, 0.6922, 2.97, 0.358, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-2-35
1452, 5owlA, 0.6921, 3.47, 0.297, 331, 276, LOW SALT STRUCTURE OF HUMAN PROTEIN KINASE CK2ALPHA IN COMPLEX WITH 3- AMINOPROPYL-4;5;6;7-TETRABROMOBENZIMIDAZOL 
1453, 5ku8B, 0.6921, 3.48, 0.292, 331, 277, CRYSTAL STRUCTURE OF CK2
1454, 5ctpB, 0.6921, 3.41, 0.295, 327, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1455, 2r3hA, 0.6921, 2.64, 0.361, 289, 266, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1456, 2oxdA, 0.6921, 3.48, 0.274, 325, 277, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE K17 K22 AND K32 INHIBITORS
1457, 1aq1A, 0.6921, 2.31, 0.375, 277, 261, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR STAUROSPORINE
1458, 6fyoA, 0.6920, 3.37, 0.269, 331, 275, X-RAY STRUCTURE OF CLK1-KD(148-484)/CPD-2 AT 2.32A 
1459, 3nr9B, 0.6920, 3.34, 0.255, 347, 275, STRUCTURE OF HUMAN CDC2-LIKE KINASE 2 (CLK2)
1460, 1v0oA, 0.6920, 2.31, 0.387, 276, 261, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
1461, 5x8iB, 0.6919, 3.24, 0.276, 327, 272, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH COMPOUND 25
1462, 5cvhA, 0.6919, 3.38, 0.292, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA
1463, 5clpB, 0.6919, 3.29, 0.299, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1464, 3tizA, 0.6919, 2.92, 0.344, 293, 270, CDK2 IN COMPLEX WITH NSC 111848
1465, 5mowA, 0.6918, 3.34, 0.300, 328, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1466, 4md9F, 0.6918, 3.48, 0.296, 327, 277, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1467, 1pxnA, 0.6918, 2.89, 0.348, 294, 270, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 4-[4-(4-METHYL-2-METHYLAMINO-THIAZOL-5-YL)- PYRIMIDIN-2-YLAMINO]-PHENOL
1468, 2pvhA, 0.6917, 3.59, 0.272, 327, 279, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1469, 1unhA, 0.6917, 2.67, 0.366, 276, 262, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1470, 5otrA, 0.6916, 3.42, 0.295, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 14
1471, 2pvmA, 0.6916, 3.44, 0.274, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1472, 2b52A, 0.6916, 2.60, 0.383, 283, 266, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH DPH- 042562
1473, 2a4lA, 0.6916, 2.52, 0.371, 286, 264, HUMAN CYCLIN-DEPENDENT KINASE 2 IN COMPLEX WITH ROSCOVITINE
1474, 1unhB, 0.6916, 2.67, 0.366, 276, 262, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1475, 5cu6A, 0.6914, 3.27, 0.297, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA
1476, 3qqgA, 0.6914, 2.95, 0.354, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR L2-5
1477, 3q9zA, 0.6914, 3.53, 0.296, 332, 277, CRYSTAL STRUCTURE OF HUMAN CK2 ALPHA IN COMPLEX WITH QUINALIZARIN AT PH 6.5
1478, 5jq5A, 0.6913, 2.61, 0.366, 287, 265, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0942
1479, 1pxkA, 0.6913, 2.70, 0.363, 290, 267, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR N-[4-(24-DIMETHYL-THIAZOL-5-YL)PYRIMIDIN-2-YL]- N -HYDROXYIMINOFORMAMIDE
1480, 1m2qA, 0.6913, 3.49, 0.274, 327, 277, CRYSTAL STRUCTURE OF 18-DI-HYDROXY-4-NITRO-XANTEN-9- ONE/CK2 KINASE COMPLEX
1481, 5ku8A, 0.6912, 3.31, 0.296, 328, 274, CRYSTAL STRUCTURE OF CK2
1482, 5mowB, 0.6911, 3.35, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1483, 3qqhA, 0.6911, 3.01, 0.354, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR L2-2
1484, 2vtoA, 0.6911, 2.63, 0.385, 283, 265, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1485, 2oxxA, 0.6911, 3.43, 0.279, 325, 276, PROTEIN KINASE CK2 IN COMPLEX WITH TETRABROMOBENZOIMIDAZOLE DERIVATIVES K17 K22 AND K32
1486, 4aguB, 0.6910, 2.82, 0.314, 276, 264, CRYSTAL STRUCTURE OF THE HUMAN CDKL1 KINASE DOMAIN
1487, 3ti1A, 0.6910, 2.89, 0.359, 294, 270, CDK2 IN COMPLEX WITH SUNITINIB
1488, 2wzjA, 0.6910, 2.81, 0.230, 310, 265, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1489, 5mmfA, 0.6909, 3.46, 0.295, 326, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1490, 5j1wB, 0.6909, 3.48, 0.271, 337, 277, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1491, 3qtzA, 0.6909, 2.89, 0.367, 294, 270, CDK2 IN COMPLEX WITH INHIBITOR RC-2-36
1492, 2wzjC, 0.6909, 2.93, 0.229, 310, 266, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1493, 1y91A, 0.6908, 2.81, 0.378, 286, 267, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A PYRAZOLO[1 5-A]PYRIMIDINE INHIBITOR
1494, 1f0qA, 0.6908, 3.57, 0.273, 329, 278, CRYSTAL STRUCTURE OF THE ALPHA SUBUNIT OF PROTEIN KINASE CK2 IN COMPLEX WITH THE NUCLEOTIDE COMPETITIVE INHIBITOR EMODIN
1495, 5oquA, 0.6907, 3.35, 0.293, 324, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
1496, 4md9H, 0.6907, 3.58, 0.295, 328, 278, CRYSTAL STRUCTURE OF SYMMETRIC CK2 HOLOENZYME WITH MUTATED ALPHA SUBUNIT (F121E TRUNCATED AT AA 336)
1497, 4au8B, 0.6907, 2.58, 0.369, 277, 263, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
1498, 5ctpA, 0.6906, 3.35, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1499, 6g33B, 0.6905, 3.57, 0.270, 337, 278, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1500, 5mpjA, 0.6905, 3.39, 0.292, 326, 274, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1501, 5cx9A, 0.6905, 3.43, 0.295, 328, 275, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1502, 5cu0B, 0.6905, 3.38, 0.299, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1503, 1wccA, 0.6905, 2.60, 0.377, 283, 265, SCREENING FOR FRAGMENT BINDING BY X-RAY CRYSTALLOGRAPHY
1504, 5mo5B, 0.6904, 3.37, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1505, 2qkrA, 0.6904, 2.51, 0.378, 273, 262, CRYPTOSPORIDIUM PARVUM CYCLIN-DEPENDENT KINASE CGD5_2510 WITH INDIRUBIN 3 -MONOXIME BOUND
1506, 5orkA, 0.6903, 3.36, 0.293, 324, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
1507, 4fkvA, 0.6903, 2.58, 0.377, 282, 265, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1508, 2wu7A, 0.6903, 3.55, 0.261, 348, 280, CRYSTAL STRUCTURE OF THE HUMAN CLK3 IN COMPLEX WITH V25
1509, 5ct0A, 0.6902, 3.38, 0.299, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1510, 3rawB, 0.6902, 3.53, 0.258, 349, 279, CRYSTAL STRUCTURE OF HUMAN CDC-LIKE KINASE 3 ISOFORM IN COMPLEX WITH LEUCETTINE L41
1511, 2wzjD, 0.6902, 3.00, 0.231, 313, 268, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1512, 5mmfB, 0.6900, 3.36, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 7 BOUND
1513, 5ieyA, 0.6900, 2.64, 0.357, 286, 266, CRYSTAL STRUCTURE OF A CDK INHIBITOR BOUND TO CDK2
1514, 3r8zA, 0.6900, 2.80, 0.361, 290, 269, CDK2 IN COMPLEX WITH INHIBITOR RC-1-136
1515, 2acxA, 0.6900, 3.28, 0.234, 495, 273, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
1516, 1pxmA, 0.6900, 2.80, 0.348, 290, 267, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR 3-[4-(24-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2- YLAMINO]-PHENOL
1517, 5mo6B, 0.6899, 3.36, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1518, 5cvhB, 0.6899, 3.38, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA
1519, 4fkiA, 0.6899, 2.72, 0.365, 287, 266, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1520, 3wblA, 0.6899, 2.62, 0.374, 283, 265, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR
1521, 2pvlA, 0.6898, 3.53, 0.278, 327, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1522, 2pvjA, 0.6898, 3.51, 0.274, 326, 277, STRUCTURE-BASED DESIGN OF PYRAZOLO[15-A][135]TRIAZINE DERIVATIVES AS POTENT INHIBITORS OF PROTEIN KINASE CK2
1523, 6ehkA, 0.6897, 3.43, 0.295, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712 AND COMPOUND 37
1524, 5modB, 0.6897, 3.38, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1525, 5cu0A, 0.6897, 3.39, 0.299, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND N-(3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)ACETAMIDE BOUND
1526, 3rjcA, 0.6897, 2.92, 0.348, 294, 270, CDK2 IN COMPLEX WITH INHIBITOR L4-12
1527, 3at3A, 0.6896, 3.59, 0.291, 332, 278, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVATIVE
1528, 5oquB, 0.6895, 3.37, 0.293, 324, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 5
1529, 4l43A, 0.6895, 2.86, 0.260, 316, 269, CRYSTAL STRUCTURES OF HUMAN P70S6K1-T389A (FORM I)
1530, 3sqqA, 0.6895, 3.02, 0.387, 288, 271, CDK2 IN COMPLEX WITH INHIBITOR RC-3-96
1531, 3fz1A, 0.6895, 2.76, 0.376, 284, 266, CRYSTAL STRUCTURE OF A BENZTHIOPHENE INHIBITOR BOUND TO HUMAN CYCLIN-DEPENDENT KINASE-2 (CDK-2)
1532, 2r7iA, 0.6895, 3.26, 0.305, 322, 272, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1533, 5oueB, 0.6894, 3.37, 0.297, 326, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 20
1534, 5otyA, 0.6893, 3.44, 0.295, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH CAM4712
1535, 5j1wA, 0.6893, 3.43, 0.268, 338, 276, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1536, 2wzjF, 0.6893, 2.95, 0.236, 310, 267, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1537, 2wzjB, 0.6893, 2.93, 0.236, 310, 267, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1538, 1jsvA, 0.6893, 2.59, 0.364, 287, 264, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[(6-AMINO-4-PYRIMIDINYL) AMINO]BENZENESULFONAMIDE
1539, 5mmrA, 0.6892, 3.40, 0.299, 326, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1540, 5j1vB, 0.6892, 3.44, 0.268, 337, 276, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1541, 5cx9B, 0.6892, 3.37, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH (METHYL 4-((3-(3-CHLORO-4-(PHENYL) BENZYLAMINO)PROPYL)AMINO)-4-OXOBUTANOATE BOUND
1542, 1e1xA, 0.6892, 2.74, 0.360, 290, 267, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR NU6027
1543, 2vtsA, 0.6891, 2.60, 0.390, 282, 264, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1544, 2r3gA, 0.6891, 2.60, 0.364, 287, 264, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1545, 5modA, 0.6889, 3.43, 0.296, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1546, 5mmrB, 0.6889, 3.37, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-((2-CHLORO-[11 -BIPHENYL]-4-YL) METHYL)BUTANE-14-DIAMINE BOUND
1547, 3pxyA, 0.6889, 3.00, 0.354, 294, 271, CDK2 IN COMPLEX WITH INHIBITOR JWS648
1548, 1zogA, 0.6889, 3.38, 0.284, 325, 275, CRYSTAL STRUCTURE OF PROTEIN KINASE CK2 IN COMPLEX WITH TBB- DERIVATIVES
1549, 5mo7A, 0.6888, 3.41, 0.299, 327, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1550, 5mo6A, 0.6888, 3.38, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1551, 5oumB, 0.6887, 3.38, 0.300, 326, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
1552, 5os7A, 0.6887, 3.41, 0.296, 326, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
1553, 4fkwA, 0.6887, 2.48, 0.376, 280, 263, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1554, 2r7iC, 0.6887, 3.21, 0.306, 321, 271, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1555, 6gmdB, 0.6886, 3.41, 0.296, 326, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
1556, 5mo7B, 0.6886, 3.36, 0.300, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1557, 5cshA, 0.6886, 3.39, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1558, 3warA, 0.6886, 3.39, 0.299, 334, 274, CRYSTAL STRUCTURE OF HUMAN CK2A
1559, 3gbzA, 0.6886, 2.85, 0.346, 274, 266, STRUCTURE OF THE CMGC CDK KINASE FROM GIARDIA LAMBLIA
1560, 3at4A, 0.6886, 3.58, 0.292, 331, 277, CRYSTAL STRUCTURE OF CK2ALPHA WITH PYRADINE DERIVERTIVE
1561, 2r7iB, 0.6886, 3.21, 0.303, 322, 271, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1562, 2wzjE, 0.6885, 2.91, 0.229, 310, 266, CATALYTIC AND UBA DOMAIN OF KINASE MARK2/(PAR-1) K82R T208E DOUBLE MUTANT
1563, 1z57A, 0.6885, 3.51, 0.264, 333, 277, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH 10Z-HYMENIALDISINE
1564, 5moeA, 0.6884, 3.35, 0.293, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1565, 3w8lB, 0.6883, 3.44, 0.291, 326, 275, CRYSTAL STRUCTURE OF HUMAN CK2 IN COMPLEX WITH INOSITOL HEXAKISPHOSPHATE
1566, 2r7iD, 0.6883, 3.26, 0.298, 322, 272, CRYSTAL STRUCTURE OF CATALYTIC SUBUNIT OF PROTEIN KINASE CK2
1567, 1m2rA, 0.6883, 3.44, 0.276, 327, 275, CRYSTAL STRUCTURE OF 58-DI-AMINO-14-DI-HYDROXY- ANTHRAQUINONE/CK2 KINASE COMPLEX
1568, 5k4jA, 0.6882, 2.64, 0.377, 282, 265, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH COMPOUND 22
1569, 4fkgA, 0.6882, 2.69, 0.370, 286, 265, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1570, 5mo5A, 0.6881, 3.38, 0.297, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1571, 5j1vA, 0.6881, 3.51, 0.268, 338, 276, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1572, 5mo8A, 0.6880, 3.43, 0.296, 325, 274, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1573, 5ct0B, 0.6879, 3.39, 0.297, 326, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH 3-(3-CHLORO-4-(PHENYL)BENZYLAMINO) PROPAN-1-OL BOUND
1574, 4lfiB, 0.6879, 3.64, 0.266, 371, 278, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1575, 4lfiA, 0.6879, 3.64, 0.266, 370, 278, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1576, 6ft8A, 0.6878, 3.52, 0.264, 338, 277, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 8G 
1577, 4mwhA, 0.6878, 3.48, 0.269, 371, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1578, 4bbmB, 0.6878, 3.24, 0.311, 292, 270, CRYSTAL STRUCTURE OF THE HUMAN CDKL2 KINASE DOMAIN WITH BOUND TCS 2312
1579, 5otoA, 0.6877, 3.45, 0.292, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
1580, 5mpjB, 0.6877, 3.40, 0.293, 324, 273, 1-(2-CHLORO-[11 -BIPHENYL]-4-YL)-N-METHYLETHANAMINE
1581, 5orhA, 0.6876, 3.39, 0.293, 324, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
1582, 3unkA, 0.6876, 3.12, 0.353, 295, 272, CDK2 IN COMPLEX WITH INHIBITOR YL5-083
1583, 5ievA, 0.6875, 2.65, 0.389, 284, 265, CRYSTAL STRUCTURE OF BAY 1000394 (RONICICLIB) BOUND TO CDK2
1584, 5otdA, 0.6873, 3.45, 0.292, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
1585, 5orjA, 0.6873, 3.41, 0.293, 325, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
1586, 2vu3A, 0.6873, 2.80, 0.370, 285, 265, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1587, 6ft9B, 0.6872, 3.47, 0.272, 337, 276, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1588, 5orjB, 0.6872, 3.41, 0.293, 324, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3
1589, 5iexA, 0.6872, 2.68, 0.361, 285, 266, CRYSTAL STRUCTURE OF (RS)-S-{4-[(5-BROMO-4-{[(2R3R)-2-HYDROXY-1- METHYLPROPYL]OXY}- PYRIMIDIN-2-YL)AMINO]PHENYL}-S- CYCLOPROPYLSULFOXIMIDE BOUND TO CDK2
1590, 6g33C, 0.6871, 3.39, 0.269, 336, 275, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1591, 5oumA, 0.6871, 3.44, 0.299, 326, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 21
1592, 5orhB, 0.6871, 3.38, 0.300, 325, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 2
1593, 3py0A, 0.6871, 3.08, 0.352, 294, 270, CDK2 IN COMPLEX WITH INHIBITOR SU9516
1594, 2r3qA, 0.6871, 2.58, 0.365, 286, 263, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1595, 5otlB, 0.6870, 3.45, 0.292, 326, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
1596, 5orkB, 0.6870, 3.38, 0.294, 323, 272, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 6
1597, 5m44A, 0.6870, 3.28, 0.295, 329, 271, COMPLEX STRUCTURE OF HUMAN PROTEIN KINASE CK2 CATALYTIC SUBUNIT WITH A THIENO[23-D]PYRIMIDIN INHIBITOR CRYSTALLIZED UNDER HIGH-SALT CONDITIONS
1598, 5cu2B, 0.6870, 3.35, 0.301, 325, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH 2-HYDROXY-5-METHYLBENZOIC ACID AND (METHYL 4-((3-(3-CHLORO-4-(PHENYL)BENZYLAMINO)PROPYL)AMINO)-4- OXOBUTANOAT BOUND
1599, 2w17A, 0.6870, 2.46, 0.378, 278, 262, CDK2 IN COMPLEX WITH THE IMIDAZOLE PYRIMIDINE AMIDE COMPOUND (S)-8B
1600, 6ft9A, 0.6869, 3.37, 0.270, 336, 274, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1601, 5ouuB, 0.6869, 3.42, 0.293, 325, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
1602, 4fi1A, 0.6868, 3.44, 0.269, 371, 275, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH ATP
1603, 2vtpA, 0.6867, 2.60, 0.384, 281, 263, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1604, 3lltA, 0.6865, 3.21, 0.230, 341, 270, CRYSTAL STRUCTURE OF PF14_0431 KINASE DOMAIN.
1605, 2hakE, 0.6865, 2.97, 0.239, 318, 268, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
1606, 5ot6A, 0.6864, 3.46, 0.296, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
1607, 5os7B, 0.6863, 3.40, 0.293, 325, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 4
1608, 5cu3A, 0.6863, 3.43, 0.297, 325, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1609, 6gmdA, 0.6861, 3.41, 0.297, 325, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 3 
1610, 5otiA, 0.6859, 3.48, 0.295, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 27
1611, 5ot5A, 0.6859, 3.47, 0.296, 326, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
1612, 5mp8B, 0.6859, 3.34, 0.295, 323, 271, CRYSTAL STRUCTURE OF CK2ALPHA WITH ZT0432 BOUND
1613, 5mo8B, 0.6859, 3.43, 0.297, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1614, 4au8A, 0.6858, 2.55, 0.373, 276, 260, CRYSTAL STRUCTURE OF COMPOUND 4A IN COMPLEX WITH CDK5 SHOWING AN UNUSUAL BINDING MODE TO THE HINGE REGION VIA A WATER MOLECULE
1615, 5moeB, 0.6856, 3.38, 0.294, 323, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH N-(3-(((2-CHLORO-[11 -BIPHENYL]-4- YL)METHYL)AMINO)PROPYL)METHANESULFONAMIDE BOUND
1616, 1fvtA, 0.6856, 2.60, 0.380, 282, 263, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
1617, 5otdB, 0.6854, 3.45, 0.293, 324, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 25
1618, 3unjA, 0.6854, 3.13, 0.352, 294, 270, CDK2 IN COMPLEX WITH INHIBITOR YL1-038-31
1619, 4wboA, 0.6853, 3.29, 0.232, 497, 272, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1620, 2acxB, 0.6853, 3.41, 0.231, 492, 273, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 6 BOUND TO AMPPNP
1621, 5othA, 0.6851, 3.49, 0.296, 326, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
1622, 5ot6B, 0.6851, 3.44, 0.300, 326, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 19
1623, 2vv9A, 0.6851, 2.50, 0.374, 279, 262, CDK2 IN COMPLEX WITH AN IMIDAZOLE PIPERAZINE
1624, 1di8A, 0.6851, 2.63, 0.375, 283, 264, THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH 4-[3-HYDROXYANILINO]-67-DIMETHOXYQUINAZOLINE
1625, 3iw4C, 0.6850, 3.16, 0.238, 332, 269, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1626, 5otoB, 0.6849, 3.45, 0.297, 324, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 30
1627, 6eiiB, 0.6848, 3.45, 0.293, 326, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
1628, 1xo2B, 0.6846, 3.06, 0.351, 289, 268, CRYSTAL STRUCTURE OF A HUMAN CYCLIN-DEPENDENT KINASE 6 COMPLEX WITH A FLAVONOL INHIBITOR FISETIN
1629, 5fp6A, 0.6844, 2.64, 0.367, 278, 264, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 3-(47-DICHLORO-1H-INDOL-3-YL)PROP-2-YN-1-OL (AT17833) IN AN ALTERNATE BINDING SITE.
1630, 3r7iA, 0.6844, 2.63, 0.371, 282, 264, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-74
1631, 3a8xA, 0.6841, 3.00, 0.228, 334, 267, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1632, 2w1hA, 0.6841, 2.72, 0.379, 283, 264, FRAGMENT-BASED DISCOVERY OF THE PYRAZOL-4-YL UREA (AT9283) A MULTI-TARGETED KINASE INHIBITOR WITH POTENT AURORA KINASE ACTIVITY
1633, 3r7uA, 0.6840, 2.58, 0.369, 282, 263, CDK2 IN COMPLEX WITH INHIBITOR KVR-1-75
1634, 5cu3B, 0.6839, 3.46, 0.293, 324, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 10 BOUND
1635, 5cshB, 0.6838, 3.35, 0.300, 323, 270, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 4 BOUND
1636, 4pniA, 0.6838, 3.26, 0.237, 492, 270, BOVINE G PROTEIN-COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH GSK2163632A
1637, 1ckpA, 0.6838, 2.66, 0.382, 279, 262, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR PURVALANOL B
1638, 5ouuA, 0.6837, 3.39, 0.295, 324, 271, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 22
1639, 1ke7A, 0.6836, 2.64, 0.380, 281, 263, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[(22- DIOXIDO-13-DIHYDRO-2-BENZOTHIEN-5-YL)AMINO]METHYLENE}-5- (13-OXAZOL-5-YL)-13-DIHYDRO-2H-INDOL-2-ONE
1640, 4yhjB, 0.6835, 3.26, 0.214, 490, 271, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
1641, 4wboD, 0.6835, 3.31, 0.232, 491, 272, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1642, 2w06A, 0.6835, 2.72, 0.379, 282, 264, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5C
1643, 1h0wA, 0.6835, 2.59, 0.365, 283, 263, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 2-AMINO-6-[CYCLOHEX-3-ENYL]METHOXYPURINE
1644, 5ot5B, 0.6834, 3.48, 0.293, 325, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 24
1645, 1ke8A, 0.6833, 2.81, 0.377, 282, 265, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 4-{[(2-OXO- 12-DIHYDRO-3H-INDOL-3-YLIDENE)METHYL]AMINO}-N-(13- THIAZOL-2-YL)BENZENESULFONAMIDE
1646, 4dglD, 0.6831, 3.69, 0.295, 328, 278, CRYSTAL STRUCTURE OF THE CK2 TETRAMERIC HOLOENZYME
1647, 5othB, 0.6830, 3.49, 0.293, 324, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 26
1648, 1h00A, 0.6830, 2.57, 0.382, 278, 262, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1649, 6eiiA, 0.6829, 3.49, 0.293, 326, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 18
1650, 4yhjA, 0.6829, 3.27, 0.207, 501, 271, STRUCTURE AND FUNCTION OF THE HYPERTENSION VARIANT A486V OF G PROTEIN- COUPLED RECEPTOR KINASE 4 (GRK4)
1651, 4ditA, 0.6826, 2.89, 0.322, 328, 261, CRYSTAL STRUCTURE OF GSK3BETA IN COMPLEX WITH A IMIDAZOPYRIDINE INHIBITOR
1652, 2r3mA, 0.6826, 2.55, 0.383, 278, 261, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1653, 4wboC, 0.6825, 3.25, 0.236, 481, 271, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1654, 1jsuA, 0.6825, 2.78, 0.381, 285, 260, P27(KIP1)/CYCLIN A/CDK2 COMPLEX
1655, 5aniA, 0.6823, 2.48, 0.372, 280, 261, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 6-CHLORO-7H- PURINE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1656, 2w99B, 0.6823, 3.23, 0.332, 291, 271, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1657, 2uznA, 0.6823, 2.58, 0.383, 279, 261, CRYSTAL STRUCTURE OF HUMAN CDK2 COMPLEXED WITH A THIAZOLIDINONE INHIBITOR
1658, 3s2pA, 0.6822, 2.69, 0.382, 279, 262, CRYSTAL STRUCTURE OF CDK2 WITH A 2-AMINOPYRIMIDINE COMPOUND
1659, 3c4yA, 0.6822, 3.36, 0.227, 478, 273, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
1660, 1h08A, 0.6822, 2.92, 0.374, 283, 265, CDK2 IN COMPLEX WITH A DISUBSTITUTED 2 4-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1661, 2vagA, 0.6821, 3.28, 0.268, 330, 272, CRYSTAL STRUCTURE OF DI-PHOSPHORYLATED HUMAN CLK1 IN COMPLEX WITH A NOVEL SUBSTITUTED INDOLE INHIBITOR
1662, 1ke5A, 0.6820, 2.67, 0.380, 281, 263, CDK2 COMPLEXED WITH N-METHYL-4-{[(2-OXO-12-DIHYDRO-3H- INDOL-3-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
1663, 5cs6A, 0.6818, 3.60, 0.297, 327, 273, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1664, 3t8oA, 0.6817, 3.28, 0.232, 493, 272, RHODOPSIN KINASE (GRK1) L166K MUTANT AT 2.5A RESOLUTION
1665, 2vtiA, 0.6817, 2.64, 0.382, 280, 262, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1666, 4fkrA, 0.6816, 2.75, 0.375, 282, 264, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1667, 4fkqA, 0.6816, 2.77, 0.366, 283, 265, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1668, 1v0oB, 0.6816, 2.39, 0.388, 274, 258, STRUCTURE OF P. FALCIPARUM PFPK5-INDIRUBIN-5-SULPHONATE LIGAND COMPLEX
1669, 4eojC, 0.6815, 2.75, 0.388, 282, 260, THR 160 PHOSPHORYLATED CDK2 H84S Q85M K89D - HUMAN CYCLIN A3 COMPLEX WITH ATP
1670, 3ezvA, 0.6815, 2.45, 0.373, 277, 260, CDK-2 WITH INDAZOLE INHIBITOR 9 BOUND AT ITS ACTIVE SITE
1671, 5clpA, 0.6814, 3.36, 0.296, 322, 270, CRYSTAL STRUCTURE OF CK2ALPHA WITH 34-DICHLOROPHENETHYLAMINE BOUND
1672, 4nj3A, 0.6814, 2.52, 0.375, 277, 261, MODULATING THE INTERACTION BETWEEN CDK2 AND CYCLIN A WITH A QUINOLINE- BASED INHIBITOR
1673, 1ke9A, 0.6814, 2.59, 0.382, 281, 262, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH 3-{[4- ({[AMINO(IMINO)METHYL]AMINOSULFONYL)ANILINO]METHYLENE}-2- OXO-23-DIHYDRO-1H-INDOLE
1674, 4jr7A, 0.6811, 3.48, 0.271, 367, 273, CRYSTAL STRUCTURE OF SCCK2 ALPHA IN COMPLEX WITH GMPPNP
1675, 6ft9C, 0.6810, 3.40, 0.266, 337, 274, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH INHIBITOR 16 
1676, 1ke6A, 0.6810, 2.54, 0.383, 280, 261, CYCLIN-DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH N-METHYL-{4- [2-(7-OXO-67-DIHYDRO-8H-[13]THIAZOLO[54-E]INDOL-8- YLIDENE)HYDRAZINO]PHENYL}METHANESULFONAMIDE
1677, 5eakA, 0.6809, 2.88, 0.246, 305, 264, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
1678, 1h25C, 0.6808, 2.54, 0.397, 278, 257, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM RETINOBLASTOMA-ASSOCIATED PROTEIN
1679, 4bzdA, 0.6807, 2.48, 0.365, 277, 260, STRUCTURE OF CDK2 IN COMPLEX WITH A BENZIMIDAZOPYRIMIDINE
1680, 3a8wB, 0.6807, 3.02, 0.229, 327, 266, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1681, 2hakF, 0.6804, 3.13, 0.235, 318, 268, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
1682, 4fr4A, 0.6803, 3.48, 0.212, 350, 274, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1683, 3r9oA, 0.6803, 2.66, 0.376, 282, 263, CDK2 IN COMPLEX WITH INHIBITOR RC-2-143
1684, 2r64A, 0.6803, 2.61, 0.383, 279, 261, CRYSTAL STRUCTURE OF A 3-AMINOINDAZOLE COMPOUND WITH CDK2
1685, 4ek6A, 0.6802, 2.64, 0.383, 278, 261, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1686, 1w0xC, 0.6802, 2.62, 0.385, 280, 262, CRYSTAL STRUCTURE OF HUMAN CDK2 IN COMPLEX WITH THE INHIBITOR OLOMOUCINE.
1687, 4fktA, 0.6800, 2.69, 0.382, 278, 262, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1688, 2w05A, 0.6800, 2.45, 0.378, 276, 259, STRUCTURE OF CDK2 IN COMPLEX WITH AN IMIDAZOLYL PYRIMIDINE COMPOUND 5B
1689, 4fkjA, 0.6797, 2.64, 0.383, 278, 261, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH AMINOPYRAZOLE INHIBITOR
1690, 4wboB, 0.6795, 3.21, 0.233, 495, 270, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH AMLEXANOX
1691, 4fkoA, 0.6795, 3.06, 0.363, 291, 267, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1692, 5otlA, 0.6794, 3.39, 0.301, 320, 269, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 29
1693, 4ek8A, 0.6793, 2.70, 0.382, 280, 262, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1694, 3ig7A, 0.6793, 2.56, 0.385, 278, 260, NOVEL CDK-5 INHIBITORS - CRYSTAL STRUCTURE OF INHIBITOR EFP WITH CDK-2
1695, 2r3jA, 0.6793, 2.62, 0.379, 278, 261, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1696, 3iw4A, 0.6792, 3.15, 0.239, 330, 268, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1697, 4fr4D, 0.6791, 3.50, 0.212, 346, 274, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1698, 3iw4B, 0.6791, 3.10, 0.247, 325, 267, CRYSTAL STRUCTURE OF PKC ALPHA IN COMPLEX WITH NVP-AEB071
1699, 2vthA, 0.6791, 2.57, 0.385, 278, 260, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN
1700, 4fr4F, 0.6790, 3.50, 0.212, 346, 274, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1701, 3rahA, 0.6790, 2.76, 0.364, 282, 264, CDK2 IN COMPLEX WITH INHIBITOR RC-2-22
1702, 2r3kA, 0.6790, 2.53, 0.385, 277, 260, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1703, 3r8mA, 0.6789, 2.99, 0.363, 286, 267, CDK2 IN COMPLEX WITH INHIBITOR L3-3
1704, 1v1kA, 0.6788, 2.51, 0.381, 277, 260, CDK2 IN COMPLEX WITH A DISUBSTITUTED 4 6-BIS ANILINO PYRIMIDINE CDK4 INHIBITOR
1705, 5otqA, 0.6786, 3.59, 0.296, 327, 274, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 33
1706, 6ccyA, 0.6784, 3.11, 0.269, 325, 268, CRYSTAL STRUCTURE OF AKT1 IN COMPLEX WITH A SELECTIVE INHIBITOR 
1707, 4fr4C, 0.6784, 3.45, 0.212, 344, 273, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1708, 3rzbA, 0.6784, 2.85, 0.386, 282, 264, CDK2 IN COMPLEX WITH INHIBITOR RC-2-23
1709, 6g33A, 0.6783, 3.45, 0.267, 335, 273, CRYSTAL STRUCTURE OF CLK1 IN COMPLEX WITH 5-IODOTUBERCIDIN 
1710, 1giiA, 0.6783, 2.67, 0.368, 279, 261, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1711, 5jq8A, 0.6782, 2.62, 0.377, 278, 260, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH INHIBITOR ICEC0943
1712, 4fksA, 0.6782, 2.56, 0.381, 275, 260, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1713, 3qtsA, 0.6781, 2.67, 0.365, 282, 263, CDK2 IN COMPLEX WITH INHIBITOR RC-2-12
1714, 2b55A, 0.6781, 2.48, 0.378, 276, 259, HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) COMPLEXED WITH INDENOPYRAXOLE DIN-101312
1715, 1g5sA, 0.6781, 2.42, 0.384, 275, 258, CRYSTAL STRUCTURE OF HUMAN CYCLIN DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH THE INHIBITOR H717
1716, 6gihA, 0.6780, 3.50, 0.298, 324, 272, CRYSTAL STRUCTURE OF CK2ALPHA WITH CAM187 BOUND 
1717, 2vtaA, 0.6780, 2.61, 0.385, 278, 260, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1718, 4fkpA, 0.6779, 2.66, 0.383, 279, 261, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH OXINDOLE INHIBITOR
1719, 5anoA, 0.6778, 2.49, 0.386, 277, 259, CRYSTAL STRUCTURE OF CDK2 PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1720, 5andA, 0.6778, 2.55, 0.386, 273, 259, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 2-IMIDAZOL-1-YL-1H- BENZIMIDAZOLE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1721, 4acmA, 0.6778, 2.50, 0.371, 277, 259, CDK2 IN COMPLEX WITH 3-AMINO-6-(4-{[2-(DIMETHYLAMINO)ETHYL] SULFAMOYL}-PHENYL)-N-PYRIDIN-3-YLPYRAZINE-2-CARBOXAMIDE
1722, 5oyfA, 0.6777, 3.61, 0.287, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 31
1723, 3rprA, 0.6777, 2.79, 0.364, 282, 264, CDK2 IN COMPLEX WITH INHIBITOR RC-2-49
1724, 3r9nA, 0.6777, 2.70, 0.361, 282, 263, CDK2 IN COMPLEX WITH INHIBITOR RC-2-21
1725, 2fvdA, 0.6777, 2.68, 0.379, 284, 261, CYCLIN DEPENDENT KINASE 2 (CDK2) WITH DIAMINOPYRIMIDINE INHIBITOR
1726, 3zduA, 0.6776, 3.08, 0.332, 297, 268, CRYSTAL STRUCTURE OF THE HUMAN CDKL3 KINASE DOMAIN
1727, 4fr4B, 0.6775, 3.47, 0.212, 350, 273, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1728, 3qtrA, 0.6774, 2.86, 0.364, 282, 264, CDK2 IN COMPLEX WITH INHIBITOR RC-1-148
1729, 2pk9C, 0.6774, 2.17, 0.375, 266, 251, STRUCTURE OF THE PHO85-PHO80 CDK-CYCLIN COMPLEX OF THE PHOSPHATE-RESPONSIVE SIGNAL TRANSDUCTION PATHWAY
1730, 1vyzA, 0.6772, 2.75, 0.383, 279, 261, STRUCTURE OF CDK2 COMPLEXED WITH PNU-181227
1731, 5tvtA, 0.6771, 3.21, 0.255, 321, 267, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
1732, 2vtjA, 0.6770, 2.52, 0.386, 276, 259, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1733, 4fr4E, 0.6769, 3.48, 0.212, 342, 273, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE-PROTEIN KINASE 32A (YANK1)
1734, 3iecA, 0.6769, 2.94, 0.248, 311, 262, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1735, 2bhhA, 0.6769, 2.38, 0.377, 274, 257, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 4-HYDROXYPIPERINDINESULFONYL-INDIRUBINE
1736, 1gihA, 0.6769, 2.51, 0.378, 276, 259, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1737, 2f2cB, 0.6766, 3.03, 0.366, 280, 262, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLINWITH THE INHIBITOR AMINOPURVALANOL
1738, 5kz8A, 0.6765, 2.75, 0.246, 302, 260, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
1739, 4ra4A, 0.6763, 3.20, 0.239, 317, 268, CRYSTAL STRUCTURE OF HUMAN PROTEIN KINASE C ALPHA IN COMPLEX WITH COMPOUND 28 ((R)-6-((3S4S)-13-DIMETHYL-PIPERIDIN-4-YL)-7-(2-FLUORO- PHENYL)-4-METHYL-210-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1740, 3iecB, 0.6763, 2.94, 0.244, 313, 262, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1741, 3ezrA, 0.6762, 2.35, 0.375, 273, 256, CDK-2 WITH INDAZOLE INHIBITOR 17 BOUND AT ITS ACTIVE SITE
1742, 2vtqA, 0.6762, 2.41, 0.381, 274, 257, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1743, 4tnbA, 0.6761, 3.37, 0.228, 529, 272, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH SANGIVAMYCIN
1744, 2jedB, 0.6759, 3.16, 0.267, 320, 266, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1745, 2i0eB, 0.6757, 2.94, 0.251, 300, 263, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1746, 1zmwB, 0.6757, 2.87, 0.241, 302, 261, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
1747, 6c9dB, 0.6756, 3.23, 0.247, 422, 267, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
1748, 4wnkA, 0.6756, 3.35, 0.236, 499, 271, CRYSTAL STRUCTURE OF BOVINE G PROTEIN COUPLED-RECEPTOR KINASE 5 IN COMPLEX WITH CCG215022
1749, 3c51A, 0.6756, 3.44, 0.221, 487, 272, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
1750, 4ysmA, 0.6755, 3.14, 0.311, 475, 264, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
1751, 3a8xB, 0.6755, 3.04, 0.231, 329, 264, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1752, 3c4yB, 0.6754, 3.41, 0.233, 466, 270, CRYSTAL STRUCTURE OF APO FORM OF G PROTEIN COUPLED RECEPTOR KINASE 1 AT 7.51A
1753, 2vtnA, 0.6753, 2.41, 0.377, 274, 257, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1754, 2r3lA, 0.6751, 2.48, 0.376, 275, 258, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1755, 2btrA, 0.6750, 2.52, 0.376, 275, 258, STRUCTURE OF CDK2 COMPLEXED WITH PNU-198873
1756, 1zmwA, 0.6750, 2.83, 0.242, 302, 260, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: T208A/S212A INACTIVE DOUBLE MUTANT
1757, 6ehuA, 0.6749, 3.64, 0.291, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1758, 5otfA, 0.6749, 3.87, 0.206, 411, 281, MRCK BETA IN COMPLEX WITH BDP-00009066
1759, 1dm2A, 0.6748, 2.46, 0.381, 274, 257, HUMAN CYCLIN-DEPENDENT KINASE 2 COMPLEXED WITH THE INHIBITOR HYMENIALDISINE
1760, 5oteA, 0.6747, 3.89, 0.206, 407, 281, MRCK BETA IN COMPLEX WITH BDP-00008900
1761, 3iecC, 0.6747, 2.97, 0.248, 311, 262, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1762, 5twlA, 0.6746, 3.23, 0.256, 319, 266, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
1763, 3rmfA, 0.6746, 2.65, 0.365, 278, 260, CDK2 IN COMPLEX WITH INHIBITOR RC-2-33
1764, 1ua2C, 0.6746, 2.64, 0.372, 286, 258, CRYSTAL STRUCTURE OF HUMAN CDK7
1765, 2i0eA, 0.6745, 3.05, 0.254, 326, 264, STRUCTURE OF CATALYTIC DOMAIN OF HUMAN PROTEIN KINASE C BETA II COMPLEXED WITH A BISINDOLYLMALEIMIDE INHIBITOR
1766, 2hakD, 0.6745, 2.85, 0.245, 309, 261, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
1767, 4ysmB, 0.6744, 3.25, 0.306, 475, 265, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA
1768, 3tnhA, 0.6743, 3.17, 0.345, 288, 264, CDK9/CYCLIN T IN COMPLEX WITH CAN508
1769, 3sw7A, 0.6742, 2.66, 0.365, 278, 260, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1770, 1ungB, 0.6742, 2.57, 0.370, 268, 254, STRUCTURAL MECHANISM FOR THE INHIBITION OF CDK5-P25 BY ROSCOVITINE ALOISINE AND INDIRUBIN.
1771, 5oszA, 0.6741, 3.55, 0.286, 327, 273, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 23
1772, 3rpyA, 0.6741, 2.58, 0.371, 277, 259, CDK2 IN COMPLEX WITH INHIBITOR RC-2-40
1773, 2j9mA, 0.6741, 2.50, 0.380, 275, 258, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH MACROCYCLIC AMINOPYRIMIDINE
1774, 4tndA, 0.6740, 3.43, 0.228, 529, 272, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 5 IN COMPLEX WITH AMP-PNP
1775, 3c4xA, 0.6740, 3.29, 0.226, 496, 270, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
1776, 5k00A, 0.6738, 3.06, 0.265, 311, 264, MELK IN COMPLEX WITH NVS-MELK5
1777, 1r78A, 0.6738, 2.41, 0.379, 273, 256, CDK2 COMPLEX WITH A 4-ALKYNYL OXINDOLE INHIBITOR
1778, 3a8wA, 0.6737, 2.89, 0.225, 326, 262, CRYSTAL STRUCTURE OF PKCIOTA KINASE DOMAIN
1779, 4uakA, 0.6736, 4.01, 0.206, 404, 282, MRCK BETA IN COMPLEX WITH ADP
1780, 4ixpA, 0.6736, 3.30, 0.237, 334, 270, CRYSTAL STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK)
1781, 3pvwA, 0.6736, 3.39, 0.199, 613, 271, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD103A)
1782, 6ehuB, 0.6735, 3.68, 0.295, 327, 275, THE CRYSTAL STRUCTURE OF CK2ALPHA IN COMPLEX WITH COMPOUND 32
1783, 6c9dA, 0.6735, 3.31, 0.246, 425, 268, CRYSTAL STRUCTURE OF KA1-AUTOINHIBITED MARK1 KINASE 
1784, 1ua2B, 0.6734, 2.68, 0.372, 286, 258, CRYSTAL STRUCTURE OF HUMAN CDK7
1785, 1ua2D, 0.6730, 2.68, 0.372, 286, 258, CRYSTAL STRUCTURE OF HUMAN CDK7
1786, 3qc9B, 0.6729, 3.35, 0.226, 481, 270, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1787, 3s1hA, 0.6728, 2.63, 0.367, 277, 259, CDK2 IN COMPLEX WITH INHIBITOR RC-2-39
1788, 4ualA, 0.6727, 3.87, 0.211, 403, 280, MRCK BETA IN COMPLEX WITH BDP00005290
1789, 3sw4A, 0.6726, 2.56, 0.372, 279, 258, CRYSTAL STRUCTURE OF THE CDK2 IN COMPLEX WITH THIAZOLYLPYRIMIDINE INHIBITOR
1790, 2jedA, 0.6726, 2.95, 0.282, 324, 262, THE CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF THE PROTEIN KINASE C THETA IN COMPLEX WITH NVP-XAA228 AT 2.32A RESOLUTION.
1791, 3nuxA, 0.6724, 2.07, 0.364, 261, 250, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1792, 2btsA, 0.6724, 2.48, 0.381, 274, 257, STRUCTURE OF CDK2 COMPLEXED WITH PNU-230032
1793, 5l2sA, 0.6723, 2.12, 0.375, 263, 251, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND ABEMACICLIB.
1794, 5es1A, 0.6723, 2.69, 0.257, 304, 257, CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
1795, 5izjB, 0.6722, 3.04, 0.254, 325, 260, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
1796, 3pfqA, 0.6722, 3.06, 0.240, 520, 263, CRYSTAL STRUCTURE AND ALLOSTERIC ACTIVATION OF PROTEIN KINASE C BETA II
1797, 3nyoB, 0.6722, 3.36, 0.237, 553, 270, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
1798, 2r0iA, 0.6722, 2.74, 0.248, 300, 258, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
1799, 5cs6B, 0.6721, 3.34, 0.298, 316, 265, CRYSTAL STRUCTURE OF CK2ALPHA WITH COMPOUND 3 BOUND
1800, 2hakC, 0.6721, 3.01, 0.244, 310, 262, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
1801, 1zrzA, 0.6721, 2.92, 0.225, 310, 262, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF ATYPICAL PROTEIN KINASE C-IOTA
1802, 5kz8B, 0.6720, 2.75, 0.252, 300, 258, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
1803, 3iecD, 0.6720, 3.01, 0.248, 311, 262, HELICOBACTER PYLORI CAGA INHIBITS PAR1/MARK FAMILY KINASES BY MIMICKING HOST SUBSTRATES
1804, 2x39A, 0.6720, 2.90, 0.267, 316, 262, STRUCTURE OF 4-AMINO-N-(4-CHLOROBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE BOUND TO PKB
1805, 3cqwA, 0.6717, 3.16, 0.272, 318, 265, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1806, 2vttA, 0.6717, 2.40, 0.384, 272, 255, IDENTIFICATION OF N-(4-PIPERIDINYL)-4-(26- DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXAMIDE (AT7519) A NOVEL CYCLIN DEPENDENT KINASE INHIBITOR USING FRAGMENT- BASED X-RAY CRYSTALLOGRAPHY AND STRUCTURE BASED DRUG DESIGN.
1807, 2r3nA, 0.6717, 2.58, 0.372, 275, 258, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH INHIBITOR
1808, 2r0iB, 0.6716, 2.77, 0.248, 300, 258, CRYSTAL STRUCTURE OF A KINASE MARK2/PAR-1 MUTANT
1809, 4eoqC, 0.6715, 2.57, 0.399, 275, 253, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH ATP
1810, 3ocbA, 0.6715, 3.04, 0.270, 315, 263, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1811, 3nyoA, 0.6715, 3.48, 0.236, 553, 271, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH AMP
1812, 3nynB, 0.6715, 3.42, 0.236, 553, 271, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
1813, 2bheA, 0.6715, 2.51, 0.381, 274, 257, HUMAN CYCLIN DEPENDENT PROTEIN KINASE 2 IN COMPLEX WITH THE INHIBITOR 5-BROMO-INDIRUBINE
1814, 3rakA, 0.6714, 2.66, 0.367, 277, 259, CDK2 IN COMPLEX WITH INHIBITOR RC-2-32
1815, 1ua2A, 0.6714, 2.69, 0.372, 286, 258, CRYSTAL STRUCTURE OF HUMAN CDK7
1816, 3nynA, 0.6713, 3.40, 0.233, 553, 270, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 6 IN COMPLEX WITH SANGIVAMYCIN
1817, 1v0pB, 0.6710, 2.19, 0.392, 258, 250, STRUCTURE OF P. FALCIPARUM PFPK5-PURVALANOL B LIGAND COMPLEX
1818, 4d2pD, 0.6709, 3.24, 0.252, 317, 266, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1819, 1urwA, 0.6707, 2.56, 0.374, 274, 257, CDK2 IN COMPLEX WITH AN IMIDAZO[12-B]PYRIDAZINE
1820, 4bghA, 0.6705, 2.56, 0.370, 275, 257, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH PAN-CDK INHIBITOR
1821, 5l2tA, 0.6704, 2.06, 0.357, 261, 249, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND RIBOCICLIB.
1822, 5isoA, 0.6704, 3.09, 0.274, 453, 263, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
1823, 3wf9A, 0.6703, 2.85, 0.268, 287, 257, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 1-OXO-1-[(4-SULFAMOYLPHENYL)AMINO]PROPAN-2-YL-2-METHYL-1 234-TETRAHYDROACRIDINE-9-CARBOXYLATE
1824, 3ralA, 0.6703, 2.69, 0.378, 277, 259, CDK2 IN COMPLEX WITH INHIBITOR RC-2-34
1825, 2xh5A, 0.6703, 2.96, 0.267, 316, 262, STRUCTURE OF 4-(4-TERT-BUTYLBENZYL)-1-(7H-PYRROLO(23-D) PYRIMIDIN-4-YL)PIPERIDIN-4-AMINE BOUND TO PKB
1826, 3wf8A, 0.6702, 2.86, 0.268, 287, 257, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A QUINOLINE DERIVATIVE 2-OXO-2-[(4-SULFAMOYLPHENYL)AMINO]ETHYL 78910- TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE-11-CARBOXYLATE
1827, 1v0bB, 0.6702, 2.20, 0.382, 261, 251, CRYSTAL STRUCTURE OF THE T198A MUTANT OF PFPK5
1828, 3c4wA, 0.6701, 3.53, 0.224, 494, 272, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
1829, 2jdoA, 0.6701, 2.86, 0.269, 314, 260, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
1830, 5ankA, 0.6699, 2.49, 0.388, 273, 255, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 246-TRIOXO-1- PHENYL-HEXAHYDROPYRIMIDINE-5-CARBOXAMIDE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1831, 1ob3B, 0.6699, 2.21, 0.392, 258, 250, STRUCTURE OF P. FALCIPARUM PFPK5
1832, 5eakB, 0.6698, 2.80, 0.248, 300, 258, OPTIMIZATION OF MICROTUBULE AFFINITY REGULATING KINASE (MARK) INHIBITORS WITH IMPROVED PHYSICAL PROPERTIES
1833, 2w9zB, 0.6698, 3.02, 0.333, 287, 264, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
1834, 3pvuA, 0.6697, 3.64, 0.208, 609, 274, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND A SELECTIVE KINASE INHIBITOR (CMPD101)
1835, 5j1wC, 0.6696, 3.18, 0.272, 316, 265, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW31 (COMPOUND 14)
1836, 3ocbB, 0.6695, 3.01, 0.267, 319, 262, AKT1 KINASE DOMAIN WITH PYRROLOPYRIMIDINE INHIBITOR
1837, 3c4wB, 0.6695, 3.44, 0.229, 518, 271, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.7A
1838, 4eorC, 0.6693, 2.41, 0.392, 270, 250, THR 160 PHOSPHORYLATED CDK2 WT - HUMAN CYCLIN A3 COMPLEX WITH THE INHIBITOR NU6102
1839, 4aw2A, 0.6693, 3.95, 0.193, 398, 280, CRYSTAL STRUCTURE OF CDC42 BINDING PROTEIN KINASE ALPHA (MRCK ALPHA)
1840, 5uvcA, 0.6691, 3.50, 0.206, 457, 272, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
1841, 2uw9A, 0.6691, 3.03, 0.251, 316, 263, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH 4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
1842, 4d2vC, 0.6690, 3.07, 0.260, 316, 262, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1843, 4d2pC, 0.6690, 3.09, 0.263, 316, 262, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1844, 3qc9C, 0.6690, 3.54, 0.224, 482, 272, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1845, 4eomC, 0.6689, 2.60, 0.399, 275, 253, THR 160 PHOSPHORYLATED CDK2 H84S Q85M Q131E - HUMAN CYCLIN A3 COMPLEX WITH ATP
1846, 3qc9D, 0.6689, 3.55, 0.224, 486, 272, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1847, 3c50B, 0.6689, 3.56, 0.228, 496, 272, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
1848, 3c50A, 0.6689, 3.55, 0.224, 499, 272, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 2.6A
1849, 3qc9A, 0.6688, 3.54, 0.221, 486, 272, CRYSTAL STRUCTURE OF CROSS-LINKED BOVINE GRK1 T8C/N480C DOUBLE MUTANT COMPLEXED WITH ADP AND MG
1850, 2eufB, 0.6688, 3.06, 0.367, 282, 259, X-RAY STRUCTURE OF HUMAN CDK6-VCYCLIN IN COMPLEX WITH THE INHIBITOR PD0332991
1851, 6b2eA, 0.6687, 2.90, 0.297, 442, 259, STRUCTURE OF FULL LENGTH HUMAN AMPK (A2B2G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4. 
1852, 1p2aA, 0.6687, 2.55, 0.377, 271, 257, THE STRUCTURE OF CYCLIN DEPENDENT KINASE 2 (CKD2) WITH A TRISUBSTITUTED NAPHTHOSTYRIL INHIBITOR
1853, 4umpB, 0.6686, 3.31, 0.260, 324, 265, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1854, 4otgA, 0.6683, 3.36, 0.228, 322, 268, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH LESTAURTINIB
1855, 4ekkA, 0.6681, 3.10, 0.251, 318, 263, AKT1 WITH AMP-PNP
1856, 1zmvB, 0.6680, 2.73, 0.242, 296, 256, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
1857, 1gijA, 0.6680, 2.51, 0.383, 273, 256, HUMAN CYCLIN DEPENDENT KINASE 2 COMPLEXED WITH THE CDK4 INHIBITOR
1858, 3ow4A, 0.6679, 3.14, 0.270, 317, 263, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1859, 5uuuA, 0.6678, 3.66, 0.204, 414, 274, DESIGN SYNTHESIS AND EVALUATION OF THE FIRST SELECTIVE AND POTENT G- PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2) INHIBITOR FOR THE POTENTIAL TREATMENT OF HEART FAILURE
1860, 4d2pB, 0.6678, 3.21, 0.259, 323, 263, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1861, 1pyeA, 0.6677, 2.29, 0.377, 266, 252, CRYSTAL STRUCTURE OF CDK2 WITH INHIBITOR
1862, 1oitA, 0.6677, 2.62, 0.383, 273, 256, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1863, 4umpD, 0.6676, 3.20, 0.254, 321, 264, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1864, 4otdA, 0.6672, 3.42, 0.228, 334, 268, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN
1865, 5twzA, 0.6670, 3.24, 0.249, 313, 265, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
1866, 2duvA, 0.6670, 2.56, 0.395, 272, 256, STRUCTURE OF CDK2 WITH A 3-HYDROXYCHROMONES
1867, 5li1A, 0.6669, 3.27, 0.225, 331, 267, STRUCTURE OF A PAR3-INHIBITORY PEPTIDE BOUND TO PKCIOTA CORE KINASE DOMAIN
1868, 4l9iB, 0.6669, 3.60, 0.221, 493, 272, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
1869, 5li9A, 0.6667, 3.08, 0.220, 329, 264, STRUCTURE OF A NUCLEOTIDE-BOUND FORM OF PKCIOTA CORE KINASE DOMAIN
1870, 3c4zA, 0.6666, 3.51, 0.225, 493, 271, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 1.84A
1871, 4d2wD, 0.6665, 3.39, 0.240, 326, 267, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1872, 1ym7D, 0.6665, 3.60, 0.190, 599, 273, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1873, 4eklA, 0.6663, 3.17, 0.269, 329, 264, AKT1 WITH GDC0068
1874, 2jdrA, 0.6663, 3.07, 0.251, 316, 263, STRUCTURE OF PKB-BETA (AKT2) COMPLEXED WITH THE INHIBITOR A- 443654
1875, 5maiA, 0.6662, 3.05, 0.257, 312, 261, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
1876, 5ihcA, 0.6662, 3.04, 0.261, 305, 261, MELK IN COMPLEX WITH NVS-MELK12B
1877, 2g9xC, 0.6662, 2.46, 0.408, 274, 250, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR NU6271
1878, 5angA, 0.6658, 2.41, 0.379, 268, 253, CRYSTAL STRUCTURE OF CDK2 IN COMPLEX WITH 7-HYDROXY-4-( MORPHOLINOMETHYL)CHROMEN-2-ONE PROCESSED WITH THE CRYSTALDIRECT AUTOMATED MOUNTING AND CRYO-COOLING TECHNOLOGY
1879, 4umqA, 0.6658, 3.07, 0.244, 314, 262, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1880, 5izjA, 0.6657, 3.25, 0.249, 328, 261, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1411
1881, 1zmuB, 0.6657, 2.77, 0.246, 296, 256, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
1882, 4cfuC, 0.6654, 2.50, 0.404, 272, 250, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
1883, 5uq3A, 0.6652, 2.55, 0.393, 270, 252, CRYSTAL STRUCTURE OF HUMAN CDK2-SPY1-P27 TERNARY COMPLEX
1884, 4gv1A, 0.6650, 3.35, 0.248, 329, 266, PKB ALPHA IN COMPLEX WITH AZD5363
1885, 4crsA, 0.6650, 3.27, 0.231, 331, 264, HUMAN PROTEIN KINASE N2 (PKN2 PRKCL2) IN COMPLEX WITH ATPGAMMAS
1886, 4q9zB, 0.6649, 3.16, 0.266, 308, 263, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1887, 4d2vD, 0.6649, 3.40, 0.256, 318, 266, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1888, 4d2tD, 0.6649, 3.30, 0.257, 319, 265, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1889, 4d2tA, 0.6648, 3.16, 0.260, 316, 262, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1890, 3o0gB, 0.6648, 2.64, 0.378, 264, 251, CRYSTAL STRUCTURE OF CDK5:P25 IN COMPLEX WITH AN ATP ANALOGUE
1891, 4d2wC, 0.6647, 3.03, 0.259, 313, 259, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1892, 1o6kA, 0.6646, 3.18, 0.246, 317, 264, STRUCTURE OF ACTIVATED FORM OF PKB KINASE DOMAIN S474D WITH GSK3 PEPTIDE AND AMP-PNP
1893, 4l3lA, 0.6645, 2.72, 0.270, 291, 256, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN (ZINC ANOMALOUS)
1894, 2hakA, 0.6645, 2.87, 0.246, 309, 260, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
1895, 4ez5A, 0.6644, 2.07, 0.368, 258, 247, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
1896, 4cztA, 0.6644, 3.55, 0.235, 294, 272, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
1897, 5j1vC, 0.6643, 3.11, 0.275, 314, 262, CRYSTAL STRUCTURE OF HUMAN CLK1 IN COMPLEX WITH PYRIDO[34- G]QUINAZOLINE DERIVATIVE ZW29 (COMPOUND 13)
1898, 4dfyE, 0.6643, 2.97, 0.260, 312, 258, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
1899, 1ym7C, 0.6643, 3.78, 0.211, 607, 275, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1900, 5he2A, 0.6641, 3.72, 0.204, 628, 274, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224406
1901, 3c4xB, 0.6641, 3.51, 0.233, 475, 270, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ATP AND MAGNESIUM CHLORIDE AT 2.9A
1902, 1ym7A, 0.6641, 3.80, 0.207, 608, 275, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1903, 3krwA, 0.6639, 3.71, 0.220, 618, 273, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (SOAK)
1904, 5d1jA, 0.6638, 2.28, 0.384, 265, 250, CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(11-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]- 4-PIPERIDINECARBOXAMIDE (BMS-387032)
1905, 3pscA, 0.6638, 3.83, 0.207, 614, 275, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
1906, 1oiqA, 0.6638, 2.36, 0.386, 264, 251, IMIDAZOPYRIDINES: A POTENT AND SELECTIVE CLASS OF CYCLIN-DEPENDENT KINASE INHIBITORS IDENTIFIED THROUGH STRUCTURE-BASED HYBRIDISATION
1907, 4bcpC, 0.6637, 2.41, 0.407, 267, 248, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1908, 1ym7B, 0.6637, 3.80, 0.207, 608, 275, G PROTEIN-COUPLED RECEPTOR KINASE 2 (GRK2)
1909, 5twyA, 0.6636, 3.04, 0.258, 313, 260, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
1910, 5twuA, 0.6636, 3.23, 0.261, 318, 261, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
1911, 4ra5A, 0.6636, 3.31, 0.264, 332, 265, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1912, 4d2tB, 0.6635, 3.41, 0.257, 323, 265, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1913, 2bcjA, 0.6635, 3.69, 0.206, 624, 272, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GALPHA-Q AND GBETAGAMMA SUBUNITS
1914, 4pnkA, 0.6634, 3.74, 0.204, 625, 274, G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH GSK180736A
1915, 3ow4B, 0.6633, 3.20, 0.270, 317, 263, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
1916, 1o6lA, 0.6633, 3.06, 0.252, 316, 262, CRYSTAL STRUCTURE OF AN ACTIVATED AKT/PROTEIN KINASE B (PKB-PIF CHIMERA) TERNARY COMPLEX WITH AMP-PNP AND GSK3 PEPTIDE
1917, 5l2iA, 0.6632, 2.18, 0.367, 260, 248, THE X-RAY CO-CRYSTAL STRUCTURE OF HUMAN CDK6 AND PALBOCICLIB.
1918, 4zy4B, 0.6632, 2.78, 0.228, 292, 254, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
1919, 3bhvC, 0.6632, 2.48, 0.402, 271, 249, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR VARIOLIN B
1920, 5f9eB, 0.6631, 3.05, 0.273, 293, 260, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1921, 1oguC, 0.6631, 2.53, 0.400, 272, 250, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 2-ARYLAMINO-4-CYCLOHEXYLMETHYL-5-NITROSO-6-AMINOPYRIMIDINE INHIBITOR
1922, 6b1uC, 0.6630, 3.10, 0.277, 459, 260, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
1923, 3mv5A, 0.6630, 3.12, 0.271, 315, 262, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
1924, 1omwA, 0.6630, 3.82, 0.211, 614, 275, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN G PROTEIN-COUPLED RECEPTOR KINASE 2 AND HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNITS
1925, 3krxA, 0.6629, 3.74, 0.216, 618, 273, HUMAN GRK2 IN COMPLEX WITH GBETGAMMA SUBUNITS AND BALANOL (CO-CRYSTAL)
1926, 4umpC, 0.6628, 3.20, 0.268, 311, 261, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1927, 3tkuB, 0.6628, 4.16, 0.213, 395, 282, MRCK BETA IN COMPLEX WITH FASUDIL
1928, 3cikA, 0.6627, 3.83, 0.204, 619, 274, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS
1929, 4ra5B, 0.6626, 3.23, 0.270, 310, 263, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH LIGAND COMPOUND 11A (6- [(13-DIMETHYL-AZETIDIN-3-YL)-METHYL-AMINO]-4(R)-METHYL-7-PHENYL-2 10-DIHYDRO-9-OXA-124A-TRIAZA-PHENANTHREN-3-ONE)
1930, 3qkkA, 0.6626, 3.22, 0.269, 326, 264, SPIROCHROMANE AKT INHIBITORS
1931, 5isoC, 0.6623, 3.03, 0.283, 429, 258, STRUCTURE OF FULL LENGTH HUMAN AMPK (NON-PHOSPHORYLATED AT T-LOOP) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
1932, 5ezvA, 0.6622, 3.25, 0.295, 441, 261, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
1933, 4zy5B, 0.6622, 2.78, 0.228, 287, 254, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
1934, 4rerA, 0.6622, 2.96, 0.292, 458, 257, CRYSTAL STRUCTURE OF THE PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX BOUND TO AMP AND CYCLODEXTRIN
1935, 4d2vB, 0.6621, 3.25, 0.260, 322, 262, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1936, 1jowB, 0.6621, 2.81, 0.373, 277, 255, CRYSTAL STRUCTURE OF A COMPLEX OF HUMAN CDK6 AND A VIRAL CYCLIN
1937, 4d2vA, 0.6620, 3.07, 0.262, 313, 260, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1938, 3tkuA, 0.6620, 4.06, 0.218, 395, 280, MRCK BETA IN COMPLEX WITH FASUDIL
1939, 1j3hA, 0.6620, 3.18, 0.238, 329, 260, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1940, 5he0A, 0.6619, 3.67, 0.205, 621, 273, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG215022
1941, 4q9zA, 0.6619, 3.30, 0.265, 331, 264, HUMAN PROTEIN KINASE C THETA IN COMPLEX WITH COMPOUND35 ((1R)-9- (AZETIDIN-3-YLAMINO)-18-DIMETHYL-35-DIHYDRO[124]TRIAZINO[34- C][14]BENZOXAZIN-2(1H)-ONE)
1942, 4bgqA, 0.6619, 3.04, 0.337, 276, 261, CRYSTAL STRUCTURE OF THE HUMAN CDKL5 KINASE DOMAIN
1943, 3tv7B, 0.6619, 3.82, 0.209, 397, 277, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
1944, 5fp5A, 0.6618, 2.36, 0.394, 264, 251, STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 WITH SMALL-MOLECULE LIGAND 4-FLUOROBENZOIC ACID (AT222) IN AN ALTERNATE BINDING SITE.
1945, 4umtA, 0.6618, 3.28, 0.246, 316, 264, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1946, 4d2pA, 0.6618, 2.96, 0.264, 313, 258, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1947, 3tv7D, 0.6618, 3.90, 0.213, 397, 277, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
1948, 1zmvA, 0.6618, 2.72, 0.232, 293, 254, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: K82R MUTANT
1949, 4ekkB, 0.6617, 3.24, 0.255, 318, 263, AKT1 WITH AMP-PNP
1950, 1j3hB, 0.6617, 3.16, 0.238, 327, 260, CRYSTAL STRUCTURE OF APOENZYME CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
1951, 3v8sB, 0.6616, 3.83, 0.217, 397, 276, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
1952, 5twuB, 0.6615, 3.25, 0.257, 315, 261, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
1953, 5f9eA, 0.6615, 3.38, 0.263, 334, 266, STRUCTURE OF PROTEIN KINASE C THETA WITH COMPOUND 10: 22-DIMETHYL-7- (2-OXIDANYLIDENE-3~{H}-IMIDAZO[45-B]PYRIDIN-1-YL)-1-(PHENYLMETHYL)- 3~{H}-QUINAZOLIN-4-ONE
1954, 3v8sD, 0.6614, 3.79, 0.218, 397, 275, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
1955, 5ih9A, 0.6613, 3.14, 0.262, 308, 260, MELK IN COMPLEX WITH NVS-MELK8A
1956, 3utoB, 0.6613, 3.44, 0.254, 566, 264, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
1957, 6b1uA, 0.6612, 3.13, 0.286, 441, 259, STRUCTURE OF FULL-LENGTH HUMAN AMPK (A2B1G1) IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR SC4 
1958, 5ih8A, 0.6612, 3.19, 0.261, 306, 261, MELK IN COMPLEX WITH NVS-MELK1
1959, 4d2tC, 0.6612, 3.00, 0.260, 313, 258, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1960, 3we4A, 0.6611, 2.76, 0.271, 286, 255, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRIMIDINE DERIVATIVE PF-4708671 2-{[4-(5-ETHYLPYRIMIDIN-4-YL)PIPERAZIN-1- YL]METHYL}-5-(TRIFLUOROMETHYL)-1H-BENZIMIDAZOLE
1961, 3bhuC, 0.6611, 2.52, 0.406, 271, 249, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 5
1962, 4cfeA, 0.6610, 3.13, 0.278, 425, 259, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
1963, 3qklA, 0.6610, 3.25, 0.270, 317, 263, SPIROCHROMANE AKT INHIBITORS
1964, 4yzbB, 0.6609, 3.51, 0.300, 464, 263, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
1965, 5he1A, 0.6608, 3.74, 0.209, 618, 273, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224062
1966, 4d2wB, 0.6608, 3.32, 0.243, 323, 263, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1967, 4umrA, 0.6607, 3.12, 0.249, 313, 261, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1968, 4l3jA, 0.6607, 2.80, 0.273, 291, 256, CRYSTAL STRUCTURES OF HUMAN P70S6K1 KINASE DOMAIN
1969, 5ntjA, 0.6606, 3.19, 0.250, 346, 260, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUND RKP032 
1970, 4dfyA, 0.6606, 2.90, 0.258, 310, 256, CRYSTAL STRUCTURE OF R194A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED ACTIVATION LOOP
1971, 4d1xA, 0.6606, 2.67, 0.378, 274, 254, CDK2 IN COMPLEX WITH LUCIFERIN
1972, 5ukmA, 0.6603, 3.73, 0.187, 621, 273, BOVINE GRK2 IN COMPLEX WITH HUMAN GBETAGAMMA SUBUNITS AND CCG258208 (14AS)
1973, 4bcoC, 0.6603, 2.42, 0.405, 269, 247, STRUCTURE OF CDK2 IN COMPLEX WITH CYCLIN A AND A 2-AMINO-4- HETEROARYL-PYRIMIDINE INHIBITOR
1974, 3utoA, 0.6603, 3.48, 0.242, 559, 264, TWITCHIN KINASE REGION FROM C.ELEGANS (FN31-NL-KIN-CRD-IG26)
1975, 1zmuA, 0.6602, 2.71, 0.249, 293, 253, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: WILD TYPE
1976, 5magA, 0.6601, 3.17, 0.265, 314, 260, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
1977, 4yzbA, 0.6600, 3.52, 0.300, 466, 263, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1521
1978, 3cquA, 0.6600, 3.24, 0.266, 318, 263, CRYSTAL STRUCTURE OF AKT-1 COMPLEXED WITH SUBSTRATE PEPTIDE AND INHIBITOR
1979, 5tx3A, 0.6599, 2.94, 0.255, 306, 255, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
1980, 5m5aA, 0.6599, 3.21, 0.263, 315, 262, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
1981, 4d2wA, 0.6599, 3.20, 0.257, 314, 261, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1982, 3qkmA, 0.6598, 3.28, 0.258, 329, 264, SPIROCYCLIC SULFONAMIDES AS AKT INHIBITORS
1983, 3qfvB, 0.6598, 4.15, 0.214, 396, 281, MRCK BETA IN COMPLEX WITH TPCA-1
1984, 3o7lD, 0.6598, 3.25, 0.241, 333, 261, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
1985, 3bhtC, 0.6598, 2.49, 0.403, 270, 248, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR MERIOLIN 3
1986, 5kz7B, 0.6596, 2.79, 0.244, 296, 254, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
1987, 4zhxC, 0.6596, 3.04, 0.283, 452, 258, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
1988, 5ezvC, 0.6595, 2.97, 0.280, 440, 257, X-RAY CRYSTAL STRUCTURE OF AMP-ACTIVATED PROTEIN KINASE ALPHA-2/ALPHA- 1 RIM CHIMAERA (ALPHA-2(1-347)/ALPHA-1(349-401)/ALPHA-2(397-END) BETA-1 GAMMA-1) CO-CRYSTALLIZED WITH C2 (5-(5-HYDROXYL-ISOXAZOL-3- YL)-FURAN-2-PHOSPHONIC ACID)
1989, 4umuA, 0.6594, 3.30, 0.246, 316, 264, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
1990, 4czuD, 0.6594, 3.57, 0.242, 302, 269, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
1991, 2f2uB, 0.6594, 3.81, 0.207, 383, 276, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
1992, 4ntsB, 0.6592, 3.17, 0.238, 341, 260, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
1993, 4cffA, 0.6592, 3.20, 0.278, 424, 259, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
1994, 4mk0A, 0.6591, 3.83, 0.186, 631, 274, CRYSTAL STRUCTURE OF G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH A A RATIONALLY DESIGNED PAROXETINE DERIVATIVE
1995, 4nttA, 0.6590, 3.26, 0.230, 339, 261, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
1996, 4czuA, 0.6589, 3.54, 0.237, 297, 270, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
1997, 4cztD, 0.6589, 3.56, 0.242, 302, 269, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
1998, 3qfvA, 0.6589, 4.09, 0.214, 395, 280, MRCK BETA IN COMPLEX WITH TPCA-1
1999, 4ae6A, 0.6588, 3.26, 0.245, 319, 261, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2000, 3mvhA, 0.6588, 3.14, 0.242, 311, 260, CRYSTAL STRUCTURE OF AKT-1-INHIBITOR COMPLEXES
2001, 3zh8A, 0.6586, 3.38, 0.217, 318, 267, A NOVEL SMALL MOLECULE APKC INHIBITOR
2002, 5kz7A, 0.6584, 2.81, 0.248, 296, 254, MARK2 COMPLEX WITH 7-[(1S)-1-(4-FLUOROPHENYL)ETHYL]-55-DIMETHYL-2-(3- PYRIDYLAMINO)PYRROLO[23-D]PYRIMIDIN-6-ONE
2003, 4d28B, 0.6584, 3.47, 0.228, 277, 267, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2004, 3uztA, 0.6584, 3.41, 0.208, 586, 264, STRUCTURE OF THE C13.18 RNA APTAMER IN COMPLEX WITH G PROTEIN-COUPLED RECEPTOR KINASE 2
2005, 4zhxA, 0.6583, 3.19, 0.291, 408, 258, NOVEL BINDING SITE FOR ALLOSTERIC ACTIVATION OF AMPK
2006, 4czuB, 0.6583, 3.53, 0.242, 287, 269, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
2007, 5ihaA, 0.6582, 3.15, 0.266, 303, 259, MELK IN COMPLEX WITH NVS-MELK8F
2008, 3e87B, 0.6581, 3.43, 0.245, 321, 265, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2009, 3e87A, 0.6581, 3.43, 0.245, 321, 265, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2010, 4umpA, 0.6580, 3.20, 0.262, 313, 260, STRUCTURE OF MELK IN COMPLEX WITH INHIBITORS
2011, 4nttB, 0.6580, 3.27, 0.238, 339, 260, STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE BOUND TO ADP AND ONE MAGNESIUM ION
2012, 4cffC, 0.6580, 3.08, 0.284, 422, 257, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A THIENOPYRIDONE DERIVATIVE (A-769662)
2013, 6c2yA, 0.6579, 3.66, 0.207, 617, 271, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257142 
2014, 4d28C, 0.6579, 3.53, 0.228, 279, 268, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2015, 1y8gB, 0.6579, 2.88, 0.251, 292, 255, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
2016, 5mahA, 0.6578, 3.25, 0.263, 316, 262, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
2017, 2vd5A, 0.6577, 3.91, 0.182, 390, 274, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
2018, 1y8gA, 0.6577, 2.83, 0.252, 292, 254, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK2/PAR-1: INACTIVE DOUBLE MUTANT WITH SELENOMETHIONINE
2019, 3e88B, 0.6576, 3.43, 0.245, 319, 265, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2020, 3e88A, 0.6576, 3.43, 0.245, 319, 265, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2021, 3j4rE, 0.6575, 3.32, 0.241, 325, 261, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
2022, 3j4rD, 0.6575, 3.32, 0.241, 325, 261, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A LINEAR CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
2023, 3j4qE, 0.6575, 3.32, 0.241, 325, 261, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
2024, 3j4qD, 0.6575, 3.32, 0.241, 325, 261, PSEUDO-ATOMIC MODEL OF THE AKAP18-PKA COMPLEX IN A BENT CONFORMATION DERIVED FROM ELECTRON MICROSCOPY
2025, 1bi8C, 0.6575, 2.47, 0.331, 264, 248, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
2026, 1bi8A, 0.6575, 2.47, 0.331, 264, 248, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURES CDK6-P19INK4D INHIBITOR COMPLEX
2027, 6b16B, 0.6574, 2.73, 0.219, 281, 251, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
2028, 5he3A, 0.6574, 3.83, 0.205, 623, 273, BOVINE GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224411
2029, 3d0eB, 0.6574, 3.43, 0.260, 322, 265, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
2030, 2qvsE, 0.6573, 3.33, 0.241, 323, 261, CRYSTAL STRUCTURE OF TYPE IIA HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
2031, 3d0eA, 0.6572, 3.40, 0.245, 322, 265, CRYSTAL STRUCTURE OF HUMAN AKT2 IN COMPLEX WITH GSK690693
2032, 4l9iA, 0.6571, 3.61, 0.222, 504, 270, BOVINE G PROTEIN COUPLED RECEPTOR KINASE 1 IN COMPLEX WITH PAROXETINE
2033, 3zuuA, 0.6569, 2.94, 0.206, 281, 257, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
2034, 5uklA, 0.6568, 3.83, 0.187, 630, 273, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG222886 (14BD)
2035, 5twyB, 0.6568, 3.01, 0.268, 306, 257, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
2036, 3zutA, 0.6567, 2.94, 0.214, 281, 257, THE STRUCTURE OF OST1 (D160A) KINASE
2037, 4ntsA, 0.6566, 3.35, 0.230, 341, 261, APO STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2038, 4ae9A, 0.6566, 3.27, 0.245, 321, 261, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
2039, 3twjA, 0.6566, 3.93, 0.221, 396, 276, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
2040, 3e8dB, 0.6565, 3.46, 0.245, 317, 265, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2041, 5deyB, 0.6561, 2.72, 0.219, 281, 251, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2042, 4auaA, 0.6561, 2.14, 0.371, 256, 245, LIGANDED X-RAY CRYSTAL STRUCTURE OF CYCLIN DEPENDENT KINASE 6 (CDK6)
2043, 5mafA, 0.6558, 3.38, 0.267, 315, 262, CRYSTAL STRUCTURE OF MELK IN COMPLEX WITH AN INHIBITOR
2044, 2iw9C, 0.6558, 2.46, 0.411, 268, 246, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A COMPLEXED WITH A BISANILINOPYRIMIDINE INHIBITOR
2045, 3zh8C, 0.6557, 3.28, 0.227, 312, 264, A NOVEL SMALL MOLECULE APKC INHIBITOR
2046, 3zh8B, 0.6557, 3.32, 0.219, 317, 265, A NOVEL SMALL MOLECULE APKC INHIBITOR
2047, 5wg4A, 0.6556, 3.74, 0.188, 621, 271, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG257284
2048, 4ynzA, 0.6556, 3.51, 0.247, 313, 267, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
2049, 3uc3A, 0.6555, 2.96, 0.267, 272, 255, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.3
2050, 5t5tA, 0.6554, 2.91, 0.307, 368, 254, AMPK BOUND TO ALLOSTERIC ACTIVATOR
2051, 5lcuA, 0.6553, 3.25, 0.246, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A S-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 01)
2052, 3nupA, 0.6553, 2.10, 0.365, 252, 244, CDK6 (MONOMERIC) IN COMPLEX WITH INHIBITOR
2053, 1stcE, 0.6553, 3.26, 0.250, 334, 260, CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH STAUROSPORINE
2054, 5m71A, 0.6552, 3.25, 0.250, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH AN (R)-METHYL SUBSTITUED FASUDIL-DERIVATIVE. 
2055, 5lcpA, 0.6552, 3.25, 0.250, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH FASUDIL (M77)
2056, 4y5qA, 0.6552, 3.87, 0.269, 449, 271, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH AMP
2057, 5wg3A, 0.6550, 3.74, 0.207, 618, 271, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG258748
2058, 3mwuA, 0.6550, 3.73, 0.272, 447, 268, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-95
2059, 4rewA, 0.6548, 2.95, 0.294, 411, 255, CRYSTAL STRUCTURE OF THE NON-PHOSPHORYLATED HUMAN ALPHA1 BETA2 GAMMA1 HOLO-AMPK COMPLEX
2060, 4cztB, 0.6548, 3.53, 0.243, 286, 268, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
2061, 3e8dA, 0.6548, 3.34, 0.247, 315, 263, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF AKT2 IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2062, 6e4uA, 0.6547, 2.92, 0.299, 365, 254, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2063, 4zy6B, 0.6546, 2.71, 0.220, 280, 250, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
2064, 4cqgA, 0.6545, 3.25, 0.269, 313, 260, THE CRYSTAL STRUCTURE OF MPK38 IN COMPLEX WITH OTSSP167 AN ORALLY-ADMINISTRATIVE MELK SELECTIVE INHIBITOR
2065, 4bfmA, 0.6545, 3.25, 0.269, 313, 260, THE CRYSTAL STRUCTURE OF MOUSE PK38
2066, 1ctpE, 0.6545, 3.30, 0.242, 332, 260, STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
2067, 1cmkE, 0.6544, 3.29, 0.242, 348, 260, CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
2068, 4qfgA, 0.6543, 2.73, 0.306, 365, 252, STRUCTURE OF AMPK IN COMPLEX WITH STAUROSPORINE INHIBITOR AND IN THE ABSENCE OF A SYNTHETIC ACTIVATOR
2069, 4iebA, 0.6543, 3.50, 0.305, 472, 262, CRYSTAL STRUCTURE OF A GLY128MET MUTANT OF THE TOXOPLASMA CDPK TGME49_101440
2070, 5dewB, 0.6542, 2.87, 0.218, 281, 252, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2071, 4cfeC, 0.6542, 2.95, 0.299, 403, 254, STRUCTURE OF FULL LENGTH HUMAN AMPK IN COMPLEX WITH A SMALL MOLECULE ACTIVATOR A BENZIMIDAZOLE DERIVATIVE (991)
2072, 3ncgA, 0.6542, 3.82, 0.271, 426, 269, ACTIVATED CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM CRYPTOSPORIDIUM PARVUM (CPCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NM-PP1
2073, 5ufuA, 0.6541, 2.94, 0.303, 368, 254, STRUCTURE OF AMPK BOUND TO ACTIVATOR
2074, 4bkzA, 0.6541, 3.17, 0.264, 309, 258, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH A BENZODIPYRAZOLE INHIBITOR
2075, 3q5iA, 0.6541, 3.48, 0.308, 470, 260, CRYSTAL STRUCTURE OF PBANKA_031420
2076, 1bx6A, 0.6540, 3.25, 0.242, 337, 260, CRYSTAL STRUCTURE OF THE POTENT NATURAL PRODUCT INHIBITOR BALANOL IN COMPLEX WITH THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2077, 4d28A, 0.6538, 3.63, 0.225, 274, 267, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2078, 3v5wA, 0.6538, 3.85, 0.187, 623, 272, HUMAN G PROTEIN-COUPLED RECEPTOR KINASE 2 IN COMPLEX WITH SOLUBLE GBETAGAMMA SUBUNITS AND PAROXETINE
2079, 5o0eA, 0.6535, 3.30, 0.246, 349, 260, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND FASUDIL 
2080, 2etkA, 0.6535, 4.11, 0.205, 400, 278, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
2081, 5lcrA, 0.6534, 3.29, 0.250, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH OPEN-CHAIN FASUDIL-DERIVATIVE (LIGAND 04)
2082, 2vd5B, 0.6534, 3.85, 0.191, 380, 272, STRUCTURE OF HUMAN MYOTONIC DYSTROPHY PROTEIN KINASE IN COMPLEX WITH THE BISINDOYLMALEIDE INHIBITOR BIM VIII
2083, 4ynzB, 0.6533, 3.69, 0.248, 323, 270, STRUCTURE OF THE N-TERMINAL DOMAIN OF SAD
2084, 5ok3A, 0.6532, 3.32, 0.246, 349, 260, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP241 AND FASUDIL 
2085, 4cztC, 0.6532, 3.52, 0.248, 286, 266, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270
2086, 1fotA, 0.6531, 3.10, 0.226, 299, 257, STRUCTURE OF THE UNLIGANDED CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT FROM SACCHAROMYCES CEREVISIAE
2087, 3lijA, 0.6530, 3.18, 0.312, 465, 256, CRYSTAL STRUCTURE OF FULL LENGTH CPCDPK3 (CGD5_820) IN COMPLEX WITH CA2+ AND AMPPNP
2088, 1bi7A, 0.6530, 2.78, 0.325, 269, 252, MECHANISM OF G1 CYCLIN DEPENDENT KINASE INHIBITION FROM THE STRUCTURE OF THE CDK6-P16INK4A TUMOR SUPPRESSOR COMPLEX
2089, 5hvuA, 0.6527, 3.99, 0.217, 394, 276, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
2090, 4cfvC, 0.6526, 2.43, 0.402, 264, 244, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2091, 4qfrA, 0.6525, 2.83, 0.302, 361, 252, STRUCTURE OF AMPK IN COMPLEX WITH CL-A769662 ACTIVATOR AND STAUROSPORINE INHIBITOR
2092, 4cfhA, 0.6525, 2.91, 0.304, 401, 253, STRUCTURE OF AN ACTIVE FORM OF MAMMALIAN AMPK
2093, 3wf7A, 0.6525, 3.07, 0.272, 288, 257, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PURINE DERIVATIVE 1-(9H-PURIN-6-YL)-N-[3-(TRIFLUOROMETHYL)PHENYL]PIPERIDINE- 4-CARBOXAMIDE
2094, 2etrA, 0.6523, 4.13, 0.209, 400, 278, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
2095, 2esmA, 0.6522, 4.02, 0.213, 400, 277, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
2096, 4qfsA, 0.6521, 2.83, 0.302, 361, 252, STRUCTURE OF AMPK IN COMPLEX WITH BR2-A769662CORE ACTIVATOR AND STAUROSPORINE INHIBITOR
2097, 3ag9B, 0.6521, 3.35, 0.249, 317, 261, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2098, 1h26C, 0.6521, 2.41, 0.410, 267, 244, CDK2/CYCLIN A IN COMPLEX WITH AN 11-RESIDUE RECRUITMENT PEPTIDE FROM P53
2099, 4c0tA, 0.6520, 2.95, 0.267, 290, 255, CANDIDA ALBICANS PKH KINASE DOMAIN
2100, 3my5C, 0.6519, 2.44, 0.406, 266, 244, CDK2/CYCLINA IN COMPLEX WITH DRB
2101, 1jvpP, 0.6519, 2.60, 0.375, 268, 251, CRYSTAL STRUCTURE OF HUMAN CDK2 (UNPHOSPHORYLATED) IN COMPLEX WITH PKF049-365
2102, 6e4wA, 0.6518, 2.86, 0.306, 361, 252, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2103, 5wg5A, 0.6518, 3.73, 0.207, 617, 270, HUMAN GRK2 IN COMPLEX WITH GBETAGAMMA SUBUNITS AND CCG224061
2104, 4cfmC, 0.6517, 2.38, 0.412, 266, 243, STRUCTURE-BASED DESIGN OF C8-SUBSTITUTED O6- CYCLOHEXYLMETHOXYGUANINE CDK1 AND 2 INHIBITORS.
2105, 5lctA, 0.6516, 3.36, 0.246, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A R-METHYL-PIPERAZINE SUBSTITUTED FASUDIL-DERIVATIVE (LIGAND 02)
2106, 4czuC, 0.6515, 3.37, 0.247, 281, 263, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.23 AT1G30270 T190D MUTANT
2107, 3daeA, 0.6515, 2.19, 0.272, 248, 243, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
2108, 6e4tA, 0.6514, 2.87, 0.306, 361, 252, STRUCTURE OF AMPK BOUND TO ACTIVATOR 
2109, 5m6yA, 0.6513, 3.36, 0.246, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A METHYLISOQUINOLINE FASUDIL-DERIVATIVE 
2110, 3d9vA, 0.6513, 3.98, 0.210, 400, 276, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
2111, 5kq5A, 0.6511, 2.78, 0.303, 362, 251, AMPK BOUND TO ALLOSTERIC ACTIVATOR
2112, 1szmA, 0.6511, 3.35, 0.258, 317, 260, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2113, 5kktB, 0.6509, 4.04, 0.221, 394, 276, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
2114, 3zutB, 0.6509, 3.22, 0.212, 282, 260, THE STRUCTURE OF OST1 (D160A) KINASE
2115, 5u7qB, 0.6505, 4.06, 0.222, 385, 275, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2116, 4bl1A, 0.6505, 3.32, 0.263, 312, 259, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH AMP-PNP
2117, 3uc4A, 0.6505, 3.22, 0.200, 295, 260, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.6
2118, 3dogC, 0.6504, 2.39, 0.407, 267, 243, STRUCTURE OF THR 160 PHOSPHORYLATED CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR N-&-N1
2119, 3zuuB, 0.6503, 3.13, 0.213, 282, 258, THE STRUCTURE OF OST1 (D160A S175D) KINASE IN COMPLEX WITH GOLD
2120, 2etrB, 0.6502, 3.95, 0.215, 398, 274, CRYSTAL STRUCTURE OF ROCK I BOUND TO Y-27632
2121, 5kksA, 0.6501, 4.01, 0.211, 395, 275, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
2122, 4d1zA, 0.6501, 2.48, 0.387, 258, 248, CDK2 IN COMPLEX WITH A LUCIFERIN DERIVATE
2123, 2etkB, 0.6501, 4.06, 0.217, 398, 277, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO HYDROXYFASUDIL
2124, 6c0tA, 0.6500, 3.52, 0.240, 334, 263, CRYSTAL STRUCTURE OF CGMP-DEPENDENT PROTEIN KINASE IALPHA (PKG IALPHA) CATALYTIC DOMAIN BOUND WITH N46 
2125, 2wmbC, 0.6500, 2.47, 0.398, 266, 244, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2126, 4bkyA, 0.6498, 3.22, 0.267, 311, 258, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE (MELK) IN COMPLEX WITH PYRROLOPYRAZOLE INHIBITOR
2127, 4b9dA, 0.6495, 3.45, 0.193, 290, 264, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
2128, 3d9vB, 0.6493, 4.11, 0.213, 398, 277, CRYSTAL STRUCTURE OF ROCK I BOUND TO H-1152P A DI- METHYLATED VARIANT OF FASUDIL
2129, 5m6vA, 0.6492, 3.44, 0.250, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A DOUBLE METHYLATED FASUDIL-DERIVATIVE 
2130, 4o0tB, 0.6490, 2.89, 0.215, 280, 251, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2131, 4apcA, 0.6490, 3.40, 0.202, 293, 263, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
2132, 2j4zB, 0.6487, 2.91, 0.245, 269, 253, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
2133, 3ag9A, 0.6486, 3.47, 0.226, 323, 261, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1012
2134, 5d9kA, 0.6485, 2.69, 0.241, 280, 249, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2135, 1oiuC, 0.6485, 2.37, 0.405, 265, 242, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2/CYCLIN A COMPLEXED WITH A 6-CYCLOHEXYLMETHYLOXY-2-ANILINO-PURINE INHIBITOR
2136, 2esmB, 0.6482, 4.08, 0.221, 398, 276, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO FASUDIL
2137, 5d9kB, 0.6481, 2.72, 0.261, 280, 249, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BI-D1870
2138, 2iw8C, 0.6481, 2.45, 0.403, 265, 243, STRUCTURE OF HUMAN THR160-PHOSPHO CDK2-CYCLIN A F82H-L83V- H84D MUTANT WITH AN O6-CYCLOHEXYLMETHYLGUANINE INHIBITOR
2139, 3hx4A, 0.6480, 3.44, 0.305, 467, 259, CRYSTAL STRUCTURE OF CDPK1 OF TOXOPLASMA GONDII TGME49_101440 IN PRESENCE OF CALCIUM
2140, 4yveA, 0.6479, 4.05, 0.214, 390, 276, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
2141, 3ddqC, 0.6479, 2.46, 0.403, 266, 243, STRUCTURE OF PHOSPHORYLATED THR160 CDK2/CYCLIN A IN COMPLEX WITH THE INHIBITOR ROSCOVITINE
2142, 5m75A, 0.6478, 3.46, 0.250, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A (S)-METHYL SUBSTITUED FASUDIL-DERIVATIVE 
2143, 5kksB, 0.6476, 4.11, 0.213, 395, 277, ROCK 1 BOUND TO AZAINDOLE THIOZOLE INHIBITOR
2144, 4apcB, 0.6476, 3.54, 0.205, 296, 264, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1)
2145, 3agmA, 0.6476, 3.43, 0.254, 337, 260, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-670
2146, 1xjdA, 0.6476, 3.02, 0.287, 280, 254, CRYSTAL STRUCTURE OF PKC-THETA COMPLEXED WITH STAUROSPORINE AT 2A RESOLUTION
2147, 3l9lA, 0.6475, 3.34, 0.251, 338, 259, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2148, 2y7jA, 0.6475, 3.16, 0.266, 284, 252, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2149, 1rekA, 0.6475, 3.34, 0.247, 336, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 8
2150, 4j8mA, 0.6474, 2.84, 0.259, 265, 251, AURORA A IN COMPLEX WITH CD532
2151, 5nw8A, 0.6473, 3.32, 0.247, 337, 259, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP032 AND FASUDIL 
2152, 5bmlA, 0.6473, 4.08, 0.215, 393, 275, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
2153, 4yvcB, 0.6473, 4.02, 0.218, 392, 275, ROCK 1 BOUND TO THIAZOLE INHIBITOR
2154, 1rejA, 0.6473, 3.35, 0.243, 333, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 1
2155, 5wngD, 0.6472, 4.00, 0.220, 396, 273, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2156, 5m0uA, 0.6472, 3.41, 0.250, 346, 260, APOSTRUCTURE STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) FROM CHO CELLS WITH A PEPTIDIC INHIBITOR FRAGMENT 
2157, 5lvpD, 0.6472, 2.94, 0.259, 276, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2158, 5lvpB, 0.6472, 2.92, 0.259, 276, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2159, 5lvpA, 0.6472, 2.87, 0.256, 275, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2160, 1sykA, 0.6472, 3.49, 0.215, 348, 261, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
2161, 5dykA, 0.6471, 3.19, 0.239, 809, 255, CRYSTAL STRUCTURE OF PF3D7_1436600
2162, 3l9mA, 0.6471, 3.35, 0.251, 338, 259, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2163, 2jdvA, 0.6471, 3.37, 0.255, 334, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH A-443654
2164, 3hkoA, 0.6470, 3.15, 0.280, 319, 254, CRYSTAL STRUCTURE OF A CDPK KINASE DOMAIN FROM CRYPTOSPORIDIUM PARVUM CGD7_40
2165, 2wmaC, 0.6469, 2.46, 0.403, 265, 243, STRUCTURAL AND THERMODYNAMIC CONSEQUENCES OF CYCLIZATION OF PEPTIDE LIGANDS FOR THE RECRUITMENT SITE OF CYCLIN A
2166, 5nttA, 0.6468, 2.83, 0.231, 276, 251, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604Y MUTANT IN COMPLEX WITH NMS-P715
2167, 5kktA, 0.6468, 3.97, 0.213, 389, 272, ROCK 1 BOUND TO AZAINDOLE THIOZOLE PIPERAZINE INHIBITOR
2168, 3ndmD, 0.6468, 4.07, 0.215, 396, 274, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2169, 1bkxA, 0.6467, 3.34, 0.243, 337, 259, A BINARY COMPLEX OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND ADENOSINE FURTHER DEFINES CONFORMATIONAL FLEXIBILITY
2170, 5u7qD, 0.6466, 4.05, 0.219, 383, 274, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2171, 1sykB, 0.6466, 3.50, 0.215, 323, 261, CRYSTAL STRUCTURE OF E230Q MUTANT OF CAMP-DEPENDENT PROTEIN KINASE REVEALS UNEXPECTED APOENZYME CONFORMATION
2172, 5kbqB, 0.6465, 2.72, 0.215, 273, 247, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
2173, 4b9dB, 0.6465, 3.49, 0.202, 295, 263, CRYSTAL STRUCTURE OF HUMAN NIMA-RELATED KINASE 1 (NEK1) WITH INHIBITOR.
2174, 3twjC, 0.6465, 3.97, 0.225, 396, 275, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
2175, 1f3mC, 0.6465, 2.84, 0.240, 287, 250, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
2176, 3daeB, 0.6464, 2.17, 0.274, 246, 241, CRYSTAL STRUCTURE OF PHOSPHORYLATED SNF1 KINASE DOMAIN
2177, 2uw7A, 0.6464, 3.45, 0.258, 335, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4-CHLORO- PHENYL)-4-(4-(1H-PYRAZOL-4-YL)-PHENYL)-PIPERIDINE
2178, 6c0uA, 0.6463, 3.54, 0.257, 338, 261, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CALPHA SUBUNIT BOUND WITH N46 
2179, 5bmlB, 0.6463, 4.01, 0.222, 395, 275, ROCK 1 BOUND TO A PYRIDINE THIAZOLE INHIBITOR
2180, 2oh0E, 0.6463, 3.45, 0.250, 336, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
2181, 1xhaA, 0.6463, 3.39, 0.254, 348, 260, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2182, 4yveB, 0.6462, 4.11, 0.221, 393, 276, ROCK 1 BOUND TO METHOXYPHENYL THIAZOLE INHIBITOR
2183, 5lmkC, 0.6461, 2.50, 0.403, 265, 243, STRUCTURE OF PHOPSHO-CDK2-CYCLIN A IN COMPLEX WITH AN ATP-COMPETITIVE INHIBITOR
2184, 4o0rB, 0.6461, 2.71, 0.215, 282, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
2185, 4dc2A, 0.6461, 3.27, 0.220, 328, 259, STRUCTURE OF PKC IN COMPLEX WITH A SUBSTRATE PEPTIDE FROM PAR-3
2186, 4c35A, 0.6461, 3.36, 0.255, 337, 259, PKA-S6K1 CHIMERA WITH COMPOUND 1 (NU1085) BOUND
2187, 1xh8A, 0.6460, 3.35, 0.251, 337, 259, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2188, 5ukkA, 0.6459, 3.88, 0.204, 613, 270, HUMAN GRK2 IN COMPLEX WITH HUMAN G-BETA-GAMMA SUBUNITS AND CCG211998 (14AK)
2189, 4d28D, 0.6459, 3.62, 0.223, 271, 264, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF SNRK3.11 AT5G35410
2190, 3igoA, 0.6459, 3.72, 0.278, 446, 263, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CDPK1 CGD3_920
2191, 2zmcA, 0.6459, 2.70, 0.248, 260, 250, CRYSTAL STRUCTURE OF HUMAN MITOTIC CHECKPOINT KINASE MPS1 CATALYTIC DOMAIN APO FORM
2192, 2v55A, 0.6459, 4.09, 0.210, 393, 276, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
2193, 1okyA, 0.6459, 3.01, 0.262, 281, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
2194, 3c51B, 0.6458, 3.52, 0.230, 461, 261, CRYSTAL STRUCTURE OF G PROTEIN COUPLED RECEPTOR KINASE 1 BOUND TO ADP AND MAGNESIUM CHLORIDE AT 3.55A
2195, 5wneD, 0.6457, 4.02, 0.220, 396, 273, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2196, 2f7xE, 0.6457, 3.45, 0.254, 336, 260, PROTEIN KINASE A BOUND TO (S)-2-(1H-INDOL-3-YL)-1-[5-((E)-2- PYRIDIN-4-YL-VINYL)-PYRIDIN-3-YLOXYMETHYL]-ETHYLAMINE
2197, 5u7rC, 0.6456, 3.94, 0.213, 387, 272, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2198, 2xchA, 0.6456, 2.91, 0.263, 278, 251, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2199, 2f2uA, 0.6456, 3.90, 0.210, 386, 272, CRYSTAL STRUCTURE OF THE RHO-KINASE KINASE DOMAIN
2200, 4l6qA, 0.6455, 4.07, 0.223, 388, 273, ROCK2 IN COMPLEX WITH BENZOXABOROLE
2201, 4l6qB, 0.6453, 4.08, 0.223, 388, 273, ROCK2 IN COMPLEX WITH BENZOXABOROLE
2202, 2uzuE, 0.6453, 3.45, 0.250, 336, 260, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2203, 3ndmB, 0.6452, 4.16, 0.214, 396, 276, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2204, 2jdtA, 0.6451, 3.38, 0.255, 334, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH ISOQUINOLINE-5- SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL) AMIDE
2205, 5n1dA, 0.6449, 3.37, 0.247, 348, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-METHYL-1-(5-PYRIDIN-3-YLOXYFURAN-2-YL) METHANAMINE
2206, 4yvcA, 0.6449, 4.00, 0.216, 388, 273, ROCK 1 BOUND TO THIAZOLE INHIBITOR
2207, 3e8eI, 0.6449, 3.45, 0.254, 345, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2208, 3dneA, 0.6449, 3.46, 0.250, 336, 260, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2209, 2v55C, 0.6448, 4.11, 0.210, 396, 276, MECHANISM OF MULTI-SITE PHOSPHORYLATION FROM A ROCK-I:RHOE COMPLEX STRUCTURE
2210, 5yksB, 0.6447, 3.67, 0.243, 325, 263, CRYSTAL STRUCTURE OF SUCROSE NONFERMENTING-RELATED KINASE (SNRK)
2211, 3uc4B, 0.6447, 3.12, 0.214, 277, 257, THE CRYSTAL STRUCTURE OF SNF1-RELATED KINASE 2.6
2212, 3nuuA, 0.6447, 3.09, 0.257, 276, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT11
2213, 2uw4A, 0.6447, 3.46, 0.254, 334, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-(5-METHYL- 1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2214, 1smhA, 0.6447, 3.45, 0.254, 348, 260, PROTEIN KINASE A VARIANT COMPLEX WITH COMPLETELY ORDERED N- TERMINAL HELIX
2215, 2ojfE, 0.6446, 3.47, 0.250, 336, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH PYRIDINE-PYRAZOLOPYRIDINE BASED INHIBITORS
2216, 2gngA, 0.6446, 3.45, 0.262, 338, 260, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE
2217, 4c34A, 0.6445, 3.37, 0.255, 336, 259, PKA-S6K1 CHIMERA WITH STAUROSPORINE BOUND
2218, 3v8sA, 0.6445, 4.07, 0.219, 395, 274, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2219, 3nusA, 0.6445, 3.01, 0.262, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT8
2220, 5n84A, 0.6444, 2.53, 0.248, 256, 246, TTK KINASE DOMAIN IN COMPLEX WITH MPS-BAY2B
2221, 5lcqA, 0.6444, 3.50, 0.254, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH LONG-CHAIN FASUDIL-DERIVATIVE (LIGAND 05)
2222, 3v8sC, 0.6444, 4.06, 0.223, 395, 274, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH INDAZOLE DERIVATIVE (COMPOUND 18)
2223, 5vibA, 0.6443, 3.32, 0.253, 308, 257, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
2224, 3ambA, 0.6443, 3.48, 0.250, 340, 260, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR VX- 680
2225, 2vo0A, 0.6443, 3.53, 0.258, 340, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2226, 2f7eE, 0.6443, 3.48, 0.254, 336, 260, PKA COMPLEXED WITH (S)-2-(1H-INDOL-3-YL)-1-(5-ISOQUINOLIN-6- YL-PYRIDIN-3-YLOXYMETHYL-ETYLAMINE
2227, 1xh5A, 0.6443, 3.38, 0.251, 335, 259, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2228, 1okzA, 0.6443, 2.92, 0.267, 276, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH UCN-01
2229, 5lvpC, 0.6442, 2.93, 0.256, 275, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN HM-PEPTIDE BOUND TO THE PIF-POCKET
2230, 3nuyA, 0.6442, 3.02, 0.262, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH FRAGMENT17
2231, 3hmpA, 0.6442, 2.63, 0.242, 258, 248, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH A QUINAZOLIN LIGAND COMPOUND 4
2232, 2biyA, 0.6442, 3.27, 0.259, 287, 255, STRUCTURE OF PDK1-S241A MUTANT KINASE DOMAIN
2233, 5ei6A, 0.6441, 2.81, 0.240, 264, 250, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2234, 4o22A, 0.6441, 3.39, 0.242, 336, 260, BINARY COMPLEX OF METAL-FREE PKAC WITH SP20.
2235, 2c1aA, 0.6441, 3.47, 0.250, 335, 260, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
2236, 1q8wA, 0.6441, 3.36, 0.251, 334, 259, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR FASUDIL (HA-1077)
2237, 5m0bA, 0.6440, 3.47, 0.246, 350, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH A SHORT-CHAINED N-(2-AMINOETHYL)ISOQUINOLINE-5-SULFONAMIDE) FASUDIL-DERIVATIVE (LIGAND 03) 
2238, 5ho7A, 0.6440, 3.02, 0.262, 280, 252, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2239, 2gnfA, 0.6440, 3.47, 0.262, 339, 260, PROTEIN KINASE A FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH Y- 27632
2240, 5n3rA, 0.6439, 3.42, 0.250, 336, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(CARBAMOYLAMINO)-4- METHYLSULFANYLBUTANOIC ACID
2241, 4nusA, 0.6439, 3.03, 0.242, 301, 252, RSK2 N-TERMINAL KINASE IN COMPLEX WITH LJH685
2242, 3l9mB, 0.6439, 3.39, 0.251, 336, 259, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 18
2243, 3dndA, 0.6439, 3.48, 0.250, 334, 260, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2244, 2uvxA, 0.6439, 3.48, 0.254, 335, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 7-AZAINDOLE
2245, 5tx3B, 0.6438, 2.91, 0.257, 300, 249, STRUCTURE OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE
2246, 5o91A, 0.6438, 2.83, 0.240, 266, 250, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) C604W MUTANT IN COMPLEX WITH CPD-5
2247, 3mvjE, 0.6437, 3.51, 0.249, 334, 261, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2248, 3l9lB, 0.6437, 3.43, 0.251, 337, 259, CRYSTAL STRUCTURE OF PKA WITH COMPOUND 36
2249, 1uvrA, 0.6437, 2.95, 0.263, 284, 251, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-8
2250, 1uu9A, 0.6437, 3.11, 0.261, 276, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-3
2251, 1svhA, 0.6437, 3.47, 0.250, 335, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 8
2252, 1re8A, 0.6437, 3.43, 0.242, 337, 260, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH BALANOL ANALOG 2
2253, 3udbB, 0.6436, 3.14, 0.211, 278, 256, CRYSTAL STRUCTURE OF SNRK2.6
2254, 2y7jC, 0.6436, 3.14, 0.271, 284, 251, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2255, 2welA, 0.6436, 2.92, 0.294, 304, 248, CRYSTAL STRUCTURE OF SU6656-BOUND CALCIUM/CALMODULIN- DEPENDENT PROTEIN KINASE II DELTA IN COMPLEX WITH CALMODULIN
2256, 1uu8A, 0.6435, 3.03, 0.266, 277, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-1
2257, 3sc1A, 0.6433, 3.06, 0.262, 278, 252, NOVEL ISOQUINOLONE PDK1 INHIBITORS DISCOVERED THROUGH FRAGMENT-BASED LEAD DISCOVERY
2258, 3orxH, 0.6433, 2.99, 0.251, 274, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2259, 3orxG, 0.6433, 2.99, 0.255, 274, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2260, 3cekA, 0.6433, 2.53, 0.236, 256, 246, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK)
2261, 3orxF, 0.6432, 2.99, 0.255, 274, 251, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2262, 2v7oA, 0.6432, 3.30, 0.292, 305, 253, CRYSTAL STRUCTURE OF HUMAN CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE II GAMMA
2263, 5ho8A, 0.6431, 3.04, 0.266, 278, 252, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2264, 3iopA, 0.6430, 2.98, 0.259, 275, 251, PDK-1 IN COMPLEX WITH THE INHIBITOR COMPOUND-8I
2265, 2r7bA, 0.6430, 2.98, 0.259, 274, 251, CRYSTAL STRUCTURE OF THE PHOSPHOINOSITIDE-DEPENDENT KINASE- 1 (PDK-1)CATALYTIC DOMAIN BOUND TO A DIBENZONAPHTHYRIDINE INHIBITOR
2266, 5ebzK, 0.6429, 3.45, 0.233, 655, 258, CRYSTAL STRUCTURE OF HUMAN IKK1
2267, 4wotD, 0.6429, 3.96, 0.217, 389, 272, ROCK2 IN COMPLEX WITH 1426382-07-1
2268, 3tv7A, 0.6429, 4.05, 0.212, 394, 273, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2269, 3kk8A, 0.6429, 3.12, 0.299, 283, 251, CAMKII SUBSTRATE COMPLEX A
2270, 3aglB, 0.6429, 3.49, 0.250, 335, 260, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
2271, 5ebzD, 0.6428, 3.37, 0.230, 655, 257, CRYSTAL STRUCTURE OF HUMAN IKK1
2272, 5ap6A, 0.6428, 2.69, 0.246, 262, 248, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2273, 2w5bA, 0.6428, 2.87, 0.234, 271, 252, HUMAN NEK2 KINASE ATPGAMMAS-BOUND
2274, 2qurA, 0.6428, 3.41, 0.247, 338, 259, CRYSTAL STRUCTURE OF F327A/K285P MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2275, 2gnhA, 0.6428, 3.41, 0.263, 338, 259, PKA FIVE FOLD MUTANT MODEL OF RHO-KINASE WITH H1152P
2276, 5uzjA, 0.6427, 4.04, 0.220, 387, 273, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
2277, 1q8uA, 0.6427, 3.49, 0.250, 341, 260, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH RHO-KINASE INHIBITOR H-1152P
2278, 3e8cD, 0.6426, 3.49, 0.254, 344, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2279, 3e8cB, 0.6426, 3.49, 0.254, 344, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2280, 2w5aA, 0.6426, 2.90, 0.214, 267, 252, HUMAN NEK2 KINASE ADP-BOUND
2281, 1ydsE, 0.6426, 3.43, 0.255, 334, 259, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H8 PROTEIN KINASE INHIBITOR [N-(2-METHYLAMINO)ETHYL]-5- ISOQUINOLINESULFONAMIDE
2282, 5n3gA, 0.6425, 3.45, 0.250, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (R)-14-OXAZEPAN-6-OL
2283, 5jzjA, 0.6425, 3.10, 0.308, 271, 250, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
2284, 2zmdA, 0.6425, 2.77, 0.241, 259, 249, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN T686A MUTANT IN COMPLEX WITH SP600125 INHIBITOR
2285, 2vo3A, 0.6425, 3.50, 0.254, 334, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  C-(4-(4- CHLOROPHENYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YL)METHYLAMINE
2286, 2gnlA, 0.6425, 3.52, 0.254, 338, 260, PKA THREEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR H- 1152P
2287, 1uu3A, 0.6425, 3.05, 0.262, 276, 252, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH LY333531
2288, 5vhbA, 0.6424, 3.49, 0.250, 325, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITOR
2289, 5n1fA, 0.6424, 3.49, 0.250, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-QUINOLIN-5-YLPYRIDINE-3-CARBOXAMIDE
2290, 4yxsA, 0.6424, 3.50, 0.250, 335, 260, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2291, 4uj2A, 0.6424, 3.52, 0.250, 335, 260, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2292, 1ydrE, 0.6424, 3.50, 0.250, 334, 260, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5- ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
2293, 5n1gA, 0.6423, 3.49, 0.250, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(2-AMINO-13-THIAZOL-4-YL)-1- OXASPIRO[4.5]DECAN-2-ONE
2294, 3e8cF, 0.6423, 3.50, 0.254, 341, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2295, 3e8cE, 0.6423, 3.50, 0.254, 336, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2296, 1koaA, 0.6423, 3.61, 0.236, 447, 259, TWITCHIN KINASE FRAGMENT (C.ELEGANS) AUTOREGULATED PROTEIN KINASE AND IMMUNOGLOBULIN DOMAINS
2297, 4xw4A, 0.6422, 3.45, 0.242, 334, 260, X-RAY STRUCTURE OF PKAC WITH AMPPNP SP20 CALCIUM IONS
2298, 4ujbA, 0.6422, 3.51, 0.250, 344, 260, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2299, 1xh9A, 0.6422, 3.50, 0.258, 336, 260, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2300, 3x2uA, 0.6421, 3.50, 0.242, 336, 260, MICHAELIS-LIKE INITIAL COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT.
2301, 3mvjB, 0.6421, 3.44, 0.227, 320, 260, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2302, 2vnwA, 0.6421, 3.55, 0.254, 334, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)METHANAMINE
2303, 2uw6A, 0.6421, 3.43, 0.255, 334, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (S)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2304, 2uw0A, 0.6421, 3.55, 0.258, 334, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  6-(4-(4-(4- CHLORO-PHENYL)-PIPERIDIN-4-YL)-PHENYL)-9H-PURINE
2305, 5oneA, 0.6420, 2.66, 0.255, 257, 247, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH FMF-03-145-1 (COMPOUND 2)
2306, 5ebzC, 0.6420, 3.41, 0.230, 655, 257, CRYSTAL STRUCTURE OF HUMAN IKK1
2307, 4w7pA, 0.6420, 4.07, 0.223, 388, 274, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2308, 3wf5A, 0.6420, 2.60, 0.282, 277, 245, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-BENZIMIDAZOL-2-YL)PIPERIDIN-1- YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
2309, 3pwyA, 0.6420, 3.07, 0.262, 281, 252, CRYSTAL STRUCTURE OF AN EXTENDER (SPD28345)-MODIFIED HUMAN PDK1 COMPLEX 2
2310, 3h9fA, 0.6420, 2.60, 0.243, 260, 247, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYRIMIDO-DIAZEPIN LIGAND
2311, 3e8cC, 0.6420, 3.50, 0.254, 341, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2312, 3e8cA, 0.6420, 3.50, 0.254, 341, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2313, 2xckA, 0.6420, 2.87, 0.257, 275, 249, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2314, 2c1bA, 0.6420, 3.52, 0.250, 335, 260, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH ( 4R2S)-5 -(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2- YLMETHANESULFONYL)ISOQUINOLINE
2315, 4nw5A, 0.6419, 3.00, 0.250, 302, 252, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 8
2316, 4c4jA, 0.6419, 2.68, 0.239, 261, 247, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
2317, 5vi9A, 0.6418, 3.32, 0.255, 306, 255, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH THE PKI PEPTIDE AND AMINOBENZOTHIAZOLE BASED INHIBITORS
2318, 5hngA, 0.6418, 3.07, 0.262, 280, 252, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2319, 5ebzF, 0.6418, 3.50, 0.224, 655, 259, CRYSTAL STRUCTURE OF HUMAN IKK1
2320, 4z84A, 0.6418, 3.51, 0.254, 335, 260, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 34A
2321, 4w7pD, 0.6418, 4.03, 0.215, 387, 274, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2322, 4uj1A, 0.6418, 3.52, 0.250, 335, 260, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2323, 4ie9A, 0.6418, 3.46, 0.247, 335, 259, BOVINE PKA C-ALPHA IN COMPLEX WITH 3-PYRIDYLMETHYL-5-METHYL-1H- PYRAZOLE-3-CARBOXYLATE
2324, 2gniA, 0.6418, 3.42, 0.266, 338, 259, PKA FIVEFOLD MUTANT MODEL OF RHO-KINASE WITH INHIBITOR FASUDIL (HA1077)
2325, 1uu7A, 0.6418, 3.19, 0.261, 280, 253, STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH BIM-2
2326, 1sveA, 0.6418, 3.49, 0.250, 341, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 1
2327, 5wnhD, 0.6417, 4.08, 0.220, 397, 273, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2328, 5imeB, 0.6417, 2.81, 0.215, 280, 246, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 (PAK1) IN COMPLEX WITH COMPOUND 9
2329, 5ebzA, 0.6417, 3.27, 0.231, 655, 255, CRYSTAL STRUCTURE OF HUMAN IKK1
2330, 5bx6A, 0.6417, 3.52, 0.250, 343, 260, PKA IN COMPLEX WITH A HALOGENATED PHTHALAZINONE FRAGMENT COMPOUND.
2331, 3x2wA, 0.6417, 3.43, 0.242, 336, 260, MICHAELIS COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2332, 3h9oA, 0.6417, 3.01, 0.259, 275, 251, PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK-1) IN COMPLEX WITH COMPOUND 9
2333, 2erzE, 0.6417, 3.51, 0.242, 334, 260, CRYSTAL STRUCTURE OF C-AMP DEPENDENT KINASE (PKA) BOUND TO HYDROXYFASUDIL
2334, 5ebzE, 0.6416, 3.39, 0.237, 655, 257, CRYSTAL STRUCTURE OF HUMAN IKK1
2335, 5o5mA, 0.6415, 3.55, 0.250, 336, 260, CRYSTAL STRUCTURE OF THE PROTEIN-KINASE A CATALYTIC SUBUNIT FROM CRITECULUS GRISEUS IN COMPLEX WITH COMPOUNDS RKP120 AND RKP117 
2336, 5n3nA, 0.6415, 3.46, 0.250, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE [(2R)-24-DIHYDROXY-4-OXOBUTYL]- TRIMETHYLAZANIUM
2337, 5n1hA, 0.6415, 3.50, 0.250, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL 4-(AMINOMETHYL)BENZOATE
2338, 5ebzG, 0.6415, 3.42, 0.230, 655, 257, CRYSTAL STRUCTURE OF HUMAN IKK1
2339, 3e8eE, 0.6415, 3.50, 0.254, 341, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2340, 3aqvA, 0.6415, 3.05, 0.264, 267, 254, HUMAN AMP-ACTIVATED PROTEIN KINASE ALPHA 2 SUBUNIT KINASE DOMAIN (T172D) COMPLEXED WITH COMPOUND C
2341, 1vebA, 0.6415, 3.49, 0.250, 338, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 5
2342, 5n3qA, 0.6414, 3.51, 0.246, 336, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINOBENZAMIDE
2343, 4axaA, 0.6414, 3.53, 0.254, 335, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1S)-2-AMINO-1-( 4-CHLOROPHENYL)-1-(4-(1H-PYRAZOL-4-YL)PHENYL)ETHAN-1-OL
2344, 5n7vA, 0.6413, 2.65, 0.247, 260, 247, TTK KINASE DOMAIN IN COMPLEX WITH MPI-0479605
2345, 5n3jA, 0.6413, 3.48, 0.250, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-NITROBENZOIC ACID
2346, 5ehyA, 0.6413, 2.52, 0.245, 255, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2347, 4ujaA, 0.6413, 3.53, 0.250, 336, 260, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2348, 4nw6A, 0.6413, 3.01, 0.250, 302, 252, RSK2 N-TERMINAL KINASE IN COMPLEX WITH 2-AMINO-7-SUBSTITUTED BENZOXAZOLE COMPOUND 27
2349, 3tv7C, 0.6413, 4.17, 0.211, 394, 275, HUMAN RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1342
2350, 2uw3A, 0.6413, 3.44, 0.255, 334, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 5-METHYL-4- PHENYL-1H-PYRAZOLE
2351, 2gnjA, 0.6413, 3.51, 0.254, 335, 260, PKA THREE FOLD MUTANT MODEL OF RHO-KINASE WITH Y-27632
2352, 1q61A, 0.6413, 3.51, 0.254, 335, 260, PKA TRIPLE MUTANT MODEL OF PKB
2353, 5ebzH, 0.6412, 3.58, 0.227, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
2354, 3zo3A, 0.6412, 3.51, 0.250, 337, 260, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2355, 5ebzB, 0.6411, 3.49, 0.225, 655, 258, CRYSTAL STRUCTURE OF HUMAN IKK1
2356, 4zegA, 0.6411, 2.64, 0.232, 260, 246, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR
2357, 2uvyA, 0.6411, 3.45, 0.255, 333, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH METHYL-(4-(9H- PURIN-6-YL)-BENZYL)-AMINE
2358, 5wnfD, 0.6410, 4.01, 0.224, 396, 272, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2359, 5uzkA, 0.6410, 3.52, 0.250, 335, 260, CRYSTAL STRUCTURE OF PKA BOUND TO AN PYRROLO PYRIDINE INHIBITOR
2360, 5ebzJ, 0.6410, 3.56, 0.235, 655, 260, CRYSTAL STRUCTURE OF HUMAN IKK1
2361, 4yxrA, 0.6410, 3.53, 0.250, 334, 260, CRYSTAL STRUCTURE OF PKA IN COMPLEX WITH INHIBITOR.
2362, 4ij9A, 0.6410, 3.45, 0.251, 335, 259, BOVINE PKA C-ALPHA IN COMPLEX WITH 2-[[5-(4-PYRIDYL)-1H-124-TRIAZOL- 3-YL]SULFANYL]-1-(2-THIOPHENYL)ETHANONE
2363, 3dbqA, 0.6410, 2.71, 0.239, 259, 247, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN
2364, 2vo7A, 0.6410, 3.53, 0.250, 335, 260, STRUCTURE OF PKA COMPLEXED WITH 4-(4-CHLOROBENZYL)-1-(7H- PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN-4-YLAMINE
2365, 2gfcA, 0.6410, 3.52, 0.254, 335, 260, CAMP-DEPENDENT PROTEIN KINASE PKA CATALYTIC SUBUNIT WITH PKI-5-24
2366, 5ap1A, 0.6409, 2.72, 0.234, 268, 248, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2367, 3orxE, 0.6409, 2.99, 0.252, 274, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2368, 1svgA, 0.6409, 3.51, 0.250, 338, 260, CRYSTAL STRUCTURE OF PROTEIN KINASE A IN COMPLEX WITH AZEPANE DERIVATIVE 4
2369, 1h1wA, 0.6409, 3.07, 0.263, 284, 251, HIGH RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PDK1 CATALYTIC DOMAIN
2370, 5u7qC, 0.6408, 4.03, 0.221, 390, 271, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2371, 5n3pA, 0.6408, 3.52, 0.246, 336, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 1H-INDOL-5-OL
2372, 5n3iA, 0.6408, 3.47, 0.250, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE METHYL (2S)-2-AMINO-3-PHENYLPROPANOATE
2373, 3rwqA, 0.6408, 3.21, 0.257, 283, 253, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2374, 3zo2A, 0.6407, 3.51, 0.250, 340, 260, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2375, 3nx8A, 0.6407, 3.51, 0.254, 333, 260, HUMAN CAMP DEPENDENT PROTEIN KINASE IN COMPLEX WITH PHENOL
2376, 3kk9A, 0.6407, 3.13, 0.296, 275, 250, CAMKII SUBSTRATE COMPLEX B
2377, 2vnyA, 0.6407, 3.57, 0.258, 334, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH (1-(9H-PURIN-6- YL)PIPERIDIN-4-YL)AMINE
2378, 2uztA, 0.6407, 3.54, 0.246, 336, 260, PKA STRUCTURES OF AKT INDAZOLE-PYRIDINE INHIBITORS
2379, 5uzjB, 0.6406, 4.09, 0.227, 386, 273, CRYSTAL STRUCTURE OF ROCK1 BOUND TO AN AMINOPYRIDINE INHIBITOR
2380, 4j7bA, 0.6406, 2.84, 0.282, 284, 248, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2381, 4c4eA, 0.6406, 2.64, 0.236, 256, 246, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
2382, 3udbD, 0.6406, 3.20, 0.212, 279, 255, CRYSTAL STRUCTURE OF SNRK2.6
2383, 3nczA, 0.6406, 4.10, 0.212, 399, 274, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2384, 3kkvA, 0.6406, 3.51, 0.254, 335, 260, STRUCTURE OF PKA WITH A PROTEIN KINASE B-SELECTIVE INHIBITOR.
2385, 2uzvA, 0.6406, 3.46, 0.251, 336, 259, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2386, 1jluE, 0.6406, 3.52, 0.242, 337, 260, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PHOSPHORYLATED SUBSTRATE PEPTIDE AND DETERGENT
2387, 1jbpE, 0.6406, 3.48, 0.242, 339, 260, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE COMPLEXED WITH A SUBSTRATE PEPTIDE ADP AND DETERGENT
2388, 5vndB, 0.6405, 3.24, 0.268, 295, 254, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
2389, 5n3tA, 0.6405, 3.48, 0.246, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 5-CHLOROTHIOPHENE-2-SULFONAMIDE
2390, 4uj9A, 0.6405, 3.54, 0.250, 339, 260, PROTEIN KINASE A IN COMPLEX WITH AN INHIBITOR
2391, 4ae6B, 0.6405, 3.64, 0.222, 321, 261, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT CALPHA 2
2392, 4z83E, 0.6404, 3.54, 0.254, 335, 260, PKAB3 IN COMPLEX WITH PYRROLIDINE INHIBITOR 47A
2393, 4yuqA, 0.6404, 3.63, 0.295, 462, 258, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
2394, 3q53A, 0.6404, 2.99, 0.223, 291, 247, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN IN COMPLEX WITH ATP
2395, 3oogA, 0.6404, 3.53, 0.250, 333, 260, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH A SMALL FRAGMENT
2396, 2f7zE, 0.6404, 3.45, 0.251, 336, 259, PROTEIN KINASE A BOUND TO (R)-1-(1H-INDOL-3-YLMETHYL)-2-(2- PYRIDIN-4-YL-[17]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE
2397, 3qcqA, 0.6403, 3.09, 0.262, 276, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-(3- AMINO-1H-INDAZOL-6-YL)-N4-ETHYL-24-PYRIMIDINEDIAMINE
2398, 3nunA, 0.6403, 3.17, 0.257, 278, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) WITH LEAD COMPOUND
2399, 2h9vA, 0.6403, 4.19, 0.204, 383, 274, STRUCTURAL BASIS FOR INDUCED-FIT BINDING OF RHO-KINASE TO THE INHIBITOR Y27632
2400, 5u7rD, 0.6402, 3.78, 0.221, 382, 267, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2401, 3rwpA, 0.6402, 3.09, 0.258, 277, 252, DISCOVERY OF A NOVEL POTENT AND SELECTIVE INHIBITOR OF 3- PHOSPHOINOSITIDE DEPENDENT KINASE (PDK1)
2402, 2uzwE, 0.6402, 3.54, 0.250, 336, 260, PKA STRUCTURES OF INDAZOLE-PYRIDINE SERIES OF AKT INHIBITORS
2403, 3p0mA, 0.6401, 3.54, 0.250, 335, 260, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2404, 2uw8A, 0.6401, 3.53, 0.254, 334, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH 2-(4-CHLORO- PHENYL)-2-PHENYL-ETHYLAMINE
2405, 2owbA, 0.6401, 2.84, 0.286, 294, 248, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2406, 3udbA, 0.6400, 3.18, 0.216, 275, 255, CRYSTAL STRUCTURE OF SNRK2.6
2407, 2pe0A, 0.6400, 3.11, 0.262, 275, 252, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 5-HYDROXY-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-13-DIHYDRO- INDOL-2-ONE COMPLEX
2408, 6cmjA, 0.6399, 3.32, 0.258, 285, 256, HUMAN CAMKK2 WITH GSK650393
2409, 4js8A, 0.6399, 2.71, 0.243, 259, 247, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401348
2410, 3nczD, 0.6399, 4.15, 0.215, 397, 275, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2411, 3nczC, 0.6399, 4.22, 0.217, 389, 276, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
2412, 2pe2A, 0.6399, 3.02, 0.263, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) 3-{5-[2-OXO-5-UREIDO-12-DIHYDRO-INDOL-(3Z)-YLIDENEMETHYL]-1H- PYRROL-3-YL}-N-(2-PIPERIDIN-1-YL-ETHYL)-BENZAMIDE COMPLEX
2413, 6b4wA, 0.6398, 2.61, 0.240, 259, 246, TTK IN COMPLEX WITH INHIBITOR
2414, 5n3kA, 0.6398, 3.53, 0.250, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE O-GUANIDINO-L-HOMOSERINE
2415, 4yuqB, 0.6398, 3.60, 0.300, 462, 257, CDPK1 FROM EIMERIA TENELLA IN COMPLEX WITH INHIBITOR UW1354
2416, 1xh6A, 0.6398, 3.40, 0.256, 331, 258, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2417, 1q8tA, 0.6398, 3.54, 0.250, 338, 260, THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH RHO-KINASE INHIBITOR Y-27632
2418, 5n9sA, 0.6397, 2.70, 0.235, 259, 247, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1161909
2419, 5bx7A, 0.6397, 3.55, 0.250, 343, 260, PKA IN COMPLEX WITH A BENZOTHIOPHENE FRAGMENT COMPOUND.
2420, 3q4zB, 0.6397, 2.74, 0.208, 279, 245, STRUCTURE OF UNPHOSPHORYLATED PAK1 KINASE DOMAIN
2421, 3pooA, 0.6397, 3.56, 0.250, 331, 260, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2422, 3l9nA, 0.6397, 3.58, 0.258, 332, 260, CRYSTAL STRUCTURE OF PKAB3 (PKA TRIPLE MUTANT V123A L173M Q181K) WITH COMPOUND 27
2423, 1q62A, 0.6397, 3.54, 0.250, 336, 260, PKA DOUBLE MUTANT MODEL OF PKB
2424, 3zo4A, 0.6396, 3.54, 0.250, 335, 260, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2425, 1xh7A, 0.6396, 3.52, 0.250, 337, 260, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2426, 1szmB, 0.6396, 3.62, 0.226, 320, 261, DUAL BINDING MODE OF BISINDOLYLMALEIMIDE 2 TO PROTEIN KINASE A (PKA)
2427, 1ydtE, 0.6395, 3.47, 0.251, 334, 259, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H89 PROTEIN KINASE INHIBITOR N-[2- (4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE
2428, 5dzcA, 0.6394, 3.40, 0.247, 816, 255, CRYSTAL STRUCTURE OF PVX_084705 IN COMPLEX WITH AMP-PNP
2429, 4ckrA, 0.6394, 3.52, 0.210, 295, 257, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH DDR1-IN-1
2430, 3vqhA, 0.6394, 3.48, 0.251, 344, 259, BROMINE SAD PARTIALLY RESOLVES MULTIPLE BINDING MODES FOR PKA INHIBITOR H-89
2431, 3qd3A, 0.6394, 3.18, 0.257, 278, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL {(3R6S)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-6-METHYL-3-PIPERIDINYL}CARBAMATE
2432, 3hmnA, 0.6394, 2.54, 0.241, 255, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH ATP
2433, 5wngA, 0.6393, 4.17, 0.208, 395, 274, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2434, 5vndA, 0.6393, 3.09, 0.258, 302, 252, CRYSTAL STRUCTURE OF FGFR1-Y563C (FGFR4 SURROGATE) COVALENTLY BOUND TO H3B-6527
2435, 5n3hA, 0.6393, 3.54, 0.246, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE PYRIDINE-3-CARBOXAMIDE
2436, 5ebzI, 0.6393, 3.40, 0.230, 655, 256, CRYSTAL STRUCTURE OF HUMAN IKK1
2437, 4wotA, 0.6393, 4.10, 0.216, 389, 273, ROCK2 IN COMPLEX WITH 1426382-07-1
2438, 4c33A, 0.6393, 3.53, 0.258, 335, 260, PKA-S6K1 CHIMERA APO
2439, 3wf6A, 0.6393, 2.72, 0.289, 277, 246, CRYSTAL STRUCTURE OF S6K1 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE DERIVATIVE 4-[4-(1H-INDOL-3-YL)-36- DIHYDROPYRIDIN-1(2H)-YL]-1H-PYRAZOLO[34-D]PYRIMIDINE
2440, 3qcsA, 0.6393, 3.18, 0.257, 276, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-[2- AMINO-6-(4-MORPHOLINYL)-4-PYRIMIDINYL]-1H-INDAZOL-3-AMINE
2441, 3ionA, 0.6393, 2.91, 0.261, 274, 249, PDK1 IN COMPLEX WITH COMPOUND 8H
2442, 3amaA, 0.6393, 3.60, 0.250, 342, 260, PROTEIN KINASE A SIXFOLD MUTANT MODEL OF AURORA B WITH INHIBITOR JNJ- 7706621
2443, 1yhvA, 0.6393, 3.05, 0.227, 293, 247, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH TWO POINT MUTATIONS (K299R T423E)
2444, 1f3mD, 0.6393, 2.74, 0.233, 285, 245, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE PAK1
2445, 5j5xA, 0.6392, 3.54, 0.250, 340, 260, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1416
2446, 5izfA, 0.6392, 3.53, 0.254, 336, 260, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1408
2447, 3e8eP, 0.6392, 3.55, 0.250, 341, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2448, 2jdsA, 0.6392, 3.54, 0.254, 334, 260, STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A- 443654
2449, 2gu8A, 0.6392, 3.57, 0.246, 335, 260, DISCOVERY OF 2-PYRIMIDYL-5-AMIDOTHIOPHENES AS NOVEL AND POTENT INHIBITORS FOR AKT: SYNTHESIS AND SAR STUDIES
2450, 1yhwA, 0.6392, 2.93, 0.228, 293, 246, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH ONE POINT MUTATIONS (K299R)
2451, 5nadA, 0.6391, 2.58, 0.242, 256, 244, TTK KINASE DOMAIN IN COMPLEX WITH BAY 1217389
2452, 5n3lA, 0.6391, 3.51, 0.246, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-[(1R)-2-AMINO-1-HYDROXYETHYL]BENZENE-1 2-DIOL
2453, 5hkmA, 0.6391, 3.01, 0.260, 272, 250, DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS
2454, 5ap7A, 0.6391, 2.75, 0.235, 263, 247, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2455, 4j53A, 0.6391, 2.77, 0.287, 293, 247, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH TAK-960
2456, 3rcjA, 0.6391, 3.01, 0.257, 281, 249, RAPID PREPARATION OF TRIAZOLYL SUBSTITUTED NH-HETEROCYCLIC KINASE INHIBITORS VIA ONE-POT SONOGASHIRA COUPLING TMS-DEPROTECTION CUAAC SEQUENCE
2457, 1z5mA, 0.6391, 3.02, 0.263, 275, 251, CRYSTAL STRUCTURE OF N1-[3-[[5-BROMO-2-[[3-[(1-PYRROLIDINYLCARBONYL) AMINO]PHENYL]AMINO]-4-PYRIMIDINYL]AMINO]PROPYL]-22- DIMETHYLPROPANEDIAMIDE COMPLEXED WITH HUMAN PDK1
2458, 5lvoA, 0.6390, 3.19, 0.258, 285, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PSE10 BOUND TO THE PIF-POCKET
2459, 4xcuA, 0.6390, 3.06, 0.259, 288, 251, CRYSTAL STRUCTURE OF FGFR4 WITH AN IRREVERSIBLE INHIBITOR
2460, 4c38A, 0.6390, 3.46, 0.259, 334, 259, PKA-S6K1 CHIMERA WITH COMPOUND 21E (CCT239066) BOUND
2461, 3zo1A, 0.6390, 3.46, 0.251, 339, 259, THE SYNTHESIS AND EVALUATION OF DIAZASPIROCYCLIC PROTEIN KINASE INHIBITORS
2462, 3fc2A, 0.6390, 2.86, 0.286, 293, 248, PLK1 IN COMPLEX WITH BI6727
2463, 2ou7A, 0.6390, 2.94, 0.289, 292, 249, STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN POLO-LIKE KINASE 1
2464, 5m0cA, 0.6389, 3.55, 0.246, 336, 260, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE FASUDIL-FRAGMENT ISOQUINOLINE-5-SULFONAMIDE 
2465, 5ei8A, 0.6389, 2.64, 0.251, 261, 247, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2466, 4xx9A, 0.6389, 3.20, 0.258, 288, 252, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RF4
2467, 4w7pB, 0.6389, 4.05, 0.218, 387, 271, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2468, 3wzkA, 0.6389, 2.68, 0.236, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH N- CYCLOPROPYL-4-(8-((THIOPHEN-2-YLMETHYL)AMINO)IMIDAZO[12-A]PYRAZIN-3- YL)BENZAMIDE
2469, 3fxzA, 0.6389, 3.06, 0.231, 292, 247, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX LAMBDA-FL172
2470, 3e8eL, 0.6389, 3.55, 0.254, 336, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2471, 2vo6A, 0.6389, 3.57, 0.254, 335, 260, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  4-(4- CHLOROBENZYL)-1-(7H-PYRROLO(23-D)PYRIMIDIN-4-YL)PIPERIDIN- 4-YLAMINE
2472, 2uvzA, 0.6389, 3.49, 0.255, 334, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH C-PHENYL-C-(4-( 9H-PURIN-6-YL)-PHENYL)-METHYLAMINE
2473, 5x3fB, 0.6387, 3.19, 0.242, 348, 252, CRYSTAL STRUCTURE OF THE YGJG-PROTEIN A-ZPA963-PKA CATALYTIC DOMAIN
2474, 5lvlA, 0.6387, 3.20, 0.262, 285, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH COMPOUND PS653 BOUND TO THE ATP-BINDING SITE
2475, 5ehlA, 0.6387, 2.68, 0.247, 258, 247, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2476, 4xw5A, 0.6387, 3.55, 0.242, 334, 260, X-RAY STRUCTURE OF PKAC WITH ATP CP20 CALCIUM IONS
2477, 4hptE, 0.6387, 3.59, 0.246, 335, 260, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING COMPLETE PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
2478, 4c37A, 0.6387, 3.54, 0.254, 335, 260, PKA-S6K1 CHIMERA WITH COMPOUND 21A (CCT196539) BOUND
2479, 3hmoA, 0.6387, 2.64, 0.252, 257, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH THE INHIBITOR STAUROSPORINE
2480, 5u7rB, 0.6386, 4.10, 0.207, 387, 271, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2481, 3etaB, 0.6386, 3.62, 0.208, 292, 259, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
2482, 5te0A, 0.6385, 3.54, 0.205, 316, 258, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH BIBF 1120
2483, 5n93A, 0.6385, 2.65, 0.240, 259, 246, TTK KINASE DOMAIN IN COMPLEX WITH TC-MPS1-12
2484, 5hhwA, 0.6385, 3.81, 0.201, 306, 264, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH CIS-(R)-7-(3-(AZETIDIN-1-YLMETHYL)CYCLOBUTYL)-5-(3-((TETRAHYDRO-2H- PYRAN-2-YL)METHOXY)PHENYL)-7H-PYRROLO[23-D]PYRIMIDIN-4-AMINE.
2485, 5ebzL, 0.6385, 3.57, 0.224, 655, 259, CRYSTAL STRUCTURE OF HUMAN IKK1
2486, 4iacA, 0.6385, 3.51, 0.242, 333, 260, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION AMP-PCP AND PSEUDO-SUBSTRATE PEPTIDE SP20
2487, 3q52A, 0.6385, 2.97, 0.228, 292, 246, STRUCTURE OF PHOSPHORYLATED PAK1 KINASE DOMAIN
2488, 5mrdA, 0.6384, 3.10, 0.252, 283, 250, HUMAN PDK1-PKCIOTA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS267 BOUND TO THE PIF-POCKET
2489, 4rqvA, 0.6384, 3.20, 0.258, 288, 252, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS2
2490, 3qcxA, 0.6384, 3.20, 0.257, 276, 253, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 6-{2- AMINO-6-[(3R)-3-METHYL-4-MORPHOLINYL]-4-PYRIMIDINYL}-1H-INDAZOL-3- AMINE
2491, 2uw5A, 0.6384, 3.49, 0.255, 333, 259, STRUCTURE OF PKA-PKB CHIMERA COMPLEXED WITH  (R)-2-(4- CHLORO-PHENYL)-2-(4-1H-PYRAZOL-4-YL)-PHENYL)-ETHYLAMINE
2492, 1xh4A, 0.6384, 3.47, 0.251, 334, 259, CRYSTAL STRUCTURES OF PROTEIN KINASE B SELECTIVE INHIBITORS IN COMPLEX WITH PROTEIN KINASE A AND MUTANTS
2493, 1irkA, 0.6384, 3.58, 0.202, 303, 258, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HUMAN INSULIN RECEPTOR
2494, 5n87A, 0.6383, 2.56, 0.241, 255, 245, TTK KINASE DOMAIN IN COMPLEX WITH NTRC 0066-0
2495, 5n3sA, 0.6383, 3.56, 0.246, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-HYDROXYBENZAMIDE
2496, 5n3mA, 0.6383, 3.51, 0.246, 337, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE D-ARGININE
2497, 5n23A, 0.6383, 3.50, 0.251, 333, 259, PROTEIN KINASE A MUTANTS AS SURROGATE MODEL FOR AURORA B WITH AT9283 INHIBITOR
2498, 4iayA, 0.6383, 3.56, 0.242, 333, 260, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2499, 1oplB, 0.6383, 3.47, 0.218, 365, 257, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
2500, 5o49A, 0.6382, 3.10, 0.258, 289, 252, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
2501, 3x2vA, 0.6382, 3.46, 0.243, 331, 259, MICHAELIS-LIKE COMPLEX OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT
2502, 3orzD, 0.6382, 3.27, 0.252, 278, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2503, 3gfwA, 0.6382, 2.55, 0.250, 253, 244, CRYSTAL STRUCTURE OF HUMAN DUAL SPECIFICITY PROTEIN KINASE (TTK) IN COMPLEX WITH A PYROLO-PYRIDIN LIGAND
2504, 5vloA, 0.6381, 3.19, 0.304, 290, 250, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2505, 5lihA, 0.6381, 3.32, 0.233, 324, 257, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
2506, 3owpA, 0.6381, 3.58, 0.250, 334, 260, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2507, 5wneA, 0.6380, 4.16, 0.212, 384, 273, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2508, 5n3oA, 0.6380, 3.57, 0.246, 335, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-(13-OXAZOL-5-YL)ANILINE
2509, 5lvmA, 0.6380, 3.10, 0.256, 283, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENINE BOUND TO THE ATP- BINDING SITE
2510, 5ljjA, 0.6380, 2.64, 0.244, 264, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH REVERSINE
2511, 4iakA, 0.6380, 3.57, 0.246, 334, 260, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH SR2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2512, 4bi0A, 0.6380, 2.56, 0.242, 254, 244, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
2513, 3ovvA, 0.6380, 3.51, 0.251, 335, 259, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2514, 3js2B, 0.6380, 3.00, 0.255, 291, 251, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
2515, 4rwiB, 0.6379, 3.24, 0.257, 280, 253, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
2516, 3e8eB, 0.6379, 3.57, 0.250, 337, 260, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2517, 1q24A, 0.6379, 3.58, 0.250, 335, 260, PKA DOUBLE MUTANT MODEL OF PKB IN COMPLEX WITH MGATP
2518, 6cmjB, 0.6378, 3.34, 0.254, 284, 256, HUMAN CAMKK2 WITH GSK650393
2519, 6aywA, 0.6378, 3.18, 0.304, 293, 250, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2520, 5mrbA, 0.6378, 2.73, 0.239, 264, 247, CRYSTAL STRUCTURE OF HUMAN MPS1 (TTK) IN COMPLEX WITH CPD-5
2521, 5hvuB, 0.6378, 3.93, 0.219, 394, 270, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH A PYRIDINE THIAZOLE PIPERIDINE INHIBITOR
2522, 5dfpA, 0.6378, 2.95, 0.232, 292, 246, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND FRAX1036
2523, 4rqkA, 0.6378, 3.22, 0.262, 285, 252, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND THE PIF-POCKET LIGAND RS1
2524, 4o6lB, 0.6378, 2.60, 0.249, 256, 245, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
2525, 2pe1A, 0.6378, 3.06, 0.263, 275, 251, CRYSTAL STRUCTURE OF HUMAN PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) {2-OXO-3-[1-(1H-PYRROL-2-YL)-ETH-(Z)-YLIDENE]-23-DIHYDRO-1H- INDOL-5-YL}-UREA {BX-517} COMPLEX
2526, 5m0lA, 0.6377, 3.49, 0.247, 338, 259, COCRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE (PKA) IN COMPLEX WITH THE METHYLATED FASUDIL-DERIVED FRAGMENT N-METHYLISOQUINOLINE-5- SULFONAMIDE (LIGAND 02) 
2527, 4dg2E, 0.6377, 3.59, 0.246, 347, 260, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
2528, 3qcyA, 0.6377, 3.17, 0.258, 275, 252, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 4-[2- AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-N-PHENYL-2- MORPHOLINECARBOXAMIDE
2529, 3idbA, 0.6377, 3.51, 0.243, 341, 259, CRYSTAL STRUCTURE OF (108-268)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2530, 1apmE, 0.6377, 3.57, 0.242, 338, 260, 2.0 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH A PEPTIDE INHIBITOR AND DETERGENT
2531, 4uwcB, 0.6376, 2.99, 0.255, 301, 251, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
2532, 3tt0A, 0.6376, 3.32, 0.264, 305, 254, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
2533, 3orzB, 0.6375, 3.28, 0.252, 278, 254, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2534, 4bhzA, 0.6374, 2.56, 0.246, 251, 244, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
2535, 3wzjA, 0.6374, 2.66, 0.237, 257, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4-(6- (CYCLOHEXYLAMINO)-8-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO) IMIDAZO[12-B]PYRIDAZIN-3-YL)-N-CYCLOPROPYLBENZAMIDE
2536, 5wnfA, 0.6373, 4.20, 0.212, 395, 274, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2537, 4wotC, 0.6373, 4.14, 0.217, 392, 272, ROCK2 IN COMPLEX WITH 1426382-07-1
2538, 3w1fA, 0.6373, 2.71, 0.236, 259, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 5-(5- ETHOXY-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-INDAZOL-3-YL)-2- METHYLBENZENESULFONAMIDE
2539, 3orxC, 0.6373, 3.09, 0.260, 283, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2540, 4w7pC, 0.6372, 4.04, 0.233, 383, 270, CRYSTAL STRUCTURE OF ROCK 1 BOUND TO YB-15-QD37
2541, 4j7bD, 0.6372, 3.04, 0.273, 281, 249, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1
2542, 4iafA, 0.6372, 3.58, 0.242, 333, 260, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2543, 4dfzE, 0.6372, 3.48, 0.243, 347, 259, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20
2544, 3orxA, 0.6372, 3.09, 0.260, 283, 250, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2545, 3nayB, 0.6372, 3.06, 0.260, 278, 250, PDK1 IN COMPLEX WITH INHIBITOR MP6
2546, 3lm5A, 0.6372, 3.08, 0.284, 274, 250, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B) IN COMPLEX WITH QUERCETIN
2547, 2rkuA, 0.6372, 2.89, 0.286, 294, 248, STRUCTURE OF PLK1 IN COMPLEX WITH BI2536
2548, 5u7qA, 0.6371, 4.09, 0.218, 388, 271, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2549, 5ta6A, 0.6371, 2.89, 0.290, 294, 248, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR.
2550, 5f0aA, 0.6371, 3.27, 0.250, 811, 252, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND 1-TERT-BUTYL-3-(3- CHLOROPHENOXY)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE INHIBITOR
2551, 4dh5A, 0.6371, 3.58, 0.242, 333, 260, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ADP PHOSPHATE AND IP20
2552, 3wyxA, 0.6371, 2.71, 0.240, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 6- ((3-(CYANOMETHOXY)-4-(1-METHYL-1H-PYRAZOL-4-YL)PHENYL)AMINO)-2- (CYCLOHEXYLAMINO)NICOTINONITRILE
2553, 3e8eA, 0.6371, 3.51, 0.251, 341, 259, CRYSTAL STRUCTURES OF THE KINASE DOMAIN OF PKA IN COMPLEX WITH ATP- COMPETITIVE INHIBITORS
2554, 3rhxA, 0.6370, 3.11, 0.254, 289, 252, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
2555, 3qamE, 0.6370, 3.60, 0.238, 348, 260, CRYSTAL STRUCTURE OF GLU208ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2556, 4wbbB, 0.6369, 3.51, 0.243, 334, 259, SINGLE TURNOVER AUTOPHOSPHORYLATION CYCLE OF THE PKA RIIB HOLOENZYME
2557, 4c36A, 0.6369, 3.57, 0.254, 335, 260, PKA-S6K1 CHIMERA WITH COMPOUND 15E (CCT147581) BOUND
2558, 2y7jB, 0.6369, 3.22, 0.268, 281, 250, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2559, 5ew8A, 0.6368, 3.11, 0.254, 291, 252, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
2560, 5d9lA, 0.6368, 3.05, 0.256, 299, 250, RSK2 N-TERMINAL KINASE IN COMPLEX WITH BIS-PHENOL PYRAZOLE
2561, 5ackA, 0.6368, 3.25, 0.258, 286, 252, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND 7 BOUND TO THE PIF-POCKET
2562, 4redB, 0.6368, 2.94, 0.259, 332, 251, CRYSTAL STRUCTURE OF HUMAN AMPK ALPHA1 KD-AID WITH K43A MUTATION
2563, 3o7lB, 0.6368, 3.55, 0.243, 326, 259, CRYSTAL STRUCTURE OF PHOSPHOLAMBAN (1-19):PKA C-SUBUNIT:AMP-PNP:MG2+ COMPLEX
2564, 5u7rA, 0.6367, 4.13, 0.221, 387, 272, IDENTIFICATION OF A NEW CLASS OF POTENT CDC7 INHIBITORS DESIGNED BY PUTATIVE PHARMACOPHORE MODEL: SYNTHESIS AND BIOLOGICAL EVALUATION OF 23-DIHYDROTHIENO[32-D]PYRIMIDIN-4(1H)-ONES
2565, 4eqcA, 0.6367, 3.10, 0.231, 296, 247, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN IN COMPLEX WITH FRAX597 INHIBITOR
2566, 3orzC, 0.6367, 3.13, 0.258, 276, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2567, 3orzA, 0.6367, 3.13, 0.258, 276, 252, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR 2A2
2568, 5o4aA, 0.6366, 3.15, 0.266, 290, 252, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
2569, 5eh0A, 0.6366, 2.62, 0.245, 258, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2570, 1fmoE, 0.6366, 3.60, 0.246, 336, 260, CRYSTAL STRUCTURE OF A POLYHISTIDINE-TAGGED RECOMBINANT CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH THE PEPTIDE INHIBITOR PKI(5-24) AND ADENOSINE
2571, 4iazA, 0.6365, 3.52, 0.243, 334, 259, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH BA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2572, 4cv8A, 0.6365, 2.64, 0.237, 255, 245, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
2573, 3uzsA, 0.6365, 3.26, 0.213, 609, 254, STRUCTURE OF THE C13.28 RNA APTAMER BOUND TO THE G PROTEIN-COUPLED RECEPTOR KINASE 2-HETEROTRIMERIC G PROTEIN BETA 1 AND GAMMA 2 SUBUNIT COMPLEX
2574, 2w5hA, 0.6365, 2.83, 0.237, 265, 249, HUMAN NEK2 KINASE APO
2575, 5wngC, 0.6364, 4.10, 0.219, 387, 270, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2576, 5lihB, 0.6364, 3.15, 0.237, 318, 253, STRUCTURE OF A PEPTIDE-SUBSTRATE BOUND TO PKCIOTA CORE KINASE DOMAIN
2577, 2v5qB, 0.6364, 2.74, 0.293, 285, 246, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
2578, 1atpE, 0.6364, 3.51, 0.240, 334, 258, 2.2 ANGSTROM REFINED CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE COMPLEXED WITH MNATP AND A PEPTIDE INHIBITOR
2579, 3tnqB, 0.6363, 3.63, 0.242, 331, 260, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2580, 3hrcA, 0.6363, 3.13, 0.256, 279, 250, CRYSTAL STRUCTURE OF A MUTANT OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ATP
2581, 4wotB, 0.6362, 4.14, 0.214, 394, 271, ROCK2 IN COMPLEX WITH 1426382-07-1
2582, 4o21A, 0.6362, 3.58, 0.242, 333, 260, PRODUCT COMPLEX OF METAL-FREE PKAC ATP-GAMMA-S AND SP20.
2583, 4j52A, 0.6362, 2.83, 0.287, 293, 247, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A PYRIMIDODIAZEPINONE INHIBITOR
2584, 3zosA, 0.6362, 3.60, 0.213, 301, 258, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
2585, 3ow3A, 0.6362, 3.53, 0.243, 334, 259, DISCOVERY OF DIHYDROTHIENO- AND DIHYDROFUROPYRIMIDINES AS POTENT PAN AKT INHIBITORS
2586, 3hrfA, 0.6362, 3.19, 0.255, 284, 251, CRYSTAL STRUCTURE OF HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH AN ALLOSTERIC ACTIVATOR BOUND TO THE PIF-POCKET
2587, 2hy81, 0.6362, 3.09, 0.227, 293, 247, PAK1 COMPLEX WITH ST2001
2588, 5odtA, 0.6361, 2.87, 0.235, 258, 247, AURORA-A IN COMPLEX WITH TACC3
2589, 5ew8B, 0.6361, 3.05, 0.263, 290, 251, FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693
2590, 4ib3A, 0.6361, 3.58, 0.242, 336, 260, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH ADP PHOSPHORYLATED PEPTIDE PSP20 AND NO METAL
2591, 3kl8G, 0.6361, 2.89, 0.286, 259, 245, CAMKIINTIDE INHIBITOR COMPLEX
2592, 2vn9B, 0.6361, 3.17, 0.293, 301, 249, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
2593, 2hakG, 0.6361, 2.91, 0.249, 297, 249, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
2594, 5ig1A, 0.6360, 3.47, 0.265, 300, 253, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
2595, 3etaA, 0.6360, 3.73, 0.204, 293, 260, KINASE DOMAIN OF INSULIN RECEPTOR COMPLEXED WITH A PYRROLO PYRIDINE INHIBITOR
2596, 3c4fB, 0.6360, 3.33, 0.264, 290, 254, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
2597, 2bdwA, 0.6360, 3.19, 0.283, 309, 251, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2598, 5wnfC, 0.6359, 3.99, 0.228, 386, 268, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2599, 3lm0A, 0.6359, 3.20, 0.271, 278, 251, CRYSTAL STRUCTURE OF HUMAN SERINE/THREONINE KINASE 17B (STK17B)
2600, 5lvnA, 0.6358, 3.14, 0.256, 283, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ADENOSINE BOUND TO THE ATP- BINDING SITE
2601, 5ehoA, 0.6358, 2.64, 0.249, 258, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2602, 4dfxE, 0.6358, 3.51, 0.243, 347, 259, CRYSTAL STRUCTURE OF MYRISTOYLATED K7C CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
2603, 4c57A, 0.6358, 3.50, 0.238, 310, 256, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
2604, 4ae9B, 0.6358, 3.71, 0.222, 321, 261, STRUCTURE AND FUNCTION OF THE HUMAN SPERM-SPECIFIC ISOFORM OF PROTEIN KINASE A (PKA) CATALYTIC SUBUNIT C ALPHA 2
2605, 3aglA, 0.6358, 3.69, 0.257, 338, 261, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR ARC-1039
2606, 2bujA, 0.6358, 3.34, 0.212, 291, 250, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2607, 5ei2A, 0.6357, 2.64, 0.249, 256, 245, RAPID DISCOVERY OF PYRIDO[34-D]PYRIMIDINE INHIBITORS OF MONOPOLAR SPINDLE KINASE 1 (MPS1) USING A STRUCTURE-BASED HYDRIDIZATION APPROACH
2608, 4x6rA, 0.6357, 3.63, 0.246, 347, 260, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2609, 4uwbB, 0.6357, 3.07, 0.259, 299, 251, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
2610, 2vn9A, 0.6357, 3.17, 0.293, 301, 249, CRYSTAL STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II DELTA ISOFORM 1 CAMKD
2611, 5am7A, 0.6356, 3.06, 0.263, 294, 251, FGFR1 MUTANT WITH AN INHIBITOR
2612, 4rrvA, 0.6356, 3.15, 0.256, 283, 250, CRYSTAL STRUCTURE OF PDK1 IN COMPLEX WITH ATP AND PIFTIDE
2613, 3qd4A, 0.6356, 3.05, 0.260, 276, 250, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH 11- DIMETHYLETHYL{(3R5R)-1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4- PYRIMIDINYL]-5-METHYL-3-PIPERIDINYL}CARBAMATE
2614, 1kobB, 0.6356, 3.38, 0.238, 352, 252, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2615, 4ysjA, 0.6354, 3.72, 0.296, 459, 257, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
2616, 4qqjA, 0.6354, 3.15, 0.262, 282, 252, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN HARBORING THE V550L GATE-KEEPER MUTATION
2617, 3oxtA, 0.6354, 3.69, 0.250, 335, 260, HUMAN CAMP-DEPENDENT PROTEIN KINASE IN COMPLEX WITH AN INHIBITOR
2618, 3js2A, 0.6354, 3.05, 0.255, 295, 251, CRYSTAL STRUCTURE OF MINIMAL KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH 5-(2-THIENYL) NICOTINIC ACID
2619, 5jznB, 0.6353, 2.99, 0.306, 266, 245, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2620, 4dh8A, 0.6353, 3.61, 0.242, 333, 260, ROOM TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20
2621, 4bi1A, 0.6353, 2.55, 0.247, 252, 243, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
2622, 3zosB, 0.6353, 3.62, 0.221, 303, 258, STRUCTURE OF THE DDR1 KINASE DOMAIN IN COMPLEX WITH PONATINIB
2623, 3fy0A, 0.6353, 3.03, 0.228, 292, 246, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH RUTHENIUM COMPLEX DW1
2624, 5vd1A, 0.6352, 3.07, 0.229, 295, 249, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
2625, 5o4aB, 0.6352, 3.08, 0.252, 291, 250, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
2626, 5jznA, 0.6352, 3.09, 0.308, 268, 247, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH NVP-TAE684
2627, 4cvaA, 0.6352, 2.59, 0.242, 254, 244, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
2628, 4ct1A, 0.6352, 3.16, 0.256, 283, 250, HUMAN PDK1-PKCZETA KINASE CHIMERA IN COMPLEX WITH ALLOSTERIC COMPOUND PS315 BOUND TO THE PIF-POCKET
2629, 2wtvC, 0.6352, 3.23, 0.250, 261, 252, AURORA-A INHIBITOR STRUCTURE
2630, 5m51A, 0.6351, 2.68, 0.238, 260, 244, NEK2 BOUND TO ARYLAMINOPURINE COMPOUND 8
2631, 4xw6A, 0.6351, 3.61, 0.242, 334, 260, X-RAY STRUCTURE OF PKAC WITH ADP FREE PHOSPHATE ION CP20 MAGNESIUM IONS
2632, 3qd0A, 0.6351, 3.16, 0.259, 274, 251, PHOSPHOINOSITIDE-DEPENDENT KINASE-1 (PDK1) KINASE DOMAIN WITH (2R5S)- 1-[2-AMINO-6-(3-AMINO-1H-INDAZOL-6-YL)-4-PYRIMIDINYL]-6-METHYL-N- PHENYL-3-PIPERIDINECARBOXAMIDE
2633, 3orxD, 0.6351, 3.08, 0.261, 282, 249, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2634, 2yacA, 0.6351, 2.78, 0.293, 290, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH NMS-P937
2635, 5ap0A, 0.6350, 2.62, 0.234, 254, 244, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2636, 5a46A, 0.6350, 3.18, 0.258, 289, 252, FGFR1 IN COMPLEX WITH DOVITINIB
2637, 4zsaA, 0.6350, 3.16, 0.238, 289, 252, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
2638, 3vquA, 0.6350, 2.71, 0.241, 258, 245, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH 4- [(4-AMINO-5-CYANO-6-ETHOXYPYRIDIN-2- YL)AMINO]BENZAMIDE
2639, 3mvjA, 0.6350, 3.50, 0.248, 334, 258, HUMAN CYCLIC AMP-DEPENDENT PROTEIN KINASE PKA INHIBITOR COMPLEX
2640, 3fjqE, 0.6350, 3.54, 0.243, 334, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA IN COMPLEX WITH PEPTIDE INHIBITOR PKI ALPHA (6-25)
2641, 4qrcA, 0.6349, 3.13, 0.262, 297, 252, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 4 IN COMPLEX WITH PONATINIB
2642, 4o6lA, 0.6349, 2.73, 0.245, 257, 245, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 401498 (N- [(1R)-1-(2-CHLOROPHENYL)PROPYL]-3-{4-[(1-METHYLPIPERIDIN-4-YL) OXY]PHENYL}-1H-INDAZOLE-5-CARBOXAMIDE)
2643, 4c4iA, 0.6349, 2.53, 0.247, 253, 243, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
2644, 4bi2A, 0.6349, 2.62, 0.250, 253, 244, SCAFFOLD FOCUSED VIRTUAL SCREENING: PROSPECTIVE APPLICATION TO THE DISCOVERY OF TTK INHIBITOR
2645, 3wyyA, 0.6349, 2.77, 0.236, 258, 246, CRYSTAL STRUCTURE OF HUMAN MPS1 CATALYTIC DOMAIN IN COMPLEX WITH (E)- 3-(4-((6-(((3S5S7S)-ADAMANTAN-1-YL)AMINO)-4-AMINO-5-CYANOPYRIDIN-2- YL)AMINO)-2-(CYANOMETHOXY)PHENYL)-N-(2-METHOXYETHYL)ACRYLAMIDE
2646, 3mfuA, 0.6349, 3.40, 0.292, 302, 250, CASK-4M CAM KINASE DOMAIN AMPPNP-MN2+
2647, 3ma6B, 0.6349, 3.24, 0.289, 266, 253, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
2648, 1ql6A, 0.6349, 3.20, 0.287, 281, 251, THE CATALYTIC MECHANISM OF PHOSPHORYLASE KINASE PROBED BY MUTATIONAL STUDIES
2649, 1cdkB, 0.6349, 3.64, 0.250, 342, 260, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2650, 5nkgA, 0.6348, 3.21, 0.198, 292, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3D
2651, 5m57A, 0.6348, 2.68, 0.234, 261, 244, NEK2 BOUND TO ARYLAMINOPURINE 6
2652, 4c4fA, 0.6348, 2.62, 0.234, 254, 244, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
2653, 3c4fA, 0.6348, 3.18, 0.266, 290, 252, FGFR TYROSINE KINASE DOMAIN IN COMPLEX WITH 3-(3- METHOXYBENZYL)-7-AZAINDOLE
2654, 2wtvB, 0.6348, 3.15, 0.251, 261, 251, AURORA-A INHIBITOR STRUCTURE
2655, 1tkiB, 0.6348, 3.18, 0.208, 321, 250, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2656, 1tkiA, 0.6348, 3.18, 0.208, 321, 250, AUTOINHIBITED SERINE KINASE DOMAIN OF THE GIANT MUSCLE PROTEIN TITIN
2657, 1kobA, 0.6348, 3.34, 0.250, 352, 252, TWITCHIN KINASE FRAGMENT (APLYSIA) AUTOREGULATED PROTEIN KINASE DOMAIN
2658, 5wnhA, 0.6347, 4.23, 0.212, 394, 274, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2659, 5wneC, 0.6347, 3.98, 0.213, 384, 268, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2660, 5ek7B, 0.6347, 2.97, 0.196, 286, 250, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
2661, 4dawA, 0.6347, 3.04, 0.228, 293, 246, CRYSTAL STRUCTURE OF PAK1 KINASE DOMAIN WITH THE RUTHENIUM PHTHALIMIDE COMPLEX
2662, 2bfxA, 0.6347, 3.08, 0.209, 269, 249, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2663, 5nkfA, 0.6346, 3.21, 0.202, 291, 252, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3B
2664, 5a46B, 0.6346, 3.15, 0.258, 297, 252, FGFR1 IN COMPLEX WITH DOVITINIB
2665, 4uwcA, 0.6346, 3.16, 0.254, 300, 252, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P3
2666, 4a06A, 0.6346, 3.17, 0.256, 282, 250, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS114 BOUND TO THE PIF-POCKET
2667, 1fgkA, 0.6346, 3.11, 0.255, 278, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
2668, 4iw0A, 0.6345, 3.57, 0.207, 647, 256, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
2669, 4cv9A, 0.6345, 2.62, 0.234, 254, 244, MPS1 KINASE WITH 3-AMINOPYRIDIN-2-ONE INHIBITORS
2670, 2fumB, 0.6345, 2.87, 0.251, 262, 247, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2671, 5wnhC, 0.6344, 4.10, 0.215, 388, 270, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
2672, 5am6A, 0.6344, 3.08, 0.259, 295, 251, NATIVE FGFR1 WITH AN INHIBITOR
2673, 3qalE, 0.6344, 3.63, 0.238, 339, 260, CRYSTAL STRUCTURE OF ARG280ALA MUTANT OF CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE
2674, 4x6qC, 0.6343, 3.60, 0.242, 334, 260, AN ISOFORM-SPECIFIC MYRISTYLATION SWITCH TARGETS RIIB PKA HOLOENZYMES TO MEMBRANES
2675, 4rwlA, 0.6343, 3.19, 0.250, 282, 252, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
2676, 4qqtA, 0.6343, 3.00, 0.268, 283, 250, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 TYROSINE KINASE DOMAIN
2677, 1fgiA, 0.6343, 3.29, 0.269, 283, 253, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
2678, 6aywB, 0.6342, 3.35, 0.303, 293, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2679, 5vcwB, 0.6342, 2.91, 0.237, 285, 249, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
2680, 5vcwA, 0.6342, 2.93, 0.229, 285, 249, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH PELITINIB
2681, 5o49B, 0.6342, 3.01, 0.253, 286, 249, HUMAN FGF IN COMPLEX WITH A COVALENT INHIBITOR
2682, 5am7B, 0.6342, 3.14, 0.255, 287, 251, FGFR1 MUTANT WITH AN INHIBITOR
2683, 4jnwA, 0.6342, 3.21, 0.208, 320, 250, BACTERIALLY EXPRESSED TITIN KINASE
2684, 3tnpF, 0.6342, 3.61, 0.242, 334, 260, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2685, 3tnpC, 0.6342, 3.61, 0.242, 334, 260, STRUCTURE AND ALLOSTERY OF THE PKA RIIB TETRAMERIC HOLOENZYME
2686, 3nayA, 0.6342, 3.11, 0.260, 278, 250, PDK1 IN COMPLEX WITH INHIBITOR MP6
2687, 3mftA, 0.6342, 3.37, 0.292, 302, 250, CASK-4M CAM KINASE DOMAIN MN2+
2688, 5ek7A, 0.6341, 2.97, 0.196, 286, 250, STRUCTURE OF THE AUTOINHIBITED EPHA2 JMS-KD
2689, 3d5uA, 0.6341, 2.93, 0.282, 288, 248, CRYSTAL STRUCTURE OF A WILDTYPE POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN.
2690, 5jr7A, 0.6340, 3.60, 0.242, 335, 260, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
2691, 5b7vA, 0.6340, 3.19, 0.258, 282, 252, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
2692, 3mfrA, 0.6340, 3.37, 0.292, 302, 250, CASK-4M CAM KINASE DOMAIN NATIVE
2693, 3fhiA, 0.6340, 3.58, 0.243, 336, 259, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN THE CATALYTIC AND REGULATORY (RI{ALPHA}) SUBUNITS OF PKA
2694, 5hznG, 0.6339, 3.38, 0.176, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2695, 5hznA, 0.6339, 3.46, 0.176, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2696, 5vczA, 0.6338, 3.09, 0.232, 294, 250, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB ISOMER
2697, 5hznC, 0.6338, 3.38, 0.176, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2698, 5ap4A, 0.6338, 2.75, 0.237, 257, 245, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2699, 4ysjB, 0.6338, 3.66, 0.297, 462, 256, CALCIUM-DEPENDENT PROTEIN KINASE FROM EIMERIA TENELLA IN COMPLEX WITH ADP
2700, 4wb5A, 0.6338, 3.64, 0.250, 335, 260, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2701, 4jnwB, 0.6338, 3.23, 0.204, 321, 250, BACTERIALLY EXPRESSED TITIN KINASE
2702, 3hyhA, 0.6338, 2.23, 0.274, 238, 237, CRYSTAL STRUCTURE OF THE PROTEIN KINASE DOMAIN OF YEAST AMP-ACTIVATED PROTEIN KINASE SNF1
2703, 1rdqE, 0.6338, 3.57, 0.239, 340, 259, HYDROLYSIS OF ATP IN THE CRYSTAL OF Y204A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE
2704, 5dewA, 0.6337, 2.93, 0.234, 295, 244, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND 5
2705, 5b7vB, 0.6337, 3.17, 0.259, 277, 251, HUMAN FGFR1 KINASE IN COMPLEX WITH CH5183284
2706, 4uwbA, 0.6337, 3.21, 0.258, 299, 252, FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE IN COMPLEX WITH JK-P5
2707, 4u42A, 0.6337, 3.07, 0.235, 282, 247, MAP4K4 T181E MUTANT BOUND TO INHIBITOR COMPOUND 1
2708, 2cpkE, 0.6337, 3.65, 0.242, 333, 260, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CYCLIC ADENOSINE MONOPHOSPHATE-DEPENDENT PROTEIN KINASE
2709, 4f63A, 0.6336, 3.13, 0.255, 278, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
2710, 4c57B, 0.6336, 3.44, 0.240, 308, 254, STRUCTURE OF GAK KINASE IN COMPLEX WITH A NANOBODY
2711, 5ap3A, 0.6335, 2.62, 0.235, 253, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2712, 4dg0E, 0.6334, 3.55, 0.243, 338, 259, CRYSTAL STRUCTURE OF MYRISTOYLATED WT CATALYTIC SUBUNIT OF CAMP- DEPENDENT PROTEIN KINASE IN COMPLEX WITH SP20 AND AMP-PNP
2713, 3mfsA, 0.6334, 3.50, 0.291, 303, 251, CASK-4M CAM KINASE DOMAIN AMPPNP
2714, 4a4lA, 0.6333, 2.81, 0.297, 290, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 5-(2-AMINO-PYRIMIDIN-4-YL)-1H-PYRROLE INHIBITOR
2715, 3tacA, 0.6333, 3.38, 0.272, 324, 250, CRYSTAL STRUCTURE OF THE LIPRIN-ALPHA/CASK COMPLEX
2716, 2vgoA, 0.6333, 3.06, 0.210, 268, 248, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2717, 5vcyA, 0.6332, 3.20, 0.216, 296, 250, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB
2718, 3p1aA, 0.6332, 3.05, 0.228, 281, 250, STRUCTURE OF HUMAN MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE- SPECIFIC CDC2-INHIBITORY KINASE MYT1 (PKMYT1)
2719, 5a4cB, 0.6331, 3.00, 0.253, 286, 249, FGFR1 LIGAND COMPLEX
2720, 5u94A, 0.6330, 3.00, 0.249, 263, 249, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PASTA KINASE PKNB IN COMPLEX WITH THE POTENTIAL THERAPUTIC KINASE INHIBITOR GSK690693.
2721, 4rwiA, 0.6330, 3.11, 0.259, 305, 251, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) APO
2722, 3orxB, 0.6330, 3.08, 0.262, 280, 248, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT INHIBITOR 1F8
2723, 3bhhA, 0.6330, 3.09, 0.296, 289, 247, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2724, 2y7jD, 0.6330, 3.34, 0.268, 281, 250, STRUCTURE OF HUMAN PHOSPHORYLASE KINASE GAMMA 2
2725, 2fumA, 0.6330, 2.83, 0.252, 263, 246, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
2726, 1agwA, 0.6330, 3.17, 0.259, 278, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
2727, 5ap5A, 0.6329, 2.59, 0.247, 252, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2728, 3ky2B, 0.6329, 3.03, 0.253, 280, 249, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
2729, 2bfyA, 0.6329, 3.14, 0.197, 270, 249, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2730, 5nkbA, 0.6327, 3.19, 0.203, 285, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4A
2731, 4wb7A, 0.6327, 3.58, 0.251, 402, 259, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2732, 4ib1A, 0.6327, 3.57, 0.243, 335, 259, STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH K+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2733, 4hpuE, 0.6327, 3.56, 0.243, 336, 259, CRYSTAL STRUCTURE OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE DISPLAYING PARTIAL PHOSPHORYL TRANSFER OF AMP-PNP ONTO A SUBSTRATE PEPTIDE
2734, 5jr7C, 0.6326, 3.54, 0.243, 335, 259, CRYSTAL STRUCTURE OF AN ACRDYS HETERODIMER [RIA(92-365):C] OF PKA
2735, 4lg4A, 0.6326, 3.09, 0.223, 289, 251, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2736, 4bkjA, 0.6326, 3.62, 0.191, 295, 257, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
2737, 3kb7A, 0.6326, 2.90, 0.296, 289, 247, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A PYRAZOLOQUINAZOLINE INHIBITOR
2738, 2fgiA, 0.6326, 3.16, 0.251, 274, 251, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
2739, 1l3rE, 0.6326, 3.66, 0.242, 338, 260, CRYSTAL STRUCTURE OF A TRANSITION STATE MIMIC OF THE CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE
2740, 5vcvA, 0.6325, 3.03, 0.238, 287, 248, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH DASATINIB
2741, 5hznE, 0.6325, 3.30, 0.177, 296, 254, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2742, 4dh3A, 0.6325, 3.65, 0.242, 333, 260, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ ATP AND IP20
2743, 4c2vA, 0.6325, 2.98, 0.220, 270, 246, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2744, 4a4oA, 0.6325, 2.83, 0.289, 290, 246, CRYSTAL STRUCTURE OF POLO-LIKE KINASE 1 IN COMPLEX WITH A 2- (2-AMINO-PYRIMIDIN-4-YL)-1567-TETRAHYDRO-PYRROLOPYRIDIN- 4-ONE INHIBITOR
2745, 2qcsA, 0.6325, 3.70, 0.246, 335, 260, A COMPLEX STRUCTURE BETWEEN THE CATALYTIC AND REGULATORY SUBUNIT OF PROTEIN KINASE A THAT REPRESENTS THE INHIBITED STATE
2746, 5vloB, 0.6324, 3.39, 0.303, 293, 251, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2747, 5ap2A, 0.6324, 2.62, 0.247, 256, 243, NATURALLY OCCURRING MUTATIONS IN THE MPS1 GENE PREDISPOSE CELLS TO KINASE INHIBITOR DRUG RESISTANCE.
2748, 4f64A, 0.6324, 3.17, 0.255, 278, 251, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
2749, 4c2wB, 0.6324, 3.14, 0.221, 277, 249, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2750, 4a07A, 0.6324, 3.16, 0.257, 282, 249, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC ACTIVATOR PS171 BOUND TO THE PIF-POCKET
2751, 3idcA, 0.6324, 3.65, 0.242, 341, 260, CRYSTAL STRUCTURE OF (102-265)RIIB:C HOLOENZYME OF CAMP- DEPENDENT PROTEIN KINASE
2752, 3c0hB, 0.6324, 3.41, 0.276, 300, 250, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2753, 5ta8A, 0.6323, 2.98, 0.290, 294, 248, CRYSTAL STRUCTURE OF PLK1 IN COMPLEX WITH A NOVEL 56- DIHYDROIMIDAZOLO[15-F]PTERIDINE INHIBITOR
2754, 5nk9A, 0.6323, 3.21, 0.207, 285, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2E
2755, 5hznF, 0.6323, 3.44, 0.176, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2756, 5hznB, 0.6323, 3.44, 0.176, 296, 256, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2757, 4uzdB, 0.6323, 3.08, 0.237, 258, 249, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
2758, 4othA, 0.6323, 3.04, 0.213, 305, 249, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH RO-31-8220
2759, 4ib0A, 0.6323, 3.57, 0.243, 334, 259, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH NA+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2760, 2vrxA, 0.6323, 3.08, 0.210, 268, 248, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2761, 2v5qA, 0.6323, 2.82, 0.293, 285, 246, CRYSTAL STRUCTURE OF WILD-TYPE PLK-1 KINASE DOMAIN IN COMPLEX WITH A SELECTIVE DARPIN
2762, 4wb7B, 0.6322, 3.59, 0.251, 402, 259, CRYSTAL STRUCTURE OF A CHIMERIC FUSION OF HUMAN DNAJ (HSP40) AND CAMP- DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2763, 3ujgA, 0.6322, 3.53, 0.228, 290, 259, CRYSTAL STRUCTURE OF SNRK2.6 IN COMPLEX WITH HAB1
2764, 3rhxB, 0.6322, 3.14, 0.260, 275, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR1 KINASE IN COMPLEX WITH ARQ 069
2765, 3pvbA, 0.6322, 3.69, 0.246, 341, 260, CRYSTAL STRUCTURE OF (73-244)RIA:C HOLOENZYME OF CAMP-DEPENDENT PROTEIN KINASE
2766, 3udbF, 0.6321, 3.25, 0.189, 273, 254, CRYSTAL STRUCTURE OF SNRK2.6
2767, 3qquA, 0.6321, 3.75, 0.185, 285, 260, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
2768, 3bhhB, 0.6321, 3.14, 0.291, 289, 247, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
2769, 2wtvD, 0.6321, 3.02, 0.253, 262, 249, AURORA-A INHIBITOR STRUCTURE
2770, 4v05A, 0.6320, 3.16, 0.259, 287, 251, FGFR1 IN COMPLEX WITH AZD4547.
2771, 4bkjB, 0.6320, 3.64, 0.195, 297, 257, CRYSTAL STRUCTURE OF THE HUMAN DDR1 KINASE DOMAIN IN COMPLEX WITH IMATINIB
2772, 2wtvA, 0.6320, 3.03, 0.253, 262, 249, AURORA-A INHIBITOR STRUCTURE
2773, 5h9bA, 0.6319, 3.28, 0.289, 269, 249, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/AMPPN
2774, 4kikA, 0.6319, 3.28, 0.251, 618, 251, HUMAN IKB KINASE BETA
2775, 5n7pA, 0.6318, 3.67, 0.246, 350, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(PYRROLIDIN-1-YL)-1H-PYRAZOLE- 4-CARBONITRILE
2776, 4iadA, 0.6318, 3.69, 0.246, 334, 260, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH MG2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2777, 4b8mA, 0.6318, 3.03, 0.211, 270, 247, AURORA B KINASE IN COMPLEX WITH VX-680
2778, 2r5tA, 0.6318, 2.89, 0.234, 284, 248, CRYSTAL STRUCTURE OF INACTIVE SERUM AND GLUCOCORTICOID- REGULATED KINASE 1 IN COMPLEX WITH AMP-PNP
2779, 4wb8A, 0.6317, 3.68, 0.250, 334, 260, CRYSTAL STRUCTURE OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT) EXON 1 DELETION
2780, 4iaiA, 0.6317, 3.58, 0.243, 333, 259, X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A IN COMPLEX WITH HIGH CA2+ CONCENTRATION ADP AND PHOSPHORYLATED PEPTIDE PSP20
2781, 6gttA, 0.6316, 2.80, 0.217, 282, 244, HUMAN STK10 BOUND TO BIRB-796 
2782, 4zsaB, 0.6316, 3.26, 0.255, 282, 251, CRYSTAL STRUCTURE OF FGFR1 KINASE DOMAIN IN COMPLEX WITH 7N
2783, 4kikB, 0.6316, 3.62, 0.244, 648, 254, HUMAN IKB KINASE BETA
2784, 2bfxB, 0.6316, 3.08, 0.222, 275, 248, MECHANISM OF AURORA-B ACTIVATION BY INCENP AND INHIBITION BY HESPERADIN.
2785, 1cdkA, 0.6316, 3.62, 0.251, 342, 259, CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
2786, 5vamA, 0.6315, 3.31, 0.221, 269, 249, BRAF IN COMPLEX WITH RAF709
2787, 4dh7A, 0.6315, 3.60, 0.243, 333, 259, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH HIGH MG2+ AMP-PNP AND IP20 
2788, 2vrxB, 0.6315, 3.10, 0.230, 274, 248, STRUCTURE OF AURORA B KINASE IN COMPLEX WITH ZM447439
2789, 5nk6A, 0.6314, 3.23, 0.203, 284, 251, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2D
2790, 4jt3A, 0.6314, 2.69, 0.250, 254, 244, CRYSTAL STRUCTURE OF TTK KINASE DOMAIN WITH AN INHIBITOR: 400740
2791, 4dh1A, 0.6314, 3.66, 0.242, 333, 260, LOW TEMPERATURE X-RAY STRUCTURE OF CAMP DEPENDENT PROTEIN KINASE A CATALYTIC SUBUNIT WITH LOW MG2+ ATP AND IP20
2792, 5zv2A, 0.6313, 3.17, 0.259, 284, 251, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
2793, 5hznH, 0.6313, 3.42, 0.176, 303, 255, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2794, 4zk5A, 0.6313, 2.94, 0.236, 286, 246, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
2795, 4rwkB, 0.6313, 2.96, 0.254, 282, 248, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
2796, 3ky2A, 0.6313, 3.18, 0.255, 307, 251, CRYSTAL STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN
2797, 4euuB, 0.6312, 3.55, 0.219, 307, 256, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
2798, 3c0hA, 0.6312, 3.42, 0.276, 300, 250, CASK CAM-KINASE DOMAIN- AMPPNP COMPLEX P1 FORM
2799, 5veeA, 0.6311, 3.15, 0.251, 289, 247, PAK4 KINASE DOMAIN IN COMPLEX WITH FRAX486
2800, 5hznD, 0.6311, 3.54, 0.183, 304, 257, STRUCTURE OF NVP-AEW541 IN COMPLEX WITH IGF-1R KINASE
2801, 5hidB, 0.6311, 3.09, 0.223, 269, 247, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
2802, 3ztxA, 0.6311, 3.12, 0.198, 269, 248, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2803, 3bwjA, 0.6311, 3.64, 0.251, 338, 259, COMPLEX OF PKA WITH THE BISUBSTRATE PROTEIN KINASE INHIBITOR LEAD COMPOUND ARC-1034
2804, 5n32A, 0.6310, 3.67, 0.242, 345, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-CHLOROBENZYL CARBAMIMIDOTHIOATE
2805, 4wsqA, 0.6310, 3.66, 0.202, 317, 257, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2806, 4rwlB, 0.6310, 2.99, 0.254, 285, 248, CRYSTAL STRUCTURE OF FGFR1 (C488A C584C) IN COMPLEX WITH 6-(7-((1- AMINOCYCLOPROPYL) METHOXY)-6-METHOXYQUINOLIN-4-YLOXY)-N-METHYL-1- NAPHTHAMIDE (E3810)
2807, 4rwjA, 0.6310, 3.18, 0.259, 307, 251, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
2808, 4dg3E, 0.6310, 3.60, 0.243, 335, 259, CRYSTAL STRUCTURE OF R336A MUTANT OF CAMP-DEPENDENT PROTEIN KINASE WITH UNPHOSPHORYLATED TURN MOTIF.
2809, 2qg5B, 0.6310, 3.12, 0.275, 280, 247, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2810, 4obpA, 0.6309, 3.02, 0.236, 285, 246, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 29) 6-(2-FLUOROPYRIDIN-4- YL)PYRIDO[32-D]PYRIMIDIN-4-AMINE
2811, 4aw0A, 0.6309, 3.16, 0.257, 283, 249, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS182 BOUND TO THE PIF-POCKET
2812, 3uokA, 0.6309, 3.07, 0.249, 265, 249, AURORA A IN COMPLEX WITH YL5-81-1
2813, 2vgoB, 0.6309, 3.16, 0.210, 277, 248, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH REVERSINE INHIBITOR
2814, 1m7nA, 0.6309, 3.80, 0.178, 299, 259, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
2815, 3uokB, 0.6308, 3.07, 0.249, 265, 249, AURORA A IN COMPLEX WITH YL5-81-1
2816, 3qquB, 0.6308, 3.62, 0.182, 288, 258, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
2817, 3otuA, 0.6308, 3.11, 0.262, 276, 248, PDK1 MUTANT BOUND TO ALLOSTERIC DISULFIDE FRAGMENT ACTIVATOR JS30
2818, 3kl8E, 0.6308, 2.85, 0.289, 256, 242, CAMKIINTIDE INHIBITOR COMPLEX
2819, 5deyA, 0.6307, 2.99, 0.230, 295, 244, CRYSTAL STRUCTURE OF PAK1 IN COMPLEX WITH AN INHIBITOR COMPOUND G-5555
2820, 4w9wA, 0.6307, 3.71, 0.209, 306, 258, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH SMALL MOLECULE AZD-7762
2821, 4nksB, 0.6307, 3.12, 0.265, 271, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
2822, 4c2wA, 0.6307, 3.18, 0.198, 268, 248, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH AMP-PNP
2823, 4aw1A, 0.6307, 3.29, 0.259, 283, 251, HUMAN PDK1 KINASE DOMAIN IN COMPLEX WITH ALLOSTERIC COMPOUND PS210 BOUND TO THE PIF-POCKET
2824, 3twjB, 0.6307, 4.23, 0.223, 395, 273, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
2825, 5n1kA, 0.6306, 3.66, 0.243, 341, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-AMINO-1-(4-FLUOROPHENYL)ETHANOL
2826, 4yomB, 0.6305, 4.09, 0.234, 322, 265, STRUCTURE OF SAD KINASE
2827, 3eknA, 0.6305, 3.92, 0.217, 297, 263, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
2828, 2vgpB, 0.6305, 3.08, 0.222, 277, 248, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2829, 1agwB, 0.6305, 3.04, 0.258, 272, 248, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR
2830, 5na0A, 0.6304, 2.61, 0.239, 253, 243, TTK KINASE DOMAIN IN COMPLEX WITH A PEG-LINKED PYRIMIDO-INDOLIZINE
2831, 4c2vB, 0.6304, 3.12, 0.222, 280, 248, AURORA B KINASE IN COMPLEX WITH THE SPECIFIC INHIBITOR BARASERTIB
2832, 1zwsF, 0.6304, 3.29, 0.300, 278, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2833, 5nk1A, 0.6303, 3.07, 0.209, 284, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1K
2834, 4v05B, 0.6303, 3.16, 0.252, 286, 250, FGFR1 IN COMPLEX WITH AZD4547.
2835, 3cc6A, 0.6303, 3.07, 0.181, 269, 248, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PROTEIN TYROSINE KINASE 2 BETA (PTK2B)
2836, 2fh9A, 0.6303, 3.15, 0.273, 255, 249, STRUCTURE AND DIMERIZATION OF THE KINASE DOMAIN FROM YEAST SNF1
2837, 5vcxA, 0.6302, 3.19, 0.237, 287, 249, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (UNTREATED) IN COMPLEX WITH SARACATINIB
2838, 5i9xA, 0.6302, 3.00, 0.210, 284, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH BOSUTINIB (SKI-606)
2839, 4euuA, 0.6302, 3.52, 0.216, 307, 255, STRUCTURE OF BX-795 COMPLEXED WITH HUMAN TBK1 KINASE DOMAIN PHOSPHORYLATED ON SER172
2840, 3twjD, 0.6302, 4.29, 0.234, 395, 274, RHO-ASSOCIATED PROTEIN KINASE 1 (ROCK 1) IN COMPLEX WITH RKI1447
2841, 5l8kA, 0.6301, 3.16, 0.232, 266, 250, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 2)
2842, 5i9yA, 0.6301, 2.96, 0.206, 287, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DASATINIB
2843, 5a4cA, 0.6301, 3.10, 0.253, 294, 249, FGFR1 LIGAND COMPLEX
2844, 3i6uA, 0.6301, 3.54, 0.306, 390, 252, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
2845, 2f57A, 0.6301, 3.21, 0.235, 297, 247, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
2846, 1m7nB, 0.6301, 3.72, 0.178, 299, 258, CRYSTAL STRUCTURE OF UNACTIVATED APO INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE DOMAIN
2847, 4lg4F, 0.6300, 2.51, 0.233, 276, 240, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2848, 3bhyA, 0.6300, 3.04, 0.301, 268, 246, CRYSTAL STRUCTURE OF HUMAN DEATH ASSOCIATED PROTEIN KINASE 3 (DAPK3) IN COMPLEX WITH A BETA-CARBOLINE LIGAND
2849, 5vd0A, 0.6299, 3.33, 0.215, 293, 251, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN IN COMPLEX WITH MK1775
2850, 4wihA, 0.6299, 3.68, 0.243, 350, 259, CRYSTAL STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS
2851, 3o23A, 0.6299, 3.71, 0.187, 293, 257, HUMAN UNPHOSPHORYLATED IGF1-R KINASE DOMAIN IN COMPLEX WITH AN HYDANTOIN INHIBITOR
2852, 3db6A, 0.6299, 2.94, 0.279, 287, 247, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 902
2853, 1fgkB, 0.6299, 2.96, 0.255, 272, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1
2854, 5dylA, 0.6298, 3.30, 0.249, 802, 249, CRYSTAL STRUCTURE OF PVX_084705
2855, 4c4gA, 0.6298, 2.62, 0.248, 251, 242, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
2856, 3thbA, 0.6298, 2.85, 0.294, 287, 245, STRUCTURE OF PLK1 KINASE DOMAIN IN COMPLEX WITH A BENZOLACTAM-DERIVED INHIBITOR
2857, 3ndmA, 0.6298, 4.07, 0.209, 383, 268, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
2858, 1phkA, 0.6298, 3.09, 0.287, 277, 247, TWO STRUCTURES OF THE CATALYTIC DOMAIN OF PHOSPHORYLASE KINASE: AN ACTIVE PROTEIN KINASE COMPLEXED WITH NUCLEOTIDE SUBSTRATE-ANALOGUE AND PRODUCT
2859, 4uwyA, 0.6297, 3.34, 0.262, 296, 252, FGFR1 APO STRUCTURE
2860, 2bdwB, 0.6297, 3.30, 0.293, 309, 249, CRYSTAL STRUCTURE OF THE AUTO-INHIBITED KINASE DOMAIN OF CALCIUM/CALMODULIN ACTIVATED KINASE II
2861, 5k5xA, 0.6296, 3.80, 0.224, 345, 259, CRYSTAL STRUCTURE OF HUMAN PDGFRA
2862, 4b8mB, 0.6296, 3.05, 0.223, 279, 247, AURORA B KINASE IN COMPLEX WITH VX-680
2863, 3lw0C, 0.6296, 3.85, 0.177, 292, 260, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2864, 3lw0A, 0.6296, 3.85, 0.177, 292, 260, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2865, 5nk7A, 0.6295, 3.10, 0.209, 284, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2A
2866, 5n7uA, 0.6295, 3.63, 0.247, 350, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-BROMO-35-DIMETHYL-1H-PYRAZOLE
2867, 4u44A, 0.6295, 3.10, 0.235, 286, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
2868, 4gu6A, 0.6295, 3.27, 0.215, 271, 251, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
2869, 1p4oA, 0.6295, 3.80, 0.178, 308, 259, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
2870, 5nkcA, 0.6294, 3.02, 0.210, 286, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2H
2871, 2j4zA, 0.6294, 3.05, 0.254, 263, 248, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-680626
2872, 2fgiB, 0.6294, 2.90, 0.260, 272, 246, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074
2873, 6babD, 0.6293, 3.28, 0.306, 291, 248, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
2874, 5vjaB, 0.6293, 3.05, 0.297, 266, 246, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2875, 4utdA, 0.6293, 2.97, 0.246, 266, 248, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION
2876, 4u45A, 0.6293, 3.00, 0.240, 289, 246, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
2877, 3lw0D, 0.6293, 3.86, 0.173, 292, 260, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2878, 3lw0B, 0.6293, 3.85, 0.177, 292, 260, IGF-1RK IN COMPLEX WITH LIGAND MSC1609119A-1
2879, 3kl8C, 0.6293, 2.79, 0.290, 256, 241, CAMKIINTIDE INHIBITOR COMPLEX
2880, 3c0iA, 0.6293, 3.29, 0.279, 298, 247, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P212121 FORM
2881, 5ezrA, 0.6292, 3.30, 0.256, 803, 250, CRYSTAL STRUCTURE OF PVX_084705 BOUND TO COMPOUND
2882, 4f64B, 0.6292, 2.96, 0.263, 272, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 6
2883, 3uo6A, 0.6292, 2.96, 0.247, 264, 247, AURORA A IN COMPLEX WITH YL5-083
2884, 5vjaA, 0.6291, 3.08, 0.297, 266, 246, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2885, 5k3yB, 0.6291, 3.07, 0.211, 277, 247, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2886, 4wnpB, 0.6291, 3.00, 0.269, 272, 245, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2887, 4f63B, 0.6291, 2.96, 0.255, 271, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 1
2888, 3uo6B, 0.6291, 2.96, 0.247, 264, 247, AURORA A IN COMPLEX WITH YL5-083
2889, 2x9eA, 0.6291, 2.75, 0.250, 253, 244, HUMAN MPS1 IN COMPLEX WITH NMS-P715
2890, 5o21B, 0.6290, 3.41, 0.245, 273, 253, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
2891, 5nk2A, 0.6290, 3.11, 0.209, 290, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2B
2892, 5n1eA, 0.6290, 3.55, 0.248, 347, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YL)-2-PIPERIDIN-1- YLACETAMIDE
2893, 5d7aA, 0.6290, 2.87, 0.229, 289, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2894, 4wb6B, 0.6290, 3.81, 0.253, 340, 261, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2895, 3ztxB, 0.6290, 3.03, 0.228, 272, 246, AURORA KINASE SELECTIVE INHIBITORS IDENTIFIED USING A TAXOL- INDUCED CHECKPOINT SENSITIVITY SCREEN.
2896, 3is5F, 0.6290, 3.22, 0.303, 266, 251, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2897, 5fetA, 0.6289, 3.30, 0.253, 802, 249, CRYSTAL STRUCTURE OF PVX_084705 IN PRESENCE OF COMPOUND 2
2898, 1p4oB, 0.6289, 3.67, 0.179, 314, 257, STRUCTURE OF APO UNACTIVATED IGF-1R KINASE DOMAIN AT 1.5A RESOLUTION.
2899, 3ii5A, 0.6288, 3.06, 0.228, 262, 246, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
2900, 1zwsD, 0.6288, 3.33, 0.300, 278, 250, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2901, 6gwrA, 0.6287, 3.68, 0.210, 300, 257, STRUCTURE OF THE KINASE DOMAIN OF HUMAN DDR1 IN COMPLEX WITH A POTENT AND SELECTIVE INHIBITOR OF DDR1 AND DDR2 
2902, 5n3cA, 0.6287, 3.70, 0.246, 348, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE THIOPHENE-3-CARBOXIMIDAMIDE
2903, 5n37A, 0.6287, 3.63, 0.247, 347, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-(13-BENZODIOXOL-5-YLMETHYL) CYCLOPENTANAMINE
2904, 5k3yA, 0.6287, 3.12, 0.198, 267, 247, CRYSTAL STRUCTURE OF AURORAB/INCENP IN COMPLEX WITH BI 811283
2905, 1zwsG, 0.6286, 3.27, 0.297, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2906, 4rwkA, 0.6285, 3.24, 0.255, 308, 251, CRYSTAL STRUCTURE OF V561M FGFR1 GATEKEEPER MUTATION (C488A C584S V561M) IN COMPLEX WITH N-{3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H- PYRAZOL-5-YL}-4-[(3R5S)-35-DIMETHYLPIPERAZIN-1-YL]BENZAMIDE (AZD4547)
2907, 4nkaB, 0.6285, 3.11, 0.246, 287, 248, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
2908, 4lg4C, 0.6285, 3.16, 0.223, 288, 251, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
2909, 3soaA, 0.6285, 3.39, 0.279, 436, 251, FULL-LENGTH HUMAN CAMKII
2910, 3hdnA, 0.6285, 2.95, 0.234, 280, 248, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 2
2911, 2x7fB, 0.6285, 2.78, 0.222, 288, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2912, 1muoA, 0.6285, 2.78, 0.239, 251, 243, CRYSTAL STRUCTURE OF AURORA-2 AN ONCOGENIC SERINE- THREONINE KINASE
2913, 6gwrB, 0.6284, 3.45, 0.205, 285, 254, STRUCTURE OF THE KINASE DOMAIN OF HUMAN DDR1 IN COMPLEX WITH A POTENT AND SELECTIVE INHIBITOR OF DDR1 AND DDR2 
2914, 1u5qA, 0.6284, 3.28, 0.229, 308, 249, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2915, 6b2qB, 0.6283, 2.97, 0.271, 266, 247, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
2916, 4otiA, 0.6283, 2.97, 0.215, 303, 247, CRYSTAL STRUCTURE OF PRK1 CATALYTIC DOMAIN IN COMPLEX WITH TOFACITINIB
2917, 3is5A, 0.6283, 2.80, 0.310, 260, 245, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2918, 3a62A, 0.6283, 2.45, 0.277, 263, 238, CRYSTAL STRUCTURE OF PHOSPHORYLATED P70S6K1
2919, 2pmnX, 0.6283, 3.54, 0.217, 340, 254, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP-SITE INHIBITOR
2920, 5fg8A, 0.6282, 3.36, 0.285, 269, 249, DROSOPHILA CAMKII-WT IN COMPLEX WITH A FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
2921, 4wsqB, 0.6282, 3.73, 0.206, 310, 257, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE (AAK1) IN COMPLEX WITH SMALL MOLECULE INHIBITOR
2922, 3uohB, 0.6282, 2.99, 0.251, 264, 247, AURORA A IN COMPLEX WITH RPM1722
2923, 3uohA, 0.6282, 2.99, 0.247, 264, 247, AURORA A IN COMPLEX WITH RPM1722
2924, 2xuuA, 0.6282, 3.27, 0.305, 301, 249, CRYSTAL STRUCTURE OF A DAP-KINASE 1 MUTANT
2925, 2x0gA, 0.6282, 3.41, 0.299, 318, 251, X-RAY STRUCTURE OF A DAP-KINASE CALMODULIN COMPLEX
2926, 2vgpA, 0.6282, 3.11, 0.223, 265, 247, CRYSTAL STRUCTURE OF AURORA B KINASE IN COMPLEX WITH A AMINOTHIAZOLE INHIBITOR
2927, 5y90A, 0.6280, 3.11, 0.233, 304, 249, MAP2K7 MUTANT -C218S
2928, 4wnpA, 0.6280, 3.09, 0.268, 273, 246, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
2929, 4w9xA, 0.6280, 3.68, 0.214, 300, 257, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH BARICITINIB
2930, 4deeA, 0.6280, 3.39, 0.244, 271, 254, AURORA A IN COMPLEX WITH ADP
2931, 2gcdA, 0.6280, 3.29, 0.229, 308, 249, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
2932, 5eykA, 0.6279, 3.02, 0.195, 263, 246, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2933, 5d7aB, 0.6279, 2.97, 0.232, 286, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2934, 4b4lA, 0.6279, 3.22, 0.298, 299, 248, CRYSTAL STRUCTURE OF AN ARD DAP-KINASE 1 MUTANT
2935, 1mruB, 0.6279, 2.96, 0.251, 271, 247, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
2936, 5vjaC, 0.6278, 3.09, 0.309, 265, 246, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
2937, 4xeyB, 0.6278, 3.33, 0.218, 359, 252, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
2938, 4dinA, 0.6278, 3.66, 0.243, 340, 259, NOVEL LOCALIZATION AND QUATERNARY STRUCTURE OF THE PKA RI BETA HOLOENZYME
2939, 1jkkA, 0.6278, 3.21, 0.300, 277, 247, 2.4A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MG.
2940, 4c4hA, 0.6277, 2.49, 0.254, 248, 240, STRUCTURE-BASED DESIGN OF ORALLY BIOAVAILABLE PYRROLOPYRIDINE INHIBITORS OF THE MITOTIC KINASE MPS1
2941, 3uojB, 0.6277, 3.03, 0.251, 263, 247, AURORA A IN COMPLEX WITH RPM1715
2942, 3uojA, 0.6277, 3.03, 0.251, 263, 247, AURORA A IN COMPLEX WITH RPM1715
2943, 3qc4A, 0.6277, 3.17, 0.269, 276, 249, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
2944, 3is5C, 0.6277, 2.89, 0.301, 259, 246, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
2945, 3c0gA, 0.6277, 3.44, 0.277, 309, 249, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
2946, 2bfyB, 0.6277, 3.10, 0.211, 278, 247, COMPLEX OF AURORA-B WITH INCENP AND HESPERADIN.
2947, 1lufA, 0.6277, 3.30, 0.188, 275, 250, CRYSTAL STRUCTURE OF THE MUSK TYROSINE KINASE: INSIGHTS INTO RECEPTOR AUTOREGULATION
2948, 5n3eA, 0.6276, 3.65, 0.247, 348, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 6-DIMETHYLAMINOPYRIDINE-3-CARBOXYLIC ACID
2949, 5n36A, 0.6276, 3.64, 0.247, 347, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3H-ISOINDOL-2-IUM-1-AMINE
2950, 5b2lA, 0.6276, 3.00, 0.243, 288, 247, A CRUCIAL ROLE OF CYS218 IN THE STABILIZATION OF AN UNPRECEDENTED AUTO-INHIBITION FORM OF MAP2K7
2951, 4tthB, 0.6276, 2.77, 0.392, 256, 240, CRYSTAL STRUCTURE OF A CDK6/VCYCLIN COMPLEX WITH INHIBITOR BOUND
2952, 4nk9A, 0.6276, 3.19, 0.249, 281, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
2953, 2weiA, 0.6276, 3.73, 0.275, 278, 258, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE IN COMPLEX WITH 3- MB-PP1
2954, 1u5rA, 0.6276, 3.19, 0.226, 308, 248, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
2955, 5n1lA, 0.6275, 3.65, 0.247, 347, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 25-DIMETHYL-N-PYRIDIN-4-YLFURAN-3- CARBOXAMIDE
2956, 5j95A, 0.6275, 3.00, 0.237, 284, 245, MAP4K4 IN COMPLEX WITH INHIBITOR
2957, 5eykB, 0.6275, 3.11, 0.202, 275, 247, CRYSTAL STRUCTURE OF AURORA B IN COMPLEX WITH BI 847325
2958, 3bu6A, 0.6275, 3.56, 0.208, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PHOSPHOPEPTIDE
2959, 2x7fC, 0.6275, 2.76, 0.223, 285, 242, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
2960, 6b2pA, 0.6274, 2.73, 0.239, 255, 243, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
2961, 4nkaA, 0.6274, 3.20, 0.245, 279, 249, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 2
2962, 3naxA, 0.6274, 2.93, 0.265, 278, 245, PDK1 IN COMPLEX WITH INHIBITOR MP7
2963, 3dfcB, 0.6274, 3.19, 0.304, 280, 247, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH AMPPNP
2964, 2zm3B, 0.6274, 3.43, 0.174, 296, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
2965, 1jktA, 0.6274, 3.33, 0.296, 276, 250, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
2966, 5nkdA, 0.6273, 3.09, 0.210, 287, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2I
2967, 5d7aC, 0.6273, 2.94, 0.220, 286, 245, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF TRAF2 AND NCK-INTERACTING PROTEIN KINASE WITH NCB-0846
2968, 4uzdA, 0.6273, 3.00, 0.240, 254, 246, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
2969, 3unzB, 0.6273, 3.07, 0.251, 263, 247, AURORA A IN COMPLEX WITH RPM1679
2970, 2yzaA, 0.6273, 2.79, 0.266, 258, 244, CRYSTAL STRUCTURE OF KINASE DOMAIN OF HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE ALPHA-2 SUBUNIT MUTANT (T172D)
2971, 5n3aA, 0.6272, 3.61, 0.252, 349, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-METHYL-5-(1-METHYLIMIDAZOL-2-YL)-13- THIAZOL-2-AMINE
2972, 5n33A, 0.6272, 3.65, 0.247, 347, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 3-AMINO-5-(TRIFLUOROMETHYL)-1H-PYRIDIN-2- ONE
2973, 5n1nA, 0.6272, 3.65, 0.247, 348, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-9-PROPAN-2-YLPURINE
2974, 5mhiA, 0.6272, 3.63, 0.244, 348, 258, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
2975, 4wb6A, 0.6272, 3.87, 0.257, 336, 261, CRYSTAL STRUCTURE OF A L205R MUTANT OF HUMAN CAMP-DEPENDENT PROTEIN KINASE A (CATALYTIC ALPHA SUBUNIT)
2976, 4redA, 0.6272, 2.80, 0.265, 327, 245, CRYSTAL STRUCTURE OF HUMAN AMPK ALPHA1 KD-AID WITH K43A MUTATION
2977, 3unzA, 0.6272, 3.07, 0.251, 263, 247, AURORA A IN COMPLEX WITH RPM1679
2978, 2qg5A, 0.6272, 3.36, 0.277, 284, 249, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
2979, 2bujB, 0.6272, 3.23, 0.215, 286, 247, CRYSTAL STRUCTURE OF THE HUMAN SERINE-THREONINE KINASE 16 IN COMPLEX WITH STAUROSPORINE
2980, 1zwsB, 0.6272, 3.30, 0.297, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2981, 5n3bA, 0.6271, 3.66, 0.247, 342, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(PYRIDIN-3-YL)ETHANAMINE
2982, 3qquD, 0.6271, 3.97, 0.180, 292, 261, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
2983, 2g15A, 0.6271, 3.16, 0.208, 301, 250, STRUCTURAL CHARACTERIZATION OF AUTOINHIBITED C-MET KINASE
2984, 4zloA, 0.6270, 2.92, 0.225, 277, 244, SERINE/THREONINE-PROTEIN KINASE PAK1 COMPLEXED WITH A DIBENZODIAZEPINE: IDENTIFICATION OF AN ALLOSTERIC SITE ON PAK1
2985, 3kl8I, 0.6270, 2.79, 0.296, 254, 240, CAMKIINTIDE INHIBITOR COMPLEX
2986, 1o6yA, 0.6270, 2.95, 0.248, 260, 246, CATALYTIC DOMAIN OF PKNB KINASE FROM MYCOBACTERIUM TUBERCULOSIS
2987, 5zv2B, 0.6269, 2.97, 0.248, 282, 246, FGFR-1 IN COMPLEX WITH LIGAND LENVATINIB 
2988, 5nk4A, 0.6269, 3.10, 0.206, 290, 248, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2C
2989, 5n1mA, 0.6269, 3.66, 0.247, 347, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE (5-CHLORO-2-METHOXYPHENYL)METHANAMINE
2990, 5fdxA, 0.6269, 3.53, 0.209, 280, 254, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
2991, 4fzaB, 0.6269, 2.91, 0.196, 281, 245, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX
2992, 1zwsE, 0.6269, 3.29, 0.297, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
2993, 5vd3A, 0.6268, 3.24, 0.214, 293, 248, CRYSTAL STRUCTURE OF HUMAN MYT1 KINASE DOMAIN (DE-PHOSPHORYLATED) IN COMPLEX WITH SARACATINIB
2994, 5auyA, 0.6268, 3.20, 0.300, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH MORIN.
2995, 3ehaA, 0.6268, 3.19, 0.304, 279, 247, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH AMPPNP
2996, 5n39A, 0.6267, 3.66, 0.247, 347, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-(23-DIHYDROBENZO[B][14]DIOXIN-6-YL) PYRROLIDINE
2997, 5ia2A, 0.6267, 3.12, 0.201, 287, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 66
2998, 2c6eA, 0.6267, 2.74, 0.251, 251, 243, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
2999, 1zwsH, 0.6267, 3.30, 0.297, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3000, 1ig1A, 0.6267, 3.23, 0.300, 280, 247, 1.8A X-RAY STRUCTURE OF TERNARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE AND MN.
3001, 5oatB, 0.6266, 3.37, 0.199, 359, 251, PINK1 STRUCTURE
3002, 4nk9B, 0.6266, 3.07, 0.247, 282, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 1
3003, 4lgdB, 0.6266, 3.42, 0.217, 350, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3004, 4eqmA, 0.6266, 3.00, 0.262, 269, 248, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3005, 2yakA, 0.6266, 3.39, 0.297, 277, 249, STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN COMPLEX WITH A RUTHENIUM OCTASPORINE LIGAND (OSV)
3006, 1wvwA, 0.6266, 3.27, 0.302, 275, 248, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3007, 5oatD, 0.6265, 3.30, 0.200, 359, 250, PINK1 STRUCTURE
3008, 5n3dA, 0.6265, 3.77, 0.250, 346, 260, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 4-(TRIFLUOROMETHYL)BENZENECARBOXIMIDAMIDE
3009, 4v01B, 0.6265, 3.16, 0.246, 275, 248, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
3010, 5oatE, 0.6264, 3.30, 0.200, 359, 250, PINK1 STRUCTURE
3011, 5n1oA, 0.6264, 3.66, 0.247, 335, 259, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE 2-CHLORO-4-(CHLOROMETHYL)-5- HYDROXYPHENYL)ETHAN-1-ONE
3012, 4eqmC, 0.6264, 3.02, 0.266, 269, 248, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3013, 4eqmB, 0.6264, 3.01, 0.262, 269, 248, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3014, 2i1mA, 0.6264, 3.37, 0.235, 311, 251, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
3015, 1jksA, 0.6264, 3.22, 0.296, 280, 247, 1.5A X-RAY STRUCTURE OF APO FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3016, 4lg4B, 0.6263, 3.33, 0.224, 284, 250, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3017, 3gu7A, 0.6263, 3.15, 0.301, 280, 246, CRYSTAL STRUCTURE OF DAPKQ23V-ADP-MG2+
3018, 3f5pH, 0.6263, 3.43, 0.182, 299, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3019, 5os5A, 0.6262, 3.28, 0.251, 267, 251, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3020, 3qquC, 0.6262, 3.87, 0.181, 293, 260, COCRYSTAL STRUCTURE OF UNPHOSPHORYLATED IGF WITH PYRIMIDINE 8
3021, 2z8cA, 0.6262, 3.57, 0.200, 297, 255, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH (4-{[5-CARBAMOYL-4-(3-METHYLANILINO)PYRIMIDIN-2- YL]AMINO}PHENYL)ACETIC ACID
3022, 5autA, 0.6261, 3.17, 0.305, 274, 246, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH ANS.
3023, 3h10A, 0.6261, 3.41, 0.245, 268, 253, AURORA A INHIBITOR COMPLEX
3024, 3f5pC, 0.6261, 3.43, 0.182, 301, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3025, 2pmlX, 0.6261, 3.51, 0.217, 340, 253, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH AN ATP ANALOGUE
3026, 4nksA, 0.6260, 3.12, 0.250, 265, 248, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH PYRAZOLAMINOPYRIMIDINE 3
3027, 3mn3A, 0.6260, 2.79, 0.262, 252, 244, AN INHIBITED CONFORMATION FOR THE PROTEIN KINASE DOMAIN OF THE SACCHAROMYCES CEREVISIAE AMPK HOMOLOG SNF1
3028, 2gcdB, 0.6260, 3.33, 0.229, 308, 249, TAO2 KINASE DOMAIN-STAUROSPORINE STRUCTURE
3029, 4rwjB, 0.6259, 3.01, 0.248, 282, 246, CRYSTAL STRUCTURE OF FGFR1 (C488A C584S) IN COMPLEX WITH AZD4547 (N- {3-[2-(35-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE)
3030, 3is5B, 0.6259, 2.99, 0.305, 260, 246, CRYSTAL STRUCTURE OF CDPK KINASE DOMAIN FROM TOXOPLASMA GONDII TGME49_018720
3031, 3f5pD, 0.6259, 3.43, 0.182, 297, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3032, 3d5wA, 0.6259, 3.22, 0.279, 284, 247, CRYSTAL STRUCTURE OF A PHOSPHORYLATED POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH ADP.
3033, 3c0gB, 0.6259, 3.40, 0.278, 320, 248, CASK CAM-KINASE DOMAIN- 3 -AMP COMPLEX P1 FORM
3034, 3gu4A, 0.6258, 3.22, 0.304, 280, 247, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP
3035, 1zwsA, 0.6258, 3.33, 0.297, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3036, 4v04B, 0.6257, 3.00, 0.244, 287, 246, FGFR1 IN COMPLEX WITH PONATINIB.
3037, 4eqmD, 0.6257, 2.86, 0.272, 268, 246, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3038, 3hdmA, 0.6257, 2.95, 0.231, 285, 247, CRYSTAL STRUCTURE OF SERUM AND GLUCOCORTICOID-REGULATED KINASE 1 IN COMPLEX WITH COMPOUND 1
3039, 3gu5A, 0.6257, 3.22, 0.304, 280, 247, CRYSTAL STRUCTURE OF DAPKQ23V-AMPPNP-MG2+
3040, 1uwhB, 0.6257, 2.95, 0.225, 264, 244, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
3041, 5oatA, 0.6256, 3.32, 0.200, 359, 250, PINK1 STRUCTURE
3042, 5nk3A, 0.6256, 3.24, 0.205, 281, 249, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1L
3043, 5av3A, 0.6256, 3.23, 0.300, 275, 247, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF IODIDE IONS.
3044, 3nw6A, 0.6256, 3.88, 0.174, 301, 259, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11A)
3045, 3h4jB, 0.6256, 3.77, 0.275, 330, 255, CRYSTAL STRUCTURE OF POMBE AMPK KDAID FRAGMENT
3046, 3f5pG, 0.6256, 3.44, 0.182, 299, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3047, 3f5pB, 0.6256, 3.44, 0.182, 298, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3048, 3beaA, 0.6256, 3.46, 0.243, 310, 251, CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE INHIBITOR
3049, 5uyjA, 0.6255, 3.11, 0.247, 281, 247, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
3050, 5oatC, 0.6255, 3.32, 0.200, 359, 250, PINK1 STRUCTURE
3051, 3f5pA, 0.6255, 3.44, 0.182, 299, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3052, 2e9oA, 0.6255, 3.14, 0.260, 269, 246, STRUCTURE OF H-CHK1 COMPLEXED WITH AA582939
3053, 5ig1B, 0.6254, 3.50, 0.267, 304, 251, CRYSTAL STRUCTURE OF S. ROSETTA CAMKII KINASE DOMAIN
3054, 5av2A, 0.6254, 3.23, 0.300, 275, 247, CRYSTAL STRUCTURE OF DAPK1-KAEMPFEROL COMPLEX IN THE PRESENCE OF BROMIDE IONS.
3055, 4v04A, 0.6254, 3.09, 0.243, 290, 247, FGFR1 IN COMPLEX WITH PONATINIB.
3056, 3kl8A, 0.6254, 2.87, 0.292, 256, 240, CAMKIINTIDE INHIBITOR COMPLEX
3057, 3f5pE, 0.6254, 3.44, 0.182, 299, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3058, 2x4fB, 0.6254, 3.11, 0.275, 288, 247, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3059, 2fumD, 0.6254, 2.86, 0.236, 258, 246, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3060, 4ow8A, 0.6253, 3.45, 0.263, 276, 255, CRYSTAL STRUCTURE OF KINASE DOMAIN OF PKNA FROM MTB
3061, 4lqpA, 0.6253, 3.71, 0.238, 383, 260, CRYSTAL STRUCTURE OF THE CBK1(T743E)-MOB2 KINASE-COACTIVATOR COMPLEX IN CRYSTAL FORM A
3062, 4fzdB, 0.6253, 2.94, 0.192, 275, 245, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH WSF MOTIF
3063, 2i0yA, 0.6253, 3.46, 0.243, 289, 251, CFMS TYROSINE KINASE (FGF KID) IN COMPLEX WITH AN ARYLAMIDE INHIBITOR
3064, 1fgiB, 0.6253, 3.04, 0.255, 272, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR
3065, 5av1A, 0.6252, 3.16, 0.301, 275, 246, CRYSTAL STRUCTURE OF DAPK1 IN THE PRESENCE OF BROMIDE IONS.
3066, 3i81A, 0.6252, 3.75, 0.175, 296, 257, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH BMS-754807 [1-(4-((5-CYCLOPROPYL- 1H-PYRAZOL-3-YL)AMINO)PYRROLO[21-F][124]TRIAZIN-2-YL)-N- (6-FLUORO-3-PYRIDINYL)-2-METHYL-L-PROLINAMIDE]
3067, 3g0eA, 0.6252, 3.67, 0.243, 332, 255, KIT KINASE DOMAIN IN COMPLEX WITH SUNITINIB
3068, 3e5aA, 0.6252, 3.20, 0.255, 264, 247, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH VX-680 AND TPX2
3069, 3d94A, 0.6252, 3.68, 0.175, 288, 257, CRYSTAL STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR KINASE IN COMPLEX WITH PQIP
3070, 1jklA, 0.6252, 3.24, 0.304, 280, 247, 1.6A X-RAY STRUCTURE OF BINARY COMPLEX OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE WITH ATP ANALOGUE
3071, 5av0A, 0.6251, 3.23, 0.300, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH 73 4 - TRIHYDROXYISOFLAVONE.
3072, 3f5pF, 0.6251, 3.53, 0.181, 299, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3073, 2w4jA, 0.6251, 3.32, 0.298, 276, 248, X-RAY STRUCTURE OF A DAP-KINASE 2-277
3074, 2j0jA, 0.6251, 3.13, 0.227, 611, 247, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
3075, 5oatF, 0.6250, 3.36, 0.199, 359, 251, PINK1 STRUCTURE
3076, 4ct2A, 0.6250, 3.09, 0.261, 277, 245, HUMAN PDK1-PKCZETA KINASE CHIMERA
3077, 3ewhA, 0.6250, 3.41, 0.223, 300, 251, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDYL-PYRIMIDINE BENZIMIDAZOLE INHIBITOR
3078, 5auvA, 0.6249, 3.24, 0.300, 275, 247, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH APIGENIN.
3079, 4uv0A, 0.6249, 3.37, 0.301, 300, 249, STRUCTURE OF A SEMISYNTHETIC PHOSPHORYLATED DAPK
3080, 4eqmF, 0.6249, 2.88, 0.272, 268, 246, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3081, 2w96B, 0.6249, 2.94, 0.357, 267, 244, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
3082, 1vzoA, 0.6249, 3.00, 0.245, 319, 245, THE STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF MSK1 REVEALS A NOVEL AUTOINHIBITORY CONFORMATION FOR A DUAL KINASE PROTEIN
3083, 5o21A, 0.6248, 3.43, 0.242, 272, 252, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED STATE WITH CHLORIDE BOUND IN THE ACTIVE SITE
3084, 5di1A, 0.6248, 3.05, 0.245, 285, 245, MAP4K4 IN COMPLEX WITH AN INHIBITOR
3085, 5auxA, 0.6248, 3.18, 0.301, 275, 246, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH KAEMPFEROL.
3086, 4rz7A, 0.6248, 3.32, 0.245, 801, 249, CRYSTAL STRUCTURE OF PVX_084705 WITH BOUND PCI32765
3087, 3f5pT, 0.6248, 3.47, 0.182, 295, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3088, 3nw5A, 0.6247, 3.68, 0.175, 302, 257, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (11B)
3089, 3gu6A, 0.6247, 3.25, 0.300, 280, 247, CRYSTAL STRUCTURE OF DAPKQ23V-ADP
3090, 3f5gA, 0.6247, 3.24, 0.300, 279, 247, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH ADP AND MG2+
3091, 6fdyU, 0.6246, 2.95, 0.246, 261, 244, UNC-51-LIKE KINASE 3 (ULK3) IN COMPLEX WITH BOSUTINIB 
3092, 5uy6A, 0.6246, 3.05, 0.252, 282, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B
3093, 3eh9A, 0.6246, 3.25, 0.296, 278, 247, CRYSTAL STRUCTURE OF DEATH ASSOCIATED PROTEIN KINASE COMPLEXED WITH ADP
3094, 1zwsC, 0.6246, 3.33, 0.297, 278, 249, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN DRP-1 KINASE
3095, 1u5qB, 0.6246, 3.34, 0.229, 308, 249, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
3096, 5cwzB, 0.6245, 2.80, 0.230, 284, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3097, 4eqmE, 0.6245, 2.89, 0.272, 268, 246, STRUCTURAL ANALYSIS OF STAPHYLOCOCCUS AUREUS SERINE/THREONINE KINASE PKNB
3098, 2c6dA, 0.6245, 3.04, 0.252, 254, 246, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH ADPNP
3099, 1mruA, 0.6245, 3.00, 0.244, 269, 246, INTRACELLULAR SER/THR PROTEIN KINASE DOMAIN OF MYCOBACTERIUM TUBERCULOSIS PKNB.
3100, 5bvkA, 0.6244, 3.68, 0.203, 278, 256, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3101, 3k5vA, 0.6244, 3.20, 0.223, 286, 247, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
3102, 3ik3B, 0.6244, 3.31, 0.217, 286, 249, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3103, 3h10D, 0.6244, 3.17, 0.250, 255, 248, AURORA A INHIBITOR COMPLEX
3104, 3dbeA, 0.6244, 2.93, 0.275, 284, 244, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH COMPOUND 557
3105, 2xzsA, 0.6244, 3.46, 0.308, 301, 250, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3106, 3kfaB, 0.6243, 3.34, 0.225, 284, 249, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3107, 2h6dA, 0.6243, 2.73, 0.264, 256, 242, PROTEIN KINASE DOMAIN OF THE HUMAN 5 -AMP-ACTIVATED PROTEIN KINASE CATALYTIC SUBUNIT ALPHA-2 (AMPK ALPHA-2 CHAIN)
3108, 5nkeA, 0.6242, 2.96, 0.199, 292, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3A
3109, 4pf4A, 0.6242, 3.24, 0.304, 278, 247, 1.1A X-RAY STRUCTURE OF THE APO CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE 1 AA 1-277
3110, 4p90B, 0.6242, 2.75, 0.218, 262, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN PAK1 IN COMPLEX WITH COMPOUND 15
3111, 3txoA, 0.6242, 3.29, 0.229, 317, 249, PKC ETA KINASE IN COMPLEX WITH A NAPHTHYRIDINE
3112, 2aypA, 0.6242, 3.05, 0.257, 268, 245, CRYSTAL STRUCTURE OF CHK1 WITH AN INDOL INHIBITOR
3113, 5i9zA, 0.6241, 2.72, 0.202, 273, 242, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH DANUSERTIB (PHA739358)
3114, 4v01A, 0.6241, 3.12, 0.243, 273, 247, FGFR1 IN COMPLEX WITH PONATINIB (CO-CRYSTALLISATION).
3115, 4o0sA, 0.6241, 3.19, 0.249, 265, 249, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3116, 3bu3A, 0.6241, 3.64, 0.204, 294, 255, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE
3117, 2hiwB, 0.6241, 3.25, 0.218, 274, 248, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
3118, 4zp5A, 0.6240, 3.14, 0.236, 284, 246, MAP4K4 IN COMPLEX WITH INHIBITOR
3119, 4lgdD, 0.6240, 3.45, 0.217, 338, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3120, 4lgdA, 0.6240, 3.47, 0.220, 350, 254, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3121, 4g9cB, 0.6240, 2.91, 0.226, 264, 243, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
3122, 4fzfB, 0.6240, 3.31, 0.189, 279, 249, CRYSTAL STRUCTURE OF MST4-MO25 COMPLEX WITH DKI
3123, 3h10B, 0.6240, 3.50, 0.233, 267, 253, AURORA A INHIBITOR COMPLEX
3124, 3g0fA, 0.6240, 3.46, 0.242, 291, 252, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3125, 2zm3D, 0.6240, 3.58, 0.181, 293, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3126, 2x4fA, 0.6240, 3.26, 0.270, 289, 248, THE CRYSTAL STRUCTURE OF THE HUMAN MYOSIN LIGHT CHAIN KINASE LOC340156.
3127, 5o0yA, 0.6239, 3.31, 0.256, 288, 250, TLK2 KINASE DOMAIN FROM HUMAN 
3128, 4f65B, 0.6239, 3.14, 0.247, 279, 247, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
3129, 3w10A, 0.6239, 3.39, 0.234, 263, 252, AURORA KINASE A COMPLEXED TO PYRAZOLE AMINOQUINOLINE I
3130, 3f5uA, 0.6239, 3.14, 0.298, 279, 245, CRYSTAL STRUCTURE OF THE DEATH ASSOCIATED PROTEIN KINASE IN COMPLEX WITH AMPPNP AND MG2+
3131, 5nkhA, 0.6238, 2.97, 0.199, 295, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 3E
3132, 3uolB, 0.6238, 3.06, 0.252, 263, 246, AURORA A IN COMPLEX WITH SO2-162
3133, 3uolA, 0.6238, 3.06, 0.252, 263, 246, AURORA A IN COMPLEX WITH SO2-162
3134, 4ymjB, 0.6237, 3.19, 0.215, 275, 246, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3135, 3kfaA, 0.6237, 3.26, 0.222, 284, 248, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
3136, 3f5pS, 0.6237, 3.48, 0.182, 295, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3137, 5fdpA, 0.6236, 3.57, 0.209, 285, 254, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2099 INHIBITOR AT 2.25 ANGSTROMS RESOLUTION.
3138, 5auzA, 0.6236, 3.14, 0.302, 274, 245, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH GENISTEIN.
3139, 3f5pM, 0.6236, 3.48, 0.182, 295, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3140, 2wkmA, 0.6236, 3.35, 0.204, 286, 250, X-RAY STRUCTURE OF PHA-00665752 BOUND TO THE KINASE DOMAIN OF C-MET
3141, 2i0vA, 0.6236, 3.51, 0.243, 303, 251, C-FMS TYROSINE KINASE IN COMPLEX WITH A QUINOLONE INHIBITOR
3142, 5osdA, 0.6235, 3.31, 0.248, 266, 250, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3143, 5bvnA, 0.6235, 3.62, 0.208, 278, 255, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3144, 5av4A, 0.6235, 3.21, 0.301, 274, 246, CRYSTAL STRUCTURE OF DAPK1-GENISTEIN COMPLEX IN THE PRESENCE OF BROMIDE IONS.
3145, 4h58C, 0.6235, 3.45, 0.221, 272, 249, BRAF IN COMPLEX WITH COMPOUND 3
3146, 3dgkA, 0.6235, 3.21, 0.301, 278, 246, CRYSTAL STRUCTURE OF A GLYCINE-RICH LOOP MUTANT OF THE DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN
3147, 5m53A, 0.6234, 2.62, 0.247, 255, 239, NEK2 BOUND TO ARYLAMINOPURINE INHIBITOR 11
3148, 4tl0A, 0.6234, 3.40, 0.297, 300, 249, CRYSTAL STRUCTURE OF DEATH-ASSOCIATED PROTEIN KINASE 1 WITH A CRUCIAL PHOSPHOMIMICKING MUTATION
3149, 2y0aA, 0.6234, 3.46, 0.304, 300, 250, STRUCTURE OF DAPK1 CONSTRUCT RESIDUES 1-304
3150, 2qg5D, 0.6234, 3.17, 0.276, 283, 246, CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840
3151, 2ghgA, 0.6234, 3.28, 0.262, 269, 248, H-CHK1 COMPLEXED WITH A431994
3152, 5nk5A, 0.6233, 2.99, 0.199, 287, 246, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1M
3153, 5grnA, 0.6233, 3.51, 0.246, 285, 252, CRYSTAL STRUCTURE OF PDGFRA IN COMPLEX WITH WQ-C-159
3154, 3kulB, 0.6233, 3.09, 0.216, 271, 245, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
3155, 3f5pI, 0.6233, 3.49, 0.182, 294, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3156, 2ydiA, 0.6233, 3.12, 0.265, 279, 245, DISCOVERY OF CHECKPOINT KINASE INHIBITOR AZD7762 BY STRUCTURE BASED DESIGN AND OPTIMIZATION OF THIOPHENE CARBOXAMIDE UREAS
3157, 6b2qC, 0.6232, 3.00, 0.273, 264, 245, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3158, 5bvoA, 0.6232, 3.60, 0.212, 276, 255, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3159, 4o0rA, 0.6232, 3.29, 0.224, 293, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3160, 4jiaA, 0.6232, 3.34, 0.224, 298, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 9
3161, 2e9nA, 0.6232, 3.15, 0.257, 269, 245, STRUCTURE OF H-CHK1 COMPLEXED WITH A767085
3162, 1k3aA, 0.6232, 3.66, 0.180, 288, 255, STRUCTURE OF THE INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR KINASE
3163, 1iepA, 0.6232, 3.19, 0.223, 274, 247, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
3164, 4uynA, 0.6231, 2.88, 0.248, 249, 242, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3165, 4lgdC, 0.6231, 3.39, 0.227, 349, 251, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3166, 3hngA, 0.6231, 3.51, 0.250, 288, 252, CRYSTAL STRUCTURE OF VEGFR1 IN COMPLEX WITH N-(4-CHLOROPHENYL)-2- ((PYRIDIN-4-YLMETHYL)AMINO)BENZAMIDE
3167, 3gu8A, 0.6231, 3.21, 0.293, 278, 246, CRYSTAL STRUCTURE OF DAPKL93G WITH N6-CYCLOPENTYLADENOSINE
3168, 1uwhA, 0.6231, 3.05, 0.234, 264, 244, THE COMPLEX OF WILD TYPE B-RAF AND BAY439006
3169, 1opjB, 0.6231, 3.32, 0.218, 288, 248, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3170, 6cd6D, 0.6230, 3.10, 0.253, 267, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3171, 5wevA, 0.6230, 3.34, 0.220, 293, 250, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
3172, 5cwzA, 0.6230, 2.83, 0.226, 284, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
3173, 5auuA, 0.6230, 3.23, 0.301, 274, 246, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH LUTEOLIN.
3174, 4ejnA, 0.6230, 2.87, 0.262, 376, 244, CRYSTAL STRUCTURE OF AUTOINHIBITED FORM OF AKT1 IN COMPLEX WITH N-(4- (5-(3-ACETAMIDOPHENYL)-2-(2-AMINOPYRIDIN-3-YL)-3H-IMIDAZO[45- B]PYRIDIN-3-YL)BENZYL)-3-FLUOROBENZAMIDE
3175, 3f5pL, 0.6230, 3.51, 0.182, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3176, 6bwkA, 0.6229, 3.16, 0.157, 263, 249, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN T357E/S358E MUTANT 
3177, 4txcA, 0.6229, 3.40, 0.297, 276, 249, CRYSTAL STRUCTURE OF DAPK1 KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3178, 2x8dA, 0.6229, 3.15, 0.261, 279, 245, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
3179, 6fdzU, 0.6228, 3.28, 0.237, 265, 249, UNC-51-LIKE KINASE 3 (ULK3) IN COMPLEX WITH MOMELOTINIB 
3180, 4w8eA, 0.6228, 3.11, 0.225, 290, 244, STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF-06645342)
3181, 3hyhB, 0.6228, 2.18, 0.289, 233, 232, CRYSTAL STRUCTURE OF THE PROTEIN KINASE DOMAIN OF YEAST AMP-ACTIVATED PROTEIN KINASE SNF1
3182, 3f5pK, 0.6228, 3.52, 0.182, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3183, 3f3zA, 0.6228, 3.06, 0.279, 271, 244, CRYSTAL STRUCTURE OF CRYPTOSPORIDIUM PARVUM CALCIUM DEPENDENT PROTEIN KINASE CGD7_1840 IN PRESENCE OF INDIRUBIN E804
3184, 2pmoX, 0.6228, 3.55, 0.213, 340, 253, CRYSTAL STRUCTURE OF PFPK7 IN COMPLEX WITH HYMENIALDISINE
3185, 2hyyB, 0.6228, 3.20, 0.224, 265, 246, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3186, 4qmwA, 0.6227, 3.21, 0.220, 286, 245, MST3 IN COMPLEX WITH PP-121 1-CYCLOPENTYL-3-(1H-PYRROLO[23- B]PYRIDIN-5-YL)-1H-PYRAZOLO[34-D]PYRIMIDIN-4-AMINE
3187, 4fl2A, 0.6227, 3.15, 0.176, 555, 250, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
3188, 3u6jA, 0.6227, 3.41, 0.239, 308, 251, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRAZOLONE INHIBITOR
3189, 3bu5A, 0.6227, 3.80, 0.214, 291, 257, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH IRS2 KRLB PEPTIDE AND ATP
3190, 3bhhD, 0.6227, 3.30, 0.293, 286, 246, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3191, 2ckeD, 0.6227, 3.45, 0.309, 300, 249, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3192, 1fpuA, 0.6227, 3.34, 0.225, 275, 249, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3193, 5oryA, 0.6226, 3.18, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3194, 5ci7A, 0.6226, 3.29, 0.267, 276, 247, STRUCTURE OF ULK1 BOUND TO A SELECTIVE INHIBITOR
3195, 5auwA, 0.6226, 3.23, 0.301, 274, 246, CRYSTAL STRUCTURE OF DAPK1 IN COMPLEX WITH QUERCETIN.
3196, 4at4A, 0.6226, 3.27, 0.215, 292, 246, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH EX429
3197, 3f5pR, 0.6226, 3.50, 0.182, 294, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3198, 3bhhC, 0.6226, 3.27, 0.293, 285, 246, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IIB ISOFORM 1 (CAMK2B)
3199, 1zysA, 0.6226, 3.09, 0.258, 271, 244, CO-CRYSTAL STRUCTURE OF CHECKPOINT KINASE CHK1 WITH A PYRROLO-PYRIDINE INHIBITOR
3200, 1u5rB, 0.6226, 3.30, 0.226, 308, 248, CRYSTAL STRUCTURE OF THE TAO2 KINASE DOMAIN: ACTIVATION AND SPECIFITY OF A STE20P MAP3K
3201, 1iepB, 0.6226, 3.32, 0.206, 274, 248, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH STI-571.
3202, 4gmyA, 0.6225, 3.35, 0.220, 298, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH 26-DICHLORO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
3203, 4aszA, 0.6225, 3.26, 0.206, 289, 247, CRYSTAL STRUCTURE OF APO TRKB KINASE DOMAIN
3204, 3i6wH, 0.6225, 3.38, 0.302, 382, 245, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
3205, 3gqlA, 0.6225, 2.96, 0.262, 287, 244, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3206, 3dlsA, 0.6225, 3.14, 0.232, 285, 246, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3207, 2zm3A, 0.6225, 3.57, 0.181, 300, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3208, 1yrpB, 0.6225, 3.22, 0.297, 275, 246, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
3209, 1yrpA, 0.6225, 3.22, 0.297, 275, 246, CATALYTIC DOMAIN OF HUMAN ZIP KINASE PHOSPHORYLATED AT THR265
3210, 1wvxA, 0.6225, 3.27, 0.305, 275, 246, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3211, 5fdxB, 0.6224, 3.45, 0.211, 274, 251, STRUCTURE OF DDR1 RECEPTOR TYROSINE KINASE IN COMPLEX WITH D2164 INHIBITOR AT 2.65 ANGSTROMS RESOLUTION.
3212, 4ythA, 0.6224, 3.26, 0.225, 287, 249, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
3213, 4f1tA, 0.6224, 3.11, 0.197, 269, 244, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO THE ROCK INHIBITOR H1152
3214, 2ckeC, 0.6224, 3.41, 0.293, 300, 249, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3215, 5l8lA, 0.6223, 3.09, 0.244, 263, 246, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 (CRYSTAL FORM 1)
3216, 4wnoA, 0.6223, 3.15, 0.269, 272, 245, STRUCTURE OF ULK1 BOUND TO AN INHIBITOR
3217, 3oy3B, 0.6223, 3.39, 0.205, 284, 249, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3218, 2hyyC, 0.6223, 3.38, 0.218, 262, 248, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3219, 2c30A, 0.6223, 3.34, 0.235, 289, 247, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 6
3220, 5vjaD, 0.6222, 2.96, 0.306, 261, 242, CRYSTAL STRUCTURE OF HUMAN ZIPPER-INTERACTING PROTEIN KINASE (ZIPK; ALIAS DAPK3) IN COMPLEX WITH A PYRAZOLO[3;4-D]PYRIMIDINONE LIGAND (HS38) 
3221, 5bvwA, 0.6222, 3.66, 0.209, 274, 254, FRAGMENT-BASED DISCOVERY OF POTENT AND SELECTIVE DDR1/2 INHIBITORS
3222, 4ymjA, 0.6222, 3.07, 0.217, 270, 244, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
3223, 4uxqA, 0.6222, 3.29, 0.264, 286, 250, FGFR4 IN COMPLEX WITH PONATINIB
3224, 4figB, 0.6222, 3.25, 0.241, 292, 245, CATALYTIC DOMAIN OF HUMAN PAK4
3225, 3f5pJ, 0.6222, 3.53, 0.182, 293, 253, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND 3- CYANOQUINOLINE INHIBITOR
3226, 1rqqB, 0.6222, 3.75, 0.207, 294, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
3227, 4yo4A, 0.6221, 3.23, 0.297, 280, 246, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT PHTHALAZINE
3228, 4f0iB, 0.6221, 3.22, 0.198, 294, 248, CRYSTAL STRUCTURE OF APO TRKA
3229, 4e26A, 0.6221, 2.99, 0.221, 270, 244, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3230, 3uo5A, 0.6221, 3.36, 0.240, 267, 250, AURORA A IN COMPLEX WITH YL1-038-31
3231, 3k5uA, 0.6221, 3.04, 0.239, 260, 247, IDENTIFICATION SAR STUDIES AND X-RAY COCRYSTAL ANALYSIS OF A NOVEL FURANO-PYRIMIDINE AURORA KINASE A INHIBITOR
3232, 3a7gB, 0.6221, 3.27, 0.215, 290, 247, HUMAN MST3 KINASE
3233, 2yaaB, 0.6221, 3.50, 0.296, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
3234, 2xzsB, 0.6221, 3.40, 0.310, 293, 248, DEATH ASSOCIATED PROTEIN KINASE 1 RESIDUES 1-312
3235, 6babB, 0.6220, 3.29, 0.310, 285, 245, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3236, 4ypdA, 0.6220, 3.30, 0.300, 281, 247, CRYSTAL STRUCTURE OF DAPK1 CATALYTIC DOMAIN IN COMPLEX WITH THE HINGE BINDING FRAGMENT 4-METHYLPYRIDAZINE
3237, 4tygA, 0.6220, 3.25, 0.258, 293, 248, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3238, 4hvsA, 0.6220, 3.57, 0.262, 326, 252, CRYSTAL STRUCTURE OF KIT KINASE DOMAIN WITH A SMALL MOLECULE INHIBITOR PLX647
3239, 3up2A, 0.6220, 3.45, 0.243, 266, 251, AURORA A IN COMPLEX WITH RPM1686
3240, 3oy3A, 0.6220, 3.29, 0.218, 284, 248, CRYSTAL STRUCTURE OF ABL T315I MUTANT KINASE DOMAIN BOUND WITH A DFG- OUT INHIBITOR AP24589
3241, 5l2qB, 0.6219, 3.26, 0.211, 282, 247, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
3242, 3udbE, 0.6219, 3.15, 0.215, 255, 246, CRYSTAL STRUCTURE OF SNRK2.6
3243, 3skcB, 0.6218, 3.20, 0.214, 276, 248, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
3244, 6cd6B, 0.6217, 3.24, 0.256, 266, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3245, 3a7hB, 0.6217, 3.28, 0.215, 290, 247, HUMAN MST3 KINASE IN COMPLEX WITH ATP
3246, 2e9uA, 0.6217, 3.05, 0.266, 269, 244, STRUCTURE OF H-CHK1 COMPLEXED WITH A780125
3247, 1jqhB, 0.6217, 3.58, 0.173, 287, 254, IGF-1 RECEPTOR KINASE DOMAIN
3248, 5dnrA, 0.6216, 3.30, 0.249, 264, 249, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P41212
3249, 4mbjB, 0.6216, 3.21, 0.210, 276, 248, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
3250, 4deaA, 0.6216, 3.42, 0.243, 266, 251, AURORA A IN COMPLEX WITH YL1-038-18
3251, 5yksA, 0.6215, 3.60, 0.254, 312, 252, CRYSTAL STRUCTURE OF SUCROSE NONFERMENTING-RELATED KINASE (SNRK)
3252, 5l2qA, 0.6215, 3.34, 0.210, 293, 248, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
3253, 4o0wA, 0.6215, 3.27, 0.241, 259, 249, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3254, 4jbqA, 0.6215, 2.88, 0.246, 257, 244, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3255, 4h58B, 0.6215, 2.98, 0.227, 262, 242, BRAF IN COMPLEX WITH COMPOUND 3
3256, 3krjA, 0.6215, 3.47, 0.244, 304, 250, CFMS TYROSINE KINASE IN COMPLEX WITH 4-CYANO-1H-IMIDAZOLE-2-CARBOXYLIC ACID (2-CYCLOHEX-1-ENYL-4-PIPERIDIN-4-YL-PHENYL)-AMIDE
3257, 3i6wF, 0.6215, 3.28, 0.303, 382, 244, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
3258, 1wmkC, 0.6215, 3.39, 0.297, 303, 249, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3259, 1wmkA, 0.6215, 3.39, 0.297, 303, 249, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3260, 6fnhA, 0.6214, 3.11, 0.198, 277, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
3261, 5osfA, 0.6214, 3.20, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3262, 5orwA, 0.6214, 3.20, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3263, 2z7rA, 0.6214, 2.94, 0.270, 265, 241, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO STAUROSPORINE
3264, 2yabB, 0.6214, 3.52, 0.296, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
3265, 2hyyA, 0.6214, 3.21, 0.224, 263, 246, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3266, 1wmkF, 0.6214, 3.39, 0.297, 303, 249, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3267, 5orzA, 0.6213, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3268, 4wnpD, 0.6213, 3.01, 0.276, 272, 243, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3269, 4figA, 0.6213, 3.19, 0.242, 292, 244, CATALYTIC DOMAIN OF HUMAN PAK4
3270, 4debA, 0.6213, 3.32, 0.249, 264, 249, AURORA A IN COMPLEX WITH RK2-17-01
3271, 4d2rA, 0.6213, 3.78, 0.175, 300, 257, HUMAN IGF IN COMPLEX WITH A DYRK1B INHIBITOR
3272, 3gubA, 0.6213, 3.30, 0.296, 278, 247, CRYSTAL STRUCTURE OF DAPKL93G COMPLEXED WITH N6-(2- PHENYLETHYL)ADENOSINE
3273, 2xkdA, 0.6213, 2.76, 0.232, 251, 241, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 12
3274, 2w4kA, 0.6213, 3.43, 0.297, 301, 249, X-RAY STRUCTURE OF A DAP-KINASE 2-302
3275, 2ckeB, 0.6213, 3.45, 0.293, 300, 249, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3276, 1wmkH, 0.6213, 3.39, 0.297, 304, 249, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3277, 1wmkG, 0.6213, 3.40, 0.297, 313, 249, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3278, 1wmkB, 0.6213, 3.39, 0.297, 314, 249, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3279, 5oseA, 0.6212, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3280, 5orrA, 0.6212, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3281, 5csxA, 0.6212, 3.18, 0.220, 261, 245, CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370
3282, 5os3A, 0.6211, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3283, 5am6B, 0.6211, 2.93, 0.263, 280, 243, NATIVE FGFR1 WITH AN INHIBITOR
3284, 3ms9B, 0.6211, 3.28, 0.223, 272, 247, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
3285, 3ik3A, 0.6211, 3.30, 0.206, 280, 247, AP24534 A PAN-BCR-ABL INHIBITOR FOR CHRONIC MYELOID LEUKEMIA POTENTLY INHIBITS THE T315I MUTANT AND OVERCOMES MUTATION-BASED RESISTANCE
3286, 5os1A, 0.6210, 3.22, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3287, 5orpA, 0.6210, 3.23, 0.246, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3288, 5kmjA, 0.6210, 3.20, 0.204, 300, 245, TRKA JM-KINASE WITH {N}-(2-PYRIDYLMETHYL)-2-[2-(2-THIENYL)INDOL-1- YL]ACETAMIDE
3289, 3lvpA, 0.6210, 3.78, 0.178, 289, 258, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3290, 3g0fB, 0.6210, 3.53, 0.250, 293, 252, KIT KINASE DOMAIN MUTANT D816H IN COMPLEX WITH SUNITINIB
3291, 2ywpA, 0.6210, 3.15, 0.265, 269, 245, CRYSTAL STRUCTURE OF CHK1 WITH A UREA INHIBITOR
3292, 2a2aD, 0.6210, 3.48, 0.292, 303, 250, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3293, 1jqhA, 0.6210, 3.59, 0.173, 291, 254, IGF-1 RECEPTOR KINASE DOMAIN
3294, 5vamB, 0.6209, 3.04, 0.240, 260, 242, BRAF IN COMPLEX WITH RAF709
3295, 5orvA, 0.6209, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3296, 5oroA, 0.6209, 3.22, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3297, 4xbrA, 0.6209, 3.18, 0.246, 315, 244, IN CELLULO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA
3298, 4o0tA, 0.6209, 3.35, 0.228, 292, 246, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3299, 3vntA, 0.6209, 3.61, 0.229, 301, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3300, 2w1cA, 0.6209, 3.29, 0.239, 261, 247, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3301, 5os0A, 0.6208, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3302, 5dn3A, 0.6208, 3.34, 0.257, 264, 249, AURORA A IN COMPLEX WITH ATP AND AA35.
3303, 4qmxA, 0.6208, 3.06, 0.222, 287, 243, MST3 IN COMPLEX WITH SARACATINIB
3304, 4asdA, 0.6208, 3.61, 0.229, 305, 253, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SORAFENIB (BAY 43-9006)
3305, 2hiwA, 0.6208, 3.33, 0.218, 274, 248, CRYSTAL STRUCTURE OF INACTIVE CONFORMATION ABL KINASE CATALYTIC DOMAIN COMPLEXED WITH TYPE II INHIBITOR
3306, 5orxA, 0.6207, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3307, 5ornA, 0.6207, 3.21, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3308, 5hidA, 0.6207, 2.85, 0.221, 257, 240, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH AZ628
3309, 4qmsA, 0.6207, 3.15, 0.217, 283, 244, MST3 IN COMPLEX WITH DASATINIB
3310, 4qmnA, 0.6207, 3.16, 0.221, 283, 244, MST3 IN COMPLEX WITH BOSUTINIB
3311, 4at5A, 0.6207, 3.30, 0.206, 294, 248, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH GW2580
3312, 2yabA, 0.6207, 3.46, 0.297, 299, 249, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH AMP
3313, 1wmkE, 0.6207, 3.43, 0.293, 313, 249, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3314, 5orsA, 0.6206, 3.25, 0.246, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3315, 5ax9A, 0.6206, 2.86, 0.228, 282, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3316, 4k9yA, 0.6206, 3.17, 0.198, 271, 248, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-[4-(6-AMINO- PURIN-9-YL)-PHENYL]-3-(5-TERT-BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-UREA
3317, 4e4xB, 0.6206, 3.21, 0.214, 274, 248, CRYSTAL STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH A DIHYDROPYRIDO[23-D]PYRIMIDINONE-BASED INHIBITOR
3318, 1wmkD, 0.6206, 3.43, 0.293, 314, 249, HUMAN DEATH-ASSOCIATED KINASE DRP-1 MUTANT S308D D40
3319, 1jqhC, 0.6206, 3.60, 0.173, 291, 254, IGF-1 RECEPTOR KINASE DOMAIN
3320, 4g9rB, 0.6205, 2.96, 0.227, 261, 242, B-RAF V600E KINASE DOMAIN BOUND TO A TYPE II DIHYDROQUINAZOLINE INHIBITOR
3321, 4fc0B, 0.6205, 3.01, 0.219, 263, 242, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3322, 3zzeA, 0.6205, 3.39, 0.204, 286, 250, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH N - ((3Z)-4-CHLORO-7-METHYL-2-OXO-12-DIHYDRO-3H-INDOL-3- YLIDENE)-2-(4-HYDROXYPHENYL)PROPANOHYDRAZIDE
3323, 3kckA, 0.6205, 3.29, 0.225, 285, 249, A NOVEL CHEMOTYPE OF KINASE INHIBITORS
3324, 2wqnA, 0.6205, 2.73, 0.225, 259, 240, STRUCTURE OF ADP-BOUND HUMAN NEK7
3325, 1opjA, 0.6205, 3.39, 0.218, 287, 248, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
3326, 5kmnA, 0.6204, 3.28, 0.198, 296, 247, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3327, 5dt3A, 0.6204, 3.29, 0.246, 263, 248, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3328, 3d5xA, 0.6204, 2.88, 0.274, 279, 241, CRYSTAL STRUCTURE OF AN ACTIVATED (THR->ASP) POLO-LIKE KINASE 1 (PLK1) CATALYTIC DOMAIN IN COMPLEX WITH WORTMANNIN.
3329, 6gt1B, 0.6203, 3.23, 0.242, 269, 248, NEK7 BOUND TO PURINE INHIBITOR 
3330, 6bkuA, 0.6203, 3.22, 0.256, 267, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B BOUND TO GSK650394
3331, 5wngB, 0.6203, 3.84, 0.223, 365, 260, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
3332, 5ortA, 0.6203, 3.30, 0.249, 264, 249, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3333, 4g9rA, 0.6203, 2.91, 0.228, 262, 241, B-RAF V600E KINASE DOMAIN BOUND TO A TYPE II DIHYDROQUINAZOLINE INHIBITOR
3334, 4agdA, 0.6203, 3.55, 0.221, 303, 253, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH SUNITINIB (SU11248) (N-2- DIETHYLAMINOETHYL)-5-((Z)-(5-FLUORO-2-OXO-1H-INDOL-3- YLIDENE)METHYL)-24-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE)
3335, 3nw7A, 0.6203, 3.92, 0.178, 297, 259, CRYSTAL STRUCTURE OF INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-1R-WT) COMPLEX WITH A CARBON-LINKED PROLINE ISOSTERE INHIBITOR (34)
3336, 2j0kB, 0.6203, 3.12, 0.225, 612, 244, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
3337, 2a27D, 0.6203, 3.38, 0.298, 304, 248, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3338, 5ax9C, 0.6202, 3.04, 0.230, 282, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
3339, 4e26B, 0.6202, 2.84, 0.229, 264, 240, BRAF IN COMPLEX WITH AN ORGANIC INHIBITOR 7898734
3340, 4aseA, 0.6202, 3.59, 0.225, 305, 253, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH TIVOZANIB (AV-951)
3341, 2xnmA, 0.6202, 2.95, 0.242, 258, 244, STRUCTURE OF NEK2 BOUND TO CCT
3342, 2a2aC, 0.6202, 3.43, 0.297, 303, 249, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3343, 4h1jA, 0.6201, 3.02, 0.184, 263, 244, CRYSTAL STRUCTURE OF PYK2 WITH THE PYRAZOLE 13A
3344, 4fifA, 0.6201, 3.29, 0.241, 293, 245, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
3345, 3ikaA, 0.6201, 3.48, 0.224, 310, 250, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M MUTANT COVALENTLY BINDING TO WZ4002
3346, 3i6wD, 0.6201, 3.35, 0.303, 382, 244, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
3347, 5gjfA, 0.6200, 2.92, 0.250, 298, 240, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 3
3348, 4fifB, 0.6200, 3.29, 0.241, 292, 245, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
3349, 4d2sA, 0.6200, 2.61, 0.251, 249, 239, HUMAN TTK IN COMPLEX WITH A DYRK1B INHIBITOR
3350, 3a7iA, 0.6200, 3.06, 0.222, 286, 243, HUMAN MST3 KINASE IN COMPLEX WITH ADENINE
3351, 2vz6A, 0.6200, 3.48, 0.289, 291, 249, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3352, 2hyyD, 0.6200, 3.25, 0.228, 264, 246, HUMAN ABL KINASE DOMAIN IN COMPLEX WITH IMATINIB (STI571 GLIVEC)
3353, 6cd6C, 0.6199, 3.08, 0.255, 265, 243, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3354, 4at3A, 0.6199, 3.28, 0.219, 289, 247, CRYSTAL STRUCTURE OF TRKB KINASE DOMAIN IN COMPLEX WITH CPD5N
3355, 3vhkA, 0.6199, 3.69, 0.228, 297, 254, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BACK POCKET BINDER
3356, 3uo4A, 0.6199, 3.37, 0.252, 266, 250, AURORA A IN COMPLEX WITH RPM1680
3357, 1uwjB, 0.6199, 3.03, 0.227, 263, 242, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3358, 1u59A, 0.6199, 3.22, 0.203, 282, 246, CRYSTAL STRUCTURE OF THE ZAP-70 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3359, 4qmyA, 0.6198, 3.07, 0.222, 287, 243, MST3 IN COMPLEX WITH STAUROSPORINE
3360, 3nczB, 0.6198, 4.06, 0.220, 379, 264, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT 2H-ISOQUINOLIN-1-ONE INHIBITOR
3361, 3cblA, 0.6198, 3.52, 0.216, 356, 250, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
3362, 2yaaA, 0.6198, 3.55, 0.296, 300, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2 IN COMPLEX WITH ATP
3363, 2ckeA, 0.6198, 3.47, 0.297, 301, 249, HUMAN DEATH-ASSOCIATED DRP-1 KINASE IN COMPLEX WITH INHIBITOR
3364, 6ccfB, 0.6197, 2.95, 0.252, 262, 242, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
3365, 6b2qA, 0.6197, 2.88, 0.277, 261, 242, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3366, 5uplA, 0.6197, 3.29, 0.245, 290, 245, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTEFACE - 2 PEPTIDE: PAK4FL CDC42 - UNREFINED
3367, 5fxsA, 0.6197, 3.80, 0.175, 308, 257, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
3368, 3vo3A, 0.6197, 3.62, 0.225, 303, 253, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN VEGFR2 WITH IMIDAZO[1 2-B]PYRIDAZINE DERIVATIVE
3369, 3ii5B, 0.6197, 2.96, 0.224, 257, 241, THE COMPLEX OF WILD-TYPE B-RAF WITH PYRAZOLO PYRIMIDINE INHIBITOR
3370, 2ya9B, 0.6197, 3.55, 0.300, 299, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
3371, 6d1zA, 0.6196, 3.26, 0.198, 290, 248, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE INHIBITOR 
3372, 3uodA, 0.6196, 3.45, 0.240, 266, 250, AURORA A IN COMPLEX WITH RPM1693
3373, 5kmlA, 0.6195, 3.29, 0.198, 296, 247, TRKA JM-KINASE WITH 1-(5-METHYL-3-PHENYL-12-OXAZOL-4-YL)-3-[[2- (TRIFLUOROMETHYL)PHENYL]METHYL]UREA
3374, 5ia0B, 0.6195, 3.00, 0.193, 266, 244, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
3375, 4uwyB, 0.6195, 2.93, 0.264, 273, 242, FGFR1 APO STRUCTURE
3376, 4g9cA, 0.6195, 2.86, 0.225, 265, 240, HUMAN B-RAF KINASE DOMAIN BOUND TO A TYPE II PYRAZOLOPYRIDINE INHIBITOR
3377, 4dbnB, 0.6195, 2.96, 0.216, 263, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3378, 3q96B, 0.6195, 3.06, 0.211, 262, 242, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
3379, 2xkfA, 0.6195, 2.74, 0.229, 250, 240, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 2
3380, 4tyiA, 0.6194, 2.91, 0.264, 277, 242, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4
3381, 4f0fA, 0.6194, 3.32, 0.204, 276, 245, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM
3382, 3q4cB, 0.6194, 2.93, 0.228, 264, 241, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
3383, 3i6wB, 0.6194, 3.32, 0.307, 382, 244, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
3384, 2a27H, 0.6194, 3.47, 0.301, 304, 249, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3385, 1t46A, 0.6194, 3.53, 0.246, 297, 252, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C-KIT TYROSINE KINASE
3386, 1jktB, 0.6194, 3.14, 0.293, 276, 246, TETRAGONAL CRYSTAL FORM OF A CATALYTIC DOMAIN OF DEATH-ASSOCIATED PROTEIN KINASE
3387, 5lxmA, 0.6193, 3.29, 0.250, 266, 248, CRYSTAL STRUCTURE OF AURORA-A BOUND TO A HYDROCARBON-STAPLED PROTEOMIMETIC OF TPX2
3388, 5e1sA, 0.6193, 3.41, 0.216, 284, 250, THE CRYSTAL STRUCTURE OF INSR TYROSINE KINASE IN COMPLEX WITH THE INHIBITOR BI 885578
3389, 3ugcA, 0.6193, 3.14, 0.215, 274, 246, STRUCTURAL BASIS OF JAK2 INHIBITION BY THE TYPE II INHIBTOR NVP-BBT594
3390, 3lauA, 0.6193, 2.95, 0.244, 251, 242, CRYSTAL STRUCTURE OF AURORA2 KINASE IN COMPLEX WITH A GSK3BETA INHIBITOR
3391, 3h3cA, 0.6193, 3.00, 0.185, 263, 243, CRYSTAL STRUCTURE OF PYK2 IN COMPLEX WITH SULFOXIMINE- SUBSTITUTED TRIFLUOROMETHYLPYRIMIDINE ANALOG
3392, 3gvuA, 0.6193, 3.22, 0.232, 271, 246, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH GLEEVEC
3393, 2a27F, 0.6193, 3.40, 0.298, 303, 248, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3394, 5os4A, 0.6192, 3.25, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3395, 5o2cA, 0.6192, 3.79, 0.258, 368, 256, CRYSTAL STRUCTURE OF WNK3 KINASE AND CCT1 DIDOMAIN IN A UNPHOSPHORYLATED STATE
3396, 4ibmB, 0.6192, 3.67, 0.216, 294, 255, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
3397, 3wzeA, 0.6192, 3.62, 0.229, 298, 253, KDR IN COMPLEX WITH LIGAND SORAFENIB
3398, 2phkA, 0.6192, 3.29, 0.272, 277, 246, THE CRYSTAL STRUCTURE OF A PHOSPHORYLASE KINASE PEPTIDE SUBSTRATE COMPLEX: KINASE SUBSTRATE RECOGNITION
3399, 6d1yA, 0.6191, 3.27, 0.194, 300, 248, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 2;4-DICHLORO-N-(3-METHYL-1-PHENYL-1H-PYRAZOL-5-YL)BENZAMIDE INHIBITOR 
3400, 5os6A, 0.6191, 3.25, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3401, 5kbqA, 0.6191, 3.38, 0.220, 289, 246, PAK1 IN COMPLEX WITH BIS-ANILINO PYRIMIDINE INHIBITOR
3402, 4qnaA, 0.6191, 3.19, 0.221, 284, 244, MST3 IN COMPLEX WITH 2-(46-DIAMINO-135-TRIAZIN-2-YL)PHENOL
3403, 4pp7B, 0.6191, 3.15, 0.215, 274, 247, HIGHLY POTENT AND SELECTIVE 3-N-METHYLQUINAZOLINE-4(3H)-ONE BASED INHIBITORS OF B-RAFV600E KINASE
3404, 3up7A, 0.6191, 3.28, 0.250, 264, 248, AURORA A IN COMPLEX WITH YL1-038-09
3405, 2zm3C, 0.6191, 3.64, 0.181, 296, 254, COMPLEX STRUCTURE OF INSULIN-LIKE GROWTH FACTOR RECEPTOR AND ISOQUINOLINEDIONE INHIBITOR
3406, 6fnfA, 0.6190, 2.84, 0.191, 267, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH NVP-BHG712 
3407, 6d20A, 0.6190, 3.36, 0.193, 296, 249, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR IN COMPLEX WITH 5-(4-FLUOROPHENYL)THIENO[2;3-D]PYRIMIDIN-4(3H)-ONE AND 5-{[2;4- DICHLORO-5-(PYRIDIN-2-YL)BENZENE-1-CARBONYL]AMINO}-N-(2-HYDROXY-2- METHYLPROPYL)-1-PHENYL-1H-PYRAZOLE-3-CARBOXAMIDE INHIBITORS 
3408, 5ia3A, 0.6190, 2.78, 0.212, 275, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH PD173955
3409, 4wd5A, 0.6190, 3.31, 0.214, 307, 248, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH QL-X138
3410, 4qmzA, 0.6190, 3.09, 0.226, 286, 243, MST3 IN COMPLEX WITH SUNITINIB
3411, 4agcA, 0.6190, 3.58, 0.230, 304, 252, CRYSTAL STRUCTURE OF VEGFR2 (JUXTAMEMBRANE AND KINASE DOMAINS) IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-( 3-((E)-2-PYRIDIN-2-YL-VINYL)-1H-INDAZOL-6-YLSULFANYL)- BENZAMIDE)
3412, 3tv4B, 0.6190, 3.23, 0.214, 276, 248, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
3413, 2hznA, 0.6190, 3.24, 0.215, 272, 246, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AFG210
3414, 2a27G, 0.6190, 3.40, 0.298, 303, 248, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3415, 1z9xC, 0.6190, 3.54, 0.299, 303, 251, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3416, 1i44A, 0.6190, 3.43, 0.215, 282, 251, CRYSTALLOGRAPHIC STUDIES OF AN ACTIVATION LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
3417, 4rfzA, 0.6189, 3.29, 0.169, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-8-FLUORO-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5- (MORPHOLINE-4-CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3- PYRIDYL]PHENYL]ISOQUINOLIN-1-ONE
3418, 4r7hA, 0.6189, 3.69, 0.237, 308, 253, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX3397
3419, 5l8jA, 0.6188, 3.15, 0.233, 253, 245, AURORA-A KINASE DOMAIN IN COMPLEX WITH VNAR-D01 S93R
3420, 4wnpC, 0.6188, 3.10, 0.276, 271, 243, STRUCTURE OF ULK1 BOUND TO A POTENT INHIBITOR
3421, 4u0iA, 0.6188, 3.56, 0.250, 297, 252, CRYSTAL STRUCTURE OF KIT IN COMPLEX WITH PONATINIB
3422, 3nrmA, 0.6188, 3.20, 0.239, 263, 247, IMIDAZO[12-A]PYRAZINE-BASED AURORA KINASE INHIBITORS
3423, 3fdnA, 0.6188, 3.11, 0.243, 261, 247, STRUCTURE-BASED DRUG DESIGN OF NOVEL AURORA KINASE A INHIBITORS: STRUCTURE BASIS FOR POTENCY AND SPECIFICITY
3424, 1fpuB, 0.6188, 3.28, 0.215, 270, 247, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN IN COMPLEX WITH A SMALL MOLECULE INHIBITOR
3425, 5w7tA, 0.6187, 3.39, 0.237, 276, 249, STRUCTURE OF PHOSPHORYLATED WNK1 
3426, 5l6wL, 0.6187, 3.38, 0.220, 290, 245, STRUCTURE OF THE LIMK1-ATPGAMMAS-CFL1 COMPLEX
3427, 5dg5B, 0.6187, 3.45, 0.221, 297, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
3428, 4ibmA, 0.6187, 3.88, 0.202, 301, 258, CRYSTAL STRUCTURE OF INSULIN RECEPTOR KINASE DOMAIN IN COMPLEX WITH AN INHIBITOR IRFIN-1
3429, 3eqrB, 0.6187, 3.25, 0.211, 271, 246, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
3430, 2a27B, 0.6187, 3.48, 0.301, 303, 249, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3431, 4rt7A, 0.6186, 3.37, 0.258, 274, 248, CRYSTAL STRUCTURE OF FLT3 WITH A SMALL MOLECULE INHIBITOR
3432, 4cegA, 0.6186, 3.25, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA A 122-403 C290A C393A BOUND TO ADP
3433, 3r21A, 0.6186, 3.10, 0.241, 254, 245, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
3434, 3ha6A, 0.6186, 3.26, 0.248, 263, 246, CRYSTAL STRUCTURE OF AURORA A IN COMPLEX WITH TPX2 AND COMPOUND 10
3435, 3dfaA, 0.6186, 3.62, 0.272, 265, 254, CRYSTAL STRUCTURE OF KINASE DOMAIN OF CALCIUM-DEPENDENT PROTEIN KINASE CGD3_920 FROM CRYPTOSPORIDIUM PARVUM
3436, 2e9vA, 0.6186, 3.11, 0.254, 268, 244, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
3437, 6gt1A, 0.6185, 3.14, 0.231, 267, 247, NEK7 BOUND TO PURINE INHIBITOR 
3438, 3vheA, 0.6185, 3.62, 0.229, 303, 253, CRYSTAL STRUCTURE OF HUMAN VEGFR2 KINASE DOMAIN WITH A NOVEL PYRROLOPYRIMIDINE INHIBITOR.
3439, 3pixA, 0.6185, 3.00, 0.184, 268, 244, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-ISOPROPYL-7- (4-METHYL-PIPERAZIN-1-YL)-4-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-2H- PHTHALAZIN-1-ONE
3440, 3idpA, 0.6185, 2.87, 0.233, 255, 240, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
3441, 3ekkA, 0.6185, 3.29, 0.214, 285, 248, INSULIN RECEPTOR KINASE COMPLEXED WITH AN INHIBITOR
3442, 2ya9A, 0.6185, 3.50, 0.297, 299, 249, CRYSTAL STRUCTURE OF THE AUTOINHIBITED FORM OF MOUSE DAPK2
3443, 2a27C, 0.6185, 3.41, 0.298, 303, 248, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3444, 6cpfA, 0.6184, 3.03, 0.246, 259, 244, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP IN AN ACTIVE CONFORMATION 
3445, 5fxqA, 0.6184, 3.67, 0.176, 302, 255, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
3446, 5c9cA, 0.6184, 2.90, 0.226, 254, 239, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
3447, 4j8nC, 0.6184, 3.34, 0.253, 266, 249, AURORA A KINASE APO
3448, 4fieB, 0.6184, 3.17, 0.243, 300, 243, FULL-LENGTH HUMAN PAK4
3449, 4fieA, 0.6184, 3.17, 0.243, 300, 243, FULL-LENGTH HUMAN PAK4
3450, 3fzoA, 0.6184, 2.96, 0.186, 262, 242, CRYSTAL STRUCTURE OF PYK2-APO PROLINE-RICH TYROSINE KINASE
3451, 3dpkA, 0.6184, 3.38, 0.243, 279, 247, CFMS TYROSINE KINASE IN COMPLEX WITH A PYRIDOPYRIMIDINONE INHIBITOR
3452, 2x4zA, 0.6184, 3.32, 0.246, 290, 244, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH PF-03758309
3453, 1t45A, 0.6184, 3.64, 0.242, 331, 252, STRUCTURAL BASIS FOR THE AUTOINHIBITION AND STI-571 INHIBITION OF C- KIT TYROSINE KINASE
3454, 6b2qD, 0.6183, 2.97, 0.276, 259, 243, DUAL INHIBITION OF THE ESSENTIAL PROTEIN KINASES A AND B IN MYCOBACTERIUM TUBERCULOSIS
3455, 5vfiA, 0.6183, 3.43, 0.172, 271, 250, BRUTON S TYROSINE KINASE (BTK) WITH GDC-0853
3456, 5ko1A, 0.6183, 3.41, 0.163, 265, 251, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 4.
3457, 4o0uA, 0.6183, 3.15, 0.235, 259, 247, CRYSTAL STRUCTURES OF HUMAN KINASE AURORA A
3458, 4i23A, 0.6183, 3.59, 0.213, 304, 253, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH DACOMITINIB (SOAKED)
3459, 3idpB, 0.6183, 2.81, 0.230, 256, 239, B-RAF V600E KINASE DOMAIN IN COMPLEX WITH AN AMINOISOQUINOLINE INHIBITOR
3460, 4xufB, 0.6182, 3.49, 0.244, 274, 250, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR QUIZARTINIB (AC220)
3461, 4ag8A, 0.6182, 3.67, 0.229, 296, 253, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH AXITINIB (AG-013736) (N-METHYL-2-(3-((E)-2-PYRIDIN-2-YL-VINYL)-1H- INDAZOL-6- YLSULFANYL)-BENZAMIDE)
3462, 3pyyA, 0.6182, 3.04, 0.216, 265, 241, DISCOVERY AND CHARACTERIZATION OF A CELL-PERMEABLE SMALL-MOLECULE C- ABL KINASE ACTIVATOR THAT BINDS TO THE MYRISTOYL BINDING SITE
3463, 2a2aB, 0.6182, 3.48, 0.293, 303, 249, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3464, 2a27E, 0.6182, 3.42, 0.298, 303, 248, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3465, 1uwjA, 0.6182, 3.00, 0.228, 264, 241, THE COMPLEX OF MUTANT V599E B-RAF AND BAY439006
3466, 5vgoA, 0.6181, 3.38, 0.169, 265, 249, BRUTON S TYROSINE KINASE (BTK) WITH COMPOUND G-744
3467, 5nclA, 0.6181, 4.15, 0.230, 418, 265, CRYSTAL STRUCTURE OF THE CBK1-MOB2 KINASE-COACTIVATOR COMPLEX WITH AN SSD1 PEPTIDE 
3468, 4zjiD, 0.6181, 3.14, 0.215, 280, 247, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3469, 5oq5A, 0.6180, 3.17, 0.284, 265, 243, STRUCTURE OF CHK1 8-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
3470, 4j8nB, 0.6180, 3.34, 0.253, 266, 249, AURORA A KINASE APO
3471, 4b6lA, 0.6180, 3.17, 0.289, 281, 246, DISCOVERY OF ORAL POLO-LIKE KINASE (PLK) INHIBITORS WITH ENHANCED SELECTIVITY PROFILE USING RESIDUE TARGETED DRUG DESIGN
3472, 2a27A, 0.6180, 3.43, 0.298, 304, 248, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 8 MONOMERS IN THE ASYMMETRIC UNIT
3473, 5walA, 0.6179, 3.52, 0.220, 286, 250, IDENTIFICATION OF AN IMIDAZOPYRIDINE SCAFFOLD TO GENERATE POTENT AND SELECTIVE TYK2 INHIBITORS THAT DEMONSTRATE ACTIVITY IN AN IN VIVO PSORIASIS MODEL
3474, 5kupA, 0.6179, 3.38, 0.169, 265, 249, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 9
3475, 4xlvA, 0.6179, 3.93, 0.206, 307, 257, CRYSTAL STRUCTURE OF THE ACTIVATED INSULIN RECEPTOR TYROSINE KINASE DIMER
3476, 4ot5A, 0.6179, 3.31, 0.173, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4-TERT-BUTYL-N- (3-{8-[4-(4-METHYL-PIPERAZINE-1-CARBONYL)-PHENYLAMINO]-IMIDAZO[12- A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
3477, 4jboA, 0.6179, 3.27, 0.245, 266, 249, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
3478, 4j8nA, 0.6179, 3.35, 0.253, 266, 249, AURORA A KINASE APO
3479, 3lvpB, 0.6179, 3.62, 0.173, 295, 255, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3480, 3fzpA, 0.6179, 2.79, 0.187, 259, 240, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH ATPGS
3481, 5dr9A, 0.6178, 3.12, 0.241, 257, 245, AURORA A KINASE IN COMPLEX WITH AA29 AND JNJ-7706621 IN SPACE GROUP P6122
3482, 4rg0A, 0.6178, 3.30, 0.169, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 2-[8-FLUORO-2- [2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(4-METHYLPIPERAZIN-1-YL)-2- PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-1-OXO-34-DIHYDROISOQUINOLIN- 6-YL]-2-METHYL-PROPANENITRILE
3483, 4qmuA, 0.6178, 3.12, 0.222, 286, 243, MST3 IN COMPLEX WITH JNJ-7706621 4-({5-AMINO-1-[(26-DIFLUOROPHENYL) CARBONYL]-1H-124-TRIAZOL-3-YL}AMINO)BENZENESULFONAMIDE
3484, 4mwiA, 0.6178, 3.52, 0.166, 266, 253, CRYSTAL STRUCTURE OF THE HUMAN MLKL PSEUDOKINASE DOMAIN
3485, 3zclA, 0.6178, 3.40, 0.213, 289, 249, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-3-(1-(1H-PYRROLO(23-B)PYRIDIN-3-YL)ETHYL)-N-ISOPROPYL-( 124)TRIAZOLO(43-B)PYRIDAZIN-6-AMINE
3486, 3kulA, 0.6178, 3.05, 0.219, 267, 242, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 8 (EPHA8)
3487, 1m52B, 0.6178, 3.33, 0.224, 272, 246, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
3488, 6dkiA, 0.6177, 3.21, 0.204, 279, 245, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 19. 
3489, 4j8nD, 0.6177, 3.26, 0.250, 265, 248, AURORA A KINASE APO
3490, 3ue4B, 0.6177, 3.32, 0.216, 268, 245, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
3491, 3dlsD, 0.6177, 3.18, 0.234, 284, 244, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3492, 6bl8B, 0.6176, 3.26, 0.224, 268, 245, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
3493, 5x02A, 0.6176, 3.38, 0.250, 305, 248, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR FF- 10101
3494, 5jzjB, 0.6176, 3.04, 0.325, 261, 240, CRYSTAL STRUCTURE OF DCLK1-KD IN COMPLEX WITH AMPPN
3495, 4f1oA, 0.6176, 3.28, 0.202, 276, 243, CRYSTAL STRUCTURE OF THE L1180T MUTANT ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM BOUND TO APPCP
3496, 3qriA, 0.6176, 3.39, 0.215, 275, 247, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
3497, 2xirA, 0.6176, 3.68, 0.225, 296, 253, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH PF-00337210 (N2-DIMETHYL-6-(7-(2-MORPHOLINOETHOXY) QUINOLIN-4-YLOXY)BENZOFURAN-3-CARBOXAMIDE)
3498, 5o23B, 0.6175, 3.32, 0.242, 278, 248, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
3499, 5hu3A, 0.6175, 3.42, 0.280, 266, 246, DROSOPHILA CAMKII-D136N IN COMPLEX WITH A PHOSPHORYLATED FRAGMENT OF THE EAG POTASSIUM CHANNEL AND MG2+/ADP
3500, 4uzhA, 0.6175, 2.99, 0.244, 251, 242, SAR156497 AN EXQUISITELY SELECTIVE INHIBITOR OF AURORA KINASES
3501, 4r7iA, 0.6175, 3.55, 0.239, 290, 251, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR GLEEVEC
3502, 4mxcA, 0.6175, 3.42, 0.221, 290, 249, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3503, 4jajA, 0.6175, 3.34, 0.253, 265, 249, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH BENZO[C][1 8]NAPHTHYRIDIN-6(5H)-ONE
3504, 4f1mA, 0.6175, 3.23, 0.201, 278, 244, CRYSTAL STRUCTURE OF THE G1179S ROCO4 KINASE DOMAIN BOUND TO APPCP FROM D. DISCOIDEUM.
3505, 3tv6B, 0.6175, 3.25, 0.214, 276, 248, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
3506, 2wqmA, 0.6175, 2.77, 0.225, 258, 240, STRUCTURE OF APO HUMAN NEK7
3507, 1ia8A, 0.6175, 3.18, 0.272, 272, 243, THE 1.7 A CRYSTAL STRUCTURE OF HUMAN CELL CYCLE CHECKPOINT KINASE CHK1
3508, 6fnhB, 0.6174, 3.14, 0.192, 271, 245, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
3509, 4otqA, 0.6174, 3.32, 0.173, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 1-[5-[3-(7-TERT- BUTYL-4-OXO-QUINAZOLIN-3-YL)-2-METHYL-PHENYL]-1-METHYL-2-OXO-3- PYRIDYL]-3-METHYL-UREA
3510, 4dedA, 0.6174, 3.39, 0.253, 265, 249, AURORA A IN COMPLEX WITH YL1-038-21
3511, 3rhkB, 0.6174, 3.84, 0.211, 299, 256, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
3512, 2z2wA, 0.6174, 3.01, 0.187, 260, 241, HUMAND WEE1 KINASE COMPLEXED WITH INHIBITOR PF0335770
3513, 2xnnA, 0.6174, 2.78, 0.229, 251, 240, STRUCTURE OF NEK2 BOUND TO CCT242430
3514, 2a2aA, 0.6174, 3.50, 0.301, 304, 249, HIGH-RESOLUTION CRYSTALLOGRAPHIC ANALYSIS OF THE AUTOINHIBITED CONFORMATION OF A HUMAN DEATH-ASSOCIATED PROTEIN KINASE
3515, 5dg5A, 0.6173, 3.49, 0.221, 297, 249, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP- 4157
3516, 4y95A, 0.6173, 3.45, 0.172, 266, 250, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3517, 4eheB, 0.6173, 3.11, 0.211, 276, 246, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
3518, 3v5qB, 0.6173, 3.21, 0.208, 265, 245, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
3519, 3k5vB, 0.6173, 3.30, 0.220, 283, 245, STRUCTURE OF ABL KINASE IN COMPLEX WITH IMATINIB AND GNF-2
3520, 5orlA, 0.6172, 3.27, 0.250, 264, 248, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3521, 4pmsA, 0.6172, 3.20, 0.214, 283, 243, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 4-NAPHTHALEN-1-YL- 1-[(5-PHENYL-124-OXADIAZOL-3-YL)METHYL]-1H-PYRROLO[32-C]PYRIDINE- 2-CARBOXYLIC ACID
3522, 4b8lA, 0.6172, 2.90, 0.195, 249, 241, AURORA B KINASE P353G MUTANT
3523, 3qrjB, 0.6172, 3.40, 0.211, 265, 247, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
3524, 2rl5A, 0.6172, 3.17, 0.224, 294, 245, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A 23-DIHYDRO-14-BENZOXAZINE INHIBITOR
3525, 2etmA, 0.6172, 3.02, 0.216, 262, 245, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3526, 1z9xB, 0.6172, 3.50, 0.301, 303, 249, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3527, 5ukfA, 0.6171, 3.58, 0.181, 322, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
3528, 5njzA, 0.6171, 2.75, 0.204, 273, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1G
3529, 5kmiA, 0.6171, 3.24, 0.200, 300, 245, TRKA JM-KINASE WITH 1-(9{H}-FLUOREN-9-YL)-3-(2-METHYL-4-PHENYL- PYRIMIDIN-5-YL)UREA
3530, 4y93A, 0.6171, 3.50, 0.179, 429, 251, CRYSTAL STRUCTURE OF THE PH-TH-KINASE CONSTRUCT OF BRUTON S TYROSINE KINASE (BTK)
3531, 3fzrA, 0.6171, 2.95, 0.186, 261, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-431396
3532, 2wgjA, 0.6171, 3.41, 0.213, 289, 249, X-RAY STRUCTURE OF PF-02341066 BOUND TO THE KINASE DOMAIN OF C-MET
3533, 2oh4A, 0.6171, 3.30, 0.223, 297, 247, CRYSTAL STRUCTURE OF VEGFR2 WITH A BENZIMIDAZOLE-UREA INHIBITOR
3534, 1m52A, 0.6171, 3.29, 0.220, 271, 245, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH PD173955
3535, 6d22A, 0.6170, 3.21, 0.198, 299, 247, CRYSTAL STRUCTURE OF TYROSINE-PROTEIN KINASE RECEPTOR 
3536, 5vioB, 0.6170, 3.16, 0.300, 271, 243, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3537, 5gjdA, 0.6170, 2.69, 0.251, 292, 235, CRYSTAL STRUCTURE OF HUMAN TAK1/TAB1 FUSION PROTEIN IN COMPLEX WITH LIGAND 2
3538, 4y95D, 0.6170, 3.35, 0.173, 265, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3539, 4rfyA, 0.6170, 3.32, 0.173, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6- (DIMETHYLAMINO)-2-[2-(HYDROXYMETHYL)-3-[1-METHYL-5-[[5-(MORPHOLINE-4- CARBONYL)-2-PYRIDYL]AMINO]-6-OXO-3-PYRIDYL]PHENYL]-34- DIHYDROISOQUINOLIN-1-ONE
3540, 2r2pA, 0.6170, 3.17, 0.209, 283, 244, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 5 (EPHA5)
3541, 1z9xA, 0.6170, 3.51, 0.301, 303, 249, HUMAN DRP-1 KINASE W305S S308A D40 MUTANT CRYSTAL FORM WITH 3 MONOMERS IN THE ASYMMETRIC UNIT
3542, 1x8bA, 0.6170, 3.08, 0.182, 259, 242, STRUCTURE OF HUMAN WEE1A KINASE: KINASE DOMAIN COMPLEXED WITH INHIBITOR PD0407824
3543, 5objA, 0.6169, 3.23, 0.244, 260, 246, AURORA A KINASE IN COMPLEX WITH 2-(3-FLUOROPHENYL)QUINOLINE-4- CARBOXYLIC ACID AND ATP
3544, 5hvjB, 0.6169, 3.30, 0.221, 284, 244, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
3545, 4otrA, 0.6169, 3.32, 0.169, 263, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 6-CYCLOPROPYL-2- [3-[5-[[5-(4-ETHYLPIPERAZIN-1-YL)-2-PYRIDYL]AMINO]-1-METHYL-6-OXO-3- PYRIDYL]-2-(HYDROXYMETHYL)PHENYL]-8-FLUORO-ISOQUINOLIN-1-ONE
3546, 3rhkA, 0.6169, 3.68, 0.206, 298, 253, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF C-MET KINASE IN COMPLEX WITH ARQ 197
3547, 3cr0A, 0.6169, 2.93, 0.187, 257, 240, WEE1 KINASE COMPLEX WITH INHIBITOR PD259_809
3548, 2f57B, 0.6169, 3.23, 0.243, 299, 243, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 5
3549, 5ia4A, 0.6168, 3.29, 0.206, 269, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH FORETINIB (XL880)
3550, 4tzrA, 0.6168, 3.87, 0.283, 461, 258, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1561
3551, 6dkbA, 0.6167, 3.02, 0.198, 272, 243, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 10B. 
3552, 4f65A, 0.6167, 3.25, 0.244, 279, 246, CRYSTAL STRUCTURE OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN IN COMPLEX WITH COMPOUND 8
3553, 3ocsA, 0.6167, 3.38, 0.169, 264, 249, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH INHIBITOR CGI1746
3554, 2j50B, 0.6167, 2.85, 0.254, 249, 240, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3555, 2j50A, 0.6167, 2.85, 0.254, 249, 240, STRUCTURE OF AURORA-2 IN COMPLEX WITH PHA-739358
3556, 5xgnA, 0.6166, 3.43, 0.221, 302, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/C797S IN COMPLEX WITH GO6976
3557, 5ugbA, 0.6166, 3.50, 0.215, 307, 251, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN IN COMPLEX WITH 4-(4-{[2- {[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9-(PROPAN-2-YL)-9H-PURIN-6- YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
3558, 4zy4A, 0.6166, 3.11, 0.228, 288, 241, CRYSTAL STRUCTURE OF P21 ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 4
3559, 4ks7A, 0.6166, 3.13, 0.244, 286, 242, PAK6 KINASE DOMAIN IN COMPLEX WITH PF-3758309
3560, 4c7tA, 0.6166, 3.06, 0.225, 259, 244, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
3561, 3f69B, 0.6166, 3.26, 0.226, 282, 248, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
3562, 2e9vB, 0.6166, 3.14, 0.262, 268, 244, STRUCTURE OF H-CHK1 COMPLEXED WITH A859017
3563, 6bu6A, 0.6165, 3.66, 0.184, 322, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
3564, 5knjB, 0.6165, 3.09, 0.163, 259, 245, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
3565, 5kmkA, 0.6165, 3.30, 0.200, 304, 245, TRKA JM-KINASE WITH 2-FLUORO-{N}-[2-(4-FLUOROPHENYL)-6-METHYL-3- PYRIDYL]-4-(TRIFLUOROMETHYL)BENZAMIDE
3566, 5eobA, 0.6165, 3.41, 0.214, 288, 248, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
3567, 4yjnA, 0.6165, 3.76, 0.281, 460, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1639
3568, 4qmtA, 0.6165, 3.23, 0.221, 284, 244, MST3 IN COMPLEX WITH HESPERADIN
3569, 4m67A, 0.6165, 3.41, 0.164, 264, 250, CRYSTAL STRUCTURE OF THE HUMAN MLKL KINASE-LIKE DOMAIN
3570, 2dylA, 0.6165, 2.78, 0.230, 272, 239, CRYSTAL STRUCTURE OF HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 7 ACTIVATED MUTANT (S287D T291D)
3571, 6cnxA, 0.6164, 3.67, 0.180, 322, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
3572, 5dr2A, 0.6164, 3.33, 0.242, 264, 248, AURORA A KINASE IN COMPLEX WITH AA30 AND ATP IN SPACE GROUP P6122
3573, 2p2hA, 0.6164, 3.17, 0.234, 292, 244, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDINYL-TRIAZINE INHIBITOR
3574, 2hziA, 0.6164, 3.34, 0.220, 268, 245, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
3575, 1rqqA, 0.6164, 3.85, 0.211, 294, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH THE SH2 DOMAIN OF APS
3576, 5j87A, 0.6163, 3.31, 0.173, 263, 248, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
3577, 4wa9B, 0.6163, 3.27, 0.220, 276, 245, THE CRYSTAL STRUCTURE OF HUMAN ABL1 WILD TYPE KINASE DOMAIN IN COMPLEX WITH AXITINIB
3578, 4bbeD, 0.6163, 3.44, 0.217, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3579, 4bbeA, 0.6163, 3.45, 0.217, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3580, 2j0kA, 0.6163, 3.10, 0.218, 598, 243, CRYSTAL STRUCTURE OF A FRAGMENT OF FOCAL ADHESION KINASE CONTAINING THE FERM AND KINASE DOMAINS.
3581, 1p14A, 0.6163, 3.44, 0.217, 287, 249, CRYSTAL STRUCTURE OF A CATALYTIC-LOOP MUTANT OF THE INSULIN RECEPTOR TYROSINE KINASE
3582, 6cswC, 0.6162, 3.58, 0.177, 319, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
3583, 4rx5A, 0.6162, 3.41, 0.169, 265, 249, BRUTON S TYROSINE KINASE (BTK) WITH PYRIDAZINONE COMPOUND 23
3584, 4bbfC, 0.6162, 3.43, 0.217, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3585, 3qrkA, 0.6162, 3.17, 0.221, 270, 244, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DP- 987
3586, 6fngA, 0.6161, 2.84, 0.196, 277, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AN ISOMER OF NVP-BHG712 
3587, 6bqqA, 0.6161, 3.23, 0.249, 271, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH BI2526
3588, 5fxrA, 0.6161, 3.81, 0.176, 300, 256, IGFR-1R COMPLEX WITH A PYRIMIDINE INHIBITOR.
3589, 5dr6A, 0.6161, 3.08, 0.246, 257, 244, AURORA A KINASE IN COMPLEX WITH AA30 AND JNJ-7706621 IN SPACE GROUP P6122
3590, 4rvtA, 0.6161, 3.00, 0.241, 281, 241, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
3591, 4li5A, 0.6161, 3.83, 0.211, 306, 256, EGFR-K IN COMPLEX WITH N-[3-[[5-CHLORO-4-(1H-INDOL-3-YL)PYRIMIDIN-2- YL]AMINO]-4-METHOXY-PHENYL] PROP-2-ENAMIDE
3592, 4hw7A, 0.6161, 3.54, 0.240, 289, 250, CRYSTAL STRUCTURE OF FMS KINASE DOMAIN WITH A SMALL MOLECULAR INHIBITOR PLX647-OME
3593, 4bbeB, 0.6161, 3.46, 0.221, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3594, 3lcdA, 0.6161, 3.25, 0.241, 290, 245, INHIBITOR BOUND TO A DFG-IN STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
3595, 1ir3A, 0.6161, 3.84, 0.207, 300, 256, PHOSPHORYLATED INSULIN RECEPTOR TYROSINE KINASE IN COMPLEX WITH PEPTIDE SUBSTRATE AND ATP ANALOG
3596, 5w7tB, 0.6160, 3.45, 0.241, 276, 249, STRUCTURE OF PHOSPHORYLATED WNK1 
3597, 5ar2B, 0.6160, 3.29, 0.207, 285, 246, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
3598, 5ajqA, 0.6160, 3.41, 0.217, 280, 249, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
3599, 4u8zA, 0.6160, 3.45, 0.222, 289, 248, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06447475)
3600, 4bbeC, 0.6160, 3.48, 0.221, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3601, 3tudA, 0.6160, 2.94, 0.191, 256, 241, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH N-(4-METHYL-3-(8-METHYL-7- OXO-2-(PHENYLAMINO)-78-DIHYDROPYRIDO[23-D]PYRIMIDIN-6-YL)PHENYL)-3- (TRIFLUOROMETHYL)BENZAMIDE
3602, 3ku2A, 0.6160, 3.74, 0.281, 457, 256, CRYSTAL STRUCTURE OF INACTIVATED FORM OF CDPK1 FROM TOXOPLASMA GONDII TGME49.101440
3603, 2xk4A, 0.6160, 2.84, 0.224, 252, 241, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 17
3604, 2wtwA, 0.6160, 3.03, 0.243, 256, 243, AURORA-A INHIBITOR STRUCTURE (2ND CRYSTAL FORM)
3605, 2hz4A, 0.6160, 3.24, 0.234, 262, 244, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
3606, 6bruA, 0.6159, 3.66, 0.180, 322, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3607, 5vioD, 0.6159, 3.22, 0.288, 271, 243, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3608, 5ia5A, 0.6159, 3.30, 0.206, 273, 247, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH GOLVATINIB (E7050)
3609, 5e8xA, 0.6159, 3.54, 0.219, 304, 247, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F) IN COMPLEX WITH STAUROSPORINE
3610, 4zogB, 0.6159, 3.21, 0.225, 268, 244, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
3611, 4y95B, 0.6159, 3.41, 0.177, 266, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3612, 4lg4E, 0.6159, 3.08, 0.242, 275, 244, STRUCTURAL BASIS FOR AUTOACTIVATION OF HUMAN MST2 KINASE AND ITS REGULATION BY RASSF5
3613, 4bbfB, 0.6159, 3.45, 0.217, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3614, 1ol7A, 0.6159, 3.33, 0.239, 261, 247, STRUCTURE OF HUMAN AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288
3615, 6brcA, 0.6158, 3.23, 0.257, 265, 245, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
3616, 5kmmA, 0.6158, 3.25, 0.200, 301, 245, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(1- NAPHTHYL)UREA
3617, 3q4cA, 0.6158, 3.00, 0.228, 264, 241, CRYSTAL STRUCTURE OF WILD TYPE BRAF KINASE DOMAIN IN COMPLEX WITH ORGANOMETALLIC INHIBITOR CNS292
3618, 2g2hB, 0.6158, 3.43, 0.223, 272, 247, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3619, 1gagA, 0.6158, 3.86, 0.207, 300, 256, CRYSTAL STRUCTURE OF THE INSULIN RECEPTOR KINASE IN COMPLEX WITH A BISUBSTRATE INHIBITOR
3620, 5uoxA, 0.6157, 3.09, 0.299, 263, 241, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3621, 5u9dA, 0.6157, 3.43, 0.181, 271, 249, DISCOVERY OF A POTENT BTK INHIBITOR WITH A NOVEL BINDING MODE USING PARALLEL SELECTIONS WITH A DNA-ENCODED CHEMICAL LIBRARY
3622, 5hvjA, 0.6157, 3.33, 0.216, 283, 245, CRYSTAL STRUCTURE OF LIMK1 D460N MUTANT IN COMPLEX WITH AMP-PNP
3623, 5htiA, 0.6157, 3.44, 0.217, 290, 249, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH LXM108
3624, 4r5yB, 0.6157, 3.03, 0.220, 254, 241, THE COMPLEX STRUCTURE OF BRAF V600E KINASE DOMAIN WITH A NOVEL BRAF INHIBITOR
3625, 4m97A, 0.6157, 3.84, 0.276, 465, 257, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM NEOSPORA CANINUM
3626, 4bn1A, 0.6157, 3.36, 0.243, 261, 247, CRYSTAL STRUCTURE OF V174M MUTANT OF AURORA-A KINASE
3627, 4ap7A, 0.6157, 3.43, 0.209, 289, 249, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( (6-(4- FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN-3-YL)METHYL) PHENOL
3628, 2x7fA, 0.6157, 2.76, 0.227, 276, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2- AND NCK-INTERACTING KINASE WITH WEE1CHK1 INHIBITOR
3629, 2g2hA, 0.6157, 3.53, 0.222, 272, 248, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3630, 2e2bA, 0.6157, 3.16, 0.218, 270, 243, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
3631, 6babA, 0.6156, 3.54, 0.304, 290, 247, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
3632, 5nkaA, 0.6156, 2.83, 0.196, 271, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2G
3633, 3zxzA, 0.6156, 3.44, 0.213, 289, 249, X-RAY STRUCTURE OF PF-04217903 BOUND TO THE KINASE DOMAIN OF C-MET
3634, 3m11A, 0.6156, 3.07, 0.246, 256, 244, CRYSTAL STRUCTURE OF AURORA A KINASE COMPLEXED WITH INHIBITOR
3635, 2j0lA, 0.6156, 3.12, 0.213, 274, 244, CRYSTAL STRUCTURE OF A THE ACTIVE CONFORMATION OF THE KINASE DOMAIN OF FOCAL ADHESION KINASE WITH A PHOSPHORYLATED ACTIVATION LOOP.
3636, 6gl9A, 0.6155, 3.55, 0.208, 292, 250, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
3637, 5os2A, 0.6155, 3.16, 0.241, 261, 245, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH AN ALLOSTERICALLY BINDING FRAGMENT
3638, 5kvtA, 0.6155, 3.40, 0.196, 287, 250, THE STRUCTURE OF TRKA KINASE DOMAIN BOUND TO THE INHIBITOR ENTRECTINIB
3639, 4otfA, 0.6155, 3.40, 0.169, 262, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH GDC0834
3640, 4i6hA, 0.6155, 3.34, 0.255, 285, 247, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE ALPHA-SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3641, 3priA, 0.6155, 3.16, 0.230, 264, 243, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3642, 2gdoA, 0.6155, 3.11, 0.269, 269, 242, 4-(AMINOALKYLAMINO)-3-BENZIMIDAZOLE-QUINOLINONES AS POTENT CHK1 INHIBITORS
3643, 2g2iA, 0.6155, 3.27, 0.220, 271, 245, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3644, 2e9pA, 0.6155, 3.30, 0.252, 269, 246, STRUCTURE OF H-CHK1 COMPLEXED WITH A771129
3645, 5xvfA, 0.6154, 3.41, 0.245, 289, 245, CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INHIBITOR CZH062
3646, 4i5pA, 0.6154, 3.43, 0.254, 284, 248, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3647, 3priB, 0.6154, 3.16, 0.230, 264, 243, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3648, 2xruA, 0.6154, 3.12, 0.246, 253, 244, AURORA-A T288E COMPLEXED WITH PHA-828300
3649, 2gqgB, 0.6154, 3.43, 0.220, 276, 246, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
3650, 2brbA, 0.6154, 3.24, 0.272, 272, 243, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3651, 1yvjA, 0.6154, 3.60, 0.215, 288, 251, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN IN COMPLEX WITH A STAUROSPORINE ANALOGUE
3652, 6eqiC, 0.6153, 3.82, 0.206, 392, 252, STRUCTURE OF PINK1 BOUND TO UBIQUITIN
3653, 5vioA, 0.6153, 3.14, 0.302, 271, 242, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3654, 5v24B, 0.6153, 3.08, 0.295, 263, 241, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
3655, 5ng2B, 0.6153, 3.40, 0.202, 278, 247, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
3656, 5kbrB, 0.6153, 2.70, 0.218, 260, 234, PAK1 IN COMPLEX WITH 7-AZAINDOLE INHIBITOR
3657, 5ikwA, 0.6153, 3.58, 0.218, 297, 252, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3658, 4y95C, 0.6153, 3.39, 0.177, 266, 249, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF BRUTON S TYROSINE KINASE WITH MUTATIONS IN THE ACTIVATION LOOP
3659, 4byiA, 0.6153, 3.13, 0.246, 254, 244, AURORA A KINASE BOUND TO A HIGHLY SELECTIVE IMIDAZOPYRIDINE INHIBITOR
3660, 2xnpA, 0.6153, 2.86, 0.228, 253, 241, STRUCTURE OF NEK2 BOUND TO CCT244858
3661, 6dkgA, 0.6152, 3.12, 0.210, 276, 243, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 13B. 
3662, 5lwmA, 0.6152, 3.47, 0.201, 290, 249, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 4 (FM381)
3663, 5ia0C, 0.6152, 2.64, 0.203, 269, 237, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
3664, 5dpvA, 0.6152, 3.12, 0.238, 257, 244, AURORA A KINASE IN COMPLEX WITH AA35 AND JNJ-7706621 IN SPACE GROUP P6122
3665, 4pmmA, 0.6152, 3.27, 0.197, 285, 244, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR N-(3-CYCLOPROPYL- 1-PHENYL-1H-PYRAZOL-5-YL)-2-{4-[3-METHOXY-4-(4-METHYL-1H-IMIDAZOL-1- YL)PHENYL]-1H-123-TRIAZOL-1-YL}ACETAMIDE
3666, 4lmnA, 0.6152, 3.37, 0.220, 292, 250, CRYSTAL STRUCTURE OF MEK1 KINASE BOUND TO GDC0973
3667, 3et7A, 0.6152, 3.01, 0.182, 261, 242, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-2318841
3668, 6b16A, 0.6151, 3.02, 0.230, 285, 239, P21-ACTIVATED KINASE 1 IN COMPLEX WITH A 4-AZAINDOLE INHIBITOR
3669, 5x2kA, 0.6151, 3.25, 0.203, 314, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH WZ4003
3670, 5vilB, 0.6151, 3.14, 0.298, 271, 242, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3671, 5vedA, 0.6151, 3.34, 0.246, 289, 244, PAK4 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3672, 5l3aA, 0.6151, 3.57, 0.220, 290, 250, FRAGMENT-BASED DISCOVERY OF 6-ARYLINDAZOLE JAK INHIBITORS
3673, 4zjiC, 0.6151, 3.33, 0.222, 281, 248, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
3674, 4w8dA, 0.6151, 3.48, 0.222, 289, 248, CRYSTAL STRUCTURE OF MST3 WITH A PYRROLOPYRIMIDINE INHIBITOR (PF- 06454589).
3675, 4uxlA, 0.6151, 3.25, 0.245, 288, 245, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH PF-06463922
3676, 4qmmA, 0.6151, 3.47, 0.222, 288, 248, MST3 IN COMPLEX WITH AT-9283 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]- 1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
3677, 4mx9A, 0.6151, 3.79, 0.281, 459, 256, CDPK1 FROM NEOSPORA CANINUM IN COMPLEX WITH INHIBITOR UW1294
3678, 4jvgD, 0.6151, 2.95, 0.237, 262, 240, B-RAF KINASE IN COMPLEX WITH BIRB796
3679, 4e4mE, 0.6151, 3.51, 0.228, 296, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3680, 4aoiA, 0.6151, 3.46, 0.209, 289, 249, CRYSTAL STRUCTURE OF C-MET KINASE DOMAIN IN COMPLEX WITH 4-( 3-((1H- PYRROLO(23-B)PYRIDIN-3-YL)METHYL)-(124)TRIAZOLO( 43-B)(124) TRIAZIN-6-YL)BENZONITRILE
3681, 3krlA, 0.6151, 3.37, 0.240, 281, 246, CFMS TYROSINE KINASE IN COMPLEX WITH 5-CYANO-FURAN-2-CARBOXYLIC ACID [4-(4-METHYL-PIPERAZIN-1-YL)-2-PIPERIDIN-1-YL-PHENYL]-AMIDE
3682, 2clqA, 0.6151, 3.04, 0.293, 263, 239, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3683, 5vilA, 0.6150, 3.12, 0.299, 271, 241, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3684, 5obrA, 0.6150, 3.07, 0.243, 255, 243, AURORA A KINASE IN COMPLEX WITH 2-(3-CHLORO-5-FLUOROPHENYL)QUINOLINE- 4-CARBOXYLIC ACID AND JNJ-7706621
3685, 4yc8B, 0.6150, 3.30, 0.214, 264, 243, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
3686, 4nzwB, 0.6150, 3.11, 0.214, 266, 243, CRYSTAL STRUCTURE OF STK25-MO25 COMPLEX
3687, 3zbxA, 0.6150, 3.44, 0.217, 282, 249, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR 6- ((6-(4-FLUOROPHENYL)-(124)TRIAZOLO(43-B)(124)TRIAZIN- 3-YL)METHYL)QUINOLINE.
3688, 3op5A, 0.6150, 3.80, 0.176, 320, 256, HUMAN VACCINIA-RELATED KINASE 1
3689, 3og7B, 0.6150, 3.07, 0.242, 254, 240, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX4032
3690, 3cohB, 0.6150, 2.89, 0.246, 247, 240, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3691, 5vioC, 0.6149, 3.07, 0.295, 271, 241, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 13)
3692, 4q2aA, 0.6149, 3.30, 0.243, 271, 247, WNK1: A CHLORIDE SENSOR VIA AUTOPHOSPHORYLATION
3693, 4jvgA, 0.6149, 2.95, 0.237, 262, 240, B-RAF KINASE IN COMPLEX WITH BIRB796
3694, 3h0zA, 0.6149, 2.86, 0.254, 248, 240, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
3695, 2fumC, 0.6149, 2.77, 0.237, 254, 240, CATALYTIC DOMAIN OF PROTEIN KINASE PKNB FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH MITOXANTRONE
3696, 5uwdA, 0.6148, 3.03, 0.198, 271, 243, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH THE COVALENT INHIBITOR CO-1686
3697, 5lwnA, 0.6148, 3.48, 0.209, 290, 249, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 5 (FM409)
3698, 5i9vA, 0.6148, 3.07, 0.193, 279, 243, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH AGS
3699, 4twpB, 0.6148, 3.36, 0.212, 271, 245, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
3700, 4mxaA, 0.6148, 3.79, 0.281, 459, 256, CDPK1 FROM NEOSPORA CANINUM IN COMPLEX WITH INHIBITOR RM-1-132
3701, 4mneC, 0.6148, 3.40, 0.216, 260, 245, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3702, 4i6fA, 0.6148, 3.45, 0.254, 285, 248, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3703, 4hyiA, 0.6148, 3.07, 0.266, 269, 241, X-RAY CRYSTAL STRUCTURE OF COMPOUND 40 BOUND TO HUMAN CHK1 KINASE DOMAIN
3704, 4e4mA, 0.6148, 3.52, 0.228, 296, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3705, 3lctA, 0.6148, 3.23, 0.178, 308, 247, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3706, 3dlsC, 0.6148, 3.09, 0.236, 281, 242, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3707, 3comB, 0.6148, 3.29, 0.248, 279, 246, CRYSTAL STRUCTURE OF MST1 KINASE
3708, 6cd6A, 0.6147, 3.08, 0.253, 264, 241, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH GSK650394
3709, 5ia1A, 0.6147, 2.81, 0.201, 261, 239, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH MLN8054
3710, 4xv9A, 0.6147, 2.95, 0.221, 261, 240, B-RAF KINASE DOMAIN IN COMPLEX WITH PLX5568
3711, 4e6qA, 0.6147, 3.45, 0.225, 296, 249, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3712, 3v5pA, 0.6147, 3.87, 0.284, 450, 257, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1288
3713, 5i3oB, 0.6146, 3.71, 0.209, 302, 253, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3714, 4ytcA, 0.6146, 3.35, 0.230, 284, 248, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
3715, 4uy9B, 0.6146, 3.28, 0.271, 315, 247, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
3716, 4rioA, 0.6146, 3.31, 0.211, 285, 246, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE CARBOXAMIDE INHIBITOR
3717, 4gt5A, 0.6146, 3.23, 0.191, 290, 246, CRYSTAL STRUCTURE OF THE INACTIVE TRKA KINASE DOMAIN
3718, 3q32B, 0.6146, 3.52, 0.228, 294, 250, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
3719, 3cs9A, 0.6146, 3.24, 0.214, 264, 243, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
3720, 6cmmA, 0.6145, 3.69, 0.180, 318, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
3721, 5l6pA, 0.6145, 3.04, 0.211, 274, 242, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 6)
3722, 5i9uA, 0.6145, 2.94, 0.207, 281, 241, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
3723, 5cf4B, 0.6145, 3.48, 0.232, 291, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3724, 4xufA, 0.6145, 3.42, 0.246, 270, 248, CRYSTAL STRUCTURE OF THE FLT3 KINASE DOMAIN BOUND TO THE INHIBITOR QUIZARTINIB (AC220)
3725, 4pmpA, 0.6145, 3.35, 0.208, 280, 245, THE STRUCTURE OF TRKA KINASE BOUND TO THE INHIBITOR 1-CYCLOPROPYL-1- [3-(13-THIAZOL-2-YL)BENZYL]-3-[4-(TRIFLUOROMETHOXY)PHENYL]UREA
3726, 4ivaA, 0.6145, 3.51, 0.224, 290, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH THE INHIBITOR TRANS-4-[(8AS)- 2-[(1R)-1-HYDROXYETHYL]IMIDAZO[45-D]PYRROLO[23-B]PYRIDIN-1(8AH)- YL]CYCLOHEXANECARBONITRILE
3727, 4i6bA, 0.6145, 3.36, 0.255, 285, 247, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
3728, 3w2oA, 0.6145, 3.62, 0.196, 305, 250, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH TAK-285
3729, 3i6wG, 0.6145, 3.30, 0.299, 369, 241, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
3730, 3gqlC, 0.6145, 2.75, 0.265, 275, 238, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3731, 6gl9B, 0.6144, 3.48, 0.209, 291, 249, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 10 (FM475) 
3732, 5wr7A, 0.6144, 3.36, 0.194, 301, 247, CRYSTAL STRUCTURE OF TRK-A COMPLEXED WITH A SELECTIVE INHIBITOR CH7057288
3733, 4wg4A, 0.6144, 3.89, 0.284, 454, 257, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1613
3734, 4nwmA, 0.6144, 3.38, 0.169, 261, 248, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
3735, 4ksqB, 0.6144, 2.96, 0.218, 255, 239, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR 5B
3736, 4afeA, 0.6144, 2.83, 0.229, 253, 240, NEK2 BOUND TO HYBRID COMPOUND 21
3737, 3zhpC, 0.6144, 3.40, 0.205, 272, 249, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
3738, 3op5B, 0.6144, 3.83, 0.172, 319, 256, HUMAN VACCINIA-RELATED KINASE 1
3739, 3cohA, 0.6144, 2.90, 0.246, 247, 240, CRYSTAL STRUCTURE OF AURORA-A IN COMPLEX WITH A PENTACYCLIC INHIBITOR
3740, 2vz6B, 0.6144, 3.68, 0.288, 294, 250, STRUCTURE OF HUMAN CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE TYPE II ALPHA (CAMK2A) IN COMPLEX WITH INDIRUBIN E804
3741, 2clqB, 0.6144, 2.85, 0.304, 259, 237, STRUCTURE OF MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 2 5
3742, 6fnjB, 0.6143, 2.99, 0.199, 262, 241, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH AN ISOMER OF NVP-BHG712 
3743, 6fckA, 0.6143, 3.42, 0.272, 269, 246, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
3744, 6btwA, 0.6143, 3.68, 0.181, 317, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
3745, 5vilC, 0.6143, 3.08, 0.295, 271, 241, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3746, 5j87C, 0.6143, 3.36, 0.173, 261, 248, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
3747, 5g1xA, 0.6143, 3.30, 0.249, 262, 245, CRYSTAL STRUCTURE OF AURORA-A KINASE IN COMPLEX WITH N-MYC
3748, 5dosA, 0.6143, 3.26, 0.241, 259, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3749, 3zc5A, 0.6143, 3.47, 0.213, 289, 249, X-RAY STRUCTURE OF C-MET KINASE IN COMPLEX WITH INHIBITOR ( S)-6-(1-(6-(1-METHYL-1H-PYRAZOL-4-YL)-(124)TRIAZOLO(43- B)PYRIDAZIN-3-YL)ETHYL)QUINOLINE.
3750, 3d4qA, 0.6143, 3.09, 0.223, 264, 242, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3751, 6cadA, 0.6142, 2.63, 0.226, 249, 235, CRYSTAL STRUCTURE OF RAF KINASE DOMAIN BOUND TO THE INHIBITOR 2A
3752, 5w5qA, 0.6142, 3.17, 0.237, 291, 245, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
3753, 5nudA, 0.6142, 2.70, 0.257, 267, 237, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
3754, 5dt4A, 0.6142, 3.25, 0.241, 259, 245, AURORA A KINASE IN COMPLEX WITH AA35 AND ATP IN SPACE GROUP P6122
3755, 4zs0A, 0.6142, 3.23, 0.246, 257, 244, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO SB-6-OH
3756, 4kspB, 0.6142, 2.87, 0.218, 256, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
3757, 4e4mD, 0.6142, 3.51, 0.228, 296, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3758, 3mssA, 0.6142, 3.17, 0.227, 264, 242, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
3759, 3mj2A, 0.6142, 3.20, 0.163, 259, 245, X-RAY CRYSTAL STRUCTURE OF ITK COMPLEXED WITH INHIBITOR BMS-509744
3760, 2yexA, 0.6142, 3.23, 0.266, 269, 244, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
3761, 2q0nA, 0.6142, 3.38, 0.245, 293, 245, STRUCTURE OF HUMAN P21 ACTIVATING KINASE 4 (PAK4) IN COMPLEX WITH A CONSENSUS PEPTIDE
3762, 2jkmA, 0.6142, 2.95, 0.228, 260, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
3763, 5uvfA, 0.6141, 3.70, 0.181, 317, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
3764, 5mjbB, 0.6141, 3.23, 0.201, 278, 244, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
3765, 5cf5B, 0.6141, 3.48, 0.232, 294, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
3766, 4xeyA, 0.6141, 3.17, 0.222, 269, 243, CRYSTAL STRUCTURE OF AN SH2-KINASE DOMAIN CONSTRUCT OF C-ABL TYROSINE KINASE
3767, 4ewhB, 0.6141, 3.40, 0.206, 273, 248, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
3768, 4e4mB, 0.6141, 3.51, 0.228, 296, 250, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 30
3769, 3tt0B, 0.6141, 2.79, 0.265, 272, 238, CO-STRUCTURE OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 KINASE DOMAIN WITH 3-(26-DICHLORO-35-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1- YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA (BGJ398)
3770, 3q32A, 0.6141, 3.53, 0.227, 291, 251, STRUCTURE OF JANUS KINASE 2 WITH A PYRROLOTRIAZINE INHIBITOR
3771, 2g2fB, 0.6141, 3.33, 0.220, 264, 245, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3772, 1zltA, 0.6141, 3.16, 0.263, 272, 243, CRYSTAL STRUCTURE OF CHK1 COMPLEXED WITH A HYMENALDISINE ANALOG
3773, 5p9gA, 0.6140, 3.40, 0.173, 265, 248, STRUCTURE OF BTK WITH RN486
3774, 5p9fA, 0.6140, 3.41, 0.173, 266, 248, BTK IN COMPLEX WITH GDC-0834
3775, 5drdA, 0.6140, 3.22, 0.245, 259, 245, AURORA A KINASE IN COMPLEX WITH ATP IN SPACE GROUP P6122
3776, 4dhfB, 0.6140, 3.09, 0.243, 258, 243, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3777, 3vn9A, 0.6140, 3.84, 0.202, 291, 257, RIFINED CRYSTAL STRUCTURE OF NON-PHOSPHORYLATED MAP2K6 IN A PUTATIVE AUTO-INHIBITION STATE
3778, 3psdB, 0.6140, 3.11, 0.223, 264, 242, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
3779, 3ms9A, 0.6140, 3.24, 0.226, 265, 243, ABL KINASE IN COMPLEX WITH IMATINIB AND A FRAGMENT (FRAG1) IN THE MYRISTATE POCKET
3780, 3lvpC, 0.6140, 3.59, 0.183, 293, 252, CRYSTAL STRUCTURE OF BISPHOSPHORYLATED IGF1-R KINASE DOMAIN (2P) IN COMPLEX WITH A BIS-AZAINDOLE INHIBITOR
3781, 3i6wA, 0.6140, 3.22, 0.304, 369, 240, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
3782, 2w9fB, 0.6140, 3.21, 0.364, 261, 242, CRYSTAL STRUCTURE OF CDK4 IN COMPLEX WITH A D-TYPE CYCLIN
3783, 2c6eB, 0.6140, 2.73, 0.248, 246, 238, AURORA A KINASE ACTIVATED MUTANT (T287D) IN COMPLEX WITH A 5-AMINOPYRIMIDINYL QUINAZOLINE INHIBITOR
3784, 4zimB, 0.6139, 3.48, 0.228, 294, 250, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
3785, 4wg5A, 0.6139, 3.76, 0.282, 464, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1647
3786, 4tyeA, 0.6139, 2.88, 0.250, 292, 240, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
3787, 4r1vA, 0.6139, 3.43, 0.218, 289, 248, IDENTIFICATION AND OPTIMIZATION OF PYRIDAZINONES AS POTENT AND SELECTIVE C-MET KINASE INHIBITORS
3788, 4nwmB, 0.6139, 3.39, 0.173, 261, 248, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-809959 AKA 4-TERT-BUTYL-N-[2-ME THYL-3-(6-{[4- (MORPHOLINE-4-CARBONYL)PHENYL]AMINO}-9H- PURIN-2-YL)PHENYL]BENZAMIDE
3789, 3cd3A, 0.6139, 3.44, 0.219, 352, 247, CRYSTAL STRUCTURE OF PHOSPHORYLATED HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V-FES) IN COMPLEX WITH STAUROSPORINE AND A CONSENSUS PEPTIDE
3790, 2hz4B, 0.6139, 3.29, 0.217, 261, 244, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
3791, 5x1qA, 0.6138, 3.38, 0.182, 283, 247, PPKA-294 WITH ATP AND MNCL2
3792, 4o0vA, 0.6138, 3.27, 0.243, 290, 243, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3793, 4mneG, 0.6138, 3.51, 0.215, 259, 246, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3794, 3zzwA, 0.6138, 3.26, 0.179, 269, 246, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
3795, 3lcoA, 0.6138, 3.63, 0.240, 293, 250, INHIBITOR BOUND TO A DFG-OUT STRUCTURE OF THE KINASE DOMAIN OF CSF-1R
3796, 2hxqA, 0.6138, 3.08, 0.266, 272, 241, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2
3797, 6fnjA, 0.6137, 2.99, 0.199, 262, 241, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH AN ISOMER OF NVP-BHG712 
3798, 5i9wA, 0.6137, 2.78, 0.202, 267, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ANP
3799, 5hibA, 0.6137, 3.50, 0.201, 314, 249, EGFR KINASE DOMAIN MUTANT TMLR WITH A PYRAZOLOPYRIMIDINE INHIBITOR
3800, 4ytiA, 0.6137, 3.28, 0.224, 284, 246, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASE
3801, 4fk3B, 0.6137, 2.79, 0.236, 257, 237, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
3802, 4dbnA, 0.6137, 2.83, 0.214, 257, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN B-RAF WITH A [1 3]THIAZOLO[54-B]PYRIDINE DERIVATIVE
3803, 4brxA, 0.6137, 2.99, 0.231, 259, 242, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH A DIARYLAMINO-135-TRIAZINE INHIBITOR
3804, 3psbB, 0.6137, 3.28, 0.221, 264, 244, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
3805, 3ce3A, 0.6137, 3.30, 0.206, 293, 247, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOPYRIDINEPYRIDONE BASED INHIBITOR
3806, 3a7fA, 0.6137, 3.49, 0.222, 283, 248, HUMAN MST3 KINASE
3807, 2hxlA, 0.6137, 3.18, 0.264, 272, 242, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1
3808, 1ol5A, 0.6137, 3.27, 0.249, 263, 245, STRUCTURE OF AURORA-A 122-403 PHOSPHORYLATED ON THR287 THR288 AND BOUND TO TPX2 1-43
3809, 5mjbA, 0.6136, 3.23, 0.200, 276, 245, KINASE DOMAIN OF HUMAN EPHB1 G703C MUTANT COVALENTLY BOUND TO A QUINAZOLINE-BASED INHIBITOR
3810, 5hvkA, 0.6136, 3.28, 0.218, 297, 243, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
3811, 4ot6A, 0.6136, 3.42, 0.173, 265, 248, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH 4- METHANESULFONYL-N-(3-{8-[4-(MORPHOLINE-4-CARBONYL)-PHENYLAMINO]- IMIDAZO[12-A]PYRAZIN-6-YL}-PHENYL)-BENZAMIDE
3812, 3mssB, 0.6136, 3.12, 0.212, 264, 241, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
3813, 3fbvD, 0.6136, 3.26, 0.258, 422, 244, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3814, 5xzwB, 0.6135, 3.55, 0.309, 379, 249, CRYSTAL STRUCTURE OF RAD53 1-466
3815, 5ng3A, 0.6135, 3.59, 0.190, 283, 252, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
3816, 5hnvA, 0.6135, 3.38, 0.182, 283, 247, CRYSTAL STRUCTURE OF PPKA
3817, 5bmsA, 0.6135, 3.29, 0.247, 290, 243, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 4 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3818, 4z16B, 0.6135, 3.34, 0.212, 276, 245, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
3819, 4u6rA, 0.6135, 3.49, 0.256, 403, 246, CRYSTAL STRUCTURE OF HUMAN IRE1 CYTOPLASMIC DOMAINS IN COMPLEX WITH A SULFONAMIDE INHIBITOR.
3820, 4r3pA, 0.6135, 3.51, 0.205, 310, 249, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
3821, 4e3cD, 0.6135, 3.53, 0.233, 624, 249, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3822, 3w2qA, 0.6135, 3.39, 0.194, 307, 247, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH HKI-272
3823, 3ppkB, 0.6135, 3.21, 0.222, 264, 243, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
3824, 3jy9A, 0.6135, 3.28, 0.224, 282, 246, JANUS KINASE 2 INHIBITORS
3825, 3dlsE, 0.6135, 3.21, 0.235, 282, 243, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3826, 2vwxA, 0.6135, 3.38, 0.198, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3827, 6ccfA, 0.6134, 2.98, 0.246, 260, 240, CRYSTAL STRUCTURE OF THE HUMAN CAMKK1A IN COMPLEX WITH HESPERADIN
3828, 5h3qA, 0.6134, 3.26, 0.193, 302, 243, CRYSTAL STRUCTURE OF TRKA KINASE WITH LIGAND
3829, 4xliB, 0.6134, 3.36, 0.253, 264, 245, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
3830, 4u43A, 0.6134, 3.11, 0.230, 287, 243, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
3831, 4qmoA, 0.6134, 3.47, 0.215, 288, 247, MST3 IN COMPLEX WITH IMIDAZOLO-OXINDOLE PKR INHIBITOR C16
3832, 4o27B, 0.6134, 3.32, 0.216, 281, 245, CRYSTAL STRUCTURE OF MST3-MO25 COMPLEX WITH WIF MOTIF
3833, 4an2A, 0.6134, 3.66, 0.217, 282, 253, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
3834, 3omvA, 0.6134, 3.04, 0.224, 264, 241, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
3835, 3mssD, 0.6134, 3.12, 0.212, 264, 241, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
3836, 3mssC, 0.6134, 3.09, 0.228, 264, 241, ABL KINASE IN COMPLEX WITH IMATINIB AND FRAGMENT (FRAG2) IN THE MYRISTATE SITE
3837, 2v7aB, 0.6134, 3.42, 0.228, 268, 246, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
3838, 5vilD, 0.6133, 3.30, 0.288, 271, 243, CRYSTAL STRUCTURE OF ASK1 KINASE DOMAIN WITH A POTENT INHIBITOR (ANALOG 6)
3839, 5ct7A, 0.6133, 2.92, 0.218, 257, 239, BRAF IN COMPLEX WITH RAF265
3840, 4rzwB, 0.6133, 2.84, 0.219, 252, 237, CRYSTAL STRUCTURE OF BRAF (R509H) KINASE DOMAIN BOUND TO AZ628
3841, 4ewhA, 0.6133, 3.34, 0.206, 274, 247, CO-CRYSTAL STRUCTURE OF ACK1 WITH INHIBITOR
3842, 3qc4B, 0.6133, 3.11, 0.264, 278, 242, PDK1 IN COMPLEX WITH DFG-OUT INHIBITOR XXX
3843, 2yerA, 0.6133, 3.25, 0.266, 268, 244, SYNTHESIS AND EVALUATION OF TRIAZOLONES AS CHECKPOINT KINASE 1 INHIBITORS
3844, 2vwyA, 0.6133, 3.38, 0.202, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3845, 2etmB, 0.6133, 2.83, 0.229, 263, 240, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN COMPLEXED WITH 7H-PYRROLO [23-D] PYRIMIDINE DERIVATIVE
3846, 2br1A, 0.6133, 3.11, 0.261, 272, 241, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3847, 5cziA, 0.6132, 3.48, 0.201, 310, 249, EGFR L858R MUTANT IN COMPLEX WITH A SHC PEPTIDE SUBSTRATE
3848, 4zy6A, 0.6132, 3.02, 0.235, 284, 238, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 29
3849, 4ztrA, 0.6132, 2.93, 0.245, 249, 241, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1141
3850, 4jdiA, 0.6132, 3.39, 0.246, 289, 244, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
3851, 3v5tA, 0.6132, 3.91, 0.284, 460, 257, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1299
3852, 3psdA, 0.6132, 3.29, 0.222, 262, 243, NON-OXIME PYRAZOLE BASED INHIBITORS OF B-RAF KINASE
3853, 3fbvK, 0.6132, 3.31, 0.257, 422, 245, CRYSTAL STRUCTURE OF THE OLIGOMER FORMED BY THE KINASE-RIBONUCLEASE DOMAIN OF IRE1
3854, 2w1gA, 0.6132, 3.16, 0.239, 254, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3855, 2vx1A, 0.6132, 3.38, 0.198, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3856, 2vx0A, 0.6132, 3.29, 0.198, 273, 247, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3857, 2vwzA, 0.6132, 3.38, 0.202, 274, 248, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3858, 2j0mB, 0.6132, 2.84, 0.222, 257, 239, CRYSTAL STRUCTURE A TWO-CHAIN COMPLEX BETWEEN THE FERM AND KINASE DOMAINS OF FOCAL ADHESION KINASE.
3859, 5ng0B, 0.6131, 3.41, 0.211, 282, 246, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
3860, 5i3rB, 0.6131, 3.73, 0.209, 302, 253, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
3861, 4ksqA, 0.6131, 2.82, 0.218, 258, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR 5B
3862, 4eevA, 0.6131, 3.25, 0.212, 283, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH LY2801653
3863, 4e6qB, 0.6131, 3.46, 0.221, 296, 249, JAK2 KINASE (JH1 DOMAIN) TRIPLE MUTANT IN COMPLEX WITH COMPOUND 12
3864, 3w2pA, 0.6131, 3.48, 0.197, 308, 249, EGFR KINASE DOMAIN T790M/L858R MUTANT WITH COMPOUND 2
3865, 3sxfA, 0.6131, 3.78, 0.282, 452, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-89
3866, 2javA, 0.6131, 2.73, 0.256, 253, 238, HUMAN KINASE WITH PYRROLE-INDOLINONE LIGAND
3867, 4qmlA, 0.6130, 3.19, 0.222, 280, 243, MST3 IN COMPLEX WITH AMP-PNP
3868, 3v5qA, 0.6130, 3.20, 0.198, 263, 243, DISCOVERY OF A SELECTIVE TRK INHIBITOR WITH EFFICACY IN RODENT CANCER TUMOR MODELS
3869, 3gqlB, 0.6130, 2.92, 0.264, 276, 239, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
3870, 3dlsF, 0.6130, 3.12, 0.236, 281, 242, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
3871, 6fnmA, 0.6129, 3.22, 0.199, 270, 246, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH DASATINIB 
3872, 5ur1B, 0.6129, 2.93, 0.272, 265, 239, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
3873, 4o0xA, 0.6129, 3.37, 0.242, 290, 244, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
3874, 4mbjA, 0.6129, 3.30, 0.208, 269, 245, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINE-BASED INHIBITOR
3875, 4m84A, 0.6129, 3.79, 0.282, 464, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1455
3876, 4bicB, 0.6129, 2.91, 0.295, 259, 237, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
3877, 4arkA, 0.6129, 3.46, 0.219, 291, 251, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF HUMAN MAP KINASE KINASE 1 (MEK1) IN COMPLEX WITH  A SMALL MOLECULE INHIBITOR AND ADP
3878, 3ppjB, 0.6129, 3.03, 0.224, 264, 241, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
3879, 3pp1A, 0.6129, 3.37, 0.209, 291, 249, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGATP
3880, 3n51A, 0.6129, 3.78, 0.282, 448, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-95
3881, 2jiuA, 0.6129, 3.45, 0.210, 303, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION IN COMPLEX WITH AEE788
3882, 1mq4A, 0.6129, 3.39, 0.243, 261, 247, CRYSTAL STRUCTURE OF AURORA-A PROTEIN KINASE
3883, 5upkB, 0.6128, 3.37, 0.246, 288, 244, CDC42 BINDS PAK4 VIA AN EXTENDED GTPASE-EFFECTOR INTERFACE - 3 PEPTIDE: PAK4CAT PAK4-N45 CDC42
3884, 5p9kA, 0.6128, 3.47, 0.173, 271, 249, CRYSTAL STRUCTURE OF BTK WITH CNX 774
3885, 5p9iA, 0.6128, 3.50, 0.172, 271, 250, BTK1 SOAKED WITH IBRUTINIB-REV
3886, 4jaiA, 0.6128, 2.99, 0.245, 249, 241, CRYSTAL STRUCTURE OF AURORA KINASE A IN COMPLEX WITH N-{4-[(6-OXO-56- DIHYDROBENZO[C][18]NAPHTHYRIDIN-1-YL)AMINO]PHENYL}BENZAMIDE
3887, 4dhfA, 0.6128, 3.01, 0.244, 258, 242, STRUCTURE OF AURORA A MUTANT BOUND TO BIOGENIDEC CPD 15
3888, 3d4qB, 0.6128, 3.11, 0.223, 264, 242, PYRAZOLE-BASED INHIBITORS OF B-RAF KINASE
3889, 6bl8A, 0.6127, 3.48, 0.228, 270, 246, PREDICTING THE CONFORMATIONAL VARIABILITY OF ABL TYROSINE KINASE USING MOLECULAR DYNAMICS SIMULATIONS AND MARKOV STATE MODELS
3890, 5x1tA, 0.6127, 3.43, 0.182, 283, 247, PPKA-294
3891, 5w91A, 0.6127, 3.87, 0.289, 451, 256, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR LZH118
3892, 5dh3B, 0.6127, 3.24, 0.238, 283, 244, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
3893, 4ztsA, 0.6127, 2.99, 0.249, 249, 241, HUMAN AURORA A CATALYTIC DOMAIN BOUND TO FK1142
3894, 4qmvA, 0.6127, 3.51, 0.218, 288, 248, MST3 IN COMPLEX WITH PF-03814735 N-{2-[(1S4R)-6-{[4- (CYCLOBUTYLAMINO)-5-(TRIFLUOROMETHYL)PYRIMIDIN-2-YL]AMINO}-1234- TETRAHYDRO-14-EPIMINONAPHTHALEN-9-YL]-2-OXOETHYL}ACETAMIDE
3895, 3s95A, 0.6127, 3.39, 0.217, 290, 244, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
3896, 6fc8A, 0.6126, 3.26, 0.262, 269, 244, CHK1 KINASE IN COMPLEX WITH COMPOUND 13
3897, 5xdkA, 0.6126, 3.57, 0.205, 307, 249, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH CO-1686
3898, 5w9rA, 0.6126, 3.87, 0.289, 445, 256, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR LJQ138
3899, 5j87D, 0.6126, 3.39, 0.181, 263, 248, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
3900, 4k8aB, 0.6126, 3.08, 0.218, 258, 243, FRAGMENT-BASED DISCOVERY OF FOCAL ADHESION KINASE INHIBITORS
3901, 4ifgA, 0.6126, 3.87, 0.285, 452, 256, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
3902, 3sdjK, 0.6126, 3.34, 0.257, 422, 245, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3903, 3sdjD, 0.6126, 3.34, 0.257, 422, 245, STRUCTURE OF RNASE-INACTIVE POINT MUTANT OF OLIGOMERIC KINASE/RNASE IRE1
3904, 3iokA, 0.6126, 3.43, 0.217, 285, 249, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
3905, 2x6dA, 0.6126, 3.21, 0.251, 255, 243, AURORA-A BOUND TO AN INHIBITOR
3906, 2g2fA, 0.6126, 3.52, 0.231, 275, 247, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
3907, 4u5jB, 0.6125, 3.29, 0.259, 267, 243, C-SRC IN COMPLEX WITH RUXOLITINIB
3908, 4qmqA, 0.6125, 3.46, 0.219, 289, 247, MST3 IN COMPLEX WITH CP-673451
3909, 4onaA, 0.6125, 3.87, 0.277, 465, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1517
3910, 4jvgB, 0.6125, 3.02, 0.237, 259, 240, B-RAF KINASE IN COMPLEX WITH BIRB796
3911, 4bbfD, 0.6125, 3.52, 0.217, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3912, 3ue4A, 0.6125, 3.40, 0.232, 270, 246, STRUCTURAL AND SPECTROSCOPIC ANALYSIS OF THE KINASE INHIBITOR BOSUTINIB BINDING TO THE ABL TYROSINE KINASE DOMAIN
3913, 3sx9A, 0.6125, 3.99, 0.283, 457, 258, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-132
3914, 2wd1A, 0.6125, 3.35, 0.220, 289, 246, HUMAN C-MET KINASE IN COMPLEX WITH AZAINDOLE INHIBITOR
3915, 2w1eA, 0.6125, 3.09, 0.244, 252, 242, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3916, 2j6mA, 0.6125, 3.54, 0.209, 306, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AEE788
3917, 5vd4A, 0.6124, 3.10, 0.183, 261, 241, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 016 A MK1775 ANALOUGUE
3918, 5j87B, 0.6124, 3.32, 0.170, 274, 247, DISCOVERY OF N-(3-(5-((3-ACRYLAMIDO-4-(MORPHOLINE-4-CARBONYL)PHENYL) AMINO)-1-METHYL-6-OXO-16-DIHYDROPYRIDIN-3-YL)-2-METHYLPHENYL)-4- (TERT-BUTYL)BENZAMIDE (CHMFL-BTK-01) AS A HIGHLY SELECTIVE IRREVERSIBLE BTK KINASE INHIBITOR
3919, 5iugA, 0.6124, 3.14, 0.180, 285, 244, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5A
3920, 5bpyA, 0.6124, 3.46, 0.169, 263, 249, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
3921, 5ar4B, 0.6124, 3.08, 0.216, 279, 241, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
3922, 4o2pA, 0.6124, 2.99, 0.247, 265, 239, KINASE DOMAIN OF CSRC IN COMPLEX WITH A SUBSTITUTED PYRAZOLOPYRIMIDINE
3923, 4gihA, 0.6124, 3.62, 0.220, 288, 250, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-{2-[(CYCLOPROPYLCARBONYL) AMINO]PYRIDIN-4-YL}BENZAMIDE
3924, 3t3uA, 0.6124, 3.78, 0.282, 452, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-130
3925, 3e63A, 0.6124, 3.56, 0.228, 290, 250, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
3926, 2kulA, 0.6124, 3.95, 0.175, 360, 257, SOLUTION STRUCTURE OF HUMAN VACCINIA RELATED KINASE 1(VRK1)
3927, 5w9eA, 0.6123, 3.88, 0.289, 451, 256, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR GXJ-186
3928, 5vc5A, 0.6123, 3.14, 0.178, 261, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PD- 166285
3929, 5mjaB, 0.6123, 3.26, 0.201, 274, 244, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
3930, 5kmoA, 0.6123, 3.39, 0.201, 291, 244, TRKA JM-KINASE WITH 1-(2-METHYL-4-PHENYL-PYRIMIDIN-5-YL)-3-(2- PYRIDYL)UREA
3931, 4gu9B, 0.6123, 3.01, 0.222, 255, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH (2-FLUORO- PHENYL)-(1H-PYRAZOLO[34-D]PYRIMIDIN-4-YL)-AMINE
3932, 3i7bA, 0.6123, 3.74, 0.283, 459, 254, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR NM-PP1
3933, 2fo0A, 0.6123, 3.34, 0.217, 465, 244, ORGANIZATION OF THE SH3-SH2 UNIT IN ACTIVE AND INACTIVE FORMS OF THE C-ABL TYROSINE KINASE
3934, 4r3rA, 0.6122, 3.52, 0.205, 309, 249, CRYSTAL STRUCTURES OF EGFR IN COMPLEX WITH MIG6
3935, 4neuA, 0.6122, 3.38, 0.182, 286, 247, X-RAY STRUCTURE OF RECEPTOR INTERACTING PROTEIN 1 (RIP1)KINASE DOMAIN WITH A 1-AMINOISOQUINOLINE INHIBITOR
3936, 3mblA, 0.6122, 3.38, 0.213, 290, 249, CRYSTAL STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK 1) IN COMPLEX WITH LIGAND AND MGADP
3937, 3l9pA, 0.6122, 3.26, 0.182, 303, 247, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
3938, 6bp0A, 0.6121, 3.72, 0.181, 317, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
3939, 5w8rA, 0.6121, 3.81, 0.282, 456, 255, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR 3CIB-PPI
3940, 5uorB, 0.6121, 3.01, 0.289, 262, 239, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
3941, 5g15A, 0.6121, 3.54, 0.223, 265, 247, STRUCTURE AURORA A (122-403) BOUND TO ACTIVATING MONOBODY MB1 AND AMPPCP
3942, 5czhA, 0.6121, 3.50, 0.201, 311, 249, EGFR L858R MUTANT IN COMPLEX WITH AN OPTIMAL PEPTIDE SUBSTRATE
3943, 4bbfA, 0.6121, 3.54, 0.217, 288, 249, AMINOALKYLPYRIMIDINE INHIBITOR COMPLEXES WITH JAK2
3944, 3wzdA, 0.6121, 3.13, 0.227, 278, 242, KDR IN COMPLEX WITH LIGAND LENVATINIB
3945, 3bi6A, 0.6121, 3.00, 0.184, 258, 239, WEE1 KINASE COMPLEX WITH INHIBITOR PD352396
3946, 2xvdA, 0.6121, 3.15, 0.201, 270, 244, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3947, 2w1fA, 0.6121, 3.18, 0.243, 253, 243, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
3948, 2oj9A, 0.6121, 3.93, 0.174, 295, 258, STRUCTURE OF IGF-1R KINASE DOMAIN COMPLEXED WITH A BENZIMIDAZOLE INHIBITOR
3949, 2itwA, 0.6121, 3.49, 0.206, 300, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AFN941
3950, 2bvaB, 0.6121, 2.93, 0.245, 274, 237, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
3951, 1wvyA, 0.6121, 3.37, 0.306, 273, 245, CRYSTAL STRUCTURES OF KINASE DOMAIN OF DAP KINASE IN COMPLEX WITH SMALL MOLECULAR INHIBITORS
3952, 5x1sA, 0.6120, 3.29, 0.184, 281, 245, PPKA-294 WITH AMPPCP
3953, 5n3fA, 0.6120, 3.64, 0.251, 318, 251, CAMP-DEPENDENT PROTEIN KINASE A FROM CRICETULUS GRISEUS IN COMPLEX WITH FRAGMENT LIKE MOLECULE N-[3-(AMINOMETHYL)PHENYL]ACETAMIDE
3954, 4uy9A, 0.6120, 3.36, 0.271, 313, 247, STRUCTURE OF MLK1 KINASE DOMAIN WITH LEUCINE ZIPPER 1
3955, 4prjA, 0.6120, 3.26, 0.253, 251, 245, AURORA A KINASE DOMAIN WITH COMPOUND 2 (N-[1-(3-CYANOBENZYL)-1H- PYRAZOL-4-YL]-6-(1H-PYRAZOL-4-YL)-1H-INDAZOLE-3-CARBOXAMIDE)
3956, 4mneB, 0.6120, 3.46, 0.224, 270, 246, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
3957, 4e3cC, 0.6120, 3.36, 0.239, 624, 247, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3958, 4cnhB, 0.6120, 3.27, 0.183, 293, 246, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 3-((1R)-1-(5-FLUORO-2- METHOXYPHENYL)ETHOXY)-5-(1-METHYL-1H-123-TRIAZOL-5-YL) PYRIDIN-2-AMINE
3959, 3hmiA, 0.6120, 3.41, 0.237, 268, 245, THE CRYSTAL STRUCTURE OF HUMAN ABL2 IN COMPLEX WITH 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
3960, 2x9fA, 0.6120, 3.16, 0.209, 265, 244, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
3961, 2cguA, 0.6120, 2.95, 0.255, 263, 239, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3962, 6fnkA, 0.6119, 3.19, 0.200, 274, 245, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
3963, 5gmpA, 0.6119, 3.38, 0.211, 305, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH XTF-262
3964, 4wunB, 0.6119, 2.82, 0.261, 268, 238, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
3965, 4e3cA, 0.6119, 3.43, 0.231, 624, 247, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3966, 4d0xA, 0.6119, 3.58, 0.227, 291, 251, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
3967, 4a4xA, 0.6119, 2.88, 0.229, 253, 240, NEK2-EDE BOUND TO CCT248662
3968, 3omvB, 0.6119, 3.04, 0.216, 264, 241, CRYSTAL STRUCTURE OF C-RAF (RAF-1)
3969, 3e8nA, 0.6119, 3.44, 0.212, 291, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) COMPLEXED WITH A POTENT INHIBITOR RDEA119 AND MGATP
3970, 3c4cB, 0.6119, 2.92, 0.218, 257, 238, B-RAF KINASE IN COMPLEX WITH PLX4720
3971, 2eb2A, 0.6119, 3.47, 0.206, 305, 248, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (G719S)
3972, 6bfaA, 0.6118, 3.81, 0.282, 464, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1553
3973, 6b8uA, 0.6118, 2.90, 0.223, 253, 238, CRYSTALS STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH AN IMIDAZOPYRIDINYL BENZAMIDE INHIBITOR
3974, 5dt0A, 0.6118, 3.18, 0.242, 259, 244, AURORA A KINASE IN COMPLEX WITH JNJ-7706621 IN SPACE GROUP P6122
3975, 4jvgC, 0.6118, 2.98, 0.226, 258, 239, B-RAF KINASE IN COMPLEX WITH BIRB796
3976, 4f09A, 0.6118, 3.38, 0.219, 288, 247, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
3977, 4anbA, 0.6118, 3.67, 0.218, 282, 252, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
3978, 2wotA, 0.6118, 3.60, 0.211, 303, 247, ALK5 IN COMPLEX WITH 4-((56-DIMETHYL-2-(2-PYRIDYL)-3- PYRIDYL)OXY)-N-(345-TRIMETHOXYPHENYL)PYRIDIN-2-AMINE
3979, 2broA, 0.6118, 3.20, 0.256, 272, 242, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3980, 2brnA, 0.6118, 3.05, 0.268, 268, 239, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
3981, 6dd4C, 0.6117, 3.81, 0.176, 317, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
3982, 4zogA, 0.6117, 3.36, 0.225, 269, 244, VX-680/MK-0457 BINDS TO HUMAN ABL1 ALSO IN INACTIVE DFG CONFORMATIONS.
3983, 4f0iA, 0.6117, 3.23, 0.202, 284, 243, CRYSTAL STRUCTURE OF APO TRKA
3984, 4e4xA, 0.6117, 3.29, 0.212, 267, 245, CRYSTAL STRUCTURE OF B-RAF KINASE DOMAIN IN COMPLEX WITH A DIHYDROPYRIDO[23-D]PYRIMIDINONE-BASED INHIBITOR
3985, 4cd0A, 0.6117, 3.23, 0.184, 295, 245, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPANE-12-DIOL
3986, 3t9tA, 0.6117, 3.47, 0.169, 263, 249, CRYSTAL STRUCTURE OF BTK MUTANT (F435TK596R) COMPLEXED WITH IMIDAZO[15-A]QUINOXALINE
3987, 3fztA, 0.6117, 2.97, 0.175, 259, 240, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH PF-4618433
3988, 2cgvA, 0.6117, 2.93, 0.261, 264, 238, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
3989, 5p9hA, 0.6116, 3.39, 0.173, 264, 248, BTK1 COCRYSTALLIZED WITH RN983
3990, 4yhfA, 0.6116, 3.35, 0.186, 268, 247, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
3991, 4gj3A, 0.6116, 3.63, 0.220, 288, 250, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3992, 4gj2A, 0.6116, 3.63, 0.220, 288, 250, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-N-[2-({[(1R2R)-2- FLUOROCYCLOPROPYL]CARBONYL}AMINO)PYRIDIN-4-YL]BENZAMIDE
3993, 4fc0A, 0.6116, 2.89, 0.228, 254, 237, CRYSTAL STRUCTURE OF HUMAN KINASE DOMAIN OF B-RAF WITH A DFG-OUT INHIBITOR
3994, 4e3cF, 0.6116, 3.49, 0.234, 624, 248, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
3995, 2yjrA, 0.6116, 3.00, 0.183, 278, 240, STRUCTURE OF F1174L MUTANT ANAPLASTIC LYMPHOMA KINASE
3996, 2xnoA, 0.6116, 2.79, 0.223, 251, 238, STRUCTURE OF NEK2 BOUND TO CCT243779
3997, 2dwbA, 0.6116, 3.29, 0.245, 259, 245, AURORA-A KINASE COMPLEXED WITH AMPPNP
3998, 6es0B, 0.6115, 3.09, 0.207, 287, 241, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
3999, 6cqhA, 0.6115, 3.52, 0.183, 316, 251, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
4000, 5w80A, 0.6115, 3.89, 0.289, 453, 256, TOXOPLASMA GONDII CDPK1 IN COMPLEX WITH INHIBITOR GXJ-237
4001, 4r5yA, 0.6115, 2.77, 0.225, 253, 236, THE COMPLEX STRUCTURE OF BRAF V600E KINASE DOMAIN WITH A NOVEL BRAF INHIBITOR
4002, 4o0yA, 0.6115, 3.39, 0.250, 290, 244, BACK POCKET FLEXIBILITY PROVIDES GROUP-II PAK SELECTIVITY FOR TYPE 1 KINASE INHIBITORS
4003, 4e3cB, 0.6115, 3.40, 0.234, 632, 248, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4004, 3psbA, 0.6115, 2.95, 0.226, 262, 239, FURO[23-C]PYRIDINE-BASED INDANONE OXIMES AS POTENT AND SELECTIVE B- RAF INHIBITORS
4005, 3f66A, 0.6115, 3.61, 0.205, 288, 249, HUMAN C-MET KINASE IN COMPLEX WITH QUINOXALINE INHIBITOR
4006, 1r0pA, 0.6115, 3.02, 0.194, 301, 242, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH THE MICROBIAL ALKALOID K-252A
4007, 5tq5A, 0.6114, 3.58, 0.228, 291, 250, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4008, 5l4qB, 0.6114, 3.67, 0.209, 287, 249, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4009, 4qmpA, 0.6114, 3.49, 0.219, 289, 247, MST3 IN COMPLEX WITH CDK1/2 INHIBITOR III 5-AMINO-3-{[4- (AMINOSULFONYL)PHENYL]AMINO}-N-(26-DIFLUOROPHENYL)-1H-124- TRIAZOLE-1-CARBOTHIOAMIDE
4010, 3lcsA, 0.6114, 3.27, 0.182, 304, 247, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4011, 3i6wC, 0.6114, 3.17, 0.303, 368, 238, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
4012, 6dd4A, 0.6113, 3.67, 0.178, 317, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
4013, 4zlyA, 0.6113, 3.61, 0.167, 270, 251, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE BOUND TO A CINNOLINE FRAGMENT
4014, 4mkcA, 0.6113, 3.25, 0.183, 303, 246, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE COMPLEXED WITH LDK378
4015, 4hvgA, 0.6113, 3.44, 0.215, 281, 246, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-2-HYDROXY-12-DIMETHYL-PROPYL)- AMIDE
4016, 3plsA, 0.6113, 3.45, 0.199, 298, 251, RON IN COMPLEX WITH LIGAND AMP-PNP
4017, 2c3kA, 0.6113, 3.07, 0.262, 262, 240, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4018, 1oplA, 0.6113, 3.44, 0.225, 451, 244, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4019, 6cpeA, 0.6112, 3.09, 0.244, 256, 242, STRUCTURE OF APO; DEPHOSPHORYLATED AURORA A (122-403) IN AN ACTIVE CONFORMATION 
4020, 5x1rA, 0.6112, 3.34, 0.184, 281, 245, PPKA-294 APO FORM
4021, 5oopA, 0.6112, 2.91, 0.283, 261, 237, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMP-PNP
4022, 4wg3A, 0.6112, 3.90, 0.285, 460, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1610
4023, 4pp7A, 0.6112, 3.15, 0.206, 267, 243, HIGHLY POTENT AND SELECTIVE 3-N-METHYLQUINAZOLINE-4(3H)-ONE BASED INHIBITORS OF B-RAFV600E KINASE
4024, 4h58A, 0.6112, 2.96, 0.222, 263, 239, BRAF IN COMPLEX WITH COMPOUND 3
4025, 3g6gA, 0.6112, 3.03, 0.251, 264, 239, EQUALLY POTENT INHIBITION OF C-SRC AND ABL BY COMPOUNDS THAT RECOGNIZE INACTIVE KINASE CONFORMATIONS
4026, 3fy2A, 0.6112, 3.06, 0.202, 285, 242, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYEFIW
4027, 3cthA, 0.6112, 3.21, 0.205, 295, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
4028, 2itxA, 0.6112, 3.57, 0.209, 307, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AMP- PNP
4029, 2itqA, 0.6112, 3.40, 0.206, 300, 247, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AFN941
4030, 2cgxA, 0.6112, 3.04, 0.268, 265, 239, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4031, 5j7bB, 0.6111, 3.19, 0.211, 281, 242, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
4032, 5i3oA, 0.6111, 3.60, 0.227, 302, 251, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4033, 5c9cB, 0.6111, 2.83, 0.220, 251, 236, CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND
4034, 4tksA, 0.6111, 3.46, 0.219, 307, 247, NATIVE-SAD PHASING FOR HUMAN EGFR KINASE DOMAIN.
4035, 3v51A, 0.6111, 3.96, 0.284, 459, 257, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR RM-1-176
4036, 3bkbA, 0.6111, 3.53, 0.221, 373, 249, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)
4037, 2hziB, 0.6111, 3.27, 0.223, 264, 242, ABL KINASE DOMAIN IN COMPLEX WITH PD180970
4038, 6cqhB, 0.6110, 3.85, 0.176, 316, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- PROPYNYL-N-ETHYL-DIHYDROPTERIDINE INHIBITOR
4039, 6bleA, 0.6110, 3.28, 0.262, 265, 244, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CP673451
4040, 5gtzA, 0.6110, 3.40, 0.211, 317, 247, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH JTS-1-39
4041, 5cavA, 0.6110, 3.65, 0.208, 306, 250, EGFR KINASE DOMAIN WITH COMPOUND 41A
4042, 4z3vA, 0.6110, 3.53, 0.172, 271, 250, FRAGMENT-BASED DISCOVERY OF A SMALL MOLECULE REVERSIBLE INHIBITOR OF BRUTON S TYROSINE KINASE
4043, 4u41A, 0.6110, 3.19, 0.240, 275, 242, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4044, 4mneF, 0.6110, 3.05, 0.221, 258, 240, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4045, 4jdhA, 0.6110, 3.36, 0.243, 289, 243, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
4046, 4bibB, 0.6110, 2.70, 0.286, 258, 234, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4047, 3zewA, 0.6110, 3.20, 0.215, 269, 242, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
4048, 3t3vA, 0.6110, 3.82, 0.290, 453, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPED KINASE INHIBITOR RM-1-87
4049, 3r22A, 0.6110, 3.03, 0.248, 255, 242, DESIGN SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZOLOPYRIDINE- SULFONAMIDES AS POTENT MULTIPLE-MITOTIC KINASE (MMK) INHIBITORS (PART I)
4050, 3d2iA, 0.6110, 3.24, 0.246, 255, 244, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240- >ARG MET302->LEU) IN COMPLEX WITH 1-{5-[2-(1-METHYL-1H- PYRAZOLO[43-D]PYRIMIDIN-7-YLAMINO)-ETHYL]-THIAZOL-2-YL}-3- (3-TRIFLUOROMETHYL-PHENYL)-UREA
4051, 5iuhA, 0.6109, 3.12, 0.177, 285, 243, CRYSTAL STRUCTURE OF THE ANAPLASTIC LYMPHOMA KINASE (ALK) IN COMPLEX WITH 5D
4052, 5drbA, 0.6109, 3.46, 0.242, 273, 248, CRYSTAL STRUCTURE OF WNK1 IN COMPLEX WITH WNK463
4053, 4jbvA, 0.6109, 3.83, 0.286, 458, 255, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1268
4054, 3lxlA, 0.6109, 3.59, 0.213, 281, 249, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
4055, 3dlsB, 0.6109, 3.20, 0.241, 280, 241, CRYSTAL STRUCTURE OF HUMAN PAS KINASE BOUND TO ADP
4056, 2xngA, 0.6109, 3.12, 0.244, 253, 242, STRUCTURE OF AURORA-A BOUND TO A SELECTIVE IMIDAZOPYRAZINE INHIBITOR
4057, 5vd9A, 0.6108, 3.20, 0.190, 261, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 097 A MK1775 ANALOGUE
4058, 4yznA, 0.6108, 3.39, 0.210, 269, 243, HUMANIZED ROCO4 BOUND TO COMPOUND 19
4059, 4gu6B, 0.6108, 2.96, 0.228, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH N-{3-[(5-CYANO- 2-PHENYL-1H-PYRROLO[23-B]PYRIDIN-4-YLAMINO)- METHYL]-PYRIDIN-2-YL}- N-METHYL-METHANESULFONAMIDE
4060, 4giiA, 0.6108, 3.66, 0.224, 289, 250, TYK2 (JH1) IN COMPLEX WITH 26-DICHLORO-4-CYANO-N-{2- [(CYCLOPROPYLCARBONYL)AMINO]PYRIDIN-4-YL}BENZAMIDE
4061, 4f0gA, 0.6108, 2.88, 0.203, 263, 236, CRYSTAL STRUCTURE OF THE ROCO4 KINASE DOMAIN FROM D. DISCOIDEUM
4062, 3eqhA, 0.6108, 3.61, 0.215, 314, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH U0126 ADP AND MG2P
4063, 3d14A, 0.6108, 3.44, 0.251, 262, 247, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-{5-[2-(THIENO[32-D]PYRIMIDIN-4-YLAMINO)- ETHYL]- THIAZOL-2-YL}-3-(3-TRIFLUOROMETHYL-PHENYL)-UREA
4064, 2v7aA, 0.6108, 3.31, 0.225, 269, 244, CRYSTAL STRUCTURE OF THE T315I ABL MUTANT IN COMPLEX WITH THE INHIBITOR PHA-739358
4065, 2f4jA, 0.6108, 3.52, 0.227, 287, 247, STRUCTURE OF THE KINASE DOMAIN OF AN IMATINIB-RESISTANT ABL MUTANT IN COMPLEX WITH THE AURORA KINASE INHIBITOR VX-680
4066, 1opkA, 0.6108, 3.39, 0.218, 449, 243, STRUCTURAL BASIS FOR THE AUTO-INHIBITION OF C-ABL TYROSINE KINASE
4067, 6cadB, 0.6107, 2.75, 0.221, 248, 235, CRYSTAL STRUCTURE OF RAF KINASE DOMAIN BOUND TO THE INHIBITOR 2A
4068, 5uvfB, 0.6107, 3.72, 0.178, 316, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO BI- D1870
4069, 5em8A, 0.6107, 3.50, 0.206, 303, 247, EGFR KINASE DOMAIN WITH PYRIDONE COMPOUND 13: 4-[(2-METHOXYPHENYL) AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2-OXIDANYLIDENE-1~{H}- PYRIDINE-3-CARBOXAMIDE
4070, 4tt7A, 0.6107, 3.36, 0.182, 291, 247, CRYSTAL STRUCTURE OF HUMAN ALK WITH A COVALENT MODIFICATION
4071, 4o91A, 0.6107, 2.77, 0.258, 293, 233, CRYSTAL STRUCTURE OF TYPE II INHIBITOR NG25 BOUND TO TAK1-TAB1
4072, 3upxA, 0.6107, 3.89, 0.285, 445, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH INHIBITOR UW1300
4073, 2fb8A, 0.6107, 3.04, 0.229, 259, 240, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
4074, 5j9yA, 0.6106, 3.62, 0.204, 300, 250, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1B
4075, 5hu9A, 0.6106, 3.40, 0.212, 266, 245, CRYSTAL STRUCTURE OF ABL1 IN COMPLEX WITH CHMFL-074
4076, 5aaeA, 0.6106, 3.25, 0.246, 252, 244, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14D)
4077, 4yhfB, 0.6106, 3.39, 0.178, 269, 247, BRUTON S TYROSINE KINASE IN COMPLEX WITH A T-BUTYL CYANOACRYLAMIDE INHIBITOR
4078, 4u7zA, 0.6106, 3.46, 0.216, 291, 250, MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK1) BOUND TO G805
4079, 4r5sA, 0.6106, 3.26, 0.213, 299, 244, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH FIIN-3
4080, 4kspA, 0.6106, 2.82, 0.219, 257, 237, CRYSTAL STRUCTURE OF HUMAN B-RAF BOUND TO A DFG-OUT INHIBITOR TAK-632
4081, 4hyhA, 0.6106, 3.14, 0.271, 263, 240, X-RAY CRYSTAL STRUCTURE OF COMPOUND 39 BOUND TO HUMAN CHK1 KINASE DOMAIN
4082, 4aqcB, 0.6106, 3.60, 0.228, 295, 250, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
4083, 3sxsA, 0.6106, 3.28, 0.198, 264, 243, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEXED WITH PP2
4084, 3s95B, 0.6106, 3.42, 0.221, 290, 244, CRYSTAL STRUCTURE OF THE HUMAN LIMK1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
4085, 2itpA, 0.6106, 3.47, 0.206, 305, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AEE788
4086, 6glbB, 0.6105, 3.51, 0.206, 288, 247, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
4087, 5vdkA, 0.6105, 3.23, 0.194, 260, 242, CRYSTAL STRUCTURE OF HUMAN WEE2 KINASE DOMAIN IN COMPLEX WITH MK1775
4088, 5usyB, 0.6105, 3.29, 0.220, 287, 245, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
4089, 5uq0B, 0.6105, 2.89, 0.270, 256, 237, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4090, 5nwzA, 0.6105, 2.87, 0.261, 271, 238, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
4091, 5l4qA, 0.6105, 3.77, 0.208, 293, 250, CRYSTAL STRUCTURE OF ADAPTOR PROTEIN 2 ASSOCIATED KINASE 1 (AAK1) IN COMPLEX WITH LKB1 (AAK1 DUAL INHIBITOR)
4092, 4x3fB, 0.6105, 3.50, 0.266, 278, 252, CRYSTAL STRUCTURE OF THE INTRACELLULAR DOMAIN OF THE M. TUBERCULOSIS SER/THR KINASE PKNA
4093, 4u43B, 0.6105, 3.50, 0.209, 302, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 6)
4094, 4fijA, 0.6105, 3.45, 0.246, 291, 244, CATALYTIC DOMAIN OF HUMAN PAK4
4095, 3upzA, 0.6105, 3.92, 0.285, 458, 256, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1) IN COMPLEX WITH BUMPLESS BKI ANALOG UW1243
4096, 3ppzB, 0.6105, 3.33, 0.236, 264, 242, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
4097, 3piyA, 0.6105, 2.81, 0.190, 262, 237, CRYSTAL STRUCTURE OF BTK KINASE DOMAIN COMPLEXED WITH R406
4098, 3eqpB, 0.6105, 3.23, 0.210, 270, 243, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
4099, 3cqeA, 0.6105, 3.02, 0.188, 258, 239, WEE1 KINASE COMPLEX WITH INHIBITOR PD074291
4100, 3b2wA, 0.6105, 3.05, 0.244, 261, 242, CRYSTAL STRUCTURE OF PYRIMIDINE AMIDE 11 BOUND TO LCK
4101, 5t18A, 0.6104, 3.22, 0.184, 261, 244, CRYSTAL STRUCTURE OF BRUTON AGAMMABULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-986142 AKA (2S)-6-FLUORO-5-[3-(8-FLUORO-1-METHYL-24-DIOXO- 1234-TETRAHYDROQUINAZOLIN-3-YL)-2-METHYLPHENYL]-2-(2- HYDROXYPROPAN-2-YL)-2349-TETRAHYDRO-1H-CARBAZOLE-8-CARBOXAMIDE
4102, 5ar7B, 0.6104, 3.11, 0.199, 278, 241, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
4103, 4twnA, 0.6104, 2.98, 0.221, 276, 240, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH BIRB796
4104, 4nfmA, 0.6104, 3.44, 0.221, 293, 249, HUMAN TAU TUBULIN KINASE 1 (TTBK1)
4105, 4ihpA, 0.6104, 3.92, 0.281, 454, 256, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
4106, 4gg7A, 0.6104, 3.52, 0.215, 278, 247, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4107, 3prfA, 0.6104, 2.99, 0.226, 262, 239, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
4108, 3eqfA, 0.6104, 3.73, 0.218, 314, 252, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH K252A AND MG2P
4109, 2gqgA, 0.6104, 3.45, 0.228, 277, 246, X-RAY CRYSTAL STRUCTURE OF DASATINIB (BMS-354825) BOUND TO ACTIVATED ABL KINASE DOMAIN
4110, 6glbA, 0.6103, 3.52, 0.206, 288, 247, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 20 (FM484) 
4111, 5usyA, 0.6103, 3.41, 0.228, 287, 246, JAK2 JH1 IN COMPLEX WITH JNJ-7706621
4112, 5jmsA, 0.6103, 3.91, 0.285, 447, 256, CRYSTAL STRUCTURE OF TGCDPK1 BOUND TO CGP060476
4113, 5aafA, 0.6103, 3.24, 0.246, 254, 244, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14A)
4114, 4yhtB, 0.6103, 2.98, 0.238, 258, 239, BRAF COMPLEXED WITH AN INHIBITOR
4115, 4gg5A, 0.6103, 3.40, 0.209, 274, 244, CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH NOVEL INHIBITOR
4116, 3vjnA, 0.6103, 3.43, 0.202, 297, 247, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH AMPPNP.
4117, 3krrA, 0.6103, 3.63, 0.227, 291, 251, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT QUINOXALINE ATP SITE INHIBITOR
4118, 3dk3B, 0.6103, 3.28, 0.223, 269, 242, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4119, 2e2bB, 0.6103, 3.03, 0.213, 262, 239, CRYSTAL STRUCTURE OF THE C-ABL KINASE DOMAIN IN COMPLEX WITH INNO-406
4120, 5y9tA, 0.6102, 3.50, 0.206, 300, 248, CRYSTAL STRUCTURE OF EGFR T790M MUTANT IN COMPLEX WITH NAQUOTINIB 
4121, 5ur1A, 0.6102, 3.02, 0.259, 278, 239, FGFR1 KINASE DOMAIN COMPLEX WITH SN37333 IN REVERSIBLE BINDING MODE
4122, 5p9mA, 0.6102, 3.57, 0.176, 271, 250, BTK1 BINDS COVALENTLY TO HY-15771 ONO-4059
4123, 4z55A, 0.6102, 3.23, 0.176, 294, 245, ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN COMPLEXED WITH PYRAZOLOPYRIMIDINE DERIVATIVE OF LDK378
4124, 4lqsA, 0.6102, 4.16, 0.252, 372, 262, CRYSTAL STRUCTURE OF THE CBK1-MOB2 KINASE-COACTIVATOR COMPLEX
4125, 4ehgA, 0.6102, 3.20, 0.226, 262, 243, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
4126, 4b0gA, 0.6102, 2.70, 0.258, 247, 236, COMPLEX OF AURORA-A BOUND TO AN IMIDAZOPYRIDINE-BASED INHIBITOR
4127, 3qriB, 0.6102, 3.37, 0.215, 262, 242, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN IN COMPLEX WITH DCC- 2036
4128, 3dk7A, 0.6102, 3.20, 0.220, 265, 241, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4129, 5jn2A, 0.6101, 3.92, 0.285, 450, 256, CRYSTAL STRUCTURE OF TGCDPK1 BOUND TO NVPACU106
4130, 5ftoA, 0.6101, 3.31, 0.179, 298, 246, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH ENTRECTINIB
4131, 5cf6B, 0.6101, 3.37, 0.232, 290, 246, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
4132, 5bq0A, 0.6101, 3.50, 0.173, 265, 249, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH BMS-824171 AKA 6-[(3R)-3-(4-TERT-BU TYLBENZAMIDO) PIPERIDIN-1-YL]-2-{[4-(MORPHOLINE-4-CARBONYL) PHENYL]AMINO}PYRIDINE- 3-CARBOXAMIDE
4133, 4zy5A, 0.6101, 3.06, 0.231, 283, 238, CRYSTAL STRUCTURE OF P21-ACTIVATED KINASE 1 IN COMPLEX WITH AN INHIBITOR COMPOUND 17
4134, 4f08A, 0.6101, 3.38, 0.227, 288, 247, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
4135, 3tv6A, 0.6101, 3.23, 0.206, 268, 243, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A METHOXYPYRAZOLOPYRIDINYL BENZAMIDE INHIBITOR
4136, 3dj7A, 0.6101, 3.38, 0.248, 257, 246, CRYSTAL STRUCTURE OF THE MOUSE AURORA-A CATALYTIC DOMAIN (ASN186->GLY LYS240->ARG MET302->LEU) IN COMPLEX WITH COMPOUND 130.
4137, 3a7jA, 0.6101, 3.34, 0.222, 286, 243, HUMAN MST3 KINASE IN COMPLEX WITH MNADP
4138, 2ogvA, 0.6101, 3.71, 0.232, 317, 250, CRYSTAL STRUCTURE OF THE AUTOINHIBITED HUMAN C-FMS KINASE DOMAIN
4139, 5i3rA, 0.6100, 3.63, 0.223, 302, 251, CRYSTAL STRUCTURE OF BMP-2-INDUCIBLE KINASE IN COMPLEX WITH AN INDAZOLE INHIBITOR
4140, 5hvkC, 0.6100, 3.36, 0.214, 291, 243, CRYSTAL STRUCTURE OF LIMK1 MUTANT D460N IN COMPLEX WITH FULL-LENGTH COFILIN-1
4141, 5fd2A, 0.6100, 3.16, 0.214, 264, 243, B-RAF WILD-TYPE KINASE DOMAIN IN COMPLEX WITH A PURINYLPYRIDINYLAMINO- BASED INHIBITOR
4142, 5e8sA, 0.6100, 3.53, 0.211, 301, 246, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)
4143, 4bb4A, 0.6100, 2.96, 0.203, 265, 241, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4144, 3pjcA, 0.6100, 3.34, 0.220, 286, 245, CRYSTAL STRUCTURE OF JAK3 COMPLEXED WITH A POTENT ATP SITE INHIBITOR SHOWING HIGH SELECTIVITY WITHIN THE JANUS KINASE FAMILY
4145, 3eqrA, 0.6100, 3.24, 0.210, 270, 243, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T74
4146, 4oboA, 0.6099, 3.30, 0.239, 275, 243, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
4147, 2xynC, 0.6099, 3.18, 0.252, 262, 242, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
4148, 2ktyA, 0.6099, 3.82, 0.176, 360, 256, SOLUTION STRUCTURE OF HUMAN VACCINIA RELATED KINASE-1
4149, 6es0A, 0.6098, 3.36, 0.213, 288, 244, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE ACTIVATION LOOP TARGETING INHIBITOR CS-R35
4150, 6d8eA, 0.6098, 3.41, 0.216, 304, 245, DISCOVERY OF A HIGHLY POTENT AND BROADLY EFFECTIVE EGFR AND HER2 EXON 20 INSERTION MUTANT INHIBITOR 
4151, 5ootA, 0.6098, 2.85, 0.271, 260, 236, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4152, 4jdkA, 0.6098, 3.41, 0.247, 288, 243, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE S PEPTIDE SUBSTRATE
4153, 4e3cE, 0.6098, 3.54, 0.229, 624, 249, X-RAY CRYSTAL STRUCTURE OF HUMAN IKK2 IN AN ACTIVE CONFORMATION
4154, 3eyhA, 0.6098, 3.69, 0.220, 285, 250, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
4155, 2fb8B, 0.6098, 3.04, 0.229, 259, 240, STRUCTURE OF THE B-RAF KINASE DOMAIN BOUND TO SB-590885
4156, 6glaB, 0.6097, 3.36, 0.216, 286, 245, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
4157, 5u6bB, 0.6097, 3.48, 0.218, 291, 248, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4158, 5tq8A, 0.6097, 3.57, 0.225, 291, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4159, 5oorA, 0.6097, 2.87, 0.266, 273, 237, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH STAUROSPORINE
4160, 3zhpD, 0.6097, 3.29, 0.208, 264, 245, HUMAN MST3 (STK24) IN COMPLEX WITH MO25BETA
4161, 3dk3A, 0.6097, 3.21, 0.224, 266, 241, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4162, 3d15A, 0.6097, 3.28, 0.242, 256, 244, CRYSTAL STRUCTURE OF MOUSE AURORA A (ASN186->GLY LYS240->ARG MET302- >LEU) IN COMPLEX WITH 1-(3-CHLORO-PHENYL)-3-{5-[2-(THIENO[32- D]PYRIMIDIN-4-YLAMINO)- ETHYL]-THIAZOL-2-YL}-UREA [SNS-314]
4163, 3b8rA, 0.6097, 3.22, 0.227, 289, 242, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4164, 2cgwA, 0.6097, 2.95, 0.256, 262, 238, IDENTIFICATION OF CHEMICALLY DIVERSE CHK1 INHIBITORS BY RECEPTOR-BASED VIRTUAL SCREENING
4165, 6cfmA, 0.6096, 3.83, 0.177, 316, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PROPYNYL-PTERIDINONE INHIBITOR
4166, 5ukfC, 0.6096, 3.93, 0.168, 317, 256, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO AN OXINDOLE INHIBITOR
4167, 5nkiA, 0.6096, 2.69, 0.208, 268, 236, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 4B
4168, 5de2A, 0.6096, 3.15, 0.238, 267, 244, STRUCTURAL MECHANISM OF NEK7 ACTIVATION BY NEK9-INDUCED DIMERISATION
4169, 4zlzA, 0.6096, 3.48, 0.173, 270, 249, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE IN COMPLEX WITH A SUBSTITUTED CINNOLINE
4170, 4l67A, 0.6096, 3.42, 0.246, 289, 244, CRYSTAL STRUCTURE OF CATALYTIC DOMAIN OF PAK4
4171, 4fiiA, 0.6096, 3.47, 0.242, 291, 244, CATALYTIC DOMAIN OF HUMAN PAK4 WITH RPKPLVDP PEPTIDE
4172, 4fihA, 0.6096, 3.36, 0.244, 291, 242, CATALYTIC DOMAIN OF HUMAN PAK4 WITH QKFTGLPRQW PEPTIDE
4173, 3zbfA, 0.6096, 3.05, 0.254, 281, 240, STRUCTURE OF HUMAN ROS1 KINASE DOMAIN IN COMPLEX WITH CRIZOTINIB
4174, 3i6wE, 0.6096, 3.25, 0.296, 368, 240, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
4175, 3eqgA, 0.6096, 3.53, 0.220, 314, 250, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH PD ADP AND MG2P
4176, 3dajA, 0.6096, 2.77, 0.254, 245, 236, CRYSTAL STRUCTURE OF AURORA A COMPLEXED WITH AN INHIBITOR DISCOVERED THROUGH SITE-DIRECTED DYNAMIC TETHERING
4177, 6cswA, 0.6095, 3.65, 0.179, 316, 252, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
4178, 5vd8A, 0.6095, 3.18, 0.191, 260, 241, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 099 A MK1775 ANALOGUE
4179, 5vd7A, 0.6095, 3.21, 0.190, 261, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 098 A MK1775 ANALOGUE
4180, 5nk0A, 0.6095, 2.80, 0.197, 273, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 1J
4181, 4tyjA, 0.6095, 3.01, 0.253, 278, 241, STRUCTURAL ANALYSIS OF THE HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE
4182, 4d55A, 0.6095, 3.00, 0.225, 260, 240, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4183, 4bicA, 0.6095, 2.89, 0.294, 260, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4184, 4appA, 0.6095, 3.41, 0.243, 291, 243, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH (S)-N-(5-(3-BENZYL-1-METHYLPIPERAZINE-4- CARBONYL)-66-DIMETHYL-1456-TETRAHYDROPYRROLO(34-C) PYRAZOL-3-YL)-3-PHENOXYBENZAMIDE
4185, 3ppjA, 0.6095, 3.00, 0.226, 262, 239, HUMAN B-RAF KINASE IN COMPLEX WITH A FUROPYRIDINE INHIBITOR
4186, 6drwA, 0.6094, 3.43, 0.232, 289, 246, JAK2 JH1 IN COMPLEX WITH JNJ-7706621 (CRYSTAL FORM 2) 
4187, 5usqA, 0.6094, 3.56, 0.208, 299, 245, ALK-5 KINASE INHIBITOR COMPLEX
4188, 5ia0A, 0.6094, 2.82, 0.197, 263, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH ALISERTIB (MLN8237)
4189, 4i5mA, 0.6094, 3.31, 0.258, 273, 244, SELECTIVE & BRAIN-PERMEABLE POLO-LIKE KINASE-2 (PLK-2) INHIBITORS THAT REDUCE -SYNUCLEIN PHOSPHORYLATION IN RAT BRAIN
4190, 4h1mA, 0.6094, 2.93, 0.155, 256, 239, CRYSTAL STRUCTURE OF PYK2 WITH THE INDOLE 10C
4191, 4bidB, 0.6094, 2.96, 0.300, 258, 237, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4192, 4aotB, 0.6094, 3.00, 0.229, 279, 240, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
4193, 3a4pA, 0.6094, 3.44, 0.224, 285, 246, HUMAN C-MET KINASE DOMAIN COMPLEXED WITH 6-BENZYLOXYQUINOLINE INHIBITOR
4194, 2xk8A, 0.6094, 2.81, 0.219, 246, 237, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 15
4195, 1mqbA, 0.6094, 2.95, 0.192, 263, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4196, 5wnhB, 0.6093, 3.85, 0.227, 365, 256, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
4197, 5valB, 0.6093, 2.94, 0.232, 254, 237, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4198, 5cf6A, 0.6093, 3.36, 0.224, 285, 246, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-[(2S)-23-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-35810- TETRAAZATRICYCLO [7.3.0.026]DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
4199, 4qt1A, 0.6093, 3.36, 0.214, 277, 243, JAK3 KINASE DOMAIN IN COMPLEX WITH 1-[(3S)-1-ISOBUTYLSULFONYL-3- PIPERIDYL]-3-(5H-PYRROLO[23-B]PYRAZIN-2-YL)UREA
4200, 4gk4A, 0.6093, 3.05, 0.203, 275, 241, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 90
4201, 3q96A, 0.6093, 2.97, 0.232, 253, 237, B-RAF KINASE DOMAIN IN COMPLEX WITH A TETRAHYDRONAPHTHALENE INHIBITOR
4202, 3ppkA, 0.6093, 2.98, 0.226, 262, 239, HUMAN B-RAF KINASE IN COMPLEX WITH A NON-OXIME FUROPYRIDINE INHIBITOR
4203, 3eqpA, 0.6093, 3.25, 0.210, 268, 243, CRYSTAL STRUCTURE OF ACK1 WITH COMPOUND T95
4204, 5tkxA, 0.6092, 3.80, 0.153, 315, 255, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
4205, 4xliA, 0.6092, 3.16, 0.246, 264, 240, CRYSTAL STRUCTURE OF ABL2/ARG KINASE IN COMPLEX WITH DASATINIB
4206, 4x7lA, 0.6092, 3.14, 0.222, 260, 239, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-4-METHYL-3-[2- (METHYLAMINO)-13-BENZOTHIAZOL-6-YL]BENZOYL}-1-METHYL-25-DIPHENYL-1 2-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4207, 4x7kA, 0.6092, 3.14, 0.222, 260, 239, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-{2-AMINO-3-[5-FLUORO-2- (METHYLAMINO)QUINAZOLIN-6-YL]-4-METHYLBENZOYL}-1-METHYL-25-DIPHENYL- 12-DIHYDRO-3H-PYRAZOL-3-ONE INHIBITOR
4208, 4u40A, 0.6092, 3.23, 0.229, 295, 245, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
4209, 4py1A, 0.6092, 3.61, 0.225, 289, 249, CRYSTAL STRUCTURE OF TYK2 IN COMPLEX WITH COMPOUND 15 6-((25- DIMETHOXYPHENYL)THIO)-3-(1-METHYL-1H-PYRAZOL-4-YL)-[124]TRIAZOLO[4 3-B]PYRIDAZINE
4210, 4mnfA, 0.6092, 3.07, 0.226, 257, 239, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
4211, 4jrnA, 0.6092, 3.63, 0.209, 349, 249, ROP18 KINASE DOMAIN IN COMPLEX WITH AMP-PNP AND SUCROSE
4212, 4fsnA, 0.6092, 2.99, 0.265, 270, 238, CRYSTAL STRUCTURE OF THE CHK1
4213, 2yiyA, 0.6092, 2.80, 0.253, 293, 233, CRYSTAL STRUCTURE OF COMPOUND 8 BOUND TO TAK1-TAB
4214, 2np8A, 0.6092, 3.13, 0.244, 256, 242, STRUCTURAL BASIS FOR THE INHIBITION OF AURORA A KINASE BY A NOVEL CLASS OF HIGH AFFINITY DISUBSTITUTED PYRIMIDINE INHIBITORS
4215, 2hz4C, 0.6092, 3.19, 0.216, 259, 241, ABL KINASE DOMAIN UNLIGATED AND IN COMPLEX WITH TETRAHYDROSTAUROSPORINE
4216, 1fvrB, 0.6092, 3.15, 0.212, 300, 240, TIE2 KINASE DOMAIN
4217, 5p9jA, 0.6091, 3.47, 0.170, 263, 247, BTK1 COCRYSTALLIZED WITH IBRUTINIB
4218, 5ng3D, 0.6091, 3.56, 0.192, 278, 250, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4219, 5i0bA, 0.6091, 3.36, 0.248, 288, 242, STRUCTURE OF PAK4
4220, 4yzmB, 0.6091, 3.14, 0.203, 262, 241, HUMANIZED ROCO4 BOUND TO LRRK2-IN1
4221, 4fobA, 0.6091, 3.30, 0.175, 295, 246, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 1
4222, 4fnyA, 0.6091, 3.09, 0.178, 273, 241, CRYSTAL STRUCTURE OF THE R1275Q ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4223, 4d1sA, 0.6091, 3.22, 0.222, 280, 243, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
4224, 3udbC, 0.6091, 3.47, 0.201, 261, 249, CRYSTAL STRUCTURE OF SNRK2.6
4225, 1xwsA, 0.6091, 3.01, 0.244, 273, 238, CRYSTAL STRUCTURE OF THE HUMAN PIM1 KINASE DOMAIN
4226, 6dkwA, 0.6090, 2.72, 0.212, 284, 236, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 3. 
4227, 5vefA, 0.6090, 3.38, 0.243, 289, 243, PAK4 KINASE DOMAIN IN COMPLEX WITH FASUDIL
4228, 5uu1A, 0.6090, 3.80, 0.149, 315, 255, CRYSTAL STRUCTURE OF HUMAN VACCINIA-RELATED KINASE 2 (VRK-2) BOUND TO BI-D1870
4229, 5j7bA, 0.6090, 3.13, 0.216, 277, 241, THE IDENTIFICATION AND PHARMACOLOGICAL CHARACTERIZATION OF 6-(TERT- BUTYLSULFONYL)-N-(5-FLUORO-1H-INDAZOL-3-YL)QUINOLIN-4-AMINE (GSK583) A HIGHLY POTENT AND SELECTIVE INHIBITOR OF RIP2 KINASE GSK583 COMPLEX
4230, 4yzmA, 0.6090, 3.17, 0.212, 260, 241, HUMANIZED ROCO4 BOUND TO LRRK2-IN1
4231, 4im0A, 0.6090, 3.57, 0.198, 619, 247, STRUCTURE OF TANK-BINDING KINASE 1
4232, 4hctA, 0.6090, 3.50, 0.165, 265, 249, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 52
4233, 2jitA, 0.6090, 3.53, 0.214, 299, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
4234, 6dkwB, 0.6089, 2.84, 0.201, 269, 239, CRYSTAL STRUCTURE OF TRK-A IN COMPLEX WITH THE PAN-TRK KINASE INHIBITOR; COMPOUND 3. 
4235, 6cmmC, 0.6089, 3.74, 0.178, 316, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
4236, 5u6bD, 0.6089, 3.49, 0.214, 291, 248, STRUCTURE OF THE AXL KINASE DOMAIN IN COMPLEX WITH A MACROCYCLIC INHIBITOR
4237, 5l6oA, 0.6089, 3.16, 0.202, 267, 242, EPHB3 KINASE DOMAIN COVALENTLY BOUND TO AN IRREVERSIBLE INHIBITOR (COMPOUND 3)
4238, 5l2qD, 0.6089, 3.29, 0.214, 294, 243, SERINE/THREONINE-PROTEIN KINASE 40 (STK40) KINASE HOMOLOGY DOMAIN
4239, 5flfE, 0.6089, 2.94, 0.265, 258, 238, DISEASE LINKED MUTATION IN FGFR
4240, 5aepA, 0.6089, 3.44, 0.227, 287, 247, NOVEL PYRROLE CARBOXAMIDE INHIBITORS OF JAK2 AS POTENTIAL TREATMENT OF MYELOPROLIFERATIVE DISORDERS
4241, 4zjiA, 0.6089, 3.01, 0.237, 278, 240, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4242, 4x7hA, 0.6089, 2.97, 0.224, 256, 237, CO-CRYSTAL STRUCTURE OF PERK BOUND TO N-{5-[(67-DIMETHOXYQUINOLIN-4- YL)OXY]PYRIDIN-2-YL}-1-METHYL-3-OXO-2-PHENYL-5-(PYRIDIN-4-YL)-23- DIHYDRO-1H-PYRAZOLE-4-CARBOXAMIDE INHIBITOR
4243, 4qo9B, 0.6089, 3.37, 0.205, 285, 244, MST3 IN COMPLEX WITH DANUSERTIB
4244, 4cljA, 0.6089, 3.27, 0.180, 295, 245, STRUCTURE OF L1196M MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4245, 4c8bB, 0.6089, 3.11, 0.208, 281, 240, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH PONATINIB
4246, 3zfxA, 0.6089, 3.21, 0.214, 267, 243, CRYSTAL STRUCTURE OF EPHB1
4247, 3tv4A, 0.6089, 3.12, 0.211, 264, 242, HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH AN BROMOPYRIDINE BENZAMIDE INHIBITOR
4248, 3l8vA, 0.6089, 3.32, 0.205, 293, 244, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A BIARYLAMINE BASED INHIBITOR
4249, 2qocA, 0.6089, 3.17, 0.206, 283, 243, HUMAN EPHA3 KINASE DOMAIN PHOSPHORYLATED AMP-PNP BOUND STRUCTURE
4250, 4jdjA, 0.6088, 3.48, 0.242, 288, 244, CRYSTAL STRUCTURE OF SERINE/THREONINE-PROTEIN KINASE PAK 4 F461V MUTANT IN COMPLEX WITH PAKTIDE T PEPTIDE SUBSTRATE
4251, 4hcuA, 0.6088, 3.43, 0.161, 263, 248, CRYSTAL STRUCTURE OF ITK IN COMPLEXT WITH COMPOUND 40
4252, 3dtwB, 0.6088, 3.08, 0.233, 269, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4253, 2y4iC, 0.6088, 3.79, 0.209, 313, 253, KSR2-MEK1 HETERODIMER
4254, 5ttvA, 0.6087, 3.46, 0.211, 280, 246, JAK3 WITH COVALENT INHIBITOR 6
4255, 5op7A, 0.6087, 2.95, 0.265, 261, 238, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
4256, 5e8wA, 0.6087, 3.64, 0.207, 303, 246, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE
4257, 4zjjA, 0.6087, 3.08, 0.237, 280, 241, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4258, 4yhtA, 0.6087, 2.88, 0.236, 256, 237, BRAF COMPLEXED WITH AN INHIBITOR
4259, 4xv1B, 0.6087, 3.01, 0.232, 249, 237, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX7904
4260, 4c3rA, 0.6087, 3.09, 0.245, 252, 241, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) BOUND TO AMPPCP
4261, 3zfxD, 0.6087, 3.21, 0.214, 265, 243, CRYSTAL STRUCTURE OF EPHB1
4262, 3zepC, 0.6087, 3.51, 0.216, 276, 245, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4263, 3socB, 0.6087, 3.74, 0.217, 309, 249, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
4264, 3f69A, 0.6087, 3.08, 0.239, 270, 243, CRYSTAL STRUCTURE OF THE MYCOBACTERIUM TUBERCULOSIS PKNB MUTANT KINASE DOMAIN IN COMPLEX WITH KT5720
4265, 2xk3A, 0.6087, 2.86, 0.227, 247, 238, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 35
4266, 6brcB, 0.6086, 3.11, 0.262, 260, 240, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH AP26113-ANALOG (ALK-IN-1)
4267, 5opvA, 0.6086, 3.00, 0.269, 261, 238, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4268, 5j95B, 0.6086, 3.44, 0.201, 300, 249, MAP4K4 IN COMPLEX WITH INHIBITOR
4269, 5edpA, 0.6086, 3.20, 0.202, 295, 243, EGFR KINASE (T790M/L858R) APO
4270, 4ft9A, 0.6086, 3.06, 0.264, 270, 239, CRYSTAL STRUCTURE OF THE CHK1
4271, 4asxB, 0.6086, 3.90, 0.218, 307, 252, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
4272, 4asxA, 0.6086, 3.74, 0.217, 310, 249, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DIHYDRO-BAUERINE C
4273, 3dv3A, 0.6086, 3.31, 0.215, 288, 246, MEK1 WITH PF-04622664 BOUND
4274, 2jkkA, 0.6086, 3.07, 0.228, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4275, 1nvrA, 0.6086, 3.02, 0.265, 264, 238, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/STAUROSPORINE
4276, 4x7nA, 0.6085, 3.14, 0.222, 259, 239, CO-CRYSTAL STRUCTURE OF PERK BOUND TO 4-[2-AMINO-4-METHYL-3-(2- METHYLQUINOLIN-6-YL)BENZOYL]-1-METHYL-25-DIPHENYL-12-DIHYDRO-3H- PYRAZOL-3-ONE INHIBITOR
4277, 4jbpA, 0.6085, 3.14, 0.247, 255, 243, NOVEL AURORA KINASE INHIBITORS REVEAL MECHANISMS OF HURP IN NUCLEATION OF CENTROSOMAL AND KINETOCHORE MICROTUBULES
4278, 4im2A, 0.6085, 3.57, 0.198, 618, 247, STRUCTURE OF TANK-BINDING KINASE 1
4279, 3zfxH, 0.6085, 3.21, 0.214, 266, 243, CRYSTAL STRUCTURE OF EPHB1
4280, 3dk6A, 0.6085, 3.19, 0.225, 262, 240, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4281, 3be2A, 0.6085, 3.10, 0.229, 290, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZAMIDE INHIBITOR
4282, 2jkqA, 0.6085, 3.06, 0.228, 258, 241, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4283, 1nvqA, 0.6085, 3.02, 0.265, 264, 238, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/UCN-01
4284, 5xfjA, 0.6084, 2.83, 0.263, 266, 236, CRYSTAL STRUCTURE OF LY2874455 IN COMPLEX OF FGFR4 GATEKEEPER MUTATION (V550M) 
4285, 5vd5A, 0.6084, 3.21, 0.191, 260, 241, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 050 A MK1775 ANALOUGUE
4286, 5tq3B, 0.6084, 3.49, 0.222, 285, 248, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4287, 5e90A, 0.6084, 3.66, 0.223, 303, 247, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249F S280T Y282FS287NA350CL352F) IN COMPLEX WITH 3-AMINO-6- [4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2- CARBOXAMIDE
4288, 3tubA, 0.6084, 3.08, 0.200, 253, 240, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-3-((1R2S)-2- PHENYLCYCLOPROPYL)UREA
4289, 3io7A, 0.6084, 3.38, 0.228, 282, 246, 2-AMINOPYRAZOLO[15-A]PYRIMIDINES AS POTENT AND SELECTIVE INHIBITORS OF JAK2
4290, 3fxxA, 0.6084, 3.18, 0.202, 288, 243, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BOUND TO SUBSTRATE KQWDNYE[PTYR]IW
4291, 2qo9A, 0.6084, 3.07, 0.207, 277, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION PHOSPHORYLATED AMP-PNP BOUND
4292, 2p55A, 0.6084, 3.46, 0.214, 289, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4293, 1p4fA, 0.6084, 3.20, 0.304, 269, 240, DEATH ASSOCIATED PROTEIN KINASE CATALYTIC DOMAIN WITH BOUND INHIBITOR FRAGMENT
4294, 6fu5B, 0.6083, 3.04, 0.204, 286, 240, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
4295, 5nwzB, 0.6083, 2.92, 0.265, 268, 238, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
4296, 5jkgA, 0.6083, 2.71, 0.264, 266, 235, THE CRYSTAL STRUCTURE OF FGFR4 KINASE DOMAIN IN COMPLEX WITH LY2874455
4297, 5hg8A, 0.6083, 3.51, 0.215, 300, 247, EGFR (L858R T790M V948R) IN COMPLEX WITH N-[3-({2-[(1-METHYL-1H- PYRAZOL-4-YL)AMINO]-7H-PYRROLO[23-D]PYRIMIDIN-4-YL}OXY)PHENYL]PROP- 2-ENAMIDE
4298, 4qyeA, 0.6083, 3.02, 0.265, 271, 238, CHK1 KINASE DOMAIN IN COMPLEX WITH DIARYLPYRAZINE COMPOUND 1
4299, 4qoxA, 0.6083, 3.96, 0.301, 462, 256, CRYSTAL STRUCTURE OF CDPK4 FROM PLASMODIUM FALCIPARUM PF3D7_0717500
4300, 3qd2B, 0.6083, 3.23, 0.228, 271, 241, CRSYTAL STRUCTURE OF MOUSE PERK KINASE DOMAIN
4301, 3dxnA, 0.6083, 3.49, 0.297, 258, 246, CRYSTAL STRUCTURE OF THE CALCIUM-DEPENDENT KINASE FROM TOXOPLASMA GONDII 541.M00134 KINASE DOMAIN.
4302, 2oiqA, 0.6083, 3.02, 0.255, 265, 239, CRYSTAL STRUCTURE OF CHICKEN C-SRC KINASE DOMAIN IN COMPLEX WITH THE CANCER DRUG IMATINIB.
4303, 2in6A, 0.6083, 2.98, 0.186, 256, 237, WEE1 KINASE COMPLEX WITH INHIBITOR PD311839
4304, 1ol6A, 0.6083, 3.00, 0.252, 245, 238, STRUCTURE OF UNPHOSPHORYLATED D274N MUTANT OF AURORA-A
4305, 6bqpA, 0.6082, 3.21, 0.264, 263, 242, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH CRENOLANIB
4306, 6bqlA, 0.6082, 3.47, 0.252, 278, 246, CRYSTAL STRUCTURE OF THE HUMAN CAMKK2B IN COMPLEX WITH TAE-226
4307, 5t6iA, 0.6082, 3.82, 0.276, 427, 254, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH 5GB
4308, 5jfsA, 0.6082, 2.83, 0.207, 277, 237, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-00593174
4309, 4p5qA, 0.6082, 3.03, 0.212, 275, 240, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH QUINOXALINE DERIVATIVES
4310, 4kabB, 0.6082, 3.10, 0.222, 258, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 3-METHYL-14- DIHYDRO-PYRAZOLO[45-C]PYRAZOLE
4311, 4gvjA, 0.6082, 3.71, 0.220, 290, 250, TYK2 (JH1) IN COMPLEX WITH ADENOSINE DI-PHOSPHATE
4312, 4as0A, 0.6082, 3.02, 0.244, 273, 238, CYCLOMETALATED PHTHALIMIDES AS PROTEIN KINASE INHIBITORS
4313, 3mygA, 0.6082, 3.25, 0.247, 252, 243, AURORA A KINASE COMPLEXED WITH SCH 1473759
4314, 3dkfA, 0.6082, 3.17, 0.219, 294, 242, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4315, 2wouA, 0.6082, 3.61, 0.211, 299, 246, ALK5 IN COMPLEX WITH 4-((4-((26-DIMETHYL-3-PYRIDYL)OXY)-2- PYRIDYL)AMINO)BENZENESULFONAMIDE
4316, 2cdzA, 0.6082, 3.38, 0.248, 289, 242, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4 IN COMPLEX WITH CGP74514A
4317, 5nk8A, 0.6081, 2.87, 0.197, 266, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH COMPOUND 2F
4318, 5ar7A, 0.6081, 3.21, 0.212, 278, 241, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BIARYL UREA
4319, 3genA, 0.6081, 3.51, 0.177, 264, 248, THE 1.6 A CRYSTAL STRUCTURE OF HUMAN BRUTON S TYROSINE KINASE BOUND TO A PYRROLOPYRIMIDINE-CONTAINING COMPOUND
4320, 1rw8A, 0.6081, 3.49, 0.207, 301, 246, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH ATP SITE INHIBITOR
4321, 5x28A, 0.6080, 3.36, 0.204, 310, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(6)
4322, 5vc6A, 0.6080, 3.17, 0.187, 259, 240, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH PHA- 848125
4323, 5valA, 0.6080, 2.90, 0.233, 254, 236, BRAF IN COMPLEX WITH N-(3-(TERT-BUTYL)PHENYL)-4-METHYL-3-(6- MORPHOLINOPYRIMIDIN-4-YL)BENZAMIDE
4324, 5uq0A, 0.6080, 3.06, 0.255, 266, 239, FGFR1 KINASE DOMAIN COMPLEX WITH FRAGMENT 22-DIMETHYL-23- DIHYDROBENZOFURAN-7-CARBOXAMIDE
4325, 5jrsA, 0.6080, 3.39, 0.175, 258, 246, CRYSTAL STRUCTURE OF BRUTON AGAMMAGLOBULINEMIA TYROSINE KINASE COMPLEXED WITH 4-[2-FLUORO-3-(4-OXO -34-DIHYDROQUINAZOLIN-3-YL) PHENYL]-7-(2-HYDROXYPROPAN-2-Y L)-9H-CARBAZOLE-1-CARBOXAMIDE
4326, 5iuiA, 0.6080, 3.29, 0.183, 303, 246, CRYSTAL STRUCTURE OF ANAPLASTIC LYPHOMA KINASE (ALK) IN COMPLEX WITH 4
4327, 5hg5A, 0.6080, 3.51, 0.215, 302, 247, EGFR (L858R T790M V948R) IN COMPLEX WITH N-{3-[(2-{[4-(4- METHYLPIPERAZIN-1-YL)PHENYL]AMINO}-7H-PYRROLO[23-D]PYRIMIDIN-4-YL) OXY]PHENYL}PROP-2-ENAMIDE
4328, 4xbuA, 0.6080, 3.47, 0.242, 292, 244, IN VITRO CRYSTAL STRUCTURE OF PAK4 IN COMPLEX WITH INKA PEPTIDE
4329, 4qyfA, 0.6080, 3.00, 0.270, 269, 237, CHK1 KINASE DOMAIN IN COMPLEX WITH AMINOPYRAZINE COMPOUND 13
4330, 4ih8A, 0.6080, 3.81, 0.287, 433, 254, CRYSTAL STRUCTURE OF TGCDPK1 WITH INHIBITOR BOUND
4331, 4id7A, 0.6080, 3.16, 0.202, 268, 242, ACK1 KINASE IN COMPLEX WITH THE INHIBITOR CIS-3-[8-AMINO-1-(4- PHENOXYPHENYL)IMIDAZO[15-A]PYRAZIN-3-YL]CYCLOBUTANOL
4332, 2itoA, 0.6080, 3.30, 0.213, 303, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH IRESSA
4333, 6fniA, 0.6079, 2.95, 0.203, 261, 237, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE WITH NVP-BHG712 
4334, 5v19B, 0.6079, 3.01, 0.305, 260, 236, STRUCTURE-BASED DRUG DESIGN OF NOVEL ASK1 INHIBITORS USING A FULLY INTEGRATED LEAD OPTIMIZATION STRATEGY
4335, 5aagA, 0.6079, 3.25, 0.243, 253, 243, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (14B)
4336, 4zjiB, 0.6079, 3.03, 0.242, 276, 240, PAK1 IN COMPLEX WITH 2-CHLORO-5-ETHYL-8-FLUORO-11-(4-METHYLPIPERAZIN- 1-YL)-DIBENZODIAZEPINE
4337, 4j95B, 0.6079, 3.52, 0.245, 282, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4338, 4g5pA, 0.6079, 3.55, 0.222, 299, 248, CRYSTAL STRUCTURE OF EGFR KINASE T790M IN COMPLEX WITH BIBW2992
4339, 3sxrA, 0.6079, 3.17, 0.207, 260, 241, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
4340, 3dk7B, 0.6079, 3.26, 0.220, 268, 241, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4341, 2qu5A, 0.6079, 3.36, 0.220, 292, 246, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZIMIDAZOLE INHIBITOR
4342, 2qohA, 0.6079, 3.24, 0.223, 271, 242, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
4343, 2gs2A, 0.6079, 3.37, 0.204, 305, 245, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN
4344, 1nvsA, 0.6079, 3.03, 0.265, 264, 238, THE COMPLEX STRUCTURE OF CHECKPOINT KINASE CHK1/SB218078
4345, 6glaA, 0.6078, 3.41, 0.216, 288, 245, CRYSTAL STRUCTURE OF JAK3 IN COMPLEX WITH COMPOUND 11 (FM481) 
4346, 6bruC, 0.6078, 3.80, 0.174, 315, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A (S)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4347, 5up3A, 0.6078, 2.90, 0.298, 258, 235, STRUCTURE-BASED DESIGN OF ASK1 INHIBITORS AS POTENTIAL FIRST-IN-CLASS AGENTS FOR HEART FAILURE
4348, 5tq3A, 0.6078, 3.46, 0.223, 282, 247, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4349, 5ng0A, 0.6078, 3.27, 0.215, 274, 242, STRUCTURE OF RIP2K(L294F) WITH BOUND AMPPCP
4350, 5dh3A, 0.6078, 3.33, 0.238, 287, 244, CRYSTAL STRUCTURE OF MST2 IN COMPLEX WITH XMU-MP-1
4351, 5ax9B, 0.6078, 3.05, 0.231, 274, 238, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE IN COMPLEX WITH COMPUND 9
4352, 5ar3A, 0.6078, 3.28, 0.220, 279, 241, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH AMP-PCP
4353, 4x7jA, 0.6078, 3.03, 0.219, 257, 237, CO-CRYSTAL STRUCTURE OF PERK WITH 2-AMINO-N-[4-METHOXY-3- (TRIFLUOROMETHYL)PHENYL]-4-METHYL-3-[2-(METHYLAMINO)QUINAZOLIN-6- YL]BENZAMIDE INHIBITOR
4354, 4u44B, 0.6078, 3.34, 0.215, 296, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 16)
4355, 4rvtB, 0.6078, 3.46, 0.209, 297, 249, MAP4K4 IN COMPLEX WITH A PYRIDIN-2(1H)-ONE DERIVATIVE
4356, 4ks8A, 0.6078, 3.40, 0.243, 286, 243, PAK6 KINASE DOMAIN IN COMPLEX WITH SUNITINIB
4357, 4gt4B, 0.6078, 3.47, 0.196, 273, 245, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4358, 4btkA, 0.6078, 3.48, 0.226, 287, 248, TTBK1 IN COMPLEX WITH INHIBITOR
4359, 4anlA, 0.6078, 3.39, 0.166, 292, 247, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE
4360, 3b8rB, 0.6078, 3.04, 0.243, 267, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4361, 3b8qB, 0.6078, 3.18, 0.228, 271, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4362, 2xynB, 0.6078, 3.28, 0.252, 264, 242, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
4363, 2eb3A, 0.6078, 3.29, 0.205, 294, 244, CRYSTAL STRUCTURE OF MUTATED EGFR KINASE DOMAIN (L858R) IN COMPLEX WITH AMPPNP
4364, 6btwC, 0.6077, 3.84, 0.174, 315, 253, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PHENYL-PTERIDINONE INHIBITOR
4365, 5tozA, 0.6077, 3.41, 0.216, 278, 245, JAK3 WITH COVALENT INHIBITOR PF-06651600
4366, 5kkrC, 0.6077, 3.82, 0.209, 309, 253, KSR2:MEK1 COMPLEX BOUND TO THE SMALL MOLECULE APS-2-79
4367, 5aadA, 0.6077, 3.20, 0.248, 252, 242, AURORA A KINASE BOUND TO AN IMIDAZOPYRIDINE INHIBITOR (7A)
4368, 4hvhA, 0.6077, 3.43, 0.217, 278, 244, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((R)-2-HYDROXY-12-DIMETHYL-PROPYL
4369, 3vjoA, 0.6077, 3.39, 0.204, 298, 245, CRYSTAL STRUCTURE OF THE WILD-TYPE EGFR KINASE DOMAIN IN COMPLEX WITH AMPPNP.
4370, 3q4tB, 0.6077, 3.84, 0.216, 308, 250, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
4371, 3jvrA, 0.6077, 3.24, 0.254, 258, 240, CHARACTERIZATION OF THE CHK1 ALLOSTERIC INHIBITOR BINDING SITE
4372, 2y6oA, 0.6077, 2.92, 0.214, 263, 238, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH DASATINIB.
4373, 2w1dA, 0.6077, 3.14, 0.245, 251, 241, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4374, 1vr2A, 0.6077, 2.98, 0.226, 275, 239, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN
4375, 5jfxA, 0.6076, 2.84, 0.198, 277, 237, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-06273340
4376, 5di1B, 0.6076, 3.48, 0.205, 300, 249, MAP4K4 IN COMPLEX WITH AN INHIBITOR
4377, 5cf5A, 0.6076, 3.40, 0.228, 287, 246, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 7-[(DIMETHYL-13-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.026] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
4378, 4j99B, 0.6076, 3.52, 0.249, 291, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
4379, 4hcvA, 0.6076, 3.49, 0.161, 263, 248, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 53
4380, 3v04A, 0.6076, 3.49, 0.218, 289, 248, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
4381, 3socA, 0.6076, 3.76, 0.221, 307, 249, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH A QUINAZOLIN
4382, 3ot3A, 0.6076, 2.87, 0.263, 259, 236, X-RAY CRYSTAL STRUCTURE OF COMPOUND 22K BOUND TO HUMAN CHK1 KINASE DOMAIN
4383, 3eqiA, 0.6076, 3.76, 0.225, 315, 253, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ADP AND MG2P
4384, 3ckxA, 0.6076, 3.05, 0.222, 276, 239, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24) IN COMPLEX WITH STAUROSPORINE
4385, 4u81A, 0.6075, 3.52, 0.217, 289, 249, MEK1 KINASE BOUND TO SMALL MOLECULE INHIBITOR G659
4386, 4eheA, 0.6075, 3.17, 0.223, 266, 242, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOTHIENOPYRIMIDINE-BASED INHIBITOR
4387, 4an9A, 0.6075, 3.67, 0.215, 281, 251, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
4388, 3prfB, 0.6075, 2.96, 0.227, 262, 238, CRYSTAL STRUCTURE OF HUMAN B-RAF KINASE DOMAIN IN COMPLEX WITH A NON- OXIME FUROPYRIDINE INHIBITOR
4389, 3i6uB, 0.6075, 3.23, 0.311, 376, 241, STRUCTURE AND ACTIVATION MECHANISM OF THE CHK2 DNA-DAMAGE CHECKPOINT KINASE
4390, 2xikA, 0.6075, 3.49, 0.220, 288, 245, STRUCTURE OF HUMAN YSK1 (YEAST SPS1-STE20-RELATED KINASE 1)
4391, 2qokA, 0.6075, 3.11, 0.220, 281, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:S768A TRIPLE MUTANT
4392, 2qhmA, 0.6075, 3.16, 0.285, 268, 239, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 2A
4393, 5o23A, 0.6074, 3.36, 0.248, 269, 246, CRYSTAL STRUCTURE OF WNK3 KINASE DOMAIN IN A MONOPHOSPHORYLATED APO STATE
4394, 5cxhA, 0.6074, 3.44, 0.207, 277, 246, SYK CATALYTIC DOMAIN COMPLEXED WITH A POTENT ORALLY BIOAVAILABLE THIAZOLE INHIBITOR
4395, 4zp5B, 0.6074, 3.47, 0.205, 300, 249, MAP4K4 IN COMPLEX WITH INHIBITOR
4396, 4ypsA, 0.6074, 3.32, 0.202, 280, 242, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4397, 3lxnA, 0.6074, 3.63, 0.222, 287, 248, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
4398, 3eqdA, 0.6074, 3.69, 0.219, 315, 251, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A BINARY COMPLEX WITH ATP-GS AND MG2P
4399, 2xk7A, 0.6074, 2.76, 0.229, 246, 236, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 23
4400, 2wtkC, 0.6074, 3.04, 0.272, 285, 239, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
4401, 2j5eA, 0.6074, 3.64, 0.205, 309, 249, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 13-JAB
4402, 6cswB, 0.6073, 3.93, 0.180, 308, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
4403, 4zjjD, 0.6073, 3.21, 0.215, 274, 242, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4404, 4aqcA, 0.6073, 3.51, 0.226, 289, 248, TRIAZOLOPYRIDINE-BASED INHIBITOR OF JANUS KINASE 2
4405, 2pl0A, 0.6073, 3.49, 0.252, 268, 246, LCK BOUND TO IMATINIB
4406, 6bu6C, 0.6072, 3.75, 0.175, 315, 252, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4407, 5y25A, 0.6072, 3.17, 0.203, 292, 241, EGFR KINASE DOMAIN MUTANT (T790M/L858R) WITH COVALENT LIGAND NS-062 
4408, 5kkrB, 0.6072, 3.26, 0.197, 272, 244, KSR2:MEK1 COMPLEX BOUND TO THE SMALL MOLECULE APS-2-79
4409, 5e8uA, 0.6072, 3.78, 0.222, 306, 248, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204DI211VY249FS280T Y282FS287NA350CL352F)
4410, 4mnfB, 0.6072, 3.07, 0.223, 257, 238, CRYSTAL STRUCTURE OF BRAF-V600E BOUND TO GDC0879
4411, 4f08B, 0.6072, 3.47, 0.227, 288, 247, DISCOVERY AND OPTIMIZATION OF C-2 METHYL IMIDAZO-PYRROLOPYRIDINES AS POTENT AND ORALLY BIOAVAILABLE JAK1 INHIBITORS WITH SELECTIVITY OVER JAK2
4412, 4e20A, 0.6072, 3.56, 0.223, 282, 247, STRUCTURE OF MOUSE TYK-2 COMPLEXED TO A 3-AMINOINDAZOLE INHIBITOR
4413, 4cmoA, 0.6072, 3.27, 0.184, 295, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 2-((1R)-1-((3-AMINO-6-(2- METHOXYPYRIDIN- -YL)PYRAZIN-2-YL)OXY)ETHYL)-4-FLUORO-N-METHYLBENZAMIDE
4414, 4an3A, 0.6072, 3.63, 0.216, 280, 250, CRYSTAL STRUCTURES OF HUMAN MEK1 WITH CARBOXAMIDE-BASED ALLOSTERIC INHIBITOR XL518 (GDC-0973) OR RELATED ANALOGS.
4415, 3qrjA, 0.6072, 3.27, 0.216, 258, 241, THE CRYSTAL STRUCTURE OF HUMAN ABL1 KINASE DOMAIN T315I MUTANT IN COMPLEX WITH DCC-2036
4416, 2io6A, 0.6072, 3.03, 0.186, 252, 237, WEE1 KINASE COMPLEXED WITH INHIBITOR PD330961
4417, 1fvrA, 0.6072, 3.21, 0.221, 299, 240, TIE2 KINASE DOMAIN
4418, 5u8lA, 0.6071, 3.53, 0.215, 289, 247, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH A SULFONYL FLUORIDE PROBE XO44
4419, 5ew3B, 0.6071, 3.13, 0.225, 266, 240, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4420, 4x2nA, 0.6071, 3.47, 0.209, 303, 244, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4421, 3zlsA, 0.6071, 3.77, 0.214, 315, 252, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 6
4422, 3zfxE, 0.6071, 3.17, 0.215, 262, 242, CRYSTAL STRUCTURE OF EPHB1
4423, 3sxrB, 0.6071, 3.07, 0.197, 258, 239, CRYSTAL STRUCTURE OF BMX NON-RECEPTOR TYROSINE KINASE COMPLEX WITH DASATINIB
4424, 3nz0A, 0.6071, 3.73, 0.212, 285, 250, NON-PHOSPHORYLATED TYK2 KINASE WITH CMP6
4425, 2bilB, 0.6071, 2.96, 0.241, 274, 237, THE HUMAN PROTEIN KINASE PIM1 IN COMPLEX WITH ITS CONSENSUS PEPTIDE PIMTIDE
4426, 1iasB, 0.6071, 3.99, 0.202, 324, 252, CYTOPLASMIC DOMAIN OF UNPHOSPHORYLATED TYPE I TGF-BETA RECEPTOR CRYSTALLIZED WITHOUT FKBP12
4427, 5xgmA, 0.6070, 3.10, 0.212, 288, 241, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M IN COMPLEX WITH GO6976
4428, 5x26A, 0.6070, 3.41, 0.208, 302, 245, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(3)
4429, 5v5yA, 0.6070, 3.10, 0.184, 259, 239, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH MK1775
4430, 5op5A, 0.6070, 2.88, 0.271, 259, 236, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIMIDINE LRRK2 INHIBITOR
4431, 5ng2A, 0.6070, 3.28, 0.207, 274, 242, STRUCTURE OF RIP2K(D146N) WITH BOUND STAUROSPORINE
4432, 5hlwA, 0.6070, 3.15, 0.224, 284, 241, CRYSTAL STRUCTURE OF C-MET MUTANT Y1230H IN COMPLEX WITH COMPOUND 14
4433, 5friA, 0.6070, 3.58, 0.211, 301, 246, ALK5 IN COMPLEX WITHA AN N-(4-ANILINO-2-PYRIDYL)ACETAMIDE INHIBITOR.
4434, 5c8mA, 0.6070, 3.29, 0.206, 302, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 17
4435, 3vidA, 0.6070, 3.16, 0.225, 299, 240, CRYSTAL STRUCTURE OF HUMAN VEGFR2 KINASE DOMAIN WITH COMPOUND A.
4436, 3tkiA, 0.6070, 3.08, 0.269, 272, 238, CRYSTAL STRUCTURE OF CHK1 IN COMPLEX WITH INHIBITOR S25
4437, 3r7oA, 0.6070, 3.61, 0.222, 299, 248, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-2461 ANALOG
4438, 2g2iB, 0.6070, 3.46, 0.217, 265, 244, A SRC-LIKE INACTIVE CONFORMATION IN THE ABL TYROSINE KINASE DOMAIN
4439, 6cfmC, 0.6069, 3.91, 0.169, 316, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A PROPYNYL-PTERIDINONE INHIBITOR
4440, 5t6aA, 0.6069, 3.83, 0.287, 431, 254, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH 5GA
4441, 5lohA, 0.6069, 2.86, 0.258, 248, 236, KINASE DOMAIN OF HUMAN GREATWALL
4442, 5ghvB, 0.6069, 3.10, 0.196, 265, 240, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4443, 4qq5A, 0.6069, 2.91, 0.277, 275, 238, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4444, 4ji9B, 0.6069, 3.51, 0.231, 288, 247, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
4445, 4deiA, 0.6069, 3.48, 0.216, 287, 245, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 24
4446, 3eqbA, 0.6069, 3.50, 0.214, 289, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4447, 3cjgA, 0.6069, 3.24, 0.241, 280, 241, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 345-TRIMETHOXY ANILINE CONTAINING PYRIMIDINE
4448, 2z7sA, 0.6069, 2.65, 0.276, 256, 232, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK1 BOUND TO PURVALNOL A
4449, 6gt1D, 0.6068, 3.04, 0.233, 260, 240, NEK7 BOUND TO PURINE INHIBITOR 
4450, 5vc4A, 0.6068, 3.28, 0.186, 261, 242, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH BOSUTINIB-ISOMER
4451, 5n50A, 0.6068, 3.07, 0.239, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(4-CHLOROPHENYL) SULFANYLACETOHYDRAZIDE
4452, 5jfvA, 0.6068, 2.86, 0.203, 277, 237, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05206283
4453, 4yjoA, 0.6068, 3.29, 0.193, 267, 244, THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222
4454, 4xyfA, 0.6068, 3.61, 0.198, 290, 248, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (S)-5-(8-FLUORO-3-(1-(3-(2- METHOXYETHOXY)QUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43-A]PYRIDIN-6- YL)-3-METHYLISOXAZOLE
4455, 4u45B, 0.6068, 3.38, 0.219, 295, 247, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 25)
4456, 4rvkA, 0.6068, 3.04, 0.261, 264, 238, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 8: N-[3-(6-CYANO-9H- PYRROLO[23-B:54-C ]DIPYRIDIN-3-YL)PHENYL]ACETAMIDE
4457, 4ftuA, 0.6068, 3.09, 0.265, 270, 238, CRYSTAL STRUCTURE OF THE CHK1
4458, 3ug1A, 0.6068, 3.48, 0.204, 296, 245, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN THE APO FORM
4459, 3h0zC, 0.6068, 2.96, 0.239, 246, 238, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4460, 2bzhB, 0.6068, 3.10, 0.243, 275, 239, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU1
4461, 2bikB, 0.6068, 3.01, 0.245, 272, 237, HUMAN PIM1 PHOSPHORYLATED ON SER261
4462, 2b4sB, 0.6068, 4.01, 0.215, 294, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
4463, 1ywvA, 0.6068, 3.04, 0.239, 274, 238, CRYSTAL STRUCTURES OF PROTO-ONCOGENE KINASE PIM1: A TARGET OF ABERRANT SOMATIC HYPERMUTATIONS IN DIFFUSE LARGE CELL LYMPHOMA
4464, 1s9jA, 0.6068, 3.49, 0.218, 289, 248, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4465, 5eycA, 0.6067, 3.58, 0.206, 288, 247, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH NAPHTHYRIDINONE INHIBITOR 5
4466, 5c8kA, 0.6067, 3.29, 0.206, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 1
4467, 2xyuA, 0.6067, 2.85, 0.215, 260, 237, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN IN COMPLEX WITH VUF 12058
4468, 2ozoA, 0.6067, 3.34, 0.201, 545, 244, AUTOINHIBITED INTACT HUMAN ZAP-70
4469, 2ituA, 0.6067, 3.32, 0.205, 304, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AFN941
4470, 2hogA, 0.6067, 3.11, 0.264, 272, 239, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 20
4471, 5ct7B, 0.6066, 2.86, 0.225, 254, 236, BRAF IN COMPLEX WITH RAF265
4472, 5ajqB, 0.6066, 3.13, 0.238, 267, 239, HUMAN LOK (STK10) IN COMPLEX WITH BOSUTINIB
4473, 4u80A, 0.6066, 3.54, 0.217, 286, 249, MEK 1 KINASE BOUND TO G799
4474, 4twpA, 0.6066, 3.30, 0.220, 266, 241, THE CRYSTAL STRUCTURE OF HUMAN ABL1 T315I GATEKEEPER MUTANT KINASE DOMAIN IN COMPLEX WITH AXITINIB
4475, 3cp9A, 0.6066, 3.22, 0.207, 288, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4476, 3a61A, 0.6066, 2.48, 0.287, 254, 230, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED P70S6K1 (FORM II)
4477, 2qohB, 0.6066, 3.26, 0.231, 281, 242, CRYSTAL STRUCTURE OF ABL KINASE BOUND WITH PPY-A
4478, 2oi4X, 0.6066, 3.02, 0.239, 275, 238, CRYSTAL STRUCTURE OF HUMAN PIM1 IN COMPLEX WITH FLUORINATED RUTHENIUM PYRIDOCARBAZOLE
4479, 2ijmB, 0.6066, 3.01, 0.212, 261, 240, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4480, 4ftiA, 0.6065, 3.05, 0.265, 270, 238, CRYSTAL STRUCTURE OF THE CHK1
4481, 3i79A, 0.6065, 3.79, 0.289, 455, 253, CALCIUM-DEPENDENT PROTEIN KINASE 1 FROM TOXOPLASMA GONDII (TGCDPK1)
4482, 3c4eA, 0.6065, 2.97, 0.236, 273, 237, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4483, 2b4sD, 0.6065, 3.98, 0.199, 294, 256, CRYSTAL STRUCTURE OF A COMPLEX BETWEEN PTP1B AND THE INSULIN RECEPTOR TYROSINE KINASE
4484, 5capA, 0.6064, 3.43, 0.208, 303, 245, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 30
4485, 4k18A, 0.6064, 3.09, 0.238, 277, 239, STRUCTURE OF PIM-1 KINASE BOUND TO 5-(4-CYANOBENZYL)-N-(4- FLUOROPHENYL)-7-HYDROXYPYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
4486, 4ccuA, 0.6064, 3.28, 0.184, 292, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-(5-(6-AMINO-5-((R)-1-(5-FLUORO-2-(2H-123-TRIAZOL-2-YL) PHENYL)ETHOXY)PYRIDIN-3-YL)-4-METHYLTHIAZOL-2-YL)PROPAN-2-OL
4487, 3qbnA, 0.6064, 3.06, 0.241, 250, 241, STRUCTURE OF HUMAN AURORA A IN COMPLEX WITH A DIAMINOPYRIMIDINE
4488, 3h0yA, 0.6064, 3.12, 0.245, 250, 241, AURORA A IN COMPLEX WITH A BISANILINOPYRIMIDINE
4489, 3dtwA, 0.6064, 3.21, 0.220, 288, 241, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZISOXAZOLE INHIBITOR
4490, 5vdaA, 0.6063, 3.25, 0.191, 259, 241, CRYSTAL STRUCTURE OF HUMAN WEE1 KINASE DOMAIN IN COMPLEX WITH RAC-IV- 101 A MK1775 ANALOGUE
4491, 5ew3A, 0.6063, 3.13, 0.229, 274, 240, HUMAN VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR) KINASE DOMAIN IN COMPLEX WITH AAL993
4492, 4njdA, 0.6063, 3.50, 0.242, 290, 244, STRUCTURE OF P21-ACTIVATED KINASE 4 WITH A NOVEL INHIBITOR KY-04031
4493, 4jq8A, 0.6063, 3.53, 0.207, 303, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4B
4494, 4hvdA, 0.6063, 3.24, 0.216, 276, 241, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-CYCLOPROPYL-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-122-TRIMETHYL-PROPYL)-AMIDE
4495, 4fszA, 0.6063, 3.07, 0.269, 268, 238, CRYSTAL STRUCTURE OF THE CHK1
4496, 3lxkA, 0.6063, 3.49, 0.215, 279, 246, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
4497, 2gsfA, 0.6063, 3.02, 0.209, 281, 239, THE HUMAN EPHA3 RECEPTOR TYROSINE KINASE AND JUXTAMEMBRANE REGION
4498, 5jfwA, 0.6062, 2.87, 0.203, 277, 237, CRYSTAL STRUCTURE OF TRKA IN COMPLEX WITH PF-05247452
4499, 5ghvA, 0.6062, 3.10, 0.196, 265, 240, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4500, 4zk5B, 0.6062, 3.32, 0.220, 294, 246, MAP4K4 IN COMPLEX WITH INHIBITOR GNE-495
4501, 3zfxI, 0.6062, 3.14, 0.212, 263, 241, CRYSTAL STRUCTURE OF EPHB1
4502, 3kf4B, 0.6062, 3.34, 0.223, 270, 242, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4503, 2qonA, 0.6062, 3.14, 0.203, 281, 241, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION Y596F:Y602F:Y742A TRIPLE MUTANT
4504, 2qhnA, 0.6062, 3.10, 0.273, 268, 238, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 1A
4505, 2brmA, 0.6062, 2.95, 0.271, 263, 236, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4506, 5t6kA, 0.6061, 3.88, 0.283, 432, 254, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH GW780159X
4507, 4x2gA, 0.6061, 3.41, 0.210, 303, 243, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4508, 4gk3A, 0.6061, 3.07, 0.204, 275, 240, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 87
4509, 3v01A, 0.6061, 3.52, 0.214, 289, 248, DISCOVERY OF NOVEL ALLOSTERIC MEK INHIBITORS POSSESSING CLASSICAL AND NON-CLASSICAL BIDENTATE SER212 INTERACTIONS.
4510, 3ma6A, 0.6061, 3.79, 0.291, 267, 254, CRYSTAL STRUCTURE OF KINASE DOMAIN OF TGCDPK1 IN PRESENCE OF 3BRB-PP1
4511, 2j2iB, 0.6061, 3.06, 0.244, 273, 238, CRYSTAL STRUCTURE OF THE HUMAB PIM1 IN COMPLEX WITH LY333531
4512, 2c3lA, 0.6061, 3.14, 0.264, 265, 239, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4513, 5xzvB, 0.6060, 3.38, 0.307, 371, 244, CRYSTAL STRUCTURE OF RAD53 1-466 IN COMPLEX WITH AMP-PNP
4514, 5hieB, 0.6060, 3.13, 0.233, 259, 240, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4515, 4m0zA, 0.6060, 3.50, 0.169, 264, 248, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 5 {4- (CARBAMOYLAMINO)-1-(7-METHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE}
4516, 4gt4A, 0.6060, 3.43, 0.193, 274, 243, STRUCTURE OF UNLIGANDED INACTIVE ROR2 KINASE DOMAIN
4517, 4g2fA, 0.6060, 3.02, 0.205, 275, 239, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 7
4518, 4d4sB, 0.6060, 3.22, 0.218, 260, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4519, 4bc6A, 0.6060, 3.16, 0.223, 285, 238, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 BOUND TO NOVEL BOSUTINIB ISOFORM 1 PREVIOUSLY THOUGHT TO BE BOSUTINIB
4520, 3ndmC, 0.6060, 3.97, 0.215, 371, 256, CRYSTAL STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A POTENT ISOQUINOLONE DERIVATIVE
4521, 1xqzA, 0.6060, 3.11, 0.238, 277, 239, CRYSTAL STRUCTURE OF HPIM-1 KINASE AT 2.1 A RESOLUTION
4522, 1eh4B, 0.6060, 3.22, 0.165, 293, 242, BINARY COMPLEX OF CASEIN KINASE-1 FROM S. POMBE WITH AN ATP COMPETITIVE INHIBITOR IC261
4523, 5opuA, 0.6059, 2.96, 0.270, 261, 237, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4524, 4gfgA, 0.6059, 3.49, 0.194, 277, 247, CRYSTAL STRUCTURE OF SPLEEN TYROSINE KINASE COMPLEXED WITH R9021
4525, 4aojA, 0.6059, 3.04, 0.196, 260, 240, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4526, 3qf9A, 0.6059, 3.13, 0.243, 274, 239, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A FURAN- THIAZOLIDINEDIONE LIGAND
4527, 3oxzA, 0.6059, 3.02, 0.223, 268, 238, CRYSTAL STRUCTURE OF ABL KINASE DOMAIN BOUND WITH A DFG-OUT INHIBITOR AP24534
4528, 3c4cA, 0.6059, 2.91, 0.219, 258, 237, B-RAF KINASE IN COMPLEX WITH PLX4720
4529, 3bz3A, 0.6059, 3.25, 0.226, 259, 243, CRYSTAL STRUCTURE ANALYSIS OF FOCAL ADHESION KINASE WITH A METHANESULFONAMIDE DIAMINOPYRIMIDINE INHIBITOR
4530, 2ittA, 0.6059, 3.43, 0.208, 302, 245, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AEE788
4531, 1ywnA, 0.6059, 2.89, 0.225, 279, 236, VEGFR2 IN COMPLEX WITH A NOVEL 4-AMINO-FURO[23-D]PYRIMIDINE
4532, 1m17A, 0.6059, 3.53, 0.211, 312, 246, EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE DOMAIN WITH 4-ANILINOQUINAZOLINE INHIBITOR ERLOTINIB
4533, 5x27A, 0.6058, 3.50, 0.211, 302, 246, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH SKLB(5)
4534, 5ugaA, 0.6058, 3.55, 0.211, 283, 247, CRYSTAL STRUCTURE OF THE EGFR KINASE DOMAIN (L858R T790M V948R) IN COMPLEX WITH 4-(4-{[2-{[(3S)-1-ACETYLPYRROLIDIN-3-YL]AMINO}-9- (PROPAN-2-YL)-9H-PURIN-6-YL]AMINO}PHENYL)-1-METHYLPIPERAZIN-1-IUM
4535, 5aaaA, 0.6058, 3.28, 0.180, 294, 244, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4536, 4x2fA, 0.6058, 3.42, 0.210, 303, 243, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4537, 4rzwA, 0.6058, 2.80, 0.235, 251, 234, CRYSTAL STRUCTURE OF BRAF (R509H) KINASE DOMAIN BOUND TO AZ628
4538, 4fodA, 0.6058, 3.32, 0.171, 308, 245, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 36
4539, 4aotA, 0.6058, 3.17, 0.237, 278, 241, CRYSTAL STRUCTURE OF HUMAN SERINE THREONINE KINASE-10 (LOK) BOUND TO GW830263A
4540, 3b8qA, 0.6058, 3.17, 0.221, 292, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NAPHTHAMIDE INHIBITOR
4541, 2y6mA, 0.6058, 2.90, 0.215, 262, 237, CRYSTAL STRUCTURE OF EPHA4 KINASE DOMAIN
4542, 2hz0A, 0.6058, 3.16, 0.212, 265, 241, ABL KINASE DOMAIN IN COMPLEX WITH NVP-AEG082
4543, 1rjbA, 0.6058, 3.36, 0.248, 298, 242, CRYSTAL STRUCTURE OF FLT3
4544, 6fu5A, 0.6057, 3.04, 0.213, 282, 239, STRUCTURE OF THE KINASE DOMAIN OF HUMAN RIPK2 IN COMPLEX WITH THE INHIBITOR CSLP18 
4545, 6dd4D, 0.6057, 3.96, 0.180, 311, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
4546, 6babC, 0.6057, 3.46, 0.303, 284, 241, THE STRUCTURE OF HUMAN CAMKII WITH BOUND INHIBITOR
4547, 5n4nA, 0.6057, 3.08, 0.244, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIMETHYL-5-(1H-124-TRIAZOL- 3-YL)THIOPHENE-2-CARBONITRILE
4548, 5fbnC, 0.6057, 3.29, 0.189, 256, 244, BTK KINASE DOMAIN WITH INHIBITOR 1
4549, 5ew9A, 0.6057, 3.50, 0.227, 257, 247, CRYSTAL STRUCTURE OF AURORA A KINASE DOMAIN BOUND TO MK-5108
4550, 5ar5A, 0.6057, 3.28, 0.219, 284, 242, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH BENZIMIDAZOLE
4551, 5a9uA, 0.6057, 3.44, 0.179, 292, 246, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4552, 4m14A, 0.6057, 3.50, 0.169, 263, 248, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE]
4553, 3zewB, 0.6057, 2.74, 0.213, 252, 235, CRYSTAL STRUCTURE OF EPHB4 IN COMPLEX WITH STAUROSPORINE
4554, 5canA, 0.6056, 3.31, 0.206, 301, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 27
4555, 4jr3A, 0.6056, 3.54, 0.211, 303, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 3G
4556, 4ix3A, 0.6056, 4.14, 0.179, 346, 251, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
4557, 4fnzA, 0.6056, 3.10, 0.174, 287, 241, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PIPERIDINE-CARBOXAMIDE INHIBITOR 2
4558, 3zfyA, 0.6056, 3.05, 0.201, 260, 239, CRYSTAL STRUCTURE OF EPHB3
4559, 3ppzA, 0.6056, 3.19, 0.236, 264, 237, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN IN COMPLEX WITH STAUROSPORINE
4560, 3eqcA, 0.6056, 3.60, 0.221, 312, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A TERNARY COMPLEX WITH COMPOUND 1 ATP-GS AND MG2P
4561, 2qobA, 0.6056, 3.18, 0.194, 279, 242, HUMAN EPHA3 KINASE DOMAIN BASE STRUCTURE
4562, 5vo6A, 0.6055, 3.14, 0.212, 271, 240, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRIDAZINE INHIBITOR
4563, 5knjA, 0.6055, 2.99, 0.167, 252, 239, PSEUDOKINASE DOMAIN OF MLKL BOUND TO COMPOUND 1.
4564, 5itaB, 0.6055, 2.99, 0.224, 252, 237, CRYSTAL STRUCTURE OF BRAF KINASE DOMAIN BOUND TO AZ-VEM
4565, 4fk6A, 0.6055, 3.70, 0.222, 285, 248, JAK1 KINASE (JH1 DOMAIN) IN COMPLEX WITH COMPOUND 72
4566, 3a7gA, 0.6055, 3.64, 0.211, 289, 247, HUMAN MST3 KINASE
4567, 2z60A, 0.6055, 3.45, 0.217, 281, 244, CRYSTAL STRUCTURE OF THE T315I MUTANT OF ABL KINASE BOUND WITH PPY-A
4568, 6cpgD, 0.6054, 3.23, 0.243, 252, 243, STRUCTURE OF DEPHOSPHORYLATED AURORA A (122-403) IN COMPLEX WITH INHIBITING MONOBODY AND AT9283 IN AN INACTIVE CONFORMATION 
4569, 6bp0C, 0.6054, 3.76, 0.175, 315, 252, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 BOUND TO (R)- 2-PHENYLAMINOPTERIDINONE INHIBITOR
4570, 5op2A, 0.6054, 3.02, 0.269, 263, 238, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4571, 5n4rA, 0.6054, 3.09, 0.244, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 2-(AZEPAN-1-YL)-1-(1H-INDOL-3-YL) PROPAN-1-ONE
4572, 5n4oA, 0.6054, 3.00, 0.236, 271, 237, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE (E)-3-(P-TOLYL)ACRYLIC ACID
4573, 5caqA, 0.6054, 3.23, 0.202, 301, 242, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 33
4574, 5bx0A, 0.6054, 3.80, 0.222, 315, 252, AN AUTOMATED MICROSCALE THERMOPHORESIS SCREENING APPROACH FOR FRAGMENT-BASED LEAD DISCOVERY
4575, 4riwD, 0.6054, 3.46, 0.233, 297, 245, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER
4576, 4m12A, 0.6054, 3.50, 0.165, 264, 248, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 7 [4- (CARBAMOYLAMINO)-1-(7-ETHOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
4577, 4ix5A, 0.6054, 4.10, 0.179, 346, 251, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
4578, 4ft7A, 0.6054, 3.02, 0.262, 270, 237, CRYSTAL STRUCTURE OF THE CHK1
4579, 4ctbA, 0.6054, 3.29, 0.184, 292, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (5R)-8-AMINO-3-FLUORO-519-DIMETHYL-20-OXO-5181920- TETRAHYDRO-711-(AZENO)PYRIDO(2 1 :23)IMIDAZO(45-H)(2511) BENZOXADIAZACYCLOTETRADECINE-14-CARBONITRILE
4580, 3vvhA, 0.6054, 3.52, 0.207, 287, 246, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4581, 2ityA, 0.6054, 3.42, 0.208, 300, 245, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH IRESSA
4582, 2gs6A, 0.6054, 3.51, 0.211, 311, 246, CRYSTAL STRUCTURE OF THE ACTIVE EGFR KINASE DOMAIN IN COMPLEX WITH AN ATP ANALOG-PEPTIDE CONJUGATE
4583, 6fnhC, 0.6053, 2.94, 0.193, 270, 238, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE WITH A PYRAZOLO[3;4-D]PYRIMIDINE FRAGMENT OF NVP-BHG712 
4584, 5wnlA, 0.6053, 3.16, 0.187, 262, 240, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN 4 (RIPK4) D143N BOUND TO STAUROSPORINE 
4585, 5ar2A, 0.6053, 3.25, 0.217, 277, 240, RIP2 KINASE CATALYTIC DOMAIN (1 - 310)
4586, 4j96B, 0.6053, 3.62, 0.252, 305, 246, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659M MUTATION IDENTIFIED IN CERVICAL CANCER.
4587, 4idtB, 0.6053, 3.40, 0.250, 335, 244, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
4588, 4fg7A, 0.6053, 2.92, 0.299, 250, 234, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-293 IN COMPLEX WITH ATP
4589, 4ehgB, 0.6053, 3.19, 0.224, 260, 241, B-RAF KINASE DOMAIN IN COMPLEX WITH AN AMINOPYRIDIMINE-BASED INHIBITOR
4590, 4cmuA, 0.6053, 3.30, 0.184, 294, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR (10R)-7-AMINO-12-FLUORO-1310 16-TETRAMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(43- H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
4591, 3cs9D, 0.6053, 3.39, 0.218, 263, 243, HUMAN ABL KINASE IN COMPLEX WITH NILOTINIB
4592, 2wtkB, 0.6053, 3.23, 0.218, 311, 243, STRUCTURE OF THE HETEROTRIMERIC LKB1-STRADALPHA-MO25ALPHA COMPLEX
4593, 1yxsA, 0.6053, 3.08, 0.244, 274, 238, CRYSTAL STRUCTURE OF KINASE PIM1 WITH P123M MUTATION
4594, 1m14A, 0.6053, 3.40, 0.212, 307, 245, TYROSINE KINASE DOMAIN FROM EPIDERMAL GROWTH FACTOR RECEPTOR
4595, 5xdlA, 0.6052, 3.27, 0.207, 292, 242, CRYSTAL STRUCTURE OF EGFR 696-1022 L858R IN COMPLEX WITH CO-1686
4596, 5n4vA, 0.6052, 3.09, 0.244, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 2-CYCLOPROPYL-45- DIMETHYLTHIENO[54-D]PYRIMIDINE-6-CARBOXYLIC ACID
4597, 5feqA, 0.6052, 3.39, 0.210, 290, 243, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE
4598, 5c8nA, 0.6052, 3.28, 0.207, 300, 242, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 23
4599, 5aa9A, 0.6052, 3.30, 0.180, 295, 244, STRUCTURE OF L1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-210 16-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H-84-(METHENO) PYRAZOLO(43-H)(2511)BENZOXADIAZACYCLOTETRADECINE-3- CARBONITRILE).
4600, 4y83B, 0.6052, 3.43, 0.227, 302, 242, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
4601, 4x2kA, 0.6052, 3.42, 0.210, 303, 243, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4602, 4x2jA, 0.6052, 3.42, 0.210, 303, 243, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4603, 4obqA, 0.6052, 2.96, 0.242, 275, 236, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4604, 4m13A, 0.6052, 3.46, 0.166, 264, 247, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 8 [4- (CARBAMOYLAMINO)-1-(7-PROPOXYNAPHTHALEN-1-YL)-1H-PYRAZOLE-3- CARBOXAMIDE]
4605, 4j98B, 0.6052, 3.55, 0.257, 304, 245, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
4606, 4ix6A, 0.6052, 4.10, 0.179, 346, 251, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
4607, 4ix4A, 0.6052, 4.19, 0.183, 346, 252, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
4608, 4fnwA, 0.6052, 3.28, 0.184, 304, 244, CRYSTAL STRUCTURE OF THE APO F1174L ANAPLASTIC LYMPHOMA KINASE CATALYTIC DOMAIN
4609, 4csvA, 0.6052, 2.91, 0.225, 244, 236, TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL BOUND TO GLEEVEC
4610, 4cliA, 0.6052, 3.30, 0.184, 294, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12-FLUORO-21016-TRIMETHYL-15 -OXO-10151617-TETRAHYDRO-2H-84-(METHENO)PYRAZOLO(43-H) (2511)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
4611, 2xynA, 0.6052, 3.30, 0.252, 264, 242, HUMAN ABL2 IN COMPLEX WITH AURORA KINASE INHIBITOR VX-680
4612, 1xr1A, 0.6052, 3.13, 0.243, 277, 239, CRYSTAL STRUCTURE OF HPIM-1 KINASE IN COMPLEX WITH AMP-PNP AT 2.1 A RESOLUTION
4613, 1py5A, 0.6052, 3.64, 0.202, 301, 247, CRYSTAL STRUCTURE OF TGF-BETA RECEPTOR I KINASE WITH INHIBITOR
4614, 5y5tA, 0.6051, 3.30, 0.198, 263, 242, CRYSTAL STRUCTURES OF SPLEEN TYROSINE KINASE IN COMPLEX WITH A NOVEL INHIBITOR 
4615, 5kz0A, 0.6051, 3.29, 0.184, 293, 244, STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH 2-[(1R)- 1-{[2-AMINO-5-(13-DIMETHYL-1H-PYRAZOL-4-YL)PYRIDIN-3-YL]OXY}ETHYL]- 4-FLUORO-NN-DIMETHYLBENZAMIDE
4616, 5edqA, 0.6051, 3.26, 0.202, 298, 243, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 15: ~{N}-(7- CHLORANYL-1~{H}-INDAZOL-3-YL)-77-DIMETHYL-2-(1~{H}-PYRAZOL-4-YL)- 5~{H}-FURO[34-D]PYRIMIDIN-4-AMINE
4617, 5cf8B, 0.6051, 3.49, 0.232, 288, 246, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
4618, 4zjjC, 0.6051, 3.29, 0.218, 276, 243, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4619, 4knbA, 0.6051, 3.44, 0.217, 273, 244, C-MET IN COMPLEX WITH OSI LIGAND
4620, 4iwdA, 0.6051, 3.67, 0.225, 299, 249, STRUCTURE OF DUALLY PHOSPHORYLATED C-MET RECEPTOR KINASE IN COMPLEX WITH AN MK-8033 ANALOG
4621, 3ri1A, 0.6051, 3.38, 0.256, 285, 242, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
4622, 3c4eB, 0.6051, 3.00, 0.232, 273, 237, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4623, 2yhvA, 0.6051, 3.26, 0.164, 291, 244, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE
4624, 2hy0A, 0.6051, 3.03, 0.270, 272, 237, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 22
4625, 6g4zA, 0.6050, 3.77, 0.230, 322, 248, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
4626, 5u6yL, 0.6050, 3.63, 0.294, 459, 245, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4627, 5u6yK, 0.6050, 3.63, 0.294, 459, 245, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4628, 5u6yJ, 0.6050, 3.63, 0.294, 459, 245, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4629, 5u6yI, 0.6050, 3.63, 0.294, 459, 245, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4630, 5u6yH, 0.6050, 3.63, 0.294, 459, 245, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4631, 5u6yG, 0.6050, 3.63, 0.294, 459, 245, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4632, 5u6yF, 0.6050, 3.63, 0.294, 459, 245, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4633, 5u6yE, 0.6050, 3.63, 0.294, 459, 245, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4634, 5u6yD, 0.6050, 3.63, 0.294, 459, 245, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4635, 5u6yC, 0.6050, 3.63, 0.294, 459, 245, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4636, 5u6yB, 0.6050, 3.63, 0.294, 459, 245, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4637, 5u6yA, 0.6050, 3.63, 0.294, 459, 245, PSEUDO-ATOMIC MODEL OF THE CAMKIIA HOLOENZYME.
4638, 5lohB, 0.6050, 2.77, 0.261, 250, 234, KINASE DOMAIN OF HUMAN GREATWALL
4639, 5j9zA, 0.6050, 3.36, 0.209, 291, 244, EGFR-T790M IN COMPLEX WITH PYRAZOLOPYRIMIDINE INHIBITOR 1A
4640, 4z16A, 0.6050, 3.20, 0.218, 271, 239, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4641, 4y85A, 0.6050, 3.50, 0.239, 307, 243, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
4642, 4xg3B, 0.6050, 3.32, 0.197, 267, 244, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4643, 4u41B, 0.6050, 3.51, 0.209, 297, 249, MAP4K4 BOUND TO INHIBITOR COMPOUND 1
4644, 4k1bA, 0.6050, 3.09, 0.239, 273, 238, STRUCTURE OF PIM-1 KINASE BOUND TO N-(5-(2-FLUOROPHENYL)-1H-PYRROLO[2 3-B]PYRIDIN-3-YL)-5-((((3R4R)-3-FLUOROPIPERIDIN-4-YL)METHYL)AMINO) PYRAZOLO[15-A]PYRIMIDINE-3-CARBOXAMIDE
4645, 4ft3A, 0.6050, 3.02, 0.270, 269, 237, CRYSTAL STRUCTURE OF THE CHK1
4646, 4ansA, 0.6050, 3.30, 0.184, 293, 244, STRUCTURE OF L1196MG1269A DOUBLE MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4647, 3skcA, 0.6050, 2.96, 0.223, 260, 238, HUMAN B-RAF KINASE IN COMPLEX WITH AN AMIDE LINKED PYRAZOLOPYRIDINE INHIBITOR
4648, 2itnA, 0.6050, 3.52, 0.215, 304, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN G719S MUTATION IN COMPLEX WITH AMP-PNP
4649, 5lmaA, 0.6049, 3.25, 0.198, 267, 243, HUMAN SPLEEN TYROSINE KINASE KINASE DOMAIN IN COMPLEX WITH AZANAPHTHYRIDINE INHIBITOR
4650, 4m15A, 0.6049, 3.47, 0.166, 263, 247, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 9 [4- (CARBAMOYLAMINO)-1-[7-(PROPAN-2-YLOXY)NAPHTHALEN-1-YL]-1H-PYRAZOLE-3- CARBOXAMIDE] AND ADP
4651, 4focA, 0.6049, 3.34, 0.176, 296, 245, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH ACYLIMINOBENZIMIDAZOLE INHIBITOR 2
4652, 4fl1A, 0.6049, 3.41, 0.197, 268, 244, STRUCTURAL AND BIOPHYSICAL CHARACTERIZATION OF THE SYK ACTIVATION SWITCH
4653, 5ndtA, 0.6048, 3.09, 0.244, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(2-(THIOPHEN-2-YL)VINYL)-3; 4-DIHYDROQUINOXALIN-2(1H)-ONE 
4654, 5n4yA, 0.6048, 3.10, 0.239, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 25-DIHYDRO-1H-ISOTHIOCHROMENO[3 4-D]PYRAZOL-3-ONE
4655, 5e8zA, 0.6048, 3.65, 0.207, 303, 246, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3- AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3- YL]PYRAZINE-2-CARBOXAMIDE
4656, 5dvrA, 0.6048, 3.80, 0.282, 386, 252, CRYSTAL STRUCTURE OF TGCDPK1 FROM TOXOPLASMA GONDII COMPLEXED WITH GW780159X
4657, 5dgzA, 0.6048, 3.09, 0.231, 273, 238, DISCOVERY OF 35-SUBSTITUTED 6-AZAINDAZOLES AS POTENT PAN-PIM INHIBITORS
4658, 4wunA, 0.6048, 3.11, 0.264, 282, 239, STRUCTURE OF FGFR1 IN COMPLEX WITH AZD4547 (N-{3-[2-(35- DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-5-YL}-4-[(3R5S)-35- DIMETHYLPIPERAZIN-1-YL]BENZAMIDE) AT 1.65 ANGSTROM
4659, 4riyD, 0.6048, 3.54, 0.228, 297, 246, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
4660, 4nfnA, 0.6048, 3.51, 0.222, 293, 248, HUMAN TAU TUBULIN KINASE 1 (TTBK1) COMPLEXED WITH 3-({5-[(4-AMINO-4- METHYLPIPERIDIN-1-YL)METHYL]PYRROLO[21-F][124]TRIAZIN-4-YL}AMINO)- 5-BROMOPHENOL
4661, 4m0yA, 0.6048, 3.54, 0.165, 263, 248, CRYSTAL STRUCTURE OF ITK IN COMPLEX WITH COMPOUND 1 [4- (CARBAMOYLAMINO)-1-(NAPHTHALEN-1-YL)-1H-PYRAZOLE-3-CARBOXAMIDE]
4662, 4idtA, 0.6048, 3.41, 0.254, 334, 244, CRYSTAL STRUCTURE OF NIK WITH 11-BROMO-5678-TETRAHYDROPYRIMIDO[4  5 :34]CYCLOHEPTA[12-B]INDOL-2-AMINE (T28)
4663, 4dceB, 0.6048, 3.23, 0.182, 284, 242, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4664, 4cqeB, 0.6048, 2.80, 0.226, 248, 234, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4665, 3q4tA, 0.6048, 3.91, 0.215, 305, 251, CRYSTAL STRUCTURE OF ACTIVIN RECEPTOR TYPE-IIA (ACVR2A) KINASE DOMAIN IN COMPLEX WITH DORSOMORPHIN
4666, 3p86A, 0.6048, 2.85, 0.220, 250, 236, CRYSTAL STRUCTURE OF CTR1 KINASE DOMAIN MUTANT D676N IN COMPLEX WITH STAUROSPORINE
4667, 2j5fA, 0.6048, 3.48, 0.207, 308, 246, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH AN IRREVERSIBLE INHIBITOR 34-JAB
4668, 2bzjA, 0.6048, 3.08, 0.235, 273, 238, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU3
4669, 2bvaA, 0.6048, 3.10, 0.232, 272, 237, CRYSTAL STRUCTURE OF THE HUMAN P21-ACTIVATED KINASE 4
4670, 1xbcA, 0.6048, 3.23, 0.195, 268, 241, CRYSTAL STRUCTURE OF THE SYK TYROSINE KINASE DOMAIN WITH STAUROSPORIN
4671, 6dd4B, 0.6047, 4.04, 0.171, 309, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N;N- DIPROPYL-DIHYDROPTERIDINE INHIBITOR 
4672, 4rpvA, 0.6047, 3.07, 0.235, 273, 238, CO-CRYSTAL STRUCTURE OF PIM1 WITH COMPOUND 3
4673, 4oboB, 0.6047, 3.51, 0.213, 297, 249, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 22) 6-(3-CHLOROPHENYL) QUINAZOLIN-4-AMINE
4674, 4n6yA, 0.6047, 3.00, 0.241, 273, 237, PIM1 COMPLEXED WITH A PHENYLCARBOXAMIDE
4675, 4fsrA, 0.6047, 3.10, 0.261, 269, 238, CRYSTAL STRUCTURE OF THE CHK1
4676, 4dceA, 0.6047, 3.18, 0.174, 288, 242, CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH A PIPERIDINE-CARBOXAMIDE INHIBITOR
4677, 4aojC, 0.6047, 3.07, 0.192, 261, 240, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4678, 3cp9B, 0.6047, 3.06, 0.227, 269, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4679, 1mqbB, 0.6047, 3.08, 0.196, 265, 240, CRYSTAL STRUCTURE OF EPHRIN A2 (EPHA2) RECEPTOR PROTEIN KINASE
4680, 5c26A, 0.6046, 3.45, 0.200, 272, 245, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 1
4681, 4rvmA, 0.6046, 3.01, 0.266, 264, 237, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 19
4682, 4rj4A, 0.6046, 3.29, 0.202, 299, 242, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 6
4683, 4anqA, 0.6046, 3.30, 0.184, 293, 244, STRUCTURE OF G1269A MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4684, 3zlxA, 0.6046, 3.83, 0.211, 312, 251, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 18
4685, 3vvhC, 0.6046, 3.57, 0.213, 283, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4686, 3ug2A, 0.6046, 3.42, 0.201, 299, 244, CRYSTAL STRUCTURE OF THE MUTATED EGFR KINASE DOMAIN (G719S/T790M) IN COMPLEX WITH GEFITINIB
4687, 3ornA, 0.6046, 3.59, 0.209, 280, 249, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4987655 AND MGAMP-PNP
4688, 3faaB, 0.6046, 4.05, 0.202, 324, 252, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH A 2- AMINOIMIDAZOLE INHIBITOR
4689, 5tq4A, 0.6045, 3.62, 0.229, 290, 249, DESIGN AND SYNTHESIS OF A PAN-JAK KINASE INHIBITOR CLINICAL CANDIDATE (PF-06263276) SUITABLE FOR INHALED AND TOPICAL DELIVERY FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE LUNGS AND SKIN
4690, 5nudB, 0.6045, 2.75, 0.255, 271, 235, FIBROBLAST GROWTH FACTOR RECEPTOR 4 KINASE DOMAIN (449-753) IN COMPLEX WITH IRREVERSIBLE LIGAND CGA159527
4691, 5calA, 0.6045, 3.33, 0.206, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 24
4692, 4xi2A, 0.6045, 3.64, 0.173, 421, 249, CRYSTAL STRUCTURE OF AN AUTO-INHIBITED FORM OF BRUTON S TRYROSINE KINASE
4693, 4qqcA, 0.6045, 2.91, 0.270, 273, 237, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE DOMAIN IN COMPLEX WITH FIIN-2 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4694, 4p7eB, 0.6045, 3.55, 0.231, 285, 247, TRIAZOLOPYRIDINE COMPOUNDS AS SELECTIVE JAK1 INHIBITORS: FROM HIT IDENTIFICATION TO GLPG0634
4695, 4lqqA, 0.6045, 4.12, 0.249, 388, 261, CRYSTAL STRUCTURE OF THE CBK1(T743E)-MOB2 KINASE-COACTIVATOR COMPLEX IN CRYSTAL FORM B
4696, 4j97A, 0.6045, 3.48, 0.254, 282, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
4697, 4ft0A, 0.6045, 3.04, 0.266, 266, 237, CRYSTAL STRUCTURE OF THE CHK1
4698, 2yn8B, 0.6045, 2.98, 0.207, 260, 237, EPHB4 KINASE DOMAIN INHIBITOR COMPLEX
4699, 2xeyA, 0.6045, 2.77, 0.270, 252, 233, CRYSTAL STRUCTURE OF CHECKPOINT KINASE 1 (CHK1) IN COMPLEX WITH INHIBITORS
4700, 2pvfA, 0.6045, 3.43, 0.250, 285, 244, CRYSTAL STRUCTURE OF TYROSINE PHOSPHORYLATED ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH ATP ANALOG AND SUBSTRATE PEPTIDE
4701, 2p2iA, 0.6045, 3.16, 0.238, 289, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A NICOTINAMIDE INHIBITOR
4702, 1zycD, 0.6045, 3.35, 0.237, 256, 245, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4703, 5caoA, 0.6044, 3.27, 0.207, 300, 242, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 29
4704, 4j97B, 0.6044, 3.49, 0.254, 283, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
4705, 4iwoA, 0.6044, 3.68, 0.210, 629, 248, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
4706, 3tjcB, 0.6044, 3.56, 0.227, 287, 247, CO-CRYSTAL STRUCTURE OF JAK2 WITH THIENOPYRIDINE 8
4707, 3nlbA, 0.6044, 2.99, 0.267, 261, 236, NOVEL KINASE PROFILE HIGHLIGHTS THE TEMPORAL BASIS OF CONTEXT DEPENDENT CHECKPOINT PATHWAYS TO CELL DEATH
4708, 3dkgA, 0.6044, 3.09, 0.225, 281, 240, STRUCTURE OF MUTANT(Y1248L) MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH INHIBITOR SGX-523
4709, 2hakB, 0.6044, 2.85, 0.248, 279, 234, CATALYTIC AND UBIQUTIN-ASSOCIATED DOMAINS OF MARK1/PAR-1
4710, 1yi6B, 0.6044, 3.41, 0.230, 274, 244, C-TERM TAIL SEGMENT OF HUMAN TYROSINE KINASE (258-533)
4711, 5aabA, 0.6043, 3.31, 0.176, 293, 244, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4712, 3tz8B, 0.6043, 3.08, 0.252, 263, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4713, 6fd3A, 0.6042, 3.65, 0.228, 296, 246, THIOPHOSPHORYLATED PAK3 KINASE DOMAIN
4714, 6cnxC, 0.6042, 3.63, 0.177, 311, 249, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
4715, 5j7hA, 0.6042, 3.24, 0.185, 291, 243, CRYSTAL STRUCTURE OF ANAPLASTIC LYMPHOMA KINASE (ALK) BOUND BY BRIGATINIB
4716, 4z16C, 0.6042, 3.21, 0.218, 271, 239, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4717, 4xmoA, 0.6042, 3.62, 0.198, 289, 247, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH (R)-5-(8-FLUORO-3-(1- FLUORO-1-(3-METHOXYQUINOLIN-6-YL)ETHYL)-[124]TRIAZOLO[43- A]PYRIDIN-6-YL)-3-METHYLISOXAZOLE
4718, 4x0mA, 0.6042, 3.44, 0.210, 303, 243, SELECTION OF FRAGMENTS FOR KINASE INHIBITOR DESIGN: DECORATION IS KEY
4719, 4lqmA, 0.6042, 3.38, 0.205, 305, 244, EGFR L858R IN COMPLEX WITH PD168393
4720, 3aoxA, 0.6042, 3.26, 0.185, 298, 243, X-RAY CRYSTAL STRUCTURE OF HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CH5424802
4721, 2c3jA, 0.6042, 3.00, 0.262, 257, 237, IDENTIFICATION OF A BURIED POCKET FOR POTENT AND SELECTIVE INHIBITION OF CHK1: PREDICTION AND VERIFICATION
4722, 5w5qB, 0.6041, 3.40, 0.215, 297, 247, MAP4K4 IN COMPLEX WITH INHIBITOR COMPOUND 12 (N3-METHYL-10-(3-METHYL- 3-(5-METHYLOXAZOL-2-YL)BUT-1-YN-1-YL)-6;7-DIHYDRO-5H-5;7- METHANOBENZO[C]IMIDAZO[1;2-A]AZEPINE-2;3-DICARBOXAMIDE) 
4723, 5mjaA, 0.6041, 3.13, 0.204, 271, 240, KINASE DOMAIN OF HUMAN EPHB1 BOUND TO A QUINAZOLINE-BASED INHIBITOR
4724, 5fboA, 0.6041, 3.17, 0.192, 255, 240, BTK-INHIBITOR CO-STRUCTURE
4725, 5eg3A, 0.6041, 3.56, 0.248, 301, 246, CRYSTAL STRUCTURE OF THE ACTIVATED FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN IN COMPLEX WITH THE CSH2 DOMAIN OF PHOSPHOLIPASE C GAMMA (PLCGAMMA)
4726, 4r6vA, 0.6041, 2.90, 0.274, 273, 237, CRYSTAL STRUCTURE OF FGF RECEPTOR (FGFR) 4 KINASE HARBORING THE V550L GATE-KEEPER MUTATION IN COMPLEX WITH FIIN-3 AN IRREVERSIBLE TYROSINE KINASE INHIBITOR CAPABLE OF OVERCOMING FGFR KINASE GATE-KEEPER MUTATIONS
4727, 4ll5A, 0.6041, 3.07, 0.245, 268, 237, CRYSTAL STRUCTURE OF PIM-1 IN COMPLEX WITH THE FLUORESCENT COMPOUND SKF86002
4728, 4ix6B, 0.6041, 4.17, 0.179, 350, 252, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE SOAKED WITH ATP
4729, 4i6qA, 0.6041, 3.37, 0.219, 277, 242, JAK3 KINASE DOMAIN IN COMPLEX WITH 2-PHENOXY-5H-PYRROLO[23- B]PYRAZINE-7-CARBOXYLIC ACID ((S)-1-CYCLOPROPYL-ETHYL)-AMIDE
4730, 3o96A, 0.6041, 2.90, 0.271, 367, 236, CRYSTAL STRUCTURE OF HUMAN AKT1 WITH AN ALLOSTERIC INHIBITOR
4731, 3fupB, 0.6041, 3.52, 0.228, 287, 246, CRYSTAL STRUCTURES OF JAK1 AND JAK2 INHIBITOR COMPLEXES
4732, 1yxuA, 0.6041, 3.11, 0.244, 273, 238, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
4733, 5ng3B, 0.6040, 3.53, 0.190, 275, 247, STRUCTURE OF INACTIVE KINASE RIP2K(K47R)
4734, 4zimA, 0.6040, 3.45, 0.224, 285, 246, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1- CARBOXAMIDE INHIBITOR
4735, 4yneA, 0.6040, 3.01, 0.205, 281, 239, (R)-2-PHENYLPYRROLIDINE SUBSTITUTE IMIDAZOPYRIDAZINES: A NEW CLASS OF POTENT AND SELECTIVE PAN-TRK INHIBITORS
4736, 4xhgA, 0.6040, 3.34, 0.177, 357, 243, STRUCTURE OF C. GLABRATA HRR25 BOUND TO ADP (FORMATE CONDITION)
4737, 4ji9A, 0.6040, 3.29, 0.222, 284, 243, JAK2 KINASE (JH1 DOMAIN) IN COMPLEX WITH TG101209
4738, 4gw8A, 0.6040, 3.11, 0.244, 273, 238, HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND LEUCETTINE L41
4739, 4aw5A, 0.6040, 3.04, 0.197, 261, 239, COMPLEX OF THE EPHB4 KINASE DOMAIN WITH AN OXINDOLE INHIBITOR
4740, 4a7cA, 0.6040, 3.12, 0.244, 273, 238, CRYSTAL STRUCTURE OF PIM1 KINASE WITH ETP46546
4741, 3qa8A, 0.6040, 3.43, 0.261, 622, 245, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4742, 3jpvA, 0.6040, 3.11, 0.239, 273, 238, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A PYRROLO[23- A]CARBAZOLE LIGAND
4743, 3dkcA, 0.6040, 3.74, 0.206, 312, 252, STRUCTURE OF MET RECEPTOR TYROSINE KINASE IN COMPLEX WITH ATP
4744, 2qo2A, 0.6040, 2.83, 0.203, 282, 236, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION DEPHOSPHORYLATED APO STRUCTURE
4745, 2ijmA, 0.6040, 3.14, 0.216, 260, 241, CRYSTAL STRUCTURE OF FOCAL ADHESION KINASE DOMAIN WITH 2 MOLECULES IN THE ASYMMETRIC UNIT COMPLEXED WITH ADP AND ATP
4746, 2brgA, 0.6040, 2.89, 0.255, 257, 235, STRUCTURE-BASED DESIGN OF NOVEL CHK1 INHIBITORS: INSIGHTS INTO HYDROGEN BONDING AND PROTEIN-LIGAND AFFINITY
4747, 5owrA, 0.6039, 2.81, 0.223, 282, 233, HUMAN STK10 BOUND TO DASATINIB
4748, 5oq8A, 0.6039, 3.01, 0.270, 261, 237, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH ARYLBENZAMIDE LRRK2 INHIBITOR
4749, 5opsA, 0.6039, 2.89, 0.272, 258, 235, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH PYRROLOPYRIDINE LRRK2 INHIBITOR
4750, 5n5mA, 0.6039, 3.08, 0.245, 272, 237, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND (R)-3-(2-((ISOQUINOLIN-5-YLMETHYL)(METHYL) CARBAMOYL)PHENYL)PYRROLIDIN-1-IUM
4751, 5e8tA, 0.6039, 3.70, 0.207, 302, 246, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)
4752, 4riyB, 0.6039, 3.22, 0.216, 293, 241, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-E909G MUTATION
4753, 4jq7A, 0.6039, 3.40, 0.209, 303, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 2A
4754, 4ftcA, 0.6039, 3.02, 0.274, 266, 237, CRYSTAL STRUCTURE OF THE CHK1
4755, 4cqeA, 0.6039, 3.01, 0.224, 250, 237, B-RAF KINASE V600E MUTANT IN COMPLEX WITH  A DIARYLTHIAZOLE B-RAF INHIBITOR
4756, 3we8A, 0.6039, 3.11, 0.235, 273, 238, PIM-1 KINASE IN COMPLEX WITH RUTHENIUM-BASED INHIBITOR
4757, 2qoqA, 0.6039, 2.94, 0.193, 284, 238, HUMAN EPHA3 KINASE AND JUXTAMEMBRANE REGION BASE AMP-PNP BOUND STRUCTURE
4758, 1yxuB, 0.6039, 3.11, 0.239, 273, 238, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH AMP
4759, 5ttuA, 0.6038, 3.37, 0.219, 271, 242, JAK3 WITH COVALENT INHIBITOR 7
4760, 5em6A, 0.6038, 3.32, 0.207, 301, 242, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 19: 4-[(2- AZANYLPYRIMIDIN-4-YL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]- 2-OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4761, 4u40B, 0.6038, 3.38, 0.220, 299, 246, MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4) BOUND TO AMPPNP
4762, 4kaoB, 0.6038, 2.96, 0.210, 254, 238, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH 1-(5-TERT- BUTYL-2-P-TOLYL-2H-PYRAZOL-3-YL)-3-(4-PYRIDIN-3- YL-PHENYL)-UREA
4763, 4j95A, 0.6038, 3.52, 0.254, 279, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4764, 4ix5B, 0.6038, 4.17, 0.190, 350, 252, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH AMP-PNP
4765, 4bieB, 0.6038, 2.97, 0.302, 257, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4766, 3cpcA, 0.6038, 3.10, 0.209, 284, 239, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A PYRIDONE INHIBITOR
4767, 2yfxA, 0.6038, 3.33, 0.189, 292, 244, STRUCTURE OF L1196M MUTANT ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4768, 2itvA, 0.6038, 3.46, 0.208, 303, 245, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH AMP-PNP
4769, 1oecA, 0.6038, 3.48, 0.250, 280, 244, FGFR2 KINASE DOMAIN
4770, 6b8yA, 0.6037, 3.69, 0.207, 304, 246, TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3- FLUOROPYRIDIN-4-YL)-2-[6-(TRIFLUOROMETHYL)PYRIDIN-2-YL]-7H-PYRROLO[2 3-D]PYRIMIDIN-4-AMINE
4771, 5kgkA, 0.6037, 3.10, 0.239, 273, 238, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 3-(4-METHOXYPHENYL)-1~{H}- PYRAZOL-5-AMINE
4772, 5fedA, 0.6037, 3.47, 0.209, 288, 244, EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
4773, 5e8yA, 0.6037, 3.57, 0.217, 298, 244, TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431AR433AE485AK488AR493A R495A) IN COMPLEX WITH STAUROSPORINE
4774, 4qyhB, 0.6037, 3.01, 0.267, 264, 236, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
4775, 3tucA, 0.6037, 3.08, 0.205, 257, 239, CRYSTAL STRUCTURE OF SYK KINASE DOMAIN WITH 1-BENZYL-N-(5-(67- DIMETHOXYQUINOLIN-4-YLOXY)PYRIDIN-2-YL)-2-OXO-12-DIHYDROPYRIDINE-3- CARBOXAMIDE
4776, 3os3A, 0.6037, 3.40, 0.211, 272, 246, MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH CH4858061 AND MGATP
4777, 2reiA, 0.6037, 2.88, 0.207, 277, 237, KINASE DOMAIN OF HUMAN EPHRIN TYPE-A RECEPTOR 7 (EPHA7)
4778, 4y85B, 0.6036, 3.47, 0.244, 306, 242, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(5-(1H-INDOL- 3-YL)-1H-PYRROLO[23-B]PYRIDIN-3-YL)-134-OXADIAZOL-2-AMINE
4779, 4rixD, 0.6036, 3.61, 0.215, 297, 247, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
4780, 4ix4B, 0.6036, 4.17, 0.179, 350, 252, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE IN COMPLEX WITH ADP
4781, 3vvhB, 0.6036, 3.59, 0.213, 290, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN COMPLEX WITH AN INHIBITOR AND MGATP
4782, 3q6uA, 0.6036, 3.40, 0.212, 287, 245, STRUCTURE OF THE APO MET RECEPTOR KINASE IN THE DUALLY-PHOSPHORYLATED ACTIVATED STATE
4783, 3eflB, 0.6036, 3.07, 0.223, 263, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH MOTESANIB
4784, 3c1xA, 0.6036, 2.96, 0.203, 290, 237, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A PYRROLOTRIAZINE BASED INHIBITOR
4785, 2r0uA, 0.6036, 3.19, 0.264, 269, 239, CRYSTAL STRUCTURE OF CHEK1 IN COMPLEX WITH INHIBITOR 54
4786, 2helA, 0.6036, 3.11, 0.208, 256, 240, CRYSTAL STRUCTURE OF A MUTANT EPHA4 KINASE DOMAIN (Y742A)
4787, 1gjoA, 0.6036, 3.52, 0.250, 280, 244, THE FGFR2 TYROSINE KINASE DOMAIN
4788, 6aydA, 0.6035, 3.07, 0.241, 272, 237, PIM1 COMPLEXED WITH N-(6-(4-HYDROXYPHENYL)-1H-INDAZOL-3-YL) CYCLOPROPANECARBOXAMIDE
4789, 5edrA, 0.6035, 3.06, 0.196, 299, 240, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 27: ~{N}-(1~{H}- INDAZOL-3-YL)-77-DIMETHYL-2-(2-METHYLPYRAZOL-3-YL)-5~{H}-FURO[34- D]PYRIMIDIN-4-AMINE
4790, 4mneE, 0.6035, 3.48, 0.215, 286, 247, CRYSTAL STRUCTURE OF THE BRAF:MEK1 COMPLEX
4791, 4jx3A, 0.6035, 3.09, 0.235, 274, 238, CRYSTAL STRUCTURE OF PIM1 KINASE
4792, 4ctcA, 0.6035, 3.33, 0.189, 288, 244, STRUCTURE OF THE HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH THE INHIBITOR 7-AMINO-3-CYCLOPROPYL-12-FLUORO- 11016-TRIMETHYL-1617-DIHYDRO-1H-84-(METHENO)PYRAZOLO(4 3-H)(2511)BENZOXADIAZACYCLOTETRADECIN-15(10H)-ONE
4793, 3nyxA, 0.6035, 3.71, 0.209, 287, 249, NON-PHOSPHORYLATED TYK2 JH1 DOMAIN WITH QUINOLINE-THIADIAZOLE- THIOPHENE INHIBITOR
4794, 3dzqA, 0.6035, 2.97, 0.206, 268, 238, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH INHIBITOR AWL-II- 38.3
4795, 2x7oA, 0.6035, 3.78, 0.199, 330, 246, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
4796, 2itzA, 0.6035, 3.41, 0.205, 302, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN L858R MUTATION IN COMPLEX WITH IRESSA
4797, 6fnlA, 0.6034, 3.03, 0.197, 262, 239, CRYSTAL STRUCTURE OF EPHRIN B4 (EPHB4) RECEPTOR PROTEIN KINASE 
4798, 5ui0B, 0.6034, 3.56, 0.253, 304, 245, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 2 HARBORING AN E565A/K659M DOUBLE GAIN-OF-FUNCTION MUTATION
4799, 5ftqA, 0.6034, 3.23, 0.178, 293, 242, CRYSTAL STRUCTURE OF THE ALK KINASE DOMAIN IN COMPLEX WITH CMPD 17
4800, 5cenA, 0.6034, 3.22, 0.272, 281, 239, CRYSTAL STRUCTURE OF DLK (KINASE DOMAIN)
4801, 4l53A, 0.6034, 2.95, 0.256, 296, 234, CRYSTAL STRUCTURE OF (1R4R)-4-{4-[7-AMINO-2-(123-BENZOTHIADIAZOL-7- YL)-3-CHLOROFURO[23-C]PYRIDIN-4-YL]-1H-PYRAZOL-1-YL}CYCLOHEXAN-1-OL BOUND TO TAK1-TAB1
4802, 4j95C, 0.6034, 3.53, 0.254, 281, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4803, 4iwqA, 0.6034, 3.85, 0.208, 626, 250, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
4804, 4fg8B, 0.6034, 3.08, 0.286, 268, 238, CRYSTAL STRUCTURE OF HUMAN CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE I 1-315 IN COMPLEX WITH ATP
4805, 2auhA, 0.6034, 4.02, 0.200, 297, 255, CRYSTAL STRUCTURE OF THE GRB14 BPS REGION IN COMPLEX WITH THE INSULIN RECEPTOR TYROSINE KINASE
4806, 1u4dB, 0.6034, 3.20, 0.209, 262, 239, STRUCTURE OF THE ACK1 KINASE DOMAIN BOUND TO DEBROMOHYMENIALDISINE
4807, 6cmmB, 0.6033, 4.06, 0.171, 310, 258, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A NN- DIPROPYNYL-DIHYDROPTERIDINE INHIBITOR
4808, 5xp5B, 0.6033, 3.39, 0.256, 267, 242, C-SRC IN COMPLEX WITH ATP-CHF
4809, 5op4A, 0.6033, 3.06, 0.274, 259, 237, STRUCTURE OF CHK1 10-PT. MUTANT COMPLEX WITH AMINOPYRIMIDINE LRRK2 INHIBITOR
4810, 5mzlA, 0.6033, 3.05, 0.236, 269, 237, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE N-QUINOLIN-5-YLPYRIDINE- 3-CARBOXAMIDE
4811, 5aacA, 0.6033, 3.34, 0.180, 292, 244, STRUCTURE OF C1156Y MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH CRIZOTINIB
4812, 4twoA, 0.6033, 3.06, 0.209, 278, 239, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH COMPOUND 164
4813, 4rvlA, 0.6033, 2.99, 0.264, 258, 235, CHK1 KINASE DOMAIN WITH DIAZACARBAZOLE COMPOUND 7: 3-(2- HYDROXYPHENYL)-9H-PYRROLO[23-B:54-C ]DIPYRIDINE-6-CARBONITRILE
4814, 4j95D, 0.6033, 3.41, 0.267, 271, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC K659N MUTATION RESPONSIBLE FOR AN UNCLASSIFIED CRANIOSYNOSTOSIS SYNDROME IN SPACE GROUP C2.
4815, 4d58B, 0.6033, 3.30, 0.214, 261, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN IN COMPLEX WITH BIS- ANILINO PYRIMIDINE INHIBITOR
4816, 3zlyA, 0.6033, 3.79, 0.216, 310, 250, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 8
4817, 5n4zA, 0.6032, 3.08, 0.241, 272, 237, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-4-(4-HYDROXYPHENYL)BUT-3-EN-2- ONE
4818, 5n4xA, 0.6032, 3.12, 0.244, 272, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 45-DIBROMOTHIOPHENE-2- CARBOHYDRAZIDE
4819, 5em7A, 0.6032, 3.22, 0.199, 300, 241, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 13: 4-[(2- METHOXYPHENYL)AMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4820, 4mbiA, 0.6032, 3.12, 0.239, 274, 238, DISCOVERY OF PYRAZOLO[15A]PYRIMIDINE-BASED PIM1 INHIBITORS
4821, 4ftrA, 0.6032, 3.02, 0.267, 258, 236, CRYSTAL STRUCTURE OF THE CHK1
4822, 4d0wA, 0.6032, 3.92, 0.230, 289, 252, PYRROLE-3-CARBOXAMIDES AS POTENT AND SELECTIVE JAK2 INHIBITORS
4823, 3a7hA, 0.6032, 3.60, 0.211, 289, 246, HUMAN MST3 KINASE IN COMPLEX WITH ATP
4824, 3zlwA, 0.6031, 3.76, 0.220, 312, 250, CRYSTAL STRUCTURE OF MEK1 IN COMPLEX WITH FRAGMENT 3
4825, 3o50A, 0.6031, 2.96, 0.249, 246, 237, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4826, 3jxwA, 0.6031, 3.12, 0.239, 274, 238, DISCOVERY OF 3H-BENZO[45]THIENO[32-D]PYRIMIDIN-4-ONES AS POTENT HIGHLY SELECTIVE AND ORALLY BIOAVAILABLE PIM KINASES INHIBITORS
4827, 3bizA, 0.6031, 3.02, 0.191, 250, 235, WEE1 KINASE COMPLEX WITH INHIBITOR PD331618
4828, 2x8eA, 0.6031, 3.17, 0.270, 259, 237, DISCOVERY OF A NOVEL CLASS OF TRIAZOLONES AS CHECKPOINT KINASE INHIBITORS - HIT TO LEAD EXPLORATION
4829, 5v80A, 0.6030, 3.12, 0.244, 273, 238, PIM1 KINASE IN COMPLEX WITH CPD1 (1-METHYL-4-(3-(6-(PIPERAZIN-1-YL) PYRIDIN-2-YL)-1H-PYRAZOLO[3;4-C]PYRIDIN-5-YL)PIPERAZIN-2-ONE) 
4830, 5feeA, 0.6030, 3.55, 0.204, 287, 245, EGFR KINASE DOMAIN T790M MUTANT IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE INHIBITOR.
4831, 5c1qB, 0.6030, 3.12, 0.244, 273, 238, SERINE/THREONINE-PROTEIN KINASE PIM-1
4832, 4wrsA, 0.6030, 3.14, 0.244, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH AN AZASPIRO PYRAZINYL-INDAZOLE INHIBITOR.
4833, 4qygB, 0.6030, 3.03, 0.267, 264, 236, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE COMPOUND 14
4834, 4obqB, 0.6030, 3.33, 0.220, 293, 245, MAP4K4 IN COMPLEX WITH INHIBITOR (COMPOUND 31) N-[3-(4- AMINOQUINAZOLIN-6-YL)-5-FLUOROPHENYL]-2-(PYRROLIDIN-1-YL)ACETAMIDE
4835, 4jrvA, 0.6030, 3.51, 0.213, 300, 244, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN IN COMPLEX WITH COMPOUND 4C
4836, 4gk2A, 0.6030, 2.98, 0.197, 265, 238, HUMAN EPHA3 KINASE DOMAIN IN COMPLEX WITH LIGAND 66
4837, 3zepB, 0.6030, 3.51, 0.223, 268, 242, CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN IN COMPLEX WITH A PYRROLOPYRAZINE-2-PHENYL ETHER INHIBITOR
4838, 3t9iA, 0.6030, 3.06, 0.245, 273, 237, PIM1 COMPLEXED WITH A NOVEL 36-DISUBSTITUTED INDOLE AT 2.6 ANG RESOLUTION
4839, 3q4uB, 0.6030, 3.37, 0.234, 300, 244, CRYSTAL STRUCTURE OF THE ACVR1 KINASE DOMAIN IN COMPLEX WITH LDN- 193189
4840, 3f3vA, 0.6030, 3.18, 0.252, 261, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4841, 3dk6B, 0.6030, 3.14, 0.219, 259, 237, CRYSTAL STRUCTURE OF MUTANT ABL KINASE DOMAIN IN COMPLEX WITH SMALL MOLECULE FRAGMENT
4842, 2jc6A, 0.6030, 3.00, 0.280, 278, 236, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4843, 6cnxB, 0.6029, 3.95, 0.173, 311, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE 1 (VRK1) BOUND TO AN N-PROPYNYL-N-ISOPENTYL-DIHYDROPTERIDIN INHIBITOR
4844, 5n52A, 0.6029, 3.09, 0.241, 268, 237, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE (E)-3-(23-DIMETHOXYPHENYL)ACRYLIC ACID
4845, 5kgeA, 0.6029, 3.12, 0.239, 273, 238, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 5-(34-DICHLOROPHENYL)- 1~{H}-PYRAZOL-3-AMINE
4846, 6bx6A, 0.6028, 2.80, 0.305, 243, 236, AMP-ACTIVATED PROTEIN KINASE (AMPK) INHIBITION BY SBI-0206965: ALPHA 2 KINASE DOMAIN BOUND TO SBI-0206965 
4847, 5x2aB, 0.6028, 3.68, 0.211, 322, 251, CRYSTAL STRUCTURE OF EGFR 696-1022 T790M/V948R IN COMPLEX WITH SKLB(3)
4848, 5wnfB, 0.6028, 3.93, 0.228, 358, 254, X-RAY CO-STRUCTURE OF RHO-ASSOCIATED PROTEIN KINASE (ROCK1) WITH A HIGHLY SELECTIVE INHIBITOR 
4849, 5flfC, 0.6028, 3.45, 0.251, 283, 243, DISEASE LINKED MUTATION IN FGFR
4850, 5aa8A, 0.6028, 3.34, 0.176, 292, 244, STRUCTURE OF C1156YL1198F MUTANT HUMAN ANAPLASTIC LYMPHOMA KINASE IN COMPLEX WITH PF-06463922 ((10R)-7-AMINO-12- FLUORO-21016-TRIMETHYL-15-OXO-10151617-TETRAHYDRO-2H- 84-(METHENO)PYRAZOLO(43-H)(2511) BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE).
4851, 4wsyA, 0.6028, 3.13, 0.239, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIAZOLAMINE-INDAZOLE INHIBITOR.
4852, 4ix3B, 0.6028, 4.19, 0.179, 350, 252, CRYSTAL STRUCTURE OF A STT7 HOMOLOG FROM MICROMONAS ALGAE
4853, 4d5hB, 0.6028, 3.27, 0.214, 260, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4854, 3kxxA, 0.6028, 3.64, 0.260, 305, 246, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
4855, 3e64A, 0.6028, 4.00, 0.229, 291, 253, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
4856, 3dy7A, 0.6028, 3.25, 0.218, 260, 243, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (MEK1) IN A COMPLEX WITH LIGAND AND MGATP
4857, 3ctjA, 0.6028, 3.13, 0.212, 289, 240, CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH A AMINOPYRIDINE BASED INHIBITOR
4858, 5n4uA, 0.6027, 3.08, 0.245, 272, 237, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND FRAGMENT LIKE MOLEKULE 5-(2-AMINO-13-THIAZOL-4- YL)-13-DIHYDROBENZIMIDAZOL-2-ONE
4859, 5kgdA, 0.6027, 3.13, 0.239, 273, 238, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR: 2-PYRIDIN-3-YL-1~{H}- BENZIMIDAZOLE
4860, 5em5A, 0.6027, 3.24, 0.203, 298, 241, EGFR KINASE DOMAIN MUTANT TMLR WITH PYRIDONE COMPOUND 2: 4-[2-(4- CHLOROPHENYL)ETHYLAMINO]-~{N}-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-2- OXIDANYLIDENE-1~{H}-PYRIDINE-3-CARBOXAMIDE
4861, 4ytfA, 0.6027, 3.74, 0.226, 283, 248, DISCOVERY OF VX-509 (DECERNOTINIB): A POTENT AND SELECTIVE JANUS KINASE (JAK) 3 INHIBITOR FOR THE TREATMENT OF AUTOIMMUNE DISEASES
4862, 4u3yB, 0.6027, 3.50, 0.210, 300, 248, APO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (MAP4K4)
4863, 4rj8A, 0.6027, 3.28, 0.207, 298, 241, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 8
4864, 4gfmA, 0.6027, 3.95, 0.230, 289, 252, JAK2 KINASE (JH1 DOMAIN) WITH 26-DICHLORO-N-(2-OXO-25- DIHYDROPYRIDIN-4-YL)BENZAMIDE
4865, 4fk3A, 0.6027, 2.88, 0.226, 251, 235, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH PLX3203
4866, 4e93A, 0.6027, 3.92, 0.225, 361, 249, CRYSTAL STRUCTURE OF HUMAN FELINE SARCOMA VIRAL ONCOGENE HOMOLOGUE (V- FES)IN COMPLEX WITH TAE684
4867, 3u6iA, 0.6027, 3.07, 0.227, 281, 238, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH PYRAZOLONE INHIBITOR 58A
4868, 3qa8G, 0.6027, 3.36, 0.262, 541, 244, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4869, 3gqiA, 0.6027, 3.70, 0.247, 304, 247, CRYSTAL STRUCTURE OF ACTIVATED RECEPTOR TYROSINE KINASE IN COMPLEX WITH SUBSTRATES
4870, 3e62A, 0.6027, 3.94, 0.226, 291, 252, FRAGMENT BASED DISCOVERY OF JAK-2 INHIBITORS
4871, 2dq7X, 0.6027, 3.46, 0.240, 262, 242, CRYSTAL STRUCTURE OF FYN KINASE DOMAIN COMPLEXED WITH STAUROSPORINE
4872, 5v5nA, 0.6026, 3.00, 0.261, 294, 234, CRYSTAL STRUCTURE OF TAKINIB BOUND TO TAK1
4873, 5cswA, 0.6026, 2.93, 0.220, 254, 236, B-RAF IN COMPLEX WITH DABRAFENIB
4874, 4zjjB, 0.6026, 3.13, 0.237, 277, 240, PAK1 IN COMPLEX WITH (S)-N-(TERT-BUTYL)-3-((2-CHLORO-5-ETHYL-8-FLUORO- DIBENZODIAZEPIN-11-YL)AMINO)PYRROLIDINE-1-CARBOXAMIDE
4875, 4xg2A, 0.6026, 3.08, 0.206, 259, 238, CRYSTAL STRUCTURE OF LIGAND-FREE SYK
4876, 4wt6A, 0.6026, 3.13, 0.244, 273, 238, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A THIADIAZOLAMINE-INDOLE INHIBITOR.
4877, 4j97C, 0.6026, 3.42, 0.259, 283, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE PATHOGENIC GAIN-OF-FUNCTION K659E MUTATION IDENTIFIED IN ENDOMETRIAL CANCER.
4878, 4gl9B, 0.6026, 3.41, 0.225, 280, 244, CRYSTAL STRUCTURE OF INHIBITORY PROTEIN SOCS3 IN COMPLEX WITH JAK2 KINASE DOMAIN AND FRAGMENT OF GP130 INTRACELLULAR DOMAIN
4879, 4fttA, 0.6026, 3.03, 0.267, 266, 236, CRYSTAL STRUCTURE OF THE CHK1
4880, 3dqwB, 0.6026, 3.51, 0.251, 278, 243, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
4881, 3c4eC, 0.6026, 3.08, 0.236, 272, 237, PIM-1 KINASE DOMAIN IN COMPLEX WITH 3-AMINOPHENYL-7- AZAINDOLE
4882, 2rfeB, 0.6026, 3.62, 0.224, 273, 246, CRYSTAL STRUCTURE OF THE COMPLEX BETWEEN THE EGFR KINASE DOMAIN AND A MIG6 PEPTIDE
4883, 2o63A, 0.6026, 3.13, 0.235, 274, 238, CRYSTAL STRUCTURE OF PIM1 WITH MYRICETIN
4884, 2jc6C, 0.6026, 2.95, 0.281, 277, 235, CRYSTAL STRUCTURE OF HUMAN CALMODULIN-DEPENDENT PROTEIN KINASE 1D
4885, 5tehA, 0.6025, 3.06, 0.254, 261, 236, C-SRC V281C KINASE DOMAIN IN COMPLEX WITH RAO-IV-156
4886, 5eydA, 0.6025, 3.51, 0.217, 289, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH AMG 337
4887, 5cf4A, 0.6025, 3.35, 0.230, 283, 244, CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH NN-DICYCLOPROPYL- 10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-35810- TETRAAZATRICYCLO[7.3.0.06] DODECA-1(9)2(6)4711-PENTAENE-11- CARBOXAMIDE
4888, 4xhhA, 0.6025, 3.38, 0.182, 358, 242, STRUCTURE OF C. GLABRATA HRR25 APO STATE
4889, 4xg7A, 0.6025, 3.51, 0.200, 266, 245, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4890, 4medA, 0.6025, 3.07, 0.236, 272, 237, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE DERIVATIVES
4891, 4fsyA, 0.6025, 3.03, 0.271, 267, 236, CRYSTAL STRUCTURE OF THE CHK1
4892, 4dehA, 0.6025, 3.48, 0.209, 286, 244, CRYSTAL STRUCTURE OF C-MET IN COMPLEX WITH TRIAZOLOPYRIDINONE INHIBITOR 3
4893, 3tzmA, 0.6025, 3.34, 0.212, 295, 241, TGF-BETA RECEPTOR TYPE 1 IN COMPLEX WITH SB431542
4894, 3rzfA, 0.6025, 3.44, 0.261, 541, 245, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPAB KINASE BETA (I4122)
4895, 3rvgA, 0.6025, 3.48, 0.224, 285, 245, CRYSTALS STRUCTURE OF JAK2 WITH A 1-AMINO-5H-PYRIDO[43-B]INDOL-4- CARBOXAMIDE INHIBITOR
4896, 3o50B, 0.6025, 3.15, 0.246, 249, 240, CRYSTAL STRUCTURE OF BENZAMIDE 9 BOUND TO AURORAA
4897, 3cpbB, 0.6025, 3.07, 0.219, 263, 237, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4898, 3cpbA, 0.6025, 3.09, 0.214, 285, 238, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BISAMIDE INHIBITOR
4899, 3ckwA, 0.6025, 2.65, 0.224, 255, 232, CRYSTAL STRUCTURE OF STERILE 20-LIKE KINASE 3 (MST3 STK24)
4900, 2jitB, 0.6025, 3.62, 0.194, 312, 248, CRYSTAL STRUCTURE OF EGFR KINASE DOMAIN T790M MUTATION
4901, 2b7aB, 0.6025, 3.59, 0.227, 287, 247, THE STRUCTURAL BASIS OF JANUS KINASE 2 INHIBITION BY A POTENT AND SPECIFIC PAN-JANUS KINASE INHIBITOR
4902, 6bu6D, 0.6024, 4.00, 0.176, 318, 255, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A BIS- DIFLUOROPHENOL-AMINOPYRIDINE INHIBITOR
4903, 5t68B, 0.6024, 3.14, 0.197, 264, 239, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
4904, 5n51A, 0.6024, 3.11, 0.241, 268, 237, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUS PEPTIDE AND FRAGMENT LIKE MOLECULE 34-DIBROMOTHIOPHENE-2-CARBOXYLIC ACID
4905, 5hczA, 0.6024, 3.43, 0.206, 300, 243, EGFR KINASE DOMAIN MUTANT TMLR WITH 3-AZETIDINYL AZAINDAZOLE COMPOUND 21
4906, 4yc8A, 0.6024, 3.29, 0.218, 259, 239, C-HELIX-OUT BINDING OF DASATINIB ANALOG TO C-ABL KINASE
4907, 4xv2B, 0.6024, 2.93, 0.221, 249, 235, B-RAF KINASE V600E ONCOGENIC MUTANT IN COMPLEX WITH DABRAFENIB
4908, 4xhkB, 0.6024, 3.13, 0.244, 269, 238, PIM1 KINASE IN COMPLEX WITH COMPOUND 1S
4909, 4xg4A, 0.6024, 3.13, 0.205, 264, 239, CRYSTAL STRUCTURE OF AN INHIBITOR-BOUND SYK
4910, 4trlA, 0.6024, 3.22, 0.200, 268, 240, STRUCTURE OF EPHRIN TYPE-A RECEPTOR 2
4911, 4j99C, 0.6024, 3.45, 0.247, 291, 243, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
4912, 3vapA, 0.6024, 3.15, 0.246, 249, 240, SYNTHESIS AND SAR STUDIES OF IMIDAZO-[12-A]-PYRAZINE AURORA KINASE INHIBITORS WITH IMPROVED OFF TARGET KINASE SELECTIVITY
4913, 3qa8B, 0.6024, 3.36, 0.262, 622, 244, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4914, 3oezA, 0.6024, 3.17, 0.252, 261, 238, CRYSTAL STRUCTURE OF THE L317I MUTANT OF THE CHICKEN C-SRC TYROSINE KINASE DOMAIN COMPLEXED WITH IMATINIB
4915, 3b2tA, 0.6024, 3.44, 0.255, 288, 243, STRUCTURE OF PHOSPHOTRANSFERASE
4916, 2w1iB, 0.6024, 3.40, 0.217, 284, 244, STRUCTURE DETERMINATION OF AURORA KINASE IN COMPLEX WITH INHIBITOR
4917, 1k2pA, 0.6024, 3.27, 0.183, 258, 241, CRYSTAL STRUCTURE OF BRUTON S TYROSINE KINASE DOMAIN
4918, 5kgiA, 0.6023, 3.13, 0.239, 273, 238, CRYSTAL STRUCTURE OF PIM1 WITH INHIBITOR 2-[34-BIS(CHLORANYL) PHENOXY]ETHANAMINE
4919, 5iisA, 0.6023, 3.24, 0.234, 273, 239, DESIGN SYNTHESIS AND STRUCTURE ACTIVITY RELATIONSHIP OF POTENT PAN- PIM KINASE INHIBITORS DERIVED FROM THE PYRIDYL-AMIDE SCAFFOLD
4920, 5hieA, 0.6023, 3.16, 0.234, 258, 239, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH DABRAFENIB
4921, 3f3wB, 0.6023, 2.97, 0.250, 260, 236, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4922, 2x81A, 0.6023, 2.95, 0.241, 242, 237, STRUCTURE OF AURORA A IN COMPLEX WITH MLN8054
4923, 5oq6A, 0.6022, 2.87, 0.269, 257, 234, STRUCTURE OF CHK1 12-PT. MUTANT COMPLEX WITH AMINOPYRIMIDO- BENZODIAZEPINONE LRRK2 INHIBITOR
4924, 5n5lA, 0.6022, 3.10, 0.245, 271, 237, CRYSTAL STRUCTURE OF HUMAN PIM-1 KINASE IN COMPLEX WITH A CONSENSUSPEPTIDE AND [2-OXO-2-(1H-PYRROL-2-YL)ETHYL] 5-BROMO-1H- INDOLE-3-CARBOXYLATE
4925, 5hi2A, 0.6022, 2.97, 0.226, 247, 234, BRAF KINASE DOMAIN B3AC LOOP DELETION MUTANT IN COMPLEX WITH SORAFENIB
4926, 5flfB, 0.6022, 3.59, 0.253, 292, 245, DISEASE LINKED MUTATION IN FGFR
4927, 4u5jA, 0.6022, 3.40, 0.260, 267, 242, C-SRC IN COMPLEX WITH RUXOLITINIB
4928, 3ri1B, 0.6022, 3.60, 0.266, 283, 244, CRYSTAL STRUCTURE OF THE CATALYTIC DOMAIN OF FGFR2 KINASE IN COMPLEX WITH ARQ 069
4929, 3r01A, 0.6022, 3.14, 0.239, 274, 238, THE DISCOVERY OF NOVEL BENZOFURAN-2-CARBOXYLIC ACIDS AS POTENT PIM-1 INHIBITORS
4930, 3qa8H, 0.6022, 3.36, 0.262, 541, 244, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4931, 3b2tB, 0.6022, 3.47, 0.251, 287, 243, STRUCTURE OF PHOSPHOTRANSFERASE
4932, 2xkeA, 0.6022, 2.74, 0.227, 243, 233, STRUCTURE OF NEK2 BOUND TO AMINIPYRAZINE COMPOUND 5
4933, 2x7oD, 0.6022, 3.72, 0.200, 330, 245, CRYSTAL STRUCTURE OF TGFBRI COMPLEXED WITH AN INDOLINONE INHIBITOR
4934, 5t68A, 0.6021, 3.18, 0.197, 266, 239, CRYSTAL STRUCTURE OF SYK CATALYTIC DOMAIN IN COMPLEX WITH A FURO[32- D]PYRIMIDINE
4935, 5dhjA, 0.6021, 3.13, 0.244, 273, 238, PIM1 IN COMPLEX WITH CPD4 (3-METHYL-5-(PYRIDIN-3-YL)-1H-PYRAZOLO[34- C]PYRIDINE)
4936, 4qyhA, 0.6021, 3.00, 0.272, 264, 235, CHK1 KINASE DOMAIN IN COMPLEX WITH DIAZACARBAZOLE GNE-783
4937, 4iaaA, 0.6021, 3.07, 0.236, 272, 237, CRYSTAL STRUCTURE OF SER/THR KINASE PIM1 IN COMPLEX WITH THIORIDAZINE
4938, 4bhnB, 0.6021, 2.97, 0.298, 257, 235, CRYSTAL STRUCTURES OF ASK1-INHIBITOR COMPLEXES
4939, 3zzwB, 0.6021, 3.45, 0.173, 265, 243, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF ROR2
4940, 3lxpA, 0.6021, 3.69, 0.227, 285, 247, STRUCTURAL AND THERMODYNAMIC CHARACTERIZATION OF THE TYK2 AND JAK3 KINASE DOMAINS IN COMPLEX WITH CP-690550 AND CMP-6
4941, 2xj0A, 0.6021, 3.15, 0.239, 274, 238, PROTEIN KINASE PIM-1 IN COMPLEX WITH FRAGMENT-4 FROM CRYSTALLOGRAPHIC FRAGMENT SCREEN
4942, 1zycB, 0.6021, 3.34, 0.230, 254, 244, CRYSTAL STRUCTURE OF EIF2ALPHA PROTEIN KINASE GCN2: WILD- TYPE IN APO FORM.
4943, 1s9iB, 0.6021, 3.55, 0.235, 291, 247, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
4944, 5wnjA, 0.6020, 3.23, 0.187, 264, 241, CRYSTAL STRUCTURE OF MURINE RECEPTOR-INTERACTING PROTEIN KINASE 4 (RIPK4) D143N IN COMPLEX WITH LESTAURTINIB 
4945, 5ttsA, 0.6020, 3.39, 0.216, 274, 241, JAK3 WITH COVALENT INHIBITOR 4
4946, 4usdB, 0.6020, 3.09, 0.229, 267, 240, HUMAN STK10 (LOK) WITH SB-633825
4947, 4iwpA, 0.6020, 3.77, 0.206, 628, 248, CRYSTAL STRUCTURE AND MECHANISM OF ACTIVATION OF TBK1
4948, 3tz9A, 0.6020, 3.18, 0.252, 261, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL130
4949, 3kf4A, 0.6020, 3.24, 0.230, 281, 239, STRUCTURAL ANALYSIS OF DFG-IN AND DFG-OUT DUAL SRC-ABL INHIBITORS SHARING A COMMON VINYL PURINE TEMPLATE
4950, 3f9nA, 0.6020, 3.12, 0.275, 253, 236, CRYSTAL STRUCTURE OF CHK1 KINASE IN COMPLEX WITH INHIBITOR 38
4951, 2z7qA, 0.6020, 2.68, 0.277, 255, 231, CRYSTAL STRUCTURE OF THE N-TERMINAL KINASE DOMAIN OF HUMAN RSK-1 BOUND TO AMP-PCP
4952, 2o65A, 0.6020, 3.06, 0.236, 274, 237, CRYSTAL STRUCTURE OF PIM1 WITH PENTAHYDROXYFLAVONE
4953, 1yxvA, 0.6020, 3.14, 0.239, 274, 238, CRYSTAL STRUCTURE OF KINASE PIM1 IN COMPLEX WITH 34-DIHYDROXY-1- METHYLQUINOLIN-2(1H)-ONE
4954, 6eimB, 0.6019, 3.26, 0.213, 295, 239, HUMAN STK10 BOUND TO GW683134A
4955, 5t8oA, 0.6019, 3.86, 0.230, 324, 248, CRYSTAL STRUCTURE OF MURINE NF-KAPPAB INDUCING KINASE (NIK) BOUND TO IMIDAZOBENZOXEPIN COMPOUND 3
4956, 5flfA, 0.6019, 3.60, 0.253, 296, 245, DISEASE LINKED MUTATION IN FGFR
4957, 5c27A, 0.6019, 3.62, 0.194, 272, 247, CRYSTAL STRUCTURE OF SYK IN COMPLEX WITH COMPOUND 2
4958, 4y83A, 0.6019, 3.55, 0.240, 299, 242, CRYSTAL STRUCTURE OF COT KINASE DOMAIN IN COMPLEX WITH 5-(2-AMINO-5- (QUINOLIN-3-YL)PYRIDIN-3-YL)-134-OXADIAZOLE-2(3H)-THIONE
4959, 4rj5A, 0.6019, 3.20, 0.200, 296, 240, EGFR KINASE (T790M/L858R) WITH INHIBITOR COMPOUND 5
4960, 4rixB, 0.6019, 3.31, 0.219, 293, 242, CRYSTAL STRUCTURE OF AN EGFR/HER3 KINASE DOMAIN HETERODIMER CONTAINING THE CANCER-ASSOCIATED HER3-Q790R MUTATION
4961, 4g5jA, 0.6019, 3.54, 0.213, 307, 244, CRYSTAL STRUCTURE OF EGFR KINASE IN COMPLEX WITH BIBW2992
4962, 4ft5A, 0.6019, 3.05, 0.267, 265, 236, CRYSTAL STRUCTURE OF THE CHK1
4963, 3tz8A, 0.6019, 3.18, 0.252, 261, 238, KINASE DOMAIN OF CSRC IN COMPLEX WITH RL104
4964, 3lpbB, 0.6019, 3.51, 0.234, 284, 244, CRYSTAL STRUCTURE OF JAK2 COMPLEXED WITH A POTENT 28-DIARYL- QUINOXALINE INHIBITOR
4965, 3kxxB, 0.6019, 3.66, 0.252, 305, 246, STRUCTURE OF THE MUTANT FIBROBLAST GROWTH FACTOR RECEPTOR 1
4966, 3fzsA, 0.6019, 2.92, 0.152, 254, 237, CRYSTAL STRUCTURE OF PYK2 COMPLEXED WITH BIRB796
4967, 3dqwA, 0.6019, 3.52, 0.251, 278, 243, C-SRC KINASE DOMAIN THR338ILE MUTANT IN COMPLEX WITH ATPGS
4968, 3bwfA, 0.6019, 3.06, 0.232, 273, 237, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AN OSMIUM COMPOUND
4969, 2xk6A, 0.6019, 2.67, 0.223, 243, 233, STRUCTURE OF NEK2 BOUND TO AMINOPYRAZINE COMPOUND 36
4970, 2bzkB, 0.6019, 3.11, 0.245, 268, 237, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH AMPPNP AND PIMTIDE
4971, 1y6bA, 0.6019, 2.87, 0.226, 266, 235, CRYSTAL STRUCTURE OF VEGFR2 IN COMPLEX WITH A 2-ANILINO-5-ARYL-OXAZOLE INHIBITOR
4972, 6g4zB, 0.6018, 3.82, 0.230, 325, 248, CRYSTAL STRUCTURE OF HUMAN NF-KAPPAB INDUCING KINASE (NIK) IN COMPLEX WITH COMPOUND 2F 
4973, 6cswD, 0.6018, 3.96, 0.181, 312, 254, CRYSTAL STRUCTURE OF THE HUMAN VACCINIA-RELATED KINASE BOUND TO A N- METHYL-N-PROPYL-DIHYDROPTERIDINE INHIBITOR
4974, 5cauA, 0.6018, 3.29, 0.203, 297, 241, EGFR KINASE DOMAIN MUTANT TMLR WITH COMPOUND 41B
4975, 4xh6A, 0.6018, 3.05, 0.232, 273, 237, CRYSTAL STRUCTURE OF PROTO-ONCOGENE KINASE PIM1 BOUND TO HISPIDULIN
4976, 4d4yB, 0.6018, 3.29, 0.210, 260, 243, FOCAL ADHESION KINASE CATALYTIC DOMAIN
4977, 3wigA, 0.6018, 3.62, 0.206, 278, 248, HUMAN MEK1 KINASE IN COMPLEX WITH CH5126766 AND MGAMP-PNP
4978, 3qa8F, 0.6018, 3.37, 0.262, 622, 244, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
4979, 3f3wA, 0.6018, 3.06, 0.245, 261, 237, DRUG RESISTANT CSRC KINASE DOMAIN IN COMPLEX WITH INHIBITOR RL45 (TYPE II)
4980, 2o64A, 0.6018, 3.23, 0.238, 274, 239, CRYSTAL STRUCTURE OF PIM1 WITH QUERCETAGETIN
4981, 2bziB, 0.6018, 3.09, 0.241, 272, 237, CRYSTAL STRUCTURE OF THE HUMAN PIM1 IN COMPLEX WITH A RUTHENIUM ORGANOMETALLIC LIGAND RU2
4982, 1s9iA, 0.6018, 3.69, 0.225, 303, 249, X-RAY STRUCTURE OF THE HUMAN MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (MEK2)IN A COMPLEX WITH LIGAND AND MGATP
4983, 5telA, 0.6017, 3.16, 0.244, 273, 238, PIM-1 KINASE IN COMPLEX WITH A 7-AZAINDOLE
4984, 5ar4A, 0.6017, 3.07, 0.224, 274, 237, RIP2 KINASE CATALYTIC DOMAIN (1 - 310) COMPLEX WITH SB-203580
4985, 4z16D, 0.6017, 3.25, 0.218, 271, 239, CRYSTAL STRUCTURE OF THE JAK3 KINASE DOMAIN COVALENTLY BOUND TO N-(3- (((5-CHLORO-2-((2-METHOXY-4-(4-METHYLPIPERAZIN-1-YL)PHENYL)AMINO) PYRIMIDIN-4-YL)AMINO)METHYL)PHENYL)ACRYLAMIDE
4986, 4ueuA, 0.6017, 3.24, 0.229, 256, 240, TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL
4987, 4j99A, 0.6017, 3.40, 0.248, 280, 242, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659T MUTATION.
4988, 4fsuA, 0.6017, 2.97, 0.272, 260, 235, CRYSTAL STRUCTURE OF THE CHK1
4989, 3vc4A, 0.6017, 3.16, 0.244, 274, 238, EXPLOITATION OF HYDROGEN BONDING CONSTRAINTS AND FLAT HYDROPHOBIC ENERGY LANDSCAPES IN PIM-1 KINASE NEEDLE SCREENING AND INHIBITOR DESIGN
4990, 3cxwA, 0.6017, 3.17, 0.239, 272, 238, CRYSTAL STRUCTURE OF HUMAN PROTO-ONCOGENE SERINE THREONINE KINASE (PIM1) IN COMPLEX WITH A CONSENSUS PEPTIDE AND A BETA CARBOLINE LIGAND I
4991, 2qu6B, 0.6017, 3.24, 0.221, 260, 240, CRYSTAL STRUCTURE OF THE VEGFR2 KINASE DOMAIN IN COMPLEX WITH A BENZOXAZOLE INHIBITOR
4992, 2psqA, 0.6017, 3.49, 0.267, 287, 243, CRYSTAL STRUCTURE OF UNPHOSPHORYLATED UNACTIVATED WILD TYPE FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN
4993, 6bskA, 0.6016, 3.15, 0.239, 273, 238, HUMAN PIM1 KINASE IN COMPLEX WITH COMPOUND 12B
4994, 5cwzC, 0.6016, 2.89, 0.230, 271, 235, CRYSTAL STRUCTURE OF THE KINASE DOMAIN OF HUMAN TRAF2 AND NCK- INTERACTING PROTEIN KINASE
4995, 4wkqA, 0.6016, 3.56, 0.212, 296, 245, 1.85 ANGSTROM STRUCTURE OF EGFR KINASE DOMAIN WITH GEFITINIB
4996, 4mxxB, 0.6016, 3.15, 0.252, 260, 238, HUMAN SRC A403T MUTANT BOUND TO KINASE INHIBITOR BOSUTINIB
4997, 4j98A, 0.6016, 3.55, 0.254, 304, 244, CRYSTAL STRUCTURE OF FGF RECEPTOR 2 (FGFR2) KINASE DOMAIN HARBORING THE GAIN-OF-FUNCTION K659Q MUTATION.
4998, 4aojB, 0.6016, 2.98, 0.203, 258, 237, HUMAN TRKA IN COMPLEX WITH THE INHIBITOR AZ-23
4999, 3qgwA, 0.6016, 2.90, 0.183, 244, 235, CRYSTAL STRUCTURE OF ITK KINASE BOUND TO AN INHIBITOR
5000, 3qa8E, 0.6016, 3.39, 0.258, 622, 244, CRYSTAL STRUCTURE OF INHIBITOR OF KAPPA B KINASE BETA
